Access ICPE Abstracts on your Mobile Device www.abstracts2view.com/ispe – Online only Abstract Supplement – Free WiFi is provided for you to access this tool Join the conversation #ICPEdublin

32nd

2 0 1 6

International Conference on Pharmacoepidemiology & Therapeutic Risk Management The Convention Center Dublin pharmacoepi.org

Jointly sponsored by: BOARD OF DIRECTORS & VOLUNTEER LEADERS

Chairs/Co-Chairs & Liaisons nd 32 Committees Archives & History 2 0 1 6 ...... Hugh Tilson, FISPE Bylaws & Policies...... Stella Blackburn, FISPE Frank W May, FISPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management Development...... Syd Phillips The Convention Center Dublin Kirk Midkiff Education ...... Joshua Gagne ISPE Officers & Board of Directors Darren Toh Tobias Gerhard, FISPE Fellowship & Awards Officers ...... John D Seeger, FISPE Finance Sonia Hernández-Díaz, FISPE, President ...... Alison Bourke, FISPE Kiyoshi Kubota, FISPE, President-Elect Tobias Gerhard, FISPE John D Seeger, FISPE, Immediate Past President Global Development...... Kiyoshi Kubota, FISPE Alison Bourke, FISPE, Vice President Finance K Arnold Chan, FISPE Vice President Finance - Elect Tobias Gerhard, FISPE, Management Oversight...... John D Seeger, FISPE Mark H Epstein, Executive Secretary Membership...... Caitlin Knox Directors Jonathan Schelfhout Morten Andersen Vincent Lo Re, FISPE Nominating ...... John D Seeger, FISPE Andrew Bate Malcolm Maclure Public Policy & Ethics...... Yola Moride, FISPE Rhonda L Bohn, FISPE June Raine Corinne de Vries, FISPE Sabine Straus Jennifer B Christian, FISPE Publications & Helga Gardarsdottir Almut G Winterstein, FISPE Communications...... Kevin Haynes, FISPE Wan-Ting Huang Wei Zhou Minah Tadrous Yea-Huei Kao Yang, FISPE Stanley A Edlavitch, Marie Lindquist Lifetime Emeritus Scholarship...... Sonia Hernández-Díaz, FISPE Scientific Program...... Mary E Ritchey 2016 ICPE Scientific Program Strategic Planning ...... Kiyoshi Kubota, FISPE Committee Councils Academic...... Daniel Prieto-Alhambra Mary E Ritchey, Chair Vera Ehrenstein Government/Regulatory...... Sabine Straus Core Program Committee Gianpiero Mazzaglia Industry/Service Providers Thamir Alshammary Krista Huybrechts ...... Susan A Oliveria, FISPE Andrew Bate Jessica Jalbert John Acquavella, FISPE Kathleen Bennett Olaf Klungel Student...... Sze Ling (Celine) Chui Kristen Bibeau Kiyoshi Kubota, FISPE Juan Hincapie Castillo Rhonda L Bohn, FISPE Deborah Layton Special Interest Groups Kimberly Brodovicz J Bradley Layton Melissa Castan Adrian Levy Adherence ...... Robert Gross, FISPE Carlos Duran Vincent Lo Re, FISPE Asian Pharmacoepidemiology Mark H Epstein David Miller Network (AsPEN) ...... Nicole Pratt Josh Gagne Susana Perez-Gutthann, FISPE Edward Chia-Cheng Lai Arlene Gallagher Lisa Pont, FISPE Biologics & Biosimilars...... Veronique Kugener Tobias Gerhard, FISPE John D Seeger, FISPE Amanda Golembesky Robert Hay Ingrid Sketis Sonia Hernández-Díaz, FISPE Almath Spooner BRACE...... Rachel Sobel, FISPE Ken Hornbuckle, FISPE Darren Toh Meredith Smith Jason Hsu Cunlin Wang Alicia Gilsenan Wang-Tin Huang Comparative Effectiveness Research (CER)...... Michelle Johnson-Funk Databases...... Bing Cai Rachael Williams 32nd

2 VOLUNTEER LEADERS & COMMITTEES

Student Chapters Drug Utilization Research...... Katja Taxis w Basel Pharmacoepidemiology Unit, University of Basel, Veronika Wirtz Switzerland & the Boston Collaborative Drug Surveillance Medical Device...... Irene B Murimi Program, Boston University, USA Chantal Holy w Center for Drug Safety & Effectiveness, Department of Leyla Sahin Epidemiology, Johns Hopkins School of Public Health, USA Medicines In Pregnancy ...... Sara Ephross w Center for Drug Safety & Pharmaceutical Health Services Molecular Epi/Biomarkers/ Research Graduate Program, University of Maryland School of Pharmacogenetics...... David Pulford Pharmacy, USA Quan-Ying Yue w Clinical and Population Health Research Program, Department Pediatrics ...... Tamar Lasky, FISPE of Quantitative Health Sciences, University of Massachusetts Jon Slaughter Medical School, USA Vaccines ...... Robert T Chen, FISPE w College of Pharmacy, University of Cincinnati, USA Liaisons w Department of Pharmaceutical Outcomes and Policy, College CIOMS...... Sabine Straus of Phamacy, University of Florida, USA ENCePP...... Yola Moride, FISPE w Department of Pharmacy Systems, Outcomes and Policy, International Joint Policy University of Illinois at Chicago, USA Committee of the Societies w Department of Pharmacy Practice, KMCH College of of Epidemiology...... Yola Moride, FISPE Pharmacy, Coimbatore, India US FDA ...... Christian Hampp w Harvard University School of Public Health, USA Regional Chapters w Health Outcomes and Pharmacy Practice, The University of Texas at Austin, USA FarmacoEpiEnRed- w Spanish Chapter...... Elisa Martín-Merino Faculty of Pharmacy, JSS University, Mysore, India Danie Prieto-Alhambra w Graduate Department of Pharmaceutical Sciences, Leslie Dan Gulf Region...... Hisham Aljadhey Faculty of Pharmacy, University of Toronto, Canada Thamir Alshammary w Pharmacoepidemiology and Pharmacoeconomics, University of Latin America...... Marcela Jirón Rhode Island, USA Working Group w Pharmacoepidemiology Program, Department of Epidemiology, Gillings School of Global Public Health, University of North Patient Engagement in Carolina at Chapel Hill, USA Pharmacoepidemiology ...... Suzanne L West, FISPE w Program for Clinical Pharmacy and Pharmaceutical Sciences, National Chen-Kung University, Taiwan w Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, USA w Talla Padmavathi College of Pharmacy, India

2016 Local Host Committee Development Committee

Kathleen Bennett, Chair Emir Hurley Syd Phillips, Chair Robert Hay Stephen Byrne Deirde McCarthy Kirk Midkiff, Co-Chair Susan Oliveria, FISPE Caitriona Cahir Frank Moriarty Dimitri Bennnett Kate Saltus Brian Cleary Marie O’Dwyer Andrzej Czarnecki, FISPE Nancy Santanello, FISPE Grainne Cousins Manju Sharma Mark Cziraky Jasmanda Wu, FISPE Eva Flahaven Sarah-Jo Sinnott Mark H Epstein Paul Gallagher Amelia Smith Janine Glover Susan Spillane Tamasine Grimes Almath Spooner Martin Henman Mary Teeling Carmel Hughes

32nd

3 ISPE SUPPORTERS

Organizational & Institutional Members

Pharmaceuticals w Department of Pharmaceutical Outcomes & Policy, College of w GlaxoSmithKline Pharmacy, University of Florida w w Sanofi-Aventis Drug Safety Research Unit, Associated Department, School of Pharmacy, Portsmouth University Service Providers w Harvard School of Public Health w RTI Health Solutions w London School of Hygiene and Tropical Medicine Government/Regulatory Agency w McGill Pharmacoepidemiology Research Unit, McGill University w Department of Epidemiology, Lazio Regional Health Service w National Taiwan University Health Data Research Center Academic Programs w Pharmacoepidemiology Program, Department of Epidemiology, w Center for Drug Safety & Effectiveness, Department of UNC Gillings School of Global Public Health, University of North Epidemiology, Johns Hopkins School of Public Health Carolina at Chapel Hill w Center for Drug Safety & Pharmaceutical Health Services w Russian National Society of Evidence-Based Pharmacotherapy Research Graduate Program, University of Maryland School of w Rutgers, The State University of New Jersey Pharmacy w University of Cincinnati, College of Pharmacy w Center for Pharmacoepidemiology Research and Training (CPeRT), Perelman School of Medicine at the University of w University of Massachusetts Medical School Pennsylvania w University of Texas at Austin - College of Pharmacy

Annual Campaign as of August 4, 2016 IN THIS PROGRAM The Society expresses its sincere appreciation to the following supporters listed below for their contributions in 32nd ICPE Agenda honor of the 32nd Annual Meeting (ICPE). Tuesday, August 23...... 12 Wednesday, August 24...... 12 Silvia Alessi-Severini Caitlin Knox Thursday, August 25...... 19 Marc Batrouni Tzuyung Douglas Kou Friday, August 26...... 26 Ulf Bergman, FISPE Erna Kristin Saturday, August 27...... 36 Harshvinder Bhullar Edward Chia-Cheng Lai Sunday, August 28...... 46 Emily Brouwer Angela Lupattelli nd Chiu-Ju Chen Malcolm Maclure 32 ICPE Posters Yoonyoung Choi Frank May, FISPE Poster Guidelines...... 58 Ghadeer Dawwas Deirdre McCarthy Poster Session A...... 59 Corinne de Vries, FISPE Hedvig Nordeng Poster Session B...... 72 Genevieve Gabb Mette Norgaard Poster Session C...... 84 Tobias Gerhard, FISPE Susan Oliveria, FISPE Indexes Alicia Gilsenan Cynthia 'Syd' Phillips Cynthia Girman, FISPE Joseph Priest Abstract Index...... 95 Laurel Habel Christopher Rowan Advertisers Index...... 108 Sean Hennessy, FISPE Montserrat Soriano Gabarro Jacqueline Hugtenburg Suzanne West, FISPE Krista Huybrechts, FISPE Yea-Huei Kao Yang, FISPE Joao Joaquim

32nd

4 ABSTRACT REVIEWERS

Organizational & Institutional Members Heshu Abdullah-Koolmees Suvapun Bunniran Bo Ding Jody Green John Acquavella, FISPE Mehmet Burcu Qian Ding Carlos Grijalva Michael Adena Johanita Burger Rachael DiSantostefano Robert Gross, FISPE Syed Ahmad, FISPE Greta Bushnell Keri Donaldson Susan Gruber Fariba Ahmadizar Anne Butler Macarius Donneyong Line Guenette Onyinye Akunne Melissa Butler Susan DosReis Jason Guertin Silvia Alessi-Severini Suzanne Cadarette Anara Richi Dossa Ezgi Gulmez G. Caleb Alexander Bing Cai Liubov Drozdova Lia Gutierrez Fawaz Alharbi John Cai Cecile Droz-Perroteau Penina Haber Ayad Ali Mona Cai Sascha Dublin Katrina Hagberg M Sanni Ali Gloria Caldwell Mai Duong Eelko Hak Ziyad Almalki Gregory Calip Julie Dupouy Susan Hall Adel Alrwisan Wendy Camelo Castillo Carlos Duran Edward Hammond Thamir Alshammary Wendy Carman Stacie Dusetzina Christian Hampp Keith Altman Deborah Casso Stanley A Edlavitch, Conference Marte Handal Carlos Alves Ola Caster Chair Emeritus Reina Haque Heather Anderson Gillian Caughey Charlotta Ekstrand Janet Hardy Colin Anderson-Smits Lucia Cea Soriano Sohéla El Kebir Raymond Harvey Elizabeth Andrews, FISPE Karynsa Cetin Habab El Kheir Kunihiko Hayashi Daniel Ankrah Edmore Chamapiwa Alan Ellis Sean Hennessy, FISPE Mary Anthony Christina Chambers Soha Elmorsy Rohini Hernandez Eirini Apostolidou Julie Chandler Cheryl Enger Sonia Hernández-Díaz, FISPE Kwame Appenteng T Craig Cheetham Sara Ephross Ulrik Hesse Alejandro Arana, FISPE Chao Chen Mara Epstein Laura Hester Ariel Arias Chih-Ying Chen Daina Esposito Juan Hincapie Castillo Hilary Armstrong Jing Chen Katherine Etter Jarno Hoekman Janet Arrowsmith Li-Chia Chen Nicholas Everage Sarah Hoffman Vijayakumar Arumugam Robert T Chen, FISPE Kevin Fain Veena Hoffman Darren Ashcroft Yingkai Cheng Soulmaz Fazeli Farsani Ken Hornbuckle, FISPE Alex Asiimwe Hsu-Chih Chien James Feinstein Hsing-Chun Hsieh Annlouise Assaf, FISPE Nam-Kyong Choi Germano Ferreira Jason Hsu Magdalene Assimon Yoonyoung Choi Kristian Filion Jason Hu Quazi Ataher Muhammad Abdul Baker Evelyn Flahavan Wei Hua Shahram Bahmanyar Chowdhury James Flory Kui Huang Nicole Baker Christian Fynbo Christiansen Michael Forstner Ting-Ying Huang Clare Barnett Carole Chrvala Joan Fortuny Wan-Ting Huang Dorothee Bartels Sze Ling (Celine) Chui Annie Fourrier-Reglat Adriana Hung Gillian Bartlett-Esquilant Cecilia Chung Jessica Franklin Krista Huybrechts, FISPE Andrew Bate Javier Cid Ruzafa Andrew Freedman Luisa Ibanez Claudia Becker André Coelho Candace Fuller Maria Inacio Sigrid Behr Jacqueline Cohen Donnie Funch Muhammad Shahid Iqbal Nusirat Bello Catherine Cohet Kari Furu Shahed Iqbal Dimitri Bennett Sandrine Colas Genevieve Gabb Lyna Irawati Kathleen Bennett Alexander Cole Joshua Gagne Syed Islam Aurore Bergamasco Paul Coplan David Gagnon Amalia Issa Ulf Bergman, FISPE Nicole Cossrow Arlene Gallagher Geetha Iyer Timothy Beukelman Grainne Cousins Steve Gao Jessica Jalbert Mondira Bhattacharya Deborah Covington Helga Gardarsdottir Cerise James Gouri Shankar Bhattacharyya Cathy Critchlow Madlen Gazarian Nakyung Jeon Kristen Bibeau Caroline Croteau Stewart Geary Susan Jick Stella Blackburn, FISPE Jeffrey Curtis Prethibha George Joao Joaquim Bianca Blanch Andrzej Czarnecki, FISPE Tobias Gerhard, FISPE Kathrin Jobski Michael Blum Anil Dasari Dina Gifkins Catherine Johannes William Blumentals Nabarun Dasgupta Andrew Gilbert, FISPE Ani John Mariette Boerstoel Ghadeer Dawwas David Gilbertson Karin Johnson Rhonda L Bohn, FISPE Marie L De Bruin Malcolm Gillies Meghan Jones Jaclyn Bosco Hilda De Jong Rosa Gini Michele Jonsson Funk Marie Bradley Josta de Jong Francesco Giorgianni Juhaeri Juhaeri Leticia Braga Kitaw Demissie Cynthia Girman, FISPE Linda Kalilani Matthew Breitenstein Petra Denig Natasa Gisev Sigal Kaplan Kimberly Brodovicz Vibha Desai Gunnar Gislason Katherine Kelley Emily Brouwer Angela DeVeaugh-Geiss Cheong Hian Goh Nicole Kellier-Steele David Brown Rahul Dhanda Negar Golchin Judy Kelly 32nd Joshua Brown Julia DiBello Inbal Goldshtein Judith Kempf 5 ABSTRACT REVIEWERS (Cont.)

Farhad Khan Sarah Maechler Susan Oliveria, FISPE Maribel Salas, FISPE Dae Kim Vittorio Maio Busuyi Olotu Nurrul Salwa Saleh Ju Hyeun Kim Anke-Hilse Maitland-van der Margaret Olsen Joseph Samuel Alan Kinlaw Zee Vicki Osborne Gabriel Sanfelix-Gimeno Victor Kiri Jacqueline Major Osemeke Osokogu Veronica Sansing Kristin Kistler Heli Malm Rita Ouellet-Hellstrom Yared Santa-Ana-Tellez Adi Klil-Drori Kenneth Man Ellie Paige Nancy Santanello, FISPE Olaf Klungel Beenish Manzoor Kristin Palmsten Ameet Sarpatwari Caitlin Knox Jialin Mao Georgios Papazisis Niklas Schmedt Oleksii Korzh Zachary Marcum Carolina Pardo Silva Chris Schneiderman Erna Kristin Andrea Margulis Byung-Joo Park, FISPE Fred Schneiweiss Whitney Krueger Morgan Marks Gurumurthy Parthasarathi Renate Schulze-Rath Kiyoshi Kubota, FISPE David Martin Elisabetta Patorno Frank Scott Hiraku Kumamaru Diana Martins Ajinkya Pawar John D Seeger, FISPE Jennifer Kuntz Sergey Martsevich Michael Peng Jodi Segal I Fan Kuo Kayleigh Mason Susana Perez-Gutthann, FISPE Harry Seifert Natalia Kutishenko Shinichi Matsuda Irene Petersen, FISPE Nandini Selvam Jean-Philippe Lafrance Tricia Maxwell Paul Petraro Enrique Seoane-Vazquez Stephan Lanes Frank May, FISPE Cynthia ‘Syd’ Phillips Sumitra Shantakumar Tamar Lasky, FISPE Giampiero Mazzaglia Carlo Piccinni Yu-Hsuan Joni Shao Julie Lauffenburger Mara McAdams DeMarco Camilla Pimentel Natalia Shcherbakova Vivian Law Leah McGrath Ratnakar Pingili Jenny Shen Deborah Layton Ann McMahon Simone Pinheiro Azadeh Shoaibi J Bradley Layton Ann McNeil Manel Pladevall Vila Patrice Simard Hoa Le Gilan Megeed Robert Platt Jason Simeone Michelle Leavy Hemalkumar Mehta Jonathan Plumb Scot Simpson Hristina Lebanova Sotero Mengue Lisa Pont, FISPE Sarah-Jo Sinnott Wanju Lee Joseph Menzin Jennifer Popovic Samantha Sites Wan-Ju Lee Kristin Meyers Gregory Powell Ingrid Sketis Charles Leonard Alexander Michel Nicole Pratt Jonathan Slaughter Adrian Levy Kirk Midkiff Daniel Prieto-Alhambra Janet Sluggett Michael Lewis, FISPE David Miller Danya Qato Meredith Smith Hu Li Donald Miller Scott Quinlan Marlene Smurzynski Lin Li Jea Young Min Thiyagu Rajakannan Rachel Sobel, FISPE Minghui Li Daniel Mines Sudha Raman Pooja Solanki Xiaojuan Li Eileen Ming Darmendra Ramcharran Xue Song Yan Li Tempei Miyaji Cristina Rebordosa Garcia Montserrat Soriano Gabarro Huifang Liang Jingping Mo Suzanne Reed Patrick Souverein David Lilienfeld, FISPE Maja Mockenhaupt Jennita Reefhuis Julia Spoendlin Jennifer Hsiang-Ling Lin Daniela Moga Adriano Reis J Michael Sprafka Mei-Shu Lin Peter Mol Christel Renoux Gayathri Sridhar Nancy Lin Nicholas Moore, FISPE Matthew Reynolds Til Stürmer, FISPE Tzu-Chieh Lin Yola Moride, FISPE Robert Reynolds, FISPE Paul Stang, FISPE Zhen-Fang Lin Ruth Moro Shannon Reynolds Kathryn Starzyk Jennifer Lind Elaine Morrato Margaret Richards Dara Stein Marie Linder Kathleen Mortimer Kathryn Richardson Michael Steinbuch, FISPE Geoffrey Liu Jerald Mullersman Nuria Riera Douglas Steinke Longjian Liu Irene Murimi Mary Ritchey Monika Stender Shusen Liu Erwan Muros Le Rouzic Donna Rivera Barbara Stephenson Wei Liu Sreedharan Nair Elena Rivero Ferrer, FISPE Walter Straus Zhiwen Liu Siva Narayanan Giuseppe Roberto Mark Stuntz Vincent Lo Re, FISPE Juliet Ndukum Christian Rochefort Brandon Suehs Luciane Lopes Mariette Nederlof Andrew Roddam Janet Sultana Sandra Lopez Leon Xinyi Ng Daniel Rosenberg Jens Sundboll Chao Lu Ella Nkhoma Kathryn Rough Mina Tadrous Jennifer Lund Alfi Yasmina Noorsyahdy Elizabeth Roughead, FISPE Ming-Hui Tai Carlotta Lunghi Beth Nordstrom Christianne Roumie Yoshinori Takeuchi Angela Lupattelli Niklas Noren Christopher Rowan Sunning Tao Julie Lynch Mette Norgaard Jason Roy Katja Taxis Theodore Lystig Fredrik Nyberg Katarzyna Sablinska Martina Teichert Erin Macdonald Josephine Ocran Susan Sacks, FISPE Bharat Thakrar Isla Mackenzie Alexis Ogdie Patricia Saddier Trenque Thierry Terri Madison Denise Oleske Ahmed Saeed Bathsheba Thomas 32nd

6 ABSTRACT REVIEWERS (Cont.)

Darren Toh Yizhou Ye Fadia Tohme-Shaya Mellissa Yong Sylvie Tomczyk Hongbo Yuan Emese Toth Zhong Yuan Gianluca Trifirò Emre Yucel Md Jamal Uddin Huifeng Yun Anan Udombhornprabha Akeem Yusuf Christine Ulbricht Jie Zhang Marianne Ulcickas Yood, FISPE Wei Zhou Krishna Undela Yanmin Zhu Hisashi Urushihara Inge Zomerdijk Carla Van Bennekom Patricia van den Bemt Helene van der Meer Angela van der Salm Marleen van Gelder Myrthe Van Herk-Sukel Lionel Van Holle Florence van Hunsel Robert Vander Stichele Vani Vannappagari THE Zdravko Vassilev Sreenivas Phani Veeranki Anila Verma Shilpa Viswanathan David Vizcaya Nataliya Volkova Peter Wahl Cunlin Wang Florence Wang Meng-Ting Wang Shirley Wang Tongtong Wang Wei Wang Ye Wang Grace Wangge Daniala Weir Lisa Weiss Suzanne L West, FISPE Anna Westerlund Bjorn Wettermark Andrew Wiese Corinne Willame James Wilson Barbara Wimmer Lesley Wise Robert Wise, FISPE Yun Sum Wong Mollie Wood Kimberley Woodcroft Alison Wright Chuntao Wu Jasmanda Hsiao-Hui Wu, FISPE Richard Wyss Fenglong Xie Wanning Xu Fei Xue ISPE’S 2017 Takuhiro Yamaguchi Huiying Yang MID-YEAR MEETING Mo Yang April 1-4, 2017 | Royal College of Physicians Yea-Huei Kao Yang, FISPE London, United Kingdom Wai Ping Yau Xibiao Ye 32nd

7 ICPE EXHIBITORS & SUPPORTERS

nd 32 ISPE gratefully acknowledges the generous support of the organizations,

2 0 1 6 institutions and programs listed below. Their contributions helped the Society enhance the scientific program content and increase attendance International Conference on Pharmacoepidemiology & Therapeutic Risk Management at the 32nd ICPE. The Convention Center Dublin

Exhibitors* Annual Meeting Sponsors*

w Analysis Group w Kantar Health Platinum w w BHE Boston Health Economic Mapi Group w HealthCore w Boehringer Ingelheim w Medical Data Vision Co. Ltd. Gold w Clinical Practice Research w Numerus w w Datalink (CPRD) w Optum Amgen Kantar Health w w w Department of Clinical w Oxon Epidemiology Analysis Group Mapi Group Epidemiology, Aarhus w w Bayer Pharma w Merck and Company University Hospital Pharmo w w BHE Boston Health w Numerus w Digital Health Labs Quintiles w Economics w Optum w Dove Medical Press RTI Health Solutions w Biogen w w w The Degge Group and Pfizer Drug Safety Research Unit w DGI, LLC Boehringer Ingelheim w Quintiles w EPID Research w w Department of Clinical w w Truven Health Analytics RTI Health Solutions Eu2P w Epidemiology, Aarhus UBC w Takeda w Evidera University Hospital w Uppsala Monitoring Centre w w w Eli Lilly and Company The Degge Group and DGI, HealthCore w WHO Collaborating w LLC w ICON Plc EPID Research Centre for Drug Statistics w Truven Health Analytics w w Evidera IMS Health GmbH & Co Methodology w w UBC w Japan Medical Data Center IMS Health GmbH & Co

Academic Supporters* Silver w Celgene w Proctor & Gamble w Center for Drug Safety & Effectiveness, Johns Hopkins University w Evalytica w Sanofi Genzyme

w Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida Bronze w Division of Pharmacoepidemiology & Pharmacoeconomics, w Shire Brigham and Women’s Hospital & Harvard Medical School w ISPE Latin-America Chapter * As of August 4, 2016 w ISPE Student Council & Student Chapters w London School of Hygiene and Tropical Medicine Badges w Pharmacoepidemiology Program, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill All attendees at the 2016 ICPE must wear their badges w to all events and conference-related functions including PhD in Pharmacoepidemiology, RCSI Population Health the Welcome Reception/Academic Showcase, scientific w Postgraduate Programme in Pharmacovigilence, Drug Safety sessions, exhibit/poster hall, and social event. Badges will be Research Unit included in the registration material. In some cases, tickets for admission will be required; e.g., courses and guests. w Rutgers, the State University of New Jersey w School of Pharmacy at University College Cork w University of Illinois at Chicago w University of Rhode Island

32nd

8 YOUR SUCCESS IS OUR GOAL

APPROVAL œ ACCESS œ LONGEVITY Partner with us to help your product hit the EVIDERA PRESENTATIONS AT ICPE mark from start to finish.

Evidera, your global leader in generating Pre-Conference Course and communicating evidence of product Selection of Databases for Pharmacoepidemiology Research value to inform healthcare decision making. Reynolds M

Symposium Epidemiology Who to Ask and How? Preference-Based Methods for Benefit-Risk Assessment? Real-World Evidence Marsh K, Hillege HL, Ataher Q, Tervonen T

Evalytica® – Software for Workshop Real-World Data Analytics What’s in a Code? Algorithm Validation in Drug Safety Studies Patient Preferences Nordstrom BL, Weiss S, Lanes S, Wang C Outcomes Research Oral Presentation Health Economics Development and Validation of an Algorithm for Identifying Pediatric Patients with Type 2 Diabetes Meta Research in Claims Data Modeling & Simulation Teltsch D, Swain RS, Farsani SF, Brodovicz KG, Kaspers S, Huse S, Sicignano N, Cristaldi C, Payer Strategy & Communications Nordstrom BL, Bartels DB

Value & Evidence Planning PLUS 5 Posters!

®

evidera.com evalytica.com Tuesday, August 23, 2016 MEETING-A-GLANCE 4:00-6:00pm...... Registration

Wednesday, August 24, 2016

7:00am 8:00am 9:00am 10:00am 11:00am 12:00pm 1:00pm 2:00pm 3:00pm 4:00pm 5:00pm 6:00pm 7:00pm

7:30am - 5:00pm Speakers’ Ready Room (Liffey Mtg Rm 4) 7:30am - 6:00pm Registration (Ground Foyer)

8:00am - 6:00pm | All Day Session (lunch included) Pharmacogenomics in the Real World (Liffey 2A) 8:30am - 12:30pm | Educational Sessions 12:30 - 2:00pm 2:00 - 6:00pm | Educational Sessions Lunch on Adherence to Pharmacotherapy (Wicklow Mtg Rm 1) Your Own Applying Benefit Risk Assessment (Liffey Mtg Rm 3) Introduction to Pharmacoepidemiology (Wicklow Hall 1) Comparative Effectiveness Research (Wicklow Mtg Rm 4) Introduction to Therapeutic Risk Management Program Evaluation Intermediate Database Utilization Workshop (Wicklow Mtg Rm 3) (Liffey Mtg Rm 3) ISPE Newcomers/Early Stage Investigators Workshop Medical Device Epidemiology (Wicklow Mtg Rm 4) (Wicklow Hall 1) Pediatric Pharmacoepidemiology (Wicklow Mtg Rm 3) Practical Skills in Protocol Writing & Computer Programming (Wicklow Mtg Rm 1) 9:00am - 5:00pm ISPE Board of Directors Meeting (Spencer Hotel) Thursday, August 25, 2016

7:00am 8:00am 9:00am 10:00am 11:00am 12:00pm 1:00pm 2:00pm 3:00pm 4:00pm 5:00pm 6:00pm 7:00pm 7:30am - 5:00pm Speakers’ Ready Room (Liffey Mtg Rm 4) 7:30am - 6:30pm Registration Open (Ground Foyer)

8:30am - 12:30pm | Educational Sessions 12:30 - 2:00pm 2:00 - 6:00pm | Educational Sessions 6:00 - 7:30pm 7:30 - 9:30pm Lunch on Welcome Reception/ Students/ Introduction to Drug Utilization (Wicklow Mtg Rm 3) Your Own Advanced Drug Utilization Workshop (Liffey Mtg Rm 1) International Early Career Intermediate Pharmacoepidemiology -- Dealing With Unmeasured Advanced Topics in Pharmacoepidemiology (Liffey Hall 1) Chapter & Academic Professionals Covariates (Wicklow Hall 1) 12:30 - 2:00pm Showcase Meet & Greet New Member/ Epidemiology of Vaccine Safety (Wicklow Mtg Rm 5) (3rd floor) (Ely Bar & Modern Pregnancy Pharmacoepidemiology (Wicklow Mtg Rm 5) Brasserie) New Investigator Field Studies to Add Value in Pharmacoepi (Liffey Mtg Rm 5) Luncheon Pharmacovigilance & Signal Detection (Liffey Mtg Rm 1) By Invitation Only Pharmacoepidemiologic Considerations for Biologics and Propensity Scores in Pharmacoepidemiology (Liffey Mtg Rm 2) (The Liffey) Biosimilars (Wicklow Mtg Rm 3) Registries and Prospective Cohort Studies (Liffey Mtg Rm 5) Regulatory Pharmacoepi (Wicklow Hall 1) Friday, August 26, 2016

7:00am 8:00am 9:00am 10:00am 11:00am 12:00pm 1:00pm 2:00pm 3:00pm 4:00pm 5:00pm 6:00pm 7:00pm

7:00am - 5:00pm 10:00- 12:15 - 1:15pm 3:00- 5:00 - 6:30pm 6:30 - 7:15pm Speakers’ Ready Room (Liffey Mtg Rm 4) 10:30am Spotlight 3:30pm Symposia & SIGs Break/ Poster Break/ Workshops Adherence 7:00am - 6:00pm Posters/ Session Posters/ Catch the Wave: (Wicklow Mtg Rm 2B) Registration Open (Ground Foyer) Exhibits Exhibits (3rd floor; lunch Diffusion of AsPEN (The (The 7:00 - 8:00am 8:00am - 6:00pm available) Methodological (Wicklow Mtg Rm 3) Cross- Exhibits/Posters (The Forum) Forum) Forum) Innovation Biologics National (Auditorium) Comparison 8:00 - 8:30am 10:30am - Noon Noon - 1:30pm 1:30 - 3:00pm 3:30 - 5:00pm (Wicklow Mtg Patient Engagement of Drug Welcome Concurrent Sessions Lunch/ Concurrent Sessions Plenary Session: Rm 2A) 7:15 - 9:00pm Poster Session A/ in Observational Utilization (The Auditorium) Meascàn de Meds: Bittersweet: Trends Real World BRACE PDS Editorial -Mary Ritchey Exhibits Pharmacoepidmiology Board-By Invitation (Liffey Brdrm 3) Utilization and Trends and Treatments in Effectiveness: How Research (EcoCem) -Kathleen E. (The Forum) (Spencer Hotel) 7:00 - 8:00am (The Liffey A) Diabetes Effective is It? (The Liffey B) Bennett CER Poster Session BRACE Yourself (The Liffey A) (The Auditorium) -Sonia Lunch Roundtable Impact of (Wicklow Mtg Rm 4) A Set-Up (The Liffey B) Discussions Cancer: Around the Pharmacovigilance (The Forum & Hernández- World in Databases Databases Diáz Adverse Events of (Liffey Mtg Rm 1) (The Liffey A) (Liffey Mtg Rm 1) 3rd Floor) Cardiovascular Treat- (The Liffey B) Membership Committee ment: Head to Toe Playing Catch-up Big Data, Big Picture - Drug Utilization/ 7:00 - 8:00am 8:30 - 10:00am (Wicklow Hall 2) (Wicklow Mtg Rm 3) in Pediatric Data Visualization HSR AsPEN SIG Plenary Session: of Health (Liffey Brdm 1) Pregnancy Global Development Pharmacoepidemiology (Wicklow Mtg Rm 1) Representative Committee (Wicklow Hall 2) (Wicklow Hall 2) and Beyond Medical Devices 7:00 - 8:00am 7:30 - 8:15am Sampling in (Liffey Hall 2) (Wicklow Mtg Rm 4) Patients, Prescriptions, Drug Utilisation in (Liffey Brdrm 3) Coffee & Tea Chapter Mtgs. Pharmacoepidemiology Older Populations Keeping an “I” in Fellowship & Awards Policy & Pennies (The Forum) Famarco (The Auditorium) (Liffey Hall 2) (Liffey Hall 2) Medications in EpiEnRed Opioid Use Committee Pregnancy (Wicklow (Liffey Hall 1) (Wicklow Mtg Rm 5) Adherence: Does Randomization (Liffey Mtg Rm 3) Staying the Course Mtg Rm 3) Data Lost and Found Finance Committee Work? Selection Bias in (Liffey Hall 1) Pragmatic Randomized Oncology Latin America (The Auditorium) (Wicklow Mtg Rm 2A) (Liffey Brdrm 1) Study Design Clinical Trials (Wicklow Public Policy Committee Considerations to (Liffey Hall 1) Molecular Epi. Mtg Rm 4) (Wicklow Mtg Rm 2B) Address Confounding Validation Using (Liffey Mtg Rm 5) Gulf Region Student Council (The Auditorium) U.S. Medicare Pediatrics (Wicklow (Wicklow Mtg Rm 1) Administrative Claims (Wicklow Mtg Rm 5) 32nd Mtg Rm 5) Data (Liffey Mtg Rm 2) Vaccines (Liffey Mtg Rm 2) 10 MEETING-A-GLANCE

Saturday, August 27

7:00am 8:00am 9:00am 10:00am 11:00am 12:00pm 1:00pm 2:00pm 3:00pm 4:00pm 5:00pm 6:00pm 7:00pm

7:00am - 5:00pm Speakers’ Ready Room (Liffey Mtg Rm 4) 11:45am- 7:00am - 6:00pm 4:00 - 5:30pm 5:30- 6:15pm 12:45pm 7:30 - 11:30pm Registration Open (Ground Foyer) Symposia & Council Spotlight Poster Social Event Workshops Session Meetings at Guinness 7:00 - 8:00am 8:00am - 6:00pm (3rd Floor; lunch Using “Big Data” Academic Storehouse Poster Exhibits/Posters (The Forum) available) in Early Safety (Liffey Mtg Rm 1) (Shuttle bus to the Session B Evidence Gathering Storehouse from Set-Up 8:00 - 9:30am 10:00 - 11:30am 11:30am - 1:00pm 1:00 - 2:30pm 2:35 - 3:30pm (The Liffey A) Government/ (The Forum & Concurrent Sessions Plenary Session: Lunch/ Concurrent Sessions Annual Regulatory the Convention 3rd Floor) Poster Session B/ Meeting of Optimal Use of (Wicklow Centre and to Patient Voice in CV Effectiveness: How Psychotropics in Exhibits ISPE Members Data from United Mtg Rm 3) ISPE meeting to Fix a Broken Heart 7:00 - 8:00am Pregnancy Clinical and (The Forum) and Awards Kingdom Electronic hotels from the (The Liffey A) Pharmacoepidemiologic (The Liffey A) Ceremony Health Records Industry/Service Coffee & Tea Round Table 3:30- Storehouse) Research (The Auditorium) (The Liffey B) Provider (The Forum) Pay Attention to Pain: Discussions Antispsychotic Use 4:00pm (The Auditorium) What’s in a Code? (Wicklow ADHD and Pain (Liffey Mtg Rm 1) Across the Life Span Break/ Algorithm Validation Mtg Rm 4) Treatment DUS (The Liffey B) Posters/ Education in Drug Safety (The Liffey B) To Take or Not to Take? Exhibits Student Council 9:30- Committee Meeting Studies (Wicklow Hall 2) (The & Chapters 10:00am (Wicklow Hall 2) Psychotropic Trends (Wicklow Mtg Rm 3) Forum) (Wicklow Break/ Drug-Induced Kidney on Populations Epidemiological Posters/ Development and Liver Injury Mtg Rm 5) from a Multinational Approach to Rare Exhibits Committee (Liffey Hall 2) Perspective (The (Wicklow Mtg Rm 4) Disease Research (Wicklow Hall 2) Forum) Biologics: (Liffey Hall 2) Publications & “Miracle Drug” Evidence Synthesis A Sticky Subject: Communications (Liffey Hall 1) in Drug Safety Diabetes Safety Committee (Liffey Hall 2) A Methods Coddle Evaluation and (Wicklow Mtg Rm 2A) (The Auditorium) Regulation Broken & Torn (Liffey Hall 1) (Liffey Hall 1) Bylaws Committee Meeting Effectiveness and Identification and (Wicklow Mtg Rm 2B) Safety of Biosimilar Validation of Outcomes Medicines (The Auditorium) (Liffey Mtg Rm 2) Perspectives from Causal Inference in the Era of Big (Healthcare) Data (The Auditorium) Sunday, August 28, 2016

7:00am 8:00am 9:00am 10:00am 11:00am 12:00pm 1:00pm 2:00pm 3:00pm 4:00pm 5:00pm 6:00pm 7:00pm

7:00am - 3:30pm Speakers’ Ready Room (Liffey Mtg Rm 4)

7:00am - 4:30pm 3:15 - 4:45pm 4:45 - 5:45 - 12:15 - 1:15pm Concurrent 5:30pm Registration Open (Ground Foyer) Spotlight Poster 6:30pm Sessions The Final 2017 ICPE Session Word 7:00 - 8:00am 8:00am - 1:45pm (3rd Floor; lunch Practice of Scientific Poster Exhibits/Posters (The Forum) available) Epidemiology in •Spotlight Program Session C Pregnancy Studies Poster Committee Set-Up 8:30 - 10:00am 10:30am - Noon Noon - 1:30pm 1:30 - 3:00pm (The Liffey A) Awards Meeting (EcoCem) (The Forum & Concurrent Sessions Plenary Session: Lunch/Poster Symposia & Session C/ Workshops Disease Burden •2017 3rd Floor) From Eve to… Multiple Database Meetings Exhibits (The Forum) from Clinical (The Liffey A) Study Design Pharmacoepidemiology Databases 7:00 - 8:00am Adjournment My Achy Breaky Heart: (The Auditorium) and Risk Management (The Liffey B) (The Coffee & Tea Noon - 1:30pm Pllanning Diabetes and CVD CV Adverse Events: Auditorium) (The Forum) ISPE Board of (The Liffey A) (The Liffey B) Directors Luncheon Affairs of the Heart Keeping Up - A Potpourri 10:00- (Liffey Mtg Rm 1) Clinical and Analytic (Wicklow Hall 2) (Wicklow Hall 2) 10:30am Considerations in 3:00- Adverse Outcomes Break/ Observational Database of Glucocorticoid and Adverse Outcomes and Posters/ 3:15pm Infectious Diseases Studies Break Immunomodulator Exhibits (The Liffey B) Use (Liffey Hall 2) (The (Ground Foyer) (Liffey Hall 2) Vaccines: Hit Me with Forum) Transitioning to ICD-10 Your Best Shot (Wicklow Hall 2) Thin Blood: Anticoagulants (Liffey Hall 1) Preference-Based (Liffey Hall 1) Analytic Approaches for Methods for Benefit- Is It Safe Enough? Controling Confounding Risk Assessment (The Auditorium) and Exposure (Liffey Hall 2) Misclassification Implications for (The Auditorium) Patients, Industry and Regulators (Liffey Hall 1) Pattern Discovery in Observational Health Data (The Auditorium)

32nd

11 PRE-CONFERENCE | TUESDAY, AUGUST 23

4:00-6:00pm Registration (Ground Foyer) If you will attend a course on Wednesday, we highly recommend that you register on Tuesday evening to avoid delays.

PRE-CONFERENCE | WEDNESDAY, AUGUST 24

7:30am-5:00pm EDUCATIONAL SESSIONS: ALL DAY COURSE (Ticket required) Speaker Ready Room 8:00am-6:00pm Pharmacogenomics in the Real World 2.0 (Liffey Meeting Room 2A) (Liffey Meeting Room 4) Content Course Directors This course will focus on the essentials every Amalia M Issa, University of the Sciences in 7:30am-6:00pm pharmacoepidemiologist should know about real Philadelphia Registration world applications of pharmacogenomics including Anke-Hilse Maitland van der Zee, Utrecht (Ground Foyer) precision medicine, companion diagnostics, the University (Individuals attending a biomarker development pipeline, common genomic Course Faculty observational designs, and the intersection of morning pre-conference Gillian Bartlett, McGill University course should arrive by big data with pharmacogenomics. This course Bruce Carleton, University of British Columbia 7:30am to register.) has expanded to include a broader definition of Marissa Dolled-Filhart, Merck Research genomic and other biomarkers, including both Laboratories 9:00am-5:00pm germ line and somatic changes. There will be short Alexander Doney, University of Dundee ISPE Board pre-course orientating videos on the ISPE website Kelly Filipski, National Cancer Institute that will cover basic definitions and concepts in of Directors Andrew Freedman, National Cancer Institute preparation for the main course, allowing the main Stephen Kimmel, University of Pennsylvania Meeting course to focus more on practical applications. Geoffrey Liu, University of Toronto (Spencer Hotel) A variety of instructional techniques (including Colin Palmer, University of Dundee didactic teaching, scenario-based advanced and Open to ISPE members; David Pulford, GlaxoSmithKline members may contact basic break-out sessions, small group round-table Wei Zhou, MD, Merck Research Laboratories [email protected] if discussions, bring your own question/ask the they would like to attend. expert sessions, and an interactive debate) will be used to keep attendees engaged throughout the day-long course. For additional information about

the educational HALF-DAY MORNING COURSES (Ticket required) courses, visit 8:30am-12:30pm pharmacoepi.org. Pediatric Pharmacoepidemiology (Wicklow Meeting Room 3)

Content Course Faculty The increasing use of medications by children Tamar Lasky, FISPE, MIE Resources and the history of excluding children from Ann W McMahon, U.S. Food and Drug clinical trials have created the need for pediatric Administration pharmacoepidemiology, a sub-specialty within Rachel E Sobel, FISPE, Pfizer Inc. pharmacoepidemiology. Unique challenges Susan dosReis, University of Maryland School in studying children, accessing data, defining of Pharmacy Department of Pharmaceutical outcomes, and designing pediatric studies Health Services Research will be discussed. This half-day course will introduce participants who have a good understanding of pharmacoepidemiology to the specific methodologic issues arising in pediatric pharmacoepidemiology and operational approaches used to study medications in children.

32nd

12 Real-world insight into drug safety and epidemiology.

Proven epidemiology research expertise powered by one of the largest healthcare data repositories.

HealthCore is on the frontline of observational research aimed at uncovering vital evidence on the utilization, safety and effectiveness of biopharmaceuticals and devices in large, real-world patient populations. C

M Our multi-disciplinary team of pharmacoepidemiologists brings a broad range of scientific expertise and operational Y experience to the timely and accurate execution of safety and risk management studies in the post-marketing CM real-world setting.

MY SM CY The HealthCore Integrated Research Environment (HIRE ) allows for the augmentation of automated claims with

CMY clinical data obtained from medical records, electronic health records, physicians, and patients – making it a rare

K and valuable resource for conducting medical product safety and risk management studies.

• Descriptive epidemiology (natural history of disease, burden of illness) • Drug and vaccine post authorization safety studies • Risk management and REMS survey studies • Active surveillance of new medical products and adverse events • Development and medical record validation of case-identifying algorithms • Multi-database study design, coordination, and execution • Data linkage capability • Systematic literature reviews • Strategic consulting

Visit Booth #5 during ICPE to learn about our full-service research solutions or contact us at [email protected].

www.healthcore.com

Safety & Epidemiology Research | HEOR | Comparative Effectiveness Research | Late Phase Research Medical Record & Survey-Based Research | Pragmatic Clinical Trials

123 Justison Street • Suite 200 • Wilmington, DE 19801 • +1 (302) 230 2000 • With offices in greater Boston and the DC Metro area. PRE-CONFERENCE | WEDNESDAY, AUGUST 24

HALF-DAY MORNING COURSES (CONT.)

8:30am–12:30pm Introduction to Pharmacoepidemiology (Wicklow Hall 1)

Content Course Faculty This half-day course will provide participants with Almut Winterstein, FISPE, University of Florida College of Pharmacy a short introduction to the basic principles and Jennifer Lund, Gillings School of Global Public Health, University of North concepts of pharmacoepidemiology. The course Carolina at Chapel Hill includes lectures on cohort studies, case-control Tobias Gerhard, FISPE, Ernest Mario School of Pharmacy, Rutgers University studies, and bias & confounding.

Medical Device Epidemiology (Wicklow Meeting Room 4)

Content Course Faculty This course provides a foundation for medical Colin Anderson-Smits, U.S Food and Drug Administration device epidemiology and its application to the real Kourtney Davis, GlaxoSmithKline PLC world. The course will incorporate didactic lectures Chantal Holy, Johnson and Johnson and interactive case studies that highlight novel Katherine Etter, Johnson and Johnson medical devices and combination products. Jessica Jalbert, LA-SER Group & Weill Cornell Medical College Mary E Ritchey, RTI Health Solutions Michael Steinbuch, FISPE, Procter and Gamble

Introduction to the Evaluation of Therapeutic Risk Management Programs (Liffey Meeting Room 3)

Content Course Faculty This course presents an overview of European Gerald Dal Pan, Center for Drug Evaluation and Research, U.S. Food and and US risk management principles, with a Drug Administration focus on methods and examples for evaluating Almath Spooner, Health Products Regulatory Authority, Ireland and Vice the effectiveness of risk minimization measures. Chair EMA’s PRAC The didactic section includes speakers from Elaine Morrato, Colorado School of Public Health European and US regulatory, industry and research Meredith Smith, Global Patient Safety at Amgen communities to present background, trends in Judith Jones, FISPE, The Degge Group, Ltd regulatory requirements, and examples of effective Lesley Wise, Takeda Development Centre Europe Ltd evaluation techniques. The workshop section Alicia Gilsenan, RTI Health Solutions asks participants to work in groups to develop an evaluation plan for one of two health outcomes of interest for a hypothetical product. The groups present their plans from this case study to the “regulatory panel (faculty)” for feedback and discussion.

32nd

14 PRE-CONFERENCE | WEDNESDAY, AUGUST 24

HALF-DAY MORNING COURSES (CONT.)

Adherence to Pharmacotherapy (Wicklow Meeting Room 1)

Content Course Faculty This course will provide an overview of measurement issues to be considered Robert Gross, FISPE, University of Pennsylvania when designing and conducting an adherence study. The course will cover the Perelman School of Medicine following topics: Jacqueline Hugtenburg, Department of Clinical • Description of different constructs of adherence that can be measured: Pharmacology and Pharmacy, VU University initiation implementation and persistence. Medical Center, Amsterdam, Netherlands • Selection of measurement techniques according to the construct being Niteesh Choudhry, Harvard Medical School; measured. Center for Healthcare Delivery Sciences, • Strengths and limitations of commonly used techniques: self-reports, Brigham and Women’s Hospital medical/pharmacy electronic data and microelectronic monitoring data, Jean-Pierre Grégoire, FISPE, Laval University, among others. Québec City, Canada • Discussion of analysis issues: choice of the duration of an adherence Petra Denig, University Medical Center interval, taking multiple drug regimens and switches into account, various Groningen, The Netherlands approaches to summarizing adherence data from the different techniques, and linking adherence data to relevant outcomes.

It begins with a promise to discover medicines that make life better.

Since 1876, we have worked tirelessly to discover medicines that make life better, finding ways to come through no matter the odds. From the development of insulin to the discovery of new treatments for mental illness, we have pioneered breakthroughs against some of the most stubborn and devastating diseases. We bring this same determination to our work today, uniting our expertise with the creativity of research partners across Hong Hu, Research Advisor, the globe to keep finding ways to make life better. Lilly Research Laboratories

To find out more about our promise, visit www.lilly.com/promise. 2016 CA Approved for External Use PRINTED IN USA ©2016, Eli Lilly and Company. ALL RIGHTS RESERVED.

32nd Lilly-ICPE-2016-Final-Program-Ad.indd 1 4/25/16 9:54 AM

15 PRE-CONFERENCE | WEDNESDAY, AUGUST 24

HALF-DAY AFTERNOON COURSES (Ticket required)

12:30–2:00pm Lunch on Your Own

2:00–6:00pm ISPE Newcomers/Early Stage Investigators Workshop (Wicklow Hall 1)

Content Course Faculty This course is aimed at early stage pharmacoepidemiologists who have been Vincent Lo Re III, FISPE, Center for in the field for less than 3 years. Participation will lead to enhancement in skills Pharmacoepidemiology Research & Training, (i.e., development of mentor-mentee relationships, research presentation, and University of Pennsylvania manuscript writing) that are crucial to early success in pharmacoepidemiology. Caitlin Knox, Quintiles We will also discuss important aspects of early stage professional development Tarek Hammad, FISPE, Merck Research in careers in government/regulatory science, academia, and industry. Laboratories Sengwee Darren Toh, Harvard Medical School & Harvard Pilgrim Health Care Institute Stella Blackburn, FISPE, Quintiles Irene Petersen, FISPE, Institute of Epidemiology & Health, University College London Quazi Ataher, Pfizer

Comparative Effectiveness Research: CER and its Role in Adaptive Licensing (Wicklow Meeting Room 4)

Content Course Faculty Increasingly, regulators are moving towards adaptive licensing, which is the Joshua Gagne, Division of progressive approval or authorization of a medical product characterized Pharmacoepidemiology and by iterative phases of data gathering and regulatory evaluation. Rigorous Pharmacoeconomics, Department of Medicine, comparative effectiveness research, which involves generating “real world” Brigham and Women’s Hospital and Harvard evidence about the benefits and risks of medical products, can play a key role Medical School in informing adaptive licensing decisions. This year’s course will start with an Olaf Klungel, Division of Pharmacoepidemiology overview of methodological aspects related to CER and then will narrow the & Clinical Pharmacology, University of Utretch focus to how evidence from comparative effectiveness research can support Danica Marinac-Dabic, FISPE, Division adaptive licensing. of Epidemiology, Center for Devices and Radiological Health, U.S. Food and Drug Administration

Intermediate Database Utilization Workshop: Using Pharmacoepidemiology Database Resources to Address Drug Safety Research (Wicklow Meeting Room 3)

Content Course Faculty This highly interactive workshop will involve participants in the following topics: Gillian Hall, FISPE • Examine the use of database resources in pharmacoepidemiology Matthew Reynolds, Evidera research; Brian Sauer, University of Utah • Define the different types of data resources available for Elieen Ming, Epi Excellence pharmacoepidemiology and the selection criteria to select the most Fergus Caskey, North Bristol, NHS Trust appropriate resource, workshop will strengthen the concepts discussed through participant interaction; • Assess the quality of electronic medical record data • Conduct validation studies through a variety of approaches • Examine characteristics of available resources for data linkage between pharmacoepidemiology resources particularly to patient registry data resources

32nd

16 PRE-CONFERENCE | WEDNESDAY, AUGUST 24

HALF-DAY AFTERNOON COURSES (CONT.)

Applying Benefit-Risk Assessment in Practical Skills in Protocol Writing and Computer the Context of Regulatory Submission Programming Relevant to Pharmacoepidemiology of New Molecular Entities (Wicklow Meeting Room 1) (Liffey Meeting Room 3) Content Content Pharmacoepidemiologic studies that involve the use of electronic healthcare · Presentation of Benefit-Risk and patient data have complex and unique characteristics that must be taken into preference information for regulatory consideration when executing the studies. This highly interactive course will interactions, especially new molecular engage participants in the following topics: submissions 1. Pre-specifying study components in a protocol, including design, analysis, · Overview of expectations for developing conduct, and reporting of the study, along with a science-based rationale and presenting the structure and content of for the choices pertaining to these components. Benefit-Risk information 2. Translating elements of the study protocol into SAS programming · Quantitative methods for Benefit-Risk assessment Course Faculty · When and how to use patient preference Christian Hampp, U. S. Food and Drug Administration, Center for Drug information to inform regulatory decision- Evaluation and Research, Office of Pharmacovigilance and Epidemiology, making Office of Surveillance and Epidemiology, Division of Epidemiology II Jessica Jalbert, LASER Analytica, Weill Cornell Medical College Course Faculty Chih-Ying (Natasha) Pratt, U. S. Food and Drug Administration, Center Tarek A Hammad, FISPE, Merck Research for Drug Evaluation and Research, Office of Pharmacovigilance and Laboratories Epidemiology, Office of Surveillance and Epidemiology, Division of Juhaeri Juhaeri, Sanofi Epidemiology II Brett Hauber, RTI Health Solutions Nicole Pratt, Quality Use of Medicines and Pharmacy Research Centre, Rebecca Noel, Eli Lilly and Company Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia Soko Setoguchi, FISPE, Duke Clinical Research Institute

MEDICAL BREAKTHROUGHS MAY COME OUT OF THE LAB. BUT THEY BEGIN IN THE HEART.

For more than a century, a very special passion has driven the people of Merck. Our goal is to develop medicines, vaccines, and animal health innovations that will improve the lives of millions. Still, we know there is much more to be done. And we’re doing it, with a long-standing commitment to research and development. We’re just as committed to expanding access to healthcare and working with others who share our passion to create a healthier world. Together, we’ll meet that challenge. With all our heart.

For more information about getting Merck medicines and vaccines for free, visit merckhelps.com or call 800-727-5400. Copyright © 2016 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All Rights Reserved. CORP-1060080-0102 01/16

32nd

17 ICPE_2016_AG_Final_Outlines.indd 1 7/8/2016 8:56:40 AM PRE-CONFERENCE | THURSDAY, AUGUST 25

7:30am–5:00pm EDUCATIONAL SESSIONS: Speakers’ HALF-DAY MORNING COURSES (Ticket required) Ready Room (Liffey Meeting 8:30am–12:30pm Room 4) Introduction to Drug Utilization Research (Wicklow Meeting Room 3)

7:30am–6:30pm Content Course Faculty Registration This educational session provides an overview of Katja Taxis, University of Groningen, The

(Ground Foyer) drug utilisation research and presents essential Netherlands methods used. The session includes interaction Hanne Strom, WHO Collaborating Centre for with participants, question, and answer sessions Drug Statistics Methodology, Norwegian and discussion during and at the end of each Institute of Public Health, Oslo, Norway presentation. At the end of the session, the Björn Wettermark, Centre for participant will be exposed to: Pharmacoepidemiology, Karolinska Institute, • Description of the theoretical framework and Stockholm, Sweden Andrew Gilbert, FISPE, practical applications of different methods University of South illustrated using selected examples Australia, Adelaide, Australia • Classification systems used in drug utilisation monitoring and research • Limitations of data sources and methods • Interpretation of aggregate and individual- based data, variation and change • Importance of drug utilisation research for public health and implications for policy decisions

PATIENT-CENTERED SOLUTIONS AT MAPI, PATIENTS ARE AT THE HEART OF EVERYTHING WE DO

Real World Evidence Mapi Group believes that listening to patients is the crucial element in improving world Real World Strategy & Analytics health. Our wide range of offerings, including strategic consulting and related services Language Services Strategic Regulatory Services in Epidemiology and Product-Related Risk Management, helps ensure that the voice of Mapi Research Trust the patient is heard throughout the development process.

www.mapigroup.com Visit us at Booth 20 for more information Health Research & Commercialization ™

32nd

19 PRE-CONFERENCE | THURSDAY, AUGUST 25

HALF-DAY MORNING COURSES (Cont.) (Ticket required)

8:30am–12:30pm Intermediate Pharmacoepidemiology -- Dealing With Unmeasured Covariates (Wicklow Hall 1)

Content Course Faculty Covariates are often poorly measured or not measured at all. Unmeasured Alexander M Walker, FISPE, World Health confounders produce bias, and they lead to divergent results in studies that Information Science Consultants ought to be near replicates of one another. Unmeasured intermediates can lead to “effects” that run contrary to simple biological cause. This course will classify the options for dealing with unmeasured covariates in study design and analysis. Students will see and be able to discuss examples of self-controlled case series and matched designs, propensity-balancing for proxy-variable control, and instrumental variable analyses.

Propensity Scores in Pharmacoepidemiology (Liffey Meeting Room 2)

Content Course Faculty Issues of bias and confounding relate to study design and analysis in the John Seeger, FISPE, Optum setting of non-random treatment assignment where compared subjects might Jeremy Rassen, Aetion differ substantially with respect to comorbidities. Failing to address a lack of balance in the covariates between treated and comparison groups can produce confounded estimates of treatment effect. Faculty will explain how propensity scores can be used to mitigate confounding through standard observational approaches (restriction, stratification, matching, regression, or weighting). The advantages and disadvantages of standard adjustment relative to propensity score-based methods will be discussed. Details of propensity score methodology (variable selection, use, and diagnostics) will also be discussed.

Pharmacovigilance & Signal Detection (Liffey Meeting Room 1)

Content Course Faculty This half-day course will introduce participants to the principles of surveillance Andrew Bate, Pfizer Ltd in pharmacovigilance with a focus on quantitative aspects and recent advances Gianluca Trifirò, University of Messina & in the field. The course will cover classical pharmacovigilance signal detection Erasmus University Medical Center using spontaneous adverse event reports, quantitative signal detection methods Joshua Gagne, Division of Pharmacoepidemiology for electronic medical record and claims data, and international initiatives, and Pharmacoeconomics, Department of including the EU-ADR project and the US FDA’s Sentinel program, aimed at Medicine, Brigham and Women’s Hospital and using routinely collected electronic healthcare data to conduct signal detection Harvard Medical School and prospective medical product safety monitoring. The course will involve Stephen Evans, FISPE, London School of lectures with ample opportunities for questions and discussion. Use of social Hygiene & Tropical Medicine media for signal detection will also be discussed.

Registries and Prospective Cohort Studies (Liffey Meeting Room 5)

Content Course Faculty This course will provide an overview of the theory and practice, including Nancy A Dreyer, FISPE, Quintiles field methods, for the design, execution and interpretation of registries and Christina D Mack, Quintiles prospective studies. Topics include regulatory, methodological and logistical Sonia Hernández-Díáz, FISPE, Department of challenges and how studies are evaluated for specific purposes. Special Epidemiology, Harvard T.H. Chan School of applications relating to pregnancy registries, emerging therapies and Post- Public Health Authorization Safety Studies will be reviewed, as well as current guides to Deborah Layton, Drug Safety Research Unit, quality for prospective studies. An interactive case study will be presented to Portsmouth University allow attendees to engage in critical reflection.

32nd

20 PRE-CONFERENCE | THURSDAY, AUGUST 25

HALF-DAY MORNING COURSES (Cont.)

8:30am–12:30pm Modern Pregnancy Pharmacoepidemiology: Methodological Challenges in Exposure Measurement and Implications for Study Design and Analysis (Wicklow Meeting Room 5)

Content Course Faculty In this half day course, we will discuss study design and analysis aspects Andrea Margulis, RTI Health Solutions related to exposure in studies of drug utilization and drug safety in pregnancy. Brian Bateman, Brigham and Women’s Hospital, The course format will consist of four short methods-focused presentations Massachusetts General Hospital, Harvard by faculty with Q&A along with two break-out sessions giving participants the Medical School opportunity to discuss and report back on the assigned readings, and a short Krista Huybrechts, FISPE, Brigham and faculty-moderated session wrap-up. Women’s Hospital and Harvard Medical School Helle Kieler, Karolinska Institutet The content of this course has changed from last year´s. While in 2015 the course provided an overview of issues that are particular to pregnancy safety research, this year the focus will be on specific challenges related to exposure measurement. Some of the topics to be covered include defining the etiologically relevant time window (including issues related to LMP estimation and differential opportunity for exposure), how to define exposure (e.g., number of prescriptions, days supply overlap, patient recall, drug class or individual drugs), how to define the comparator group (e.g., unexposed with same condition, active comparator, exposed during a different time window in pregnancy), dose-response analyses, value of positive controls (i.e., assess known associations between the exposure and an outcome), and sensitivity analysis evaluating potential bias associated with exposure misclassification. Advantages and disadvantages of different approaches will be discussed.

Value through Innovation

Even with more than 128 years of experience, we remain intensely curious. For the sake of future generations. Boehringer Ingelheim has always remained true to its character as an independent family-owned company, today operating with 145 affiliates. Research is our driving force. And we equate success as a pharmaceutical company with the steady introduction of truly innovative medicines. With more than 47,500 employees worldwide and a track record built up in more than 128 years, we are continuously dedicated to improving the outlook for a healthier life. Global Epidemiology contributes substantially to achieving these goals by evaluating target populations and our products in real world settings. Would you like to join our epidemiological research group? Please send an e-mail to [email protected] indicating your interest. www.boehringer-ingelheim.com

32nd

21 PRE-CONFERENCE | THURSDAY, AUGUST 25

EDUCATIONAL SESSIONS: HALF-DAY AFTERNOON COURSES (Registration required)

12:30-2:00pm 2:00–6:00pm Lunch on Advanced Topics in Pharmacoepidemiology (Liffey Hall 1) Your Own Course Instructors/Presentations: Heather Whitaker, The Open University: Advances 12:30-2:00pm Kenneth J Rothman, FISPE, RTI Health Solutions: in the Self-controlled Case Series Method New Member/ The Significance of the ASA Statement on Suzanne Cadarette, University of Toronto: New Investigator Significance and P-Vales Diffusion of Methods Innovation in Robert Glynn, Pharmacoepidemiology Luncheon Brigham and Women’s Hospital and Harvard Medical School: Competing Risks in (The Liffey) Pharmacoepidemiology Ticket Required. By Invitation Only. Advanced Drug Utilization Research (Liffey Meeting Room 1)

Content Course Faculty This interactive educational program includes Petra Denig, University of Groningen presentations, question and answer sessions and a Eimir Hurley, Trinity College Dublin final discussion with the faculty panel. The session Libby Roughead, FISPE, School of Pharmacy will involve participants in the: and Medical Sciences, University of South Australia • Use of drug utilisation information from Lisa Pont, FISPE, Australian Institute of Health administrative health data to improve Innovation, Macquarie University medicines use • Use of prescribing quality indicators to assess prescribing • Application of principles derived from Health Services and Implementation Research to the design of a clinical intervention • Methods for evaluating the effect of clinical or policy interventions • Interpretation of the evaluation data and dissemination of results Pharmacoepidemiologic Considerations for Biologics and Biosimilars (Wicklow Meeting Room 3)

Content Course Faculty This interactive workshop will involve participants in Nancy A Dreyer, FISPE, Quintiles Real World & the following topics: Late Phase Research and University of North Carolina • Update on the current landscape of biologics Thijs Giezen, Foundation Pharmacy for Hospitals and biosimilars in Haarlem, Haarlem, the Netherlands; Expert • Review regulatory guidelines, particularly at the Medicines Evaluation Board in the focused on postmarketing, pharmacovigilance, Netherlands; Member of the EMA Biosimilars and risk management requirements for Working Party biologics and biosimilars Gianluca Trifirò,University of Messina and • Understand challenges and methodological Erasmus Medical Center considerations when conducting post- Brian D Bradbury, Amgen, Inc. and University of marketing studies of biologics and biosimilars. California Los Angeles School of Public Health • Discuss primary data collection and use Jaclyn L F Bosco, Quintiles Real World & Late of multiple data sources for evaluating Phase Research and Boston University School comparative safety and effectiveness of of Public Health biologics and biosimilars

32nd

22 PRE-CONFERENCE | THURSDAY, AUGUST 25

HALF-DAY AFTERNOON COURSES (Cont.)

2:00–6:00pm Epidemiology of Vaccine Safety (Wicklow Meeting Room 5)

Content Course Faculty This half-day course aims to establish an understanding of some of the ways in S Rizwan Ahmad, FISPE, Georgetown University which vaccine safety is monitored after licensure, including passive surveillance Robert T Chen, FISPE, Centers for Disease methods, common observational vaccine-safety study designs and methods, Control and Prevention active safety surveillance using sequential analysis, and investigation of signals Steven Bailey, Pfizer that arise from active surveillance. The course will involve lectures with ample Patricia Saddier, Merck opportunities for audience participation (questions and discussion). Martin Kuldorff, Harvard Pilgrim Health Institute Katherine Yih, Harvard Pilgrim Health Institute

Using Field Studies to Value-add in Pharmacoepidemiology (Liffey Meeting Room 5)

Content Course Faculty This course provides basic theory and practical tips in conducting Veronika Wirtz, Boston University School of pharmacoepidemiologic studies when required information is not captured in Public Health databases or when large databases are not available. Common study designs Katja Taxis, University of Groningen used to collect data through observation, medical records or questionnaires will Annie Fourrier-Reglat, University Bordeaux be presented and the strengths and limitations of working without large databases Lisa Pont, FISPE, Australian Institute of Health discussed. Hands on experience via a workshop will expose course participants to Innovation, Macquarie University different study designs and rich discussions on how to answer relevant questions about safety and utilization of medicines in primary and secondary care settings using field studies. numerus

Discover the power of statistics Statistical, epidemiological and health economic analyses for drug development

€£$

Clinical Health Technology Observational Development Assessment Research Expert statistical design, analysis Added value for health economics Analytical solutions that utilise the and reporting of phase I-III trials based on sound statistical principals full potential of real world data

Germany | United Kingdom | Switzerland www.numerus.com

32nd

23 PRE-CONFERENCE | THURSDAY, AUGUST 25

HALF-DAY AFTERNOON COURSES (Cont.) (Ticket required)

2:00–6:00pm 6:00–7:00pm Regulatory Pharmacoepi Welcome Reception/International Chapter & Academic (Wicklow Hall 1) Showcase (3rd Floor)

Content w Sponsored by Optum • Understand the intent and structure of Kathleen Bennett, regulation to protect the Public Health. • Chair, 2016 Local Host Committee Mary E Ritchey, • Appreciate the challenges of decision making • Chair, 2016 Scientific Program Committee Sonia Hernández-Díaz, FISPE, with weak data. • ISPE President • Know about practical approaches typically International Chapter & Academic Showcase Participants chosen by regulators. • Recognize the challenges epidemiology faces w Center for Drug Safety & Effectiveness, Johns Hopkins University to provide sufficient information for public w health decision making. Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, • Gain an overview of worldwide challenges University of Florida for drug regulatory agencies and variation in w Division of Pharmacoepidemiology & Pharmacoeconomics, Brigham and approaches. Women’s Hospital & Harvard Medical School • Know about current strategies to strengthen w ISPE Gulf Chapter regulation in the face of these challenges. w ISPE Latin-America Chapter Course Faculty w ISPE Student Council & Student Chapters Gerald Dal Pan, Center for Drug Evaluation and w London School of Hygiene and Tropical Medicine Research, Food and Drug Administration w June Raine, Medicines and Healthcare Pharmacoepidemiology Program, Department of Epidemiology, Gillings Regulatory Products Agency School of Global Public Health, University of North Carolina at Chapel Hill Stephen JW Evans, FISPE, London School of w PhD in Pharmacoepidemiology, RCSI Population Health Hygiene and Tropical Medicine w Postgraduate Programme in Pharmacovigilence, Drug Safety Research Unit w Rutgers, the State University of New Jersey w School of Pharmacy at University College Cork w University of Illinois at Chicago w University of Rhode Island

7:30-9:30pm Students/Early Career Professionals Meet & Greet Open to all students, recent (Ely Bar & Brasserie) graduates and young professionals.

w Registration required -- limited capacity. Organized by the Student Council. Please contact [email protected] for more information, and to RSVP.

32nd

24 Superior delivery

Better Connecting outcomes insights

Real-world insights are driving healthcare decisions on safety, efficacy, effectiveness and value. To develop the evidence you need to satisfy diverse stakeholders, start by integrating therapeutic expertise, real-world data and powerful analytics technology. Harness post-approval research to maximize value, contain costs and drive better outcomes.

Contact us US Direct: +1 973 850 7571 Visit us at Booth #12 www.quintiles.com Copyright Quintiles © 2016 08.0001-3-07.16 [email protected] Learn how at www.quintiles.com/RWLPR MAIN CONFERENCE | FRIDAY, AUGUST 26

7:00–8:00am 7:30-8:15am Coffee & Tea (The Forum) Chapter Meetings Poster Session A Set-Up • FarmacoEpiEnRed (Wicklow Meeting Room 3) Latin America (The Forum & 3rd Floor) • (Wicklow Meeting Room 4) • Gulf Region (Wicklow Meeting Room 5) Guidelines for Cross-National 8:00am-6:00pm Comparison of Drug Utilization Exhibits/Posters (The Forum) (Liffey Boardroom 3) 8:00-8:30am Open to all who are interested. WELCOME (The Auditorium)

This special session will present the draft guideline, w Mary E Ritchey, produced by a group of experts from IMI-Protect, Chair, 2016 Scientific Committee w Kathleen E Bennett, EuroDURG and WHO CC for Pharmaceutical Policy Chair, 2016 Local Host Committee w and Regulation. The project was selected and Sonia Hernández-Díaz, FISPE, President, ISPE funded by the ISPE Strategic Planning Committee under the Society’s Call for Manuscripts Initiative. 8:30-10:00am PLENARY SESSION (The Auditorium) Based on a literature search, a review template for CNC DU studies was built to address the main methodological issues, (standardize the information Representative Sampling in Pharmacoepidemiology: extraction, assess the risk of bias in the exposure A Hot Topic or Hot Air? estimation of each country or region compared, and evaluate the validity of the comparison between Speakers: countries or regions). The information gathered w Charlie Poole, University of North Carolina, Chapel Hill was used to develop good practice guidelines for w Stephen JW Evans, FISPE, London School of Hygiene and Tropical designing, conducting, analyzing and reporting Medicine CNC DU studies. w Xavier Kurz, European Medicines Agency The project leaders will present the results and Moderator: discuss with the audience whether the following w Jessica Franklin, Harvard Medical School and Brigham and Women’s areas were well addressed: reliability and validity of Hospital population coverage; drug coverage; drug terminology issues; biases affecting accuracy and precision of A recent, highly publicized paper, “Perils and potentials of self-selected entry exposure estimates. Comments will be collected and to epidemiological studies and surveys,” published in the Journal of the embedded in a final draft of the guidelines. Royal Statistical Society, put forth the argument that all epidemiologic studies should be based on representative samples of a specific patient population. Next steps will be discussed to ensure that For example, in a study of diabetes treatments, the target population might standardized guidelines will enhance the validity and be all adult type 2 diabetes patients in the United States, and a representative reliability of CNC DU studies, and facilitate their peer sample could be formed either by randomly selecting patients from the target review, correct interpretation of CNC DU studies, population into the study or by using a different sampling method, accompanied and adequate translation into pharmaceutical policy by sampling weights to adjust estimates for non-random sampling. decision-making. The final draft of the guidelines will be submitted to the ISPE membership for comments While representative sampling is the norm in fields such as survey research, consistent with the ISPE Policy Manual and sent to where the focus is on estimating measures that characterize a specific the ISPE Board for action. population, it is almost never used in research aiming to estimate causal effects, including both randomized trials and observational studies of treatments. 7:00am–5:00pm Some argue that without representativeness the effects estimated from such Speakers’ Ready Room studies are applicable only to the patients directly in the study and cannot be (Liffey Meeting Room 4) extrapolated to other populations, rendering the research essentially useless. Under this view, most pharmacoepidemiology studies conducted to date are 7:00–8:00am invalid. This contentious issue is stirring an important debate in the research Project on SCAN (AsPEN SIG) community, as evidenced by the more than 30 comments that were published alongside the paper. (Liffey Boardroom 1) Open to all who are interested. This session will explore the role of representative sampling in pharmacoepidemiology from different perspectives. Dr. Poole will 7:00am–6:00pm present background on representative sampling, its main methods, and Registration (Ground Foyer) practical issues in its application to pharmacoepidemiology, providing a pharmacoepidemiologist’s viewpoint. Dr. Evans will provide a statistician’s perspective, challenging several of the epidemiologists’ viewpoints. Dr. Kurz will 32nd share the views and experience of regulators.

26 MAIN CONFERENCE | FRIDAY, AUGUST 26

10:00-10:30am 10:30am-Noon CONCURRENT SESSIONS: CONTRIBUTED PAPERS Break/Posters/ Meascàn de Meds: Utilization and Trends (The Liffey A) Exhibits (The Moderators: Gianluca Trifirò& Björn Wettermark Auditorium) 10:30am 11:15am w Time-Trends and Predictors of Oral Disease w Cardiovascular Medication Utilization by Modifying Drug Treatment for Multiple Educational Level Among Heart Failure Sclerosis [1] Patients: A Population-Based Cohort Study Rishi J Desai, Mufaddal Mahesri, Eimir Hurley, in the Lazio Region, Italy [4] Joshua J Gagne, Angela Tong, Tanuja Chinis, Anna Maria Bargagli, Silvia Cascini, Claudia Sarah Minden, Olga S Matlin, William H Marino, Marina Davoli, Nera Agabiti. (Italy) Shrank, Niteesh Choudhry. (United States) 11:30am 10:45am w Influenza Vaccination Uptake Among Adult w Drug Utilization Patterns in Relapsing- Asthma Patients in the United States [5] Remitting Multiple Sclerosis: A Population- Sascha van Boemmel-Wegmann, Haesuk Park. Based Cohort Study [2] (United States) Irene Eriksson, Thomas Cars, Fredrik Piehl, 11:45am Rickard Malmström, Björn Wettermark, Mia w The Impact of a Blood Glucose Test Strip von Euler. (Sweden) Quantity Limit Policy on Clinical Outcomes 11:00am [6] w Psoriasis Patients New to Specialist Care in Diana Martins, Mina Tadrous, Michael Paterson, Sweden 2007-2009: A Two-Year Follow-Up Baiju R Shah, Muhammad M Mamdani, Jack of Treatment Allocation [3] V Tu, Anna Chu, David N Juurlink, Samantha David Hägg, Marie Eriksson, Marcus Schmitt- Singh, Tara Gomes. (Canada) Egenolf, Anders Sundström. (Sweden)

BRACE Yourself (The Liffey B) Moderators: Elizabeth Andrews, FISPE & Inge Zomerdijk

10:30am 11:15am w Risk Minimization Evaluation in a Distributed w An Association Between Beliefs About Data Network – An IMEDS Evaluation Pilot Medicines and Drug Non-Adherence in Assessment of the 2010 Class Label Change Patients with Chronic Diseases in China [10] for Proton Pump Inhibitors [7] Li Wei, Sarah Chapman, Xiaomei Li, Xin Li, Ruoling Rachel E Sobel, Andrew Bate, James Marshall, Chen, Angel Chater, Rob Horne. (United Kingdom) Gregory Daniel, Troy McCall, Jeffery Brown, 11:30am Robert F Reynolds. (United States) w Improving Medicines Management at 10:45am Patients Hospital Discharge [11] w The Impact Of Risk Minimisation Measures Alice V Gilbert, Michael S Roberts, Desmond On The Incidence And Prevalence Of Use B Williams, Bhavini Patel, Joanna Wallace, Of Strontium Ranelate At The Population Andrew L Gilbert. (Australia) Level: Preliminary Results Of A Multi- 11:45am National Cohort Study Including 5 European w Everyone Isn’t Average: Quantifying Countries [8] Heterogeneity in Crohn’s Disease Patients’ Klara Berencsi, Cristina Reyes Reyes, Lars Benefit-Risk Tradeoff Preferences [12] Pedersen, Preciosa Coloma, Francesco Lapi, Meenakshi Bewtra, F Reed Johnson, Shelby Monica Simonetti, Peter Rijnbeek, Miriam C Reed, Frank I Scott, James D Lewis. (United Sturkenboom, Daniel Prieto-Alhambra. (United States) Kingdom) 11:00am w Evaluating Patient Knowledge of Risks and Safe Use of Xarelto (Rivaroxaban) [9] Laurie J Zografos, Kiliana Suzart, Andrea Horvat-Broecker, Montse Soriano-Gabarró, Dan L Wolin, Brian Calingaert, Eric K Davenport, Kelly A Hollis, Elizabeth Andrews. (United States)

32nd

27 MAIN CONFERENCE | FRIDAY, AUGUST 26

10:30am-Noon CONCURRENT SESSIONS: CONTRIBUTED PAPERS

Diabetes: Adverse Events of Cardiovascular Treatment: Head to Toe (Wicklow Hall 2) Moderators: Deb Casso & Yea-Huei Kao Yang, FISPE

10:30am 11:00am w Clinical Outcomes Of Concomitant Use Of w Statins and Reduced Risk of Liver Cancer: Evidence for Confounding Warfarin And Selective Serotonin Reuptake [15] Inhibitors [13] Laurel A Habel, Ninah Achacoso, Bruce Fireman, Gary D Friedman. Yaa-Hui Dong, Katsiaryna Bykov, Niteesh K (United States) Choudhry, Macarius M Donneyong, Krista 11:15am F Huybrechts, Raisa Levin, Sebastian w Acute Liver Injuries and Antiarrhythmic Drugs: A Case-Referent Study Schneeweiss, Joshua J Gagne. (United States) from the PGRx Surveillance System on Medicine Use [16] 10:45am Lamiae Grimaldi-Bensouda, Jacques Benichou, Michel Rossignol, w Propranolol Use and Survival from Breast Dominique Larrey, Lucien Abenhaim, Thierry Poynard. (United Kingdom) Cancer: A Pooled Analysis of 133,251 Breast 11:30am Cancer Patients from the European Cancer w Association of Idiopathic Inflammatory Myositis with Statin Exposure: Pharmacoepidemiology Network [14] A Population Based Case Control Study [17] Chris Cardwell, Anton Pottegård, Evelien Vaes, Gillian E Caughey, Genevieve M Gabb, Saffron Ronson, Michael Ward, Hans Garmo, Chris Brown, Pauline Vissers, Catherine L Hill, Vidya Limaye. (Australia Michael O’Rorke, Kala Visvanathan, Deirdre Cronin-Fenton, Harlinde De Schutter, Mats 11:45am Lambe, Des Powe, Myrthe van Herk-Sukel, w Confounding of the Association Between Statins and Parkinson Anna Gavin, Søren Friis, Linda Sharp, Kathleen Disease: Review and Meta-Analysis [18] Bennett. (United Kingdom) Katsiaryna Bykov, Kazuki Yoshida, Marc G Weisskopf, Joshua J Gagne. (United States)

Pregnancy and Beyond (Liffey Hall 2) Moderators: Sara Ephross & Kathryn Rough

10:30am 11:15am w Ondansetron Use Among Pregnancies w Risk Comparison for Prenatal Use of Different Analgesics and Selected Identified In The Sentinel Distributed Birth Defects [22] Database [19] Julia D Interrante, Elizabeth C Ailes, Jennifer N Lind, Marlene Anderka, Lockwood G Taylor, Patty Greene, Steven T Marcia L Feldkamp, Martha M Werler, Suzanne M Gilboa, Margaret A Bird, Marsha E Reichman, Leyla Sahin, Melissa Honein, Cheryl S Broussard. (United States) S Tassinari, Susan E Andrade, Katherine 11:30am Haffenreffer, Darren Toh. (United States) w High Exposure to Phthalates from Medications and Male Genital 10:45am Malformations [23] w Use Of Antibiotics During Pregnancy And Katherine E Kelley, Sonia Hernández-Díaz, Russ Hauser, Allen A Mitchell. The Risk Of Spontaneous Abortion [20] (United States) Flory T Muanda, Odile Sheehy, Anick Bérard. 11:45am (Canada) w Language Development in 3 Year Old Children After Prenatal Exposure 11:00am to Opioids [24] w Pregnancy Outcomes in Women with Eva Skovlund, Marte Handal, Randi M Selmer, Ragnhild E Brandlistuen, Chronic Hypertension Initiated on Labetalol Svetlana Skurtveit. (Norway) versus Methyldopa [21] Brian T Bateman, Krista F Huybrechts, Jacqueline Cohen, Helen Mogun, Rishi J Desai, Elisabetta Patorno, Sonia Hernández-Díaz, . (United States)

32nd

28 MAIN CONFERENCE | FRIDAY, AUGUST 26

10:30am-Noon CONCURRENT SESSIONS: CONTRIBUTED PAPERS

Keeping an “I” in Opioid Use (Liffey Hall 1) Moderators: Paul Coplan & Eileen Ming

10:30am 11:15am w Serious Opioid Toxicity in Children with Non-Cancer Pain: w The Role of Socioeconomic Status in A Retrospective Cohort Study [25] Regional Variation of Opioid Utilisation in Cecilia P Chung, S Todd Callahan, William O Cooper, William D Dupont, the Greater London Area [28] Katherine T Murray, Kathi Hall, Judith A Dudley, C Michael Stein, Wayne A Ji Hye Bing, Teng-Chou Chen, Li-Chia Chen, Ray. (United States) Roger Knaggs. (United Kingdom) 10:45am 11:30am w Long-Acting Oxycodone Co-Prescribing Among US Nursing Home w Opioid Tolerance Prior to Initiation of High- Residents [26] Dose Oxycodone in Commercially-Insured Kevin M Fain, G Caleb Alexander, Carlos Castillo-Salgado, David D Dore. Adults in the US, 2010-2014 [29] (United States) Jessica C Young, Jennifer L Lund, Nabarun 11:00am Dasgupta, Michele Jonsson Funk. (United w Doctor/Pharmacy Shopping Measures for Opioid Analgesics and States) Diagnosed Abuse and Addiction in a US Administrative Database [27] 11:45am Daina B Esposito, M Soledad Cepeda, Ruihua Yin, Howard Chicoat, Paul w The Preventable Risk of Fentanyl Coplan, Stephan Lanes. (United States) Prescribing [30] Shawn C Bugden, Kevin J Friesen, Cornelius Woelk. (Canada)

ALMOST 1 IN 3 PEOPLE OUR SCIENTISTS DIE FROM WON’T CARDIOVASCULAR DISEASE ACCEPT THAT

According to the World Health Organization (WHO), infarctions and strokes. Which heart patient cardiovascular diseases are the number one cause wouldn’t love to benefi t from that? of death throughout the world. To fi nd out how our innovations are helping That’s why we’re investigating treatments to to change lives for the better, visit manage heart failure, as well as prevent myocardial www.bayer.com/cvd1902.

nd 4654_Bayer_Ad_CVD_7.5"x5"_ICPE.indd 1 18.05.162032 15:58

29 MAIN CONFERENCE | FRIDAY, AUGUST 26

1:30-3:00pm CONCURRENT SESSIONS: CONTRIBUTED PAPERS

Data Lost and Found (The Auditorium) Moderators: Til Stürmer, FISPE & Marie Linder

10:30am 11:15am w Effects of Expanding the Look-Back Period w Avoiding Pitfalls When Combining Multiple Imputation and Propensity to All Available Data in the Assessment of Scores [34] Covariates [31] Emily Granger, Mark Lunt, Jamie C Sergeant. (United Kingdom) Sonja S Nakasian, Jeremy Rassen, Jessica M 11:30am Franklin. (United States) w Generalizing Randomized Clinical Trials: Challenges Due to Missing 10:45am Data on the Target Population [35] w Classifying Patient Histories in Medicare Jin-Liern Hong, Michele Jonsson Funk, Robert LoCasale, Sara Dempster, Claims: Fixed vs. All-Available Lookbacks Stephen R Cole, Til Stürmer. (United States) [32] 11:45am Mitchell M Conover, Til Stürmer, Charles Poole, w Confounding by Healthcare System Characteristics in Comparative Robert J Glynn, Ross J Simpson, Jr., Michele Effectiveness Research [36] Jonsson Funk. (United States) Jessica M Franklin, Macarius M Donneyong, Rishi J Desai, Mehul D 11:00am Patel, Panagiotis Mavros, Leona Markson, Caroline McKay, Sebastian w Recency of Comorbid Diseases and One- Schneeweiss. (United States) Year Mortality: A Registry-Based Cohort Study in Denmark [33] Morten Madsen, Vera Ehrenstein, Henrik T Sørensen. (Denmark)

Noon -1:30pm Noon-1:30pm Lunch/Poster Session A/Exhibits ISPE Committee/Council Meetings (The Forum) (Open to all participants; Lunch available.)

• Membership Committee (Wicklow Meeting Room 3) Lunch/Roundtable Discussions • Global Development Committee (Wicklow Meeting Room 4) (Liffey Meeting Room 1) • Fellowship & Awards Committee (Wicklow Meeting Room 5) Roundtable Discussions • Finance Committee (Wicklow Meeting Room 2a) To foster the ability of the more junior participants • Public Policy Committee (Wicklow Meeting Room 2b) to network and first-timers to meet others attending • Student Council (open to all students) (Wicklow Meeting Room 1) the ICPE, ISPE is hosting several informal lunchtime discussion roundtables on Friday and Saturday. 12:15-1:15pm The facilitators are listed below. There will be NO Spotlight Poster Session (3rd Floor; Lunch available) formal presentations made at the roundtables. The objectives are discussion, information exchange, • Adherence and networking. Seating is limited; first-come, • Databases first-served. • Devices • Pediatrics • Gianluca Trifirò Role and Responsibilities of Pharmacoepidemiologists in Academia • Kate Lapane, FISPE Medication Issues in Vulnerable Populations • Stella Blackburn, FISPE Adaptive Pathways

32nd

30 MAIN CONFERENCE | FRIDAY, AUGUST 26

1:30-3:00pm CONCURRENT SESSIONS: CONTRIBUTED PAPERS

Bittersweet: Trends and Treatments in Diabetes (The Liffey A) Moderators: Ken Hornbuckle, FISPE & Rosa Gini

1:30pm 2:30pm w Preferential Prescribing of Linagliptin to Patients with Renal or Cardiac w Trends Of Use Of Non-Insulin Antidiabetic Disorders in Japan [39] Drugs Between 2006-2013 In France [41] Soulmaz Fazeli Farsani, Atsushi Taniguchi, Rie Ikeda, Kimberly G Mickael Arnaud, Julien Bezin, Bernard Bégaud, Brodovicz, Dorothee B Bartels. (Germany) Antoine Pariente, Francesco Salvo. (France) 1:45pm 2:45pm w Estimated Life Expectancy and Cause-Specific Mortality in White, w Antidepressants and the Risk of Type 2 South Asian and Black Patients with Type 2 Diabetes [38] Diabetes Mellitus Among Publicly-Insured Alison K Wright, Evangelos Kontopantelis, Martin K Rutter, Darren M U.S. Youth [42] Ashcroft. (United Kingdom) Mehmet Burcu, Julie M Zito, Susan dosReis, 2:00pm Fadia T Shaya, Daniel J Safer. (United States) w Trends In Incidence, Prevalence And Prescribing In Type 2 Diabetes Mellitus [37] Manuj Sharma, Irwin Nazareth, Irene Petersen. (United Kingdom) 2:15pm w Augmentation Patterns Amongst Metformin Initiators with Type 2 Diabetes Mellitus (T2DM) [40] Chandrasekar Gopalakrishnan, Sebastian Schneeweiss, John D Seeger, Jun Liu, Elisabetta Patorno. (United States)

Pharma client

EPID Partners Research

Registers

32nd

31 MAIN CONFERENCE | FRIDAY, AUGUST 26

1:30-3:00pm CONCURRENT ORAL PRESENTATION SESSIONS

Cancer: Around the World in Databases (The Liffey B) Moderators: Jason C Hsu & James Kaye

1:30pm 2:30pm w Predictors of Induction Chemoimmunotherapy Among Older US Adults w Low-Dose Aspirin and Survival Benefit in with Follicular Lymphoma [43] Gastrointestinal Malignancies [47] Laura L Hester, Steven I Park, Jennifer L Lund. (United States) Martine A Frouws, Esther Bastiaannet, Ruth E 1:45pm Langley, John WK Chia, Myrthe PP Van Herk- w Validation of Claims-Based Definitions of Incident Colorectal Cancer Sukel, Hein Putter, Cornelis JH Van de Velde, (CRC) in a North Carolina (NC) Medicare Population [44] Johanneke EA Portielje, Gerrit-Jan Liefers. (Netherlands) Monica E D’Arcy, Til Stürmer, Anne Marie Meyer, Michele Jonsson-Funk, Robert Sandler, John Baron, Melissa Troester, Jennifer Lund. (United States) 2:45pm w Initiation and Adherence with Bone- 2:00pm Targeting Agents in US Men with Bone w Clinical Outcomes of Stage II and III Breast Cancer Patients in Metastases from Prostate Cancer [48] Denmark [45] Anne M Butler, Karynsa Cetin, Rohini K Deirdre Cronin-Fenton, Anders Kjærsgaard, Mette Nørgaard, Justyna Hernandez, Robert A Overman, Jungin Kim, Amelio, Alex Liede, Rohini K Hernandez, Henrik T Sørensen. (Denmark) B Diane Reams, Bradford R Hirsch, Amy P 2:15pm Abernethy, Alexander Liede, M Alan Brookhart. w Post-Diagnostic Statin Use and Breast Cancer Survival: A Nationwide (United States) Cohort Study in Scotland [46] Úna C Mc Menamin, Chris R Cardwell, Carmel M Hughes, Liam J Murray. (United Kingdom)

32nd

32 MAIN CONFERENCE | FRIDAY, AUGUST 26

1:30-3:00pm CONCURRENT ORAL PRESENTATION SESSIONS

Playing Catch-up in Pediatric Pharmacoepidemiology (Wicklow Hall 2) Moderators: Susan Oliveria, FISPE & Sudha Raman

1:30pm 2:15pm w Birth Cohort Effects on Overall and Subtype-Specific Antibiotic Use w ADHD Treatment and Diagnosis – Among Infants Born in Denmark 2004-2012 [49] Importance of Relative Age in Grade in Alan C Kinlaw, Henrik T Sørensen, Jennifer L Lund, Lars Pedersen, Julie L Norway [52] Daniels, Michael D Kappelman, Til Stürmer. (United States) Øystein Karlstad, Kari Furu, Siri E Håberg, Inger 1:45pm Johanne Bakken. (Norway) w Development and Validation of an Algorithm for Identifying Pediatric 2:30pm Patients with Type 2 Diabetes in Claims Data [50] w Safety of Stimulants in Children with Dana Y Teltsch, Richard S Swain, Soulmaz Fazeli Farsani, Kimberly G Epilepsy: A Retrospective Cohort Study [53] Brodovicz, Stefan Kaspers, Samuel Huse, Nicholas Sicignano, Beth L Xinyue Liu, Paul Carney, Regina Bussing, Nordstrom, Dorothee B Bartels. (United States) Richard Segal, Linda Cottler, Almut Winterstein. 2:00pm (United States) w Suicide Trends and Risk Factors in Youth Aged 10-19 Years, Texas, 2:45pm USA [51] w Comparative Effectiveness Of NSAID Deanna A Oleske, Denise M Oleske, Sharon M Derrick, Merrill O Hines. Treatment Versus No Treatment For PDA In (United States) Preterm Infants [54] Jonathan L Slaughter, Patricia B Reagan, Thomas B Newman, Mark A Klebanoff. (United States)

Patients, Prescriptions, Policy & Pennies (Liffey Hall 2) Moderator: David Martin

1:30pm 2:30pm w Potential Impact of Proposed Limits on Clinical Data Collected from w Between Risk Management and Primary Care for a National Research Database [55] Pharmacoepidemiology: Where Do Post- Wilhelmine Meeraus, Jennifer Campbell, Daniel Dedman, Arlene Gallagher, Authorisation Safety Studies Stand Today? Antonis Kousoulis, Tarita Murray-Thomas, Jessie Oyinlola, Helen [59] Strongman, Rachael Williams, Tim Williams. (United Kingdom Mariana F Almas, Pierre Engel, Marieke L De Bruin, Kathryn Starzyk, Blackburn Stella, 1:45pm w The Impact of State Chemotherapy Parity Laws on Use and Spending Dreyer A Nancy (United Kingdom) for Oral Chemotherapy [56] 2:45pm Stacie B Dusetzina, Haiden A Huskamp, Aaron N Winn, Ethan M Basch, w The Availability of Pharmacies and Nancy L Keating. (United States) Pharmacy Services in the United States: 2007-2015 [60] 2:00pm w Disclosure of Industry Payments to Prescribers: Industry Payments Dima Qato, Shannon Zenk, Jocelyn Wilder, Might Be a Factor Impacting Generic Drug Prescribing [57] Rachel Harrington, Darrel Gaskin, Caleb Alexander. (United States) Jingjing Qian, Richard Hansen, Daniel Surry, Jennifer Howard, Zippora Kiptanui, Ilene Harris. (United States) 2:15pm w What has Been Achieved Five Years After Approval of New Drugs with the Requirement to Set up Patient Registries? A Follow-Up Study [58] Carla J Jonker, Marijke HM van den Berg, Arno W Hoes, Peter M Mol. (Netherlands)

32nd

33 MAIN CONFERENCE | FRIDAY, AUGUST 26

1:30-3:00pm CONCURRENT ORAL PRESENTATION SESSIONS Adherence: Staying the Course Study Design Considerations to Address Confounding (Liffey Hall 1) (The Auditorium) Moderators: Julie Lauffenburger & Moderators: Darren Toh & Rob Heerdink Robert Vander Stichele 1:30pm 1:30pm w Instrumental Variable Analysis Using Pooled Data in w Longitudinal Asthma Management Profiles: Pharmacoepidemiology: A Simulation Study [67] Visualisation of Patient Histories Using Md Jamal Uddin, M Abdul Baker Chowdhury. (Bangladesh) Multiple Data Sources [61] Andrew McAfee Award for the Best Abstract Submitted by a Eric H Van Ganse, Sandrine Herbage, Researcher or Student living in a Developing Country Alexandra L Dima, Marijn de Bruin, Nathalie 1:45pm Texier, Flore Jacoud, Maeva Nolin, Laurent w A Reference-Likelihood Alternative to Inverse Probability of Treatment Laforest, The ASTROLAB Group. (France) Weighting [68] 1:45pm Colin Dormuth. (Canada) w Determinants of Antihypertensive 2:00pm Adherence Trajectories Among Older US w Variation in Propensity-Adjusted Marginal Estimates of Treatment Adults in the First Year After Initiation [62] Effect [69] Jennifer Jones, Carri Casteel, Yvonne Golightly, Jessica M Franklin, Wesley Eddings, Robert J Glynn, Sebastian Laura Loehr, Virginia Pate, Steve Marshall, Til Schneeweiss. (United States) Stürmer. (United States) 2:15pm 2:00pm w The Impact of Study Design and Analysis on “Measurable” and w Impact of Statin-Related Media Coverage “Un-Measurable” Patient Characteristics in Observational Studies of on the Use of Statins: An Interrupted Time Glucose-Lowering Drugs in Type 2 Diabetes Mellitus (T2DM) [70] Series Analysis Using UK Primary Care Data [63] Elisabetta Patorno, Chandrasekar Gopalakrishnan, Jessica Franklin, Kimberly Brodovicz, John Seeger, Dorothee Bartels, Jun Liu, Sebastian Anthony Matthews, Emily Herrett, Antonio Schneeweiss. (United States) Gasparrini, Tjeerd Van Staa, Ben Goldacre, Laim Smeeth, Krishnan Bhaskaran. (United 2:30pm w Kingdom) Calendar Time as an Instrumental Variable in Assessing the Risk of 2:15pm Heart Failure with Antihyperglycemic Drugs [71] w Changes in Statin Adherence in Response Mugdha Gokhale, John B Buse, Christina Mack, Til Stürmer. (United States) 2:45pm to a Myocardial Infarction: The Impact of a Stressful Life Event on Medication Taking w Propensity Score Trimming to Identify the Target Population for Behavior [64] Comparative Effectiveness Research [72] Ryan P Hickson, Izabela E Annis, Ley A Killeya- Robert J Glynn, Til Stürmer. (United States Jones, Gang Fang. (United States) 3:00-3:30pm 2:30pm w Comparative Adherence of Overactive Break/Posters/Exhibits (The Forum) Bladder Agents Among Older Patients [65] Samantha Singh, Wayne Khuu, Mina Tadrous, Diana Martins, Muhammad Mamdani, Dean Elterman, Tara Gomes. (Canada) 2:45pm w Self-Reported Adherence to Different Classes of Antiretroviral Medication as a Predictor of HIV Viral Suppression [66] Joseph A Delaney, Robin M Nance, Mari Kitahara, Joseph Eron, Greer Burkeholder, James Willig, Michael Mugavero, Chris Matthewa, Michael Saag, Katerina Christopoulous, Ken Mayer, Susan Heckbert, Heidi M Crane. (United States)

32nd

34 MAIN CONFERENCE | FRIDAY, AUGUST 26

3:30-5:00pm 5:00-6:30pm PLENARY SESSION SYMPOSIA AND WORKSHOPS

Real World Effectiveness: How Catch the Wave: Diffusion of Methodological Innovation in Effective is It? (The Auditorium) Pharmacoepidemiology [73] (The Auditorium) w Suzanne M Cadarette, Robert W Platt, Joann K Ban, Giulia P Consiglio, Speakers: Mina Tadrous, Malcolm K Maclure. (Canada) w Sarah Garner Patient Engagement in Observational Pharmacoepidmiology National Institute for Health and Care Excellence w Elizabeth B Andrews, FISPE Research: Where are We, Where do We Need to be and RTI-Health Solutions What are the Steps for Getting There? [74] (The Liffey B) w Tjeerd van Staa w Robert F Reynolds, Anne Trontell, Zhanna Jumadilova, Louis Fiore, Liam Health eResearch Centre, Farr Institute for Smeeth. (United States) Health Informatics Research Impact of Pharmacovigilance: From PRAC Strategy to University of Manchester Demonstrable Better Health Protection [75] (The Liffey A) Moderator: w w Almath Spooner Peter Arlett, Marieke De Bruin, Robert Reynolds, Gerald Dal Pan, Saad Shakir, Almath Spooner, Xavier Kurz, June M Raine. (United Kingdom) EMA’s PRAC, Health Products Regulatory Authority, Ireland Big Data, Big Picture - Data Visualization of Health [76] Health organisations, decision makers and (Wicklow Hall 2) w regulators sometimes require information on real Alison Bourke, Patrick B Ryan, Noémie Elhadad, Adam Perer. (United Kingdom) world effectiveness of medicines after authorization (post-authorisation effectiveness studies, PAES). Drug Utilisation In Older Populations: The Irish View On When evaluating real world effectiveness, Knowing Right From Wrong [77] (Liffey Hall 2) observational evidence may be required as (Sponsored by the Drug Utilization Research Special Interest Group) randomised controlled trials are inappropriate, w Lisa G Pont, Katja Taxis, Veronika Wirtz, Paul Gallagher, Stephen Byrne, impossible or inadequate. Delivering timely decision Annie Fourrier-Reglat. (Australia) relevant data is essential; however, because of the potential for bias, it has been suggested Does Randomization Work? Selection Bias in Pragmatic that observational studies are only suitable for Randomized Clinical Trials and Unblinded Observational the study of adverse (non-predictable) effects Studies [78] of drugs and not for measuring their intended (Liffey Hall 1) effects. Much ongoing research is focused on (Sponsored by the CER Special Interest Group) determining the value of observational studies in w Cynthia J Girman, Kourtney J Davis, Liam Smeeth, Sarah Garner, Mary E effectiveness evaluation and the inference that can Ritchey, Corrine De Vries, Andrew W Roddam. (United States) be drawn from such analyses. The IMI ‘GetReal’ initiative (www.imi-getreal.eu) is one example that Exploring Innovative Methods to Conduct Validation Using aims to show how robust new methods of RWE United States Medicare Administrative Claims Data [79] collection and synthesis could be adopted earlier (Liffey Meeting Room 2) in pharmaceutical R&D and the healthcare decision w Elizabeth Andrews, Til Stürmer, Leah J McGrath, Michele Jonsson Funk, making process. Jennifer L Lund, Catherine B Johannes, Alicia W Gilsenan, Christopher This plenary session will focus on the real world Powers. (United States) effectiveness from different perspectives (decision makers, academics, regulators) and the challenges 6:30-7:15pm that are encountered as well as offering thoughts on Special Interest Group (SIG) Meetings (Open to all participants) the how research could and should evolve. • Adherence (Wicklow Meeting Room 2B) • Medical Devices (Liffey Boardroom 3) Specific topics covered during this session include: • AsPEN (Wicklow Meeting Room 3) • Medications in Pregnancy Biologics & Biosimilars • Breadth/types of research aims/objectives • (Liffey Meeting Room 3) (Wicklow Meeting Room 2A) • Molecular Epi./Biomarkers/ across perspectives/countries • BRACE (EcoCem) Pharmacogenetics • Timely and relevant data for decision makers/ • Comparative Effectiveness (Liffey Meeting Room 5) regulators etc. Research (Wicklow Meeting Room 4) • Oncology (Liffey Boardroom 1) • Generating or retrieving data for effectiveness • Database (Liffey Meeting Room 1) • Pediatrics (Wicklow Meeting Room 5) research (e.g. claims data for outcomes • Drug Utilization/Health Services • Vaccines (Liffey Meeting Room 2) research, electronic health records) Research (Wicklow Meeting Room 1) • Methodological considerations of bias and confounding 7:15-9:00pm PDS Editorial Board (Spencer Hotel) (By Invitation Only) 32nd

35 MAIN CONFERENCE | SATURDAY, AUGUST 27

7:00-8:00am 8:00-9:30am CONCURRENT SESSIONS: CONTRIBUTED PAPERS Coffee & Tea Psychotropics in Pregnancy (The Liffey A) (The Forum) Moderators: Janet Hardy & Caitlin Knox

Poster Session B 8:00am 8:45am Set-up w Antidepressant Medication and the Risk of w Is There a Dose-Response Relation Between (The Forum & Pregnancy-Induced Hypertension [402] the Use of Lithium in Early Pregnancy and the Risk of Cardiac Malformations? [405] 3rd Floor) Loes F ter Heijne, Neily Zakiyah, Jens HJ Bos, Eelko Hak, Catharina CM Schuiling-Veninga. Elisabetta Patorno, Krista Huybrechts, Brian (Netherlands) Bateman, Helen Mogun, Rishi Desai, Sonia 7:00am-5:00pm 8:15am Hernández-Díaz. (United States) Speakers’ Ready w Gestational Exposure to SSRIs and Risk of 9:00am Room Preeclampsia in Pregnancy: A Study from the w Associations Between Treatment with (Liffey Meeting Norwegian Mother and Child Cohort Study Selective Serotonin Reuptakeinhibitors Accounting for Time-Varying Severity of (SSRIs) Before and After Pregnancy [406] Room 4) Depressive and Anxiety Symptoms [403] Irene Petersen, Cormac Sammon, Kate Angela Lupattelli, Mollie Wood, Olav Spigset, Walters, Michael Sharpe, Jane Walker, Sarah 7:00am-6:00pm Kate Lapane, Hedvig Nordeng. (Norway) Hardoon. (United Kingdom) Registration 8:30am 9:15am (Ground Foyer) w Continuation of Atypical Antipsychotic w Risk Of Neurodevelopmental Disorders Medications During Pregnancy and the Risk Following Prenatal Valproate Exposure: An 8:00am-6:00pm of Gestational Diabetes [404] Observational Cohort Study Using The Health Exhibits/Posters Yoonyoung Park, Sonia Hernández-Díaz, , Improvement Network [407] (The Forum) Brian T Bateman, Jacqueline Cohen, Elisabetta Cormac J Sammon, Rachel L McCrea, David P Patorno, Helen Mogun, Krista F Huybrechts. Osborn, Stephen JW Evans, Phillip J Cowen, (United States) Irwin Nazareth, Irene Petersen. (United Kingdom)

Better Health, Brighter Future

Takeda is proud to sponsor the 2016 ICPE.

For more than 230 years, we have been serving society with innovative medicines and helping patients reclaim valuable moments of life from illness. Now, with new healthcare solutions from prevention to care and cure, we are determined to help even more people enjoy their lives to the fullest.

We continue to transform the future of healthcare by unifying our strengths around the world. We are a diverse organization committed to working with local communities to fully understand their needs and deliver industry-leading solutions with a sense of urgency, dedication and unparalleled efficiency.

Our passion for healthcare and commitment to improving lives will enable us to make the next 230 years healthier and brighter for people around the world.

©2015 Takeda Pharmaceuticals International Co. All rights reserved. To learn more, visit us at TakedaPIC.com.

nd 32

36 MAIN CONFERENCE | SATURDAY, AUGUST 27

8:00-9:30am CONCURRENT SESSIONS: CONTRIBUTED PAPERS Psychotropics in Pregnancy (The Liffey A) Pay Attention to Pain: ADHD and Pain Treatment DUS (The Liffey B) Moderators: Janet Hardy & Caitlin Knox Moderators: Judith Jones, FISPE & Mina Tadrous

8:00am 8:45am w Frequency and Predictors of Analgesic Prescribing in US Nursing w Prescribing Trends of Attention-Deficit Home Residents with Persistent Pain [408] Hyperactivity Disorder (ADHD) Medications Kevin M Fain, G Caleb Alexander, David D Dore, Carlos Castillo-Salgado. in UK Primary Care, 1995-2015 [411] (United States) Christel Renoux, Ju-Young Shin, Sophie 8:15am Dell’Aniello, Emma Fergusson, Samy Suissa, w Prevalence and Trends of Analgesic Medication Utilisation in Patients CNODES Canadian Network for Observational Undergoing Total Joint Replacement Surgery [409] Drug Effect Studies. (Canada) Maria CS Inacio, Kara Cashman, Nicole L Pratt, Marianne H Gilliam, 9:00am Stephen E Graves, Elizabeth E Roughead. (Australia) w Drug Utilization of Lisdexamfetamine Dimesylate in European Countries [412] 8:30am w Global Utilization of Attention Deficit Hyperactivity Disorder Birgit Ehlken, Dorothea von Bredow, William A Medications – Preliminary Results [410] Blumentals, Barbara Thun, Jacco Keja, Tricia Maxwell. (Germany) Sudha R Raman, Kenneth KC Man, Anick Berard, Takoua Boukhris, Yea-Huei Kao Yang, Kiyoshi Kubota, Hidefumi Nakamura, Chien-Chou Su, 9:15am Miriam CJM Sturkenboom, Ian CK Wong. (United States) w Treatment Patterns in Adults with Newly Treated Attention Deficit/Hyperactivity Disorder [413] Yanmin Zhu, Wei Liu, Yan Li, Paul S Kubilis, Almut G Winterstein. (United States) (Netherlands)

DEPARTMENT OF CLINICAL EPIDEMIOLOGY AT AUH IN DENMARK IS PROUD TO SPONSOR THE 2016 ICPE

Better clinical care through research

VISIT US AT BOOTH # 24

AARHUS AU UNIVERSITY DEPARTMENT OF CLINICAL EPIDEMIOLOGY kea.au.dk

32nd

37 MAIN CONFERENCE | SATURDAY, AUGUST 27

8:00-9:30am CONCURRENT SESSIONS: CONTRIBUTED PAPERS Psychotropic Trends on Populations from a Multinational Perspective (Wicklow Hall 2) Moderators: Yola Moride, FISPE & Maire O'Dwyer

8:00am 9:00am w Psychotropic Medicine Use in Australia (2006 to 2014); Annual w Benzodiazepines and Mortality: A Marginal Incidence, Prevalence and Patterns of Use [414] Structural Model (MSM) Application in Jonathan Brett, Benjamin J Daniels, Emily Karanges, Sallie-Ann Pearson, Claims Data [418] Carl Schneider. (Australia) Krista F Huybrechts, Shirley Wang, Robert 8:15am Glynn, Raisa Levin, Elisabetta Patorno. (United w Incidence of Mood and Anxiety Disorders and Psychotropic Use in States) Spouses of Dementia Patients: A Population-Based Study [415] 9:15am I Fan Kuo, Andrew Basham, Heather Prior, Silvia Alessi-Severini, James w Impact of Paliperidone Palmitate versus Bolton, Alan Katz, Shahin Shooshtari. (Canada) Oral Atypical Antipsychotics on Healthcare Resource Use and Costs in Veterans with 8:30am Schizophrenia with Limited Antipsychotic w Sustained Use of Benzodiazepines and High Dose Escalation in a Exposure in the Prior 12 Months [419] Canadian Population [416] Patrick Lefebvre, Erik Muser, Kruti Joshi, Maral Silvia Alessi-Severini, James M Bolton, Murray W Enns, Matthew E Dahl, DerSarkissian, Rachel Bhak, Andrew Kageleiry, Dan Chateau, David M Collins, Jitender Sareen. (Canada) Mei S Duh, Brian Shiner, Yinong Young-Xu. 8:45am (United States) w Antidepressant and Benzodiazepine Co-Initiation and Subsequent Long-Term Benzodiazepine Use in Adults with Depression, United States 2001-2014 [417] Greta A Bushnell, Til Stürmer, Bradley N Gaynes, Virginia Pate, Matthew Miller. (United States)

A Sticky Subject: Diabetes Safety (Liffey Hall 2) Moderators: James Lewis, FISPE & Christian Hampp

8:00am 8:45am w Final Results of a Large Multi-National Postmarketing Safety Study w Metformin and Cancer Risk in Type 2 Evaluating Use of the Oral Anti-Diabetic Drug Saxagliptin and Risk of Diabetes: An Application of Marginal Five Outcomes [420] Structural Models with Inverse Probability Vincent Lo Re III, Dena M Carbonari, Craig W Newcomb, M Elle Saine, of Treatment Weights in the Clinical Practice Jason A Roy, Serena Cardillo, Kevin Haynes, Stephen E Kimmel, Peter P Research Datalink [423] Reese, David J Margolis, Andrea J Apter, K Rajender Reddy, Harshvinder Ruth E Farmer, Deborah Ford, Liam Smeeth, Bhullar, Arlene M Gallagher, Daina B Esposito, Brian L Strom. (United States) Nishi Chaturvedi, Richard Kaplan, Krishnan 8:15am Bhaskaran. (United Kingdom) w Use of Incretin Agents and Risk of Acute and Chronic Pancreatitis: A 9:00am Population-Based Cohort Study [421] w Impact of Glycaemic Control on Risk of Lotte M Knapen, Ronaldus GPJ de Jong, Johanna HM Driessen, Yolande Infections in 69 318 Patients with Type 2 C Keulemans, Nielka P van Erp, Marie L de Bruin, Hubert GM Leufkens, Diabetes: A Population-Based Cohort Study Sander Croes, Frank de Vries. (Netherlands) [424] 8:30am Anil Mor, Olaf M Dekkers, Jens S Nielsen, w Use of Non-Insulin Blood Glucose Lowering Drugs and the Risk of Henning Beck-Nielsen, Henrik T Sørensen, Acute Pancreatitis [422] Reimar W Thomsen. (Denmark) Gwen MC Masclee, Ingrid Leal, Lorenza Scotti, Giorgia De Berardis, Irene 9:15am Bezemer, Miguel Gil, Anita McGrogan, Niklas Schmedt, John D Seeger, w Estimated Effects of Treatment Changes on Gianluca Trifirò, Serena Pecchioli, Manel Pladevall-Vila, Mark M Smits, Emergency Care Utilization in a Cohort of Peter Rijnbeek, Miriam CJM Sturkenboom, Silvana A Romio. (Netherlands) Patients with Type 1 Diabetes [425] Richard S Swain, G Caleb Alexander, Dana Y Teltsch, MAJ Christina L Cristaldi, Janet T Holbrook, Jodi B Segal. (United States)

32nd

38 MAIN CONFERENCE | SATURDAY, AUGUST 27

8:00-9:30am CONCURRENT SESSIONS: CONTRIBUTED PAPERS Broken & Torn (Liffey Hall 1) Moderators: Daniel Prieto-Alhambra & Andrew Roddam

8:00am 8:45am w 35-Year Trends in First-Time w Total Hip and Knee Replacement Among Incident Osteoarthritis and Hospitalizations for Hip Fracture and Rheumatoid Arthritis Patients Within the UK Clinical Practice Research Subsequent 0-30 and 31-365 Days Mortality: Datalink (CPRD) Compared to Hospital Episode Statistics (HES): A 1980-2014 [426] Validation Study [429] Alma B Pedersen, Vera Ehrenstein, Szimonetta Samuel Hawley, Antonella Delmestri, Andrew Judge, Christopher J Edwards, Szepligeti, Astrid Lunde, Anna Westerlund, Cyrus Cooper, Nigel K Arden, Daniel Prieto-Alhambra. (United Kingdom) Ylva Trolle Lagerros, Grethe S Tell, Henrik Toft 9:00am Sørensen. (Denmark) w Modular versus Monobloc Neck Stems Primary Total Hip Arthroplasty 8:15am Survivorship. Result of a Prospective Series of 324,108 THA at 6-Years w Association of Gout Diagnosis with Follow-Up [430] Increased Risk of Joint Replacement: A Sandrine Colas, Assia Allalou, Rosemary Dray-Spira, Mahmoud Zureik. Population-Based Cohort Study of Older (France) Adults [427] 9:15am

Sylvie Perreault, Alyssa B Klein, Robert w Incidence and Trends in ACL Reconstruction Among Commercially- Morlock. (Canada) Insured Individuals in the United States, 2002-2013 [431] 8:30am Mackenzie M Herzog, Stephen W Marshall, Virginia Pate, Jennifer L Lund, w Validation of Fracture Risk Assesment Tool Jeffrey T Spang. (United States) Using Real-World Data [428] Inbal Goldshtein, Yariv Gerber, Sophia Ish- Shalom, Moshe Leshno. (Israel

Identification and Validation of Outcomes(Liffey Meeting Room 2) Moderators: Helga Gardarsdottir & Richard Wyss

8:00am 8:45am w A Comparison of Methods for Estimating w Validity of Cardiac Examination, Procedure, and Surgery Codes in the Values for Sparse and Irregularly Spaced Danish National Patient Registry [435] Continuous Outcome Measures in Kasper Adelborg, Jens Sundbøll, Troels Munch, Trine Frøslev, Henrik T Electronic Health Record (EHR) Data [432] Sørensen, Hans E Bøtker, Morten Schmidt. (Denmark) Therese M Sheppard, William G Dixon, Robyn 9:00am Tamblyn. (United Kingdom) w Validity of Cardiovascular Diagnoses in the Danish National Patient 8:15am Registry [436] w A Comparison Of Structured Data Query Jens Sundbøll, Kasper Adelborg, Troels Munch, Trine Frøslev, Henrik T Methods Versus Natural Language Sørensen, Hans E Bøtker, Morten Schmidt. (Denmark) Processing To Identify Metastatic Melanoma 9:15am Cases From Electronic Health Records [433] w Validation of Cardiovascular Events and Covariates in CPRD GOLD Using Paul R Dexter, Jinghua He, Lawrence Mark, Questionnaires to General Practitioners (GPS) [437] David Haggstrom, Charity Hilton, Joel Martin, Andrea V Margulis, Cristina Varas-Lorenzo, Christine L Bui, Lisa J McQuay, Jarod Baker, Jon Duke, Siu L Hui, Xiaochun Li. Ryan Ziemiecki, Maria Reynolds, Cristina Rebordosa, Manel Pladevall-Vila, (United States) Joan Fortuny, Elena Rivero-Ferrer, Estel Plana, Willem Jan Atsma, Kwame 8:30am Appenteng, Billy Franks, Stefan de Vogel, Milbhor D’Silva, Susana Perez- w Additive versus Multiplicative Survival Gutthann, Alejandro Arana. (Spain) Models: Prediction and Understanding of Effect Modification [434] Shirley V Wang, Jessica M Franklin. (United States)

9:30-10:00am Break/Posters/Exhibits (The Forum) 32nd

39 MAIN CONFERENCE | SATURDAY, AUGUST 27

10:00-11:30am 11:30am-1:00pm PLENARY SESSION ISPE Committee Meetings (Open to all participants; Lunch available.) Patient Voice in Clinical and • Education Committee • Publications Committee Pharmacoepidemiologic Research (Wicklow Meeting Room 3) (Wicklow Meeting Room 2a) (The Auditorium) • Development Committee • Bylaws Committee (Wicklow Meeting Room 4) (Wicklow Meeting Room 2b) Speakers: w Derick Mitchell, Science and Industry (IPPOSI) 11:45am-12:45pm w Rachel Lynch, FibroIreland Spotlight Poster Session w Irene Petersen, FISPE, University College London and Aarhus University (3rd Floor; Lunch available) w Cindy Girman, FISPE, CERobs Consulting, • AsPEN • DUR LLC and UNC Chapel Hill • BRACE • Medicines in Pregnancy Moderator: w Ken Hornbuckle, FISPE, Eli Lilly and Company 1:00-2:30pm CONCURRENT SESSIONS: This plenary session will focus on current efforts to include the patients’ voice in clinical and CONTRIBUTED PAPERS pharmacoepidemiologic research. Speakers will be asked to comment on patient engagement CV Effectiveness: How to Fix a Broken Heart (The Liffey A) as it relates to benefit-risk, safety and Moderator: Monteserrat Soriano-Gabarro pharmacoepidemiology studies. Specific topics covered during this session include: 1:00pm • Evolving paradigm (including, how should w Calcium Intake and 10 Year Risk of Incident Coronary Artery pharmacoepidemiologists leverage patients’ Calcification in the Multi-Ethnic Study of Atherosclerosis [438] voice in their research and how to increase Bridget Kruszka, Ka He, Joseph A Delaney, Gregory L Burke, Alvaro patient awareness of the importance of the Alonso, Diane Bild, Matthew J Budoff, Erin D Michos, John JB Anderson. health data for research) (United States) • Patient engagement in study development 1:15pm (including, refinement of study objectives, w Model Observational Bridging Study on the Effectiveness of Ezetimibe selection of study design, outcome definitions Upon Cardiovascular Outcomes [439] and recruitment strategy) and implementation • Patient engagement in interpretation, Jean Dallongeville, Denis Getsios, Jean Ferrières, Lucien Abenhaim, Michel communication and dissemination of study Rossignol Rossignol, Lamiae Grimaldi-Bensouda, Billy Amzal. (United findings Kingdom) 1:30pm 11:30am-1:00pm w Clinical Impact of an Interaction Between Clopidogrel and Selective Lunch/Poster Session B/Exhibits Serotonin Reuptake Inhibitors [440] (The Forum) Katsiaryna Bykov, Sebastian Schneeweiss, Macarius M Donneyong, Yaa-Hui Dong, Niteesh K Choudhry, Joshua J Gagne. (United States) Roundtable Discussions 1:45pm (Liffey Meeting Room 1) w Effectiveness of Recommended Drug Classes in Secondary Prevention of Acute Coronary Syndrome in France [441] To foster the ability of the more junior participants to network and first-timers to meet others attending Julien Bezin, Rolf Groenwold, Sanni Ali, Régis Lassalle, Anthonius de Boer, the ICPE, ISPE is hosting several informal lunchtime Nicholas Moore, Olaf Klungel, Antoine Pariente. (France) discussion roundtables on Friday and Saturday. 2:00pm The facilitators are listed below. There will be NO w Treatment with Carvedilol, Bisoprolol or Metoprolol Tartrate and the formal presentations made at the roundtables. The Risk of Mortality and Hospital Readmission Among Older Adults with objectives are discussion, information exchange, Heart Failure [442] and networking. Seating is limited; first-come, Sylvie Perreault, Simon de Denus, Michel White, Brian White-Guay, Marc first-served. Dorais, Marie-Pierre Dubé, Jean-Lucien Rouleau. (Canada) 2:15pm • Libby Roughead, FISPE, Building Sustainable Research Collaborations w Real-Life Statin Use and LDL-Cholesterol Reduction in a General Population: A Retrospective Study of Primary Care Electronic Medical • Thomas MacDonald, FISPE, Experimental Medicine Records [443] Maria Garcia-Gil, Marc Comas-Cufí, Elí León-Paz, Lia Alves-Cabratosa, • Ryan Kilpatrick, Positioning Epidemiologists for Success in Working for or with Biopharma Anna Ponjoan, Ruth Martí, Jordi Blanch, Rafel Ramos. (Spain)

32nd

40 MAIN CONFERENCE | SATURDAY, AUGUST 27

1:00-2:30pm CONCURRENT SESSIONS: CONTRIBUTED PAPERS Antispsychotic Use Across the Life Span (The Liffey B) Moderators: Wendy Camelo Castillo & Deborah Layton

1:00pm 2:00pm w Psychotropic Medications and the Risk of Neonatal Withdrawal [444] w Examining the Impact of UK Drug Safety Krista F Huybrechts, Brian T Bateman, Sonia Hernández-Díaz, , Rishi J Warnings on Antipsychotic Drug Prescribing Desai, Kathryn Rough, Helen Mogun, Elisabetta Patorno. (United States) to Older People with Dementia [448] 1:15pm Susan J Stocks, Roger T Webb, Evangelos w Channeling Bias in a Comparative Effectiveness Study of a Newly Kontopanatelis, Alistair Burns, Darren M Launched Antipsychotic [445] Ashcroft. (United Kingdom) Jessica J Jalbert, Christiane Gasse, Sumeet Bakshi, Yann Hamon, Kristel 2:15pm Van Impe, Pierre Cherubin, Ludger Hargarter, Andreas Schreiner, Joris w Antipsychotic Use, Frailty and Health Diels, Billy Amzal. (United States) Outcomes Among Residents of Assisted 1:30pm Living [449] w Mortality Risk of Second-Generation Antipsychotic (SGA) Kathryn Stock, Colleen J Maxwell, Joseph E Augmentation for Adult Depression [446] Amuah, Kate Lapane, Suzanne L Tyas, Susan Tobias Gerhard, T Scott Stroup, Christoph Correll, Brian L Strom, Cecilia E Bronskill, Andrew M Morris, Chaim M Bell, Huang, Zhiqiang Tan, Stephen Crystal, Mark Olfson. (United States) David B Hogan. (Canada) 1:45pm w Comparative Safety of Antipsychotic Medications in Hospitalized Myocardial Infarction Patients [447] Yoonyoung Park, Brian T Bateman, Dae Kim, Sonia Hernández-Díaz, , Elisabetta Patorno, Robert J Glynn, Helen Mogun, Krista F Huybrechts. (United States)

 

   


 



"
!


"




  
 " 


 

 




 #
"

 
  


 

 
! 




 

  
 
 

$

 #
!

!



 


 



 
! 
 !
"""




 




   

  "
   

 

 

%



 
! 

 

#
 
!
   

 
!

 
#

32nd  ,


*





%'
+
 
 &



(! && #"
(
'
 



( ' #")"'
"'%"' #"
#"%"
#"
%!#$ ! # #+
#"
   41 MAIN CONFERENCE | SATURDAY, AUGUST 27

1:00-2:30pm CONCURRENT SESSIONS: CONTRIBUTED PAPERS To Take or Not to Take? (Wicklow Hall 2) Moderators: Katja Taxis & Zhen-Fang Lin

1:00pm 1:45pm w Medication Taking Behaviour and Adverse w Is Hospitalisation Associated with the Unintentional Discontinuation of Health Outcomes in Community Dwelling Appropriate Long-Term Medication in the GP Prescribing Record Post Older Patients [450] Discharge? [453] Caitriona Cahir, Tom Fahey, Conor Teljeur, Patrick Redmond, Ron McDowell, Tamasine Grimes, Fiona Boland, Atieh Kathleen Bennett. (Ireland) Zarabzadeh, Ronan McDonnell, Carmel Hughes, Tom Fahey. (Ireland) 1:15pm 2:00pm w Adherence to Anti-Hypertensive Medication in w Reducing Patients’ Cumulative Exposure to Anticholinergic and the Elderly: A Prospective Cohort Study [451] Sedative Medication With Medication Reviews: A Randomized Paul Dillon, Paul Gallagher, Susan Smith, David Controlled Trial [454] Williams, Derek Stewart, Gráinne Cousins. Helene G van der Meer, Hans Wouters, Niesko Pras, Katja Taxis. (Ireland) (Netherlands) 1:30pm 2:15pm w Too Many, Too Few, Or Too Unsafe? Impact w Treatment Association with Preventable Hospitalizations in Older Of Inappropriate Prescribing On Mortality, Adults with Serious Mental Illness [455] And Hospitalisation In Community-Dwelling Ting-Ying Huang, Linda Simoni-Wastila. (United States) Adults, Aged 80 And Older [452] Maarten Wauters, Monique Elseviers, Bert Vaes, Jan Degryse, Robert Vander Stichele, Thierry Christiaens, Majda Azermai. (Belgium)

Drug-Induced Kidney and Liver Injury (Liffey Hall 2) Moderators: Judy Kelly & Susana Perez-Gutthann, FISPE

1:00pm 1:45pm w Acetaminophen Overdose-Related Morbidity w Diagnosis-Based Cohort Augmentation Using Laboratory (lab) Data in and Mortality in Canada [456] the FDA Sentinel Initiative: The Case of Chronic Kidney Disease (CKD) Samina Aziz, Andrew Slot, Vincent Punch, [459] Lucye Galand, Steven McFaul, Lisa Lange, David Smith, Susan Shetterly, James Flory, Joshua Gagne, Kevin Haynes, Lisa Marc Berthiaume. (Canada) J Herrinton, Christine Lu, Elisabetta Patorno, Marsha Raebel. (United States) 1:15pm 2:00pm w Comparative Hepatotoxicity of w Development of Risk Model to Predict Drug Induced Acute Kidney Echinocandins in Hospitalized Patients (pts): Injury in Hospitalized Patients [460] A Retrospective Cohort Study [457] Nakyung Jeon, Ben Staley, Carl Henriksen, Gigi Lipori, Almut G Francis Vekeman, Lisa S Weiss, Jalal Aram, Winterstein. (United States) Raluca Ionescu-Ittu, Shahrzad Moosavi, Student Award Recipient – Second Best Abstract Submitted by a Yongling Xiao, Wendy Y Cheng, Rachel Bhak, Student/Post-Doc Margaret Tawadrous, Mei Sheng Duh. (Canada) 2:15pm 1:30pm w Evaluation of the Risk of Acute Kidney Injury (AKI) Associated With w Detection and Quantification of Vancomycin Plus Piperacillin-Tazobactam (VPT) Compared With Flucloxacillin-Induced Liver Injury: A Vancomycin Plus Cefepime (VC) [461] Population-Based Cohort Study [458] Nakyung Jeon, Ben Staley, Kenneth P Klinker, Aakash B Ghandi, Almut G Kevin Wing, Krishnan Bhaskaran, Louise Winterstein. (United States) Pealing, Adrian Root, Liam Smeeth, Tjeerd P van Staa, Olaf H Klungel, Robert F Reynolds, Ian Douglas. (United Kingdom)

32nd

42 MAIN CONFERENCE | SATURDAY, AUGUST 27

1:00-2:30pm CONCURRENT SESSIONS: CONTRIBUTED PAPERS Biologics: “Miracle Drug” (Liffey Hall 1) Moderators: Mary Anthony & Timothy Beukelman

1:00pm w The Risk of Hospitalized Infection Associated with New Use of 1:45pm Abatacept versus TNF Inhibitors in Juvenile Idiopathic Arthritis [462] w Comparative Safety and Effectiveness of Denosumab versus Zoledronic Acid in Timothy Beukelman, Fenglong Xie, Melissa M Mannion, Lang Chen, Jie Patients with Osteoporosis: A Cohort Study Zhang, John Baddley, Kenneth G Saag, Jeffrey R Curtis. (United States) [465] 1:15pm Nam-Kyong Choi, Daniel H Solomon, Theodore w In Search of Predictors of Erythropoiesis-Stimulating Agents (ESAs) N Tsacogianis, Joan E Landon, Hong Ji Song, Resistance: A Population-Based Study [463] Seoyoung C Kim. (United States) Ylenia Ingrasciotta, Francesco Giorgianni, Ilaria Marcianò, Jenny Bolcato, 2:00pm Roberta Pirolo, Alessandro Chinellato, Achille P Caputi, Gianluca Trifirò. w A Real World Comparison of Methods for (Italy) Assessing Dosing Patterns of Biologic 1:30pm Therapies for Psoriasis [466] w Comparative Effectiveness and Safety of Erythropoiesis-Stimulating Ireny YK Iskandar, Richard B Warren, Ian Agents (Biosimilars versus Originators) in Clinical Practice: A Evans, Kathleen McElhone, Caroline M Owen, Population-Based Cohort Study [464] A David Burden, Catherine H Smith, Nick J Francesco Trotta, Valeria Belleudi, Fusco Danilo, Laura Amato, Alessandra Reynolds, Christopher EM Griffiths, Darren M Mecozzi, Flavia Mayer, Massimo Sansone, Marina Davoli, Antonio Addis. Ashcroft. (United Kingdom) (Italy) 2:15 pm w Trends in the Utilization of Biologics for Inflammatory Bowel Disease in the United States [467] Chao Chen, Abraham Hartzema. (United States)

A Methods Coddle (The Auditorium) Moderators: Robert Platt & Edmore Chamapiwa

1:00pm 1:45pm w Baseline and Time-Varying Determinants of Statin Adherence [468] w Performance of the Propensity Score in Chintan Dave, Abraham Hartzema, Haesuk Park, Almut Winterstein. the Presence of Nondifferential Exposure (United States) Misclassification: A Simulation Study [471] Mollie E Wood, Stavroula Chrysanthopoulou, 1:15pm w Determining Prescription Durations from the Parametric Waiting Time Hedvig Nordeng, Kate Lapane. (Norway) Distribution [469] 2:00pm Henrik Støvring, Anton Pottegård, Jesper Hallas. (Denmark) w Exposure Misclassification and Inverse Probability Weighting: A Plasmode 1:30pm Simulation [472] w Assessing and Reducing the Impact of Drug Exposure Measurement Errors Due to Non-Adherence: A Simulation Study [470] Mitchell M Conover, Kenneth J Rothman, Til Stürmer, Charles Poole, Michele Jonsson Funk. Yishu Wang, Michal Abrahamowicz. (Canada) (United States) 2:15pm w Evaluation of the Two-Stage Residual Inclusion Method for Instrumental Variable Estimation in Survival Analysis: A Simulation Study [473] Bianca Kollhorst, Michal Abrahamowicz, Iris Pigeot. (Germany)

32nd

43 MAIN CONFERENCE | SATURDAY, AUGUST 27

2:35-3:30pm (Open to all participants) (The Auditorium) ANNUAL MEETING OF ISPE MEMBERS & AWARDS CEREMONY

ANNUAL MEETING Student Awards --Third Best Abstract: Xiaojuan Li, University of Call to Order & Presidential Address North Carolina at Chapel Hill w Sonia Hernández-Diáz, FISPE, ISPE President --Second Best Abstract: Nakyung Jeon, Financial Report University of Florida w Alison Bourke, FISPE, Vice President, Finance The Stanley A. Edlavitch Award & Oral Presentation AWARDS CEREMONY (Best abstract submitted by a student/post-doc)

The Ronald D. Mann Best Paper Awards for Manuscripts • Rebecca Burne, McGill University Published in Pharmacoepidemiology and Drug Safety (PDS) New Statistical Methods for Using Validation 2015, Volume 24: Subsamples to Adjust for Time-Dependent Unmeasured Confounders in Marginal First Prize Structural Cox Models [474] Domperidone, Cytochrome P450 3A4 Isoenzyme Inhibitors and Rebecca Burne, Michal Abrahamowicz. (Canada) Ventricular Arrhythmia: A Nationwide Case–Crossover Study. Pharmacoepidemiol Drug Saf 2015: 24; pages 841-848 Induction of ISPE Fellows (FISPE) Hung-Lin Chen and Fei-Yuan Hsiao • John F Acquavella Honorable Mentions • Krista F Huybrechts • Tamar Lasky Alcohol Misuse, Genetics, and Major Bleeding Among Warfarin • Danica Marinac-Dabic Therapy Patients in a Community Setting. Pharmacoepidemiol Drug • Irene Petersen Saf 2015: 24; pages 619-627 • Maribel Salas Joshua A Roth, Katharine Bradley, Kenneth E Thummel, David L Veenstra • Rachel E Sobel and Denise Boudreau • Jasmanda H Wu Exposure to Systemic Antibacterial Medications During Pregnancy BOARD TRANSITION and Risk of Childhood Cancer. Pharmacoepidemiol Drug Saf 2015: 24; 821-829 Retiring Board Members & Officers Natalie C Momen, Jørn Olsen, Mika Gissler, Helle Kieler, Bengt Haglund and Jiong Li • Rhonda L Bohn, FISPE Jennifer B Christian, FISPE Presenters • • Yea-Huei Kao Yang, FISPE • Brian L Strom, FISPE, Editor-In-Chief • Alison Bourke, FISPE, Vice President Finance • Sean Hennessy, FISPE, Regional Editor for the Americas • John Seeger, FISPE, Immediate Past • Hubert G M Leufkens, FISPE, Regional Editor for Europe President

• Byung Joo Park, FISPE, Regional Editor for Asia-Pacific and ROW Induction of New Board Members nd 32 ICPE • Dorothee B Bartels, Industry/Service Provider • Mary E Ritchey, Chair, 2016 Scientific Program Committee (Europe/Africa) • Kathleen E Bennett, Local Host Committee • Lisa Gai Pont, FISPE, Academic (Asia/Pacific) • Lisa Gai Pont, FISPE, Spotlight Poster Sessions • Jennita Reefhuis, Government/Regulatory • J Bradley Layton, Spotlight Poster Sessions (Americas) • Vincent Lo Re, FISPE, Newcomer Track • June Raine, Government/Regulatory (Europe/ • Kristen B Bibeau, Luncheon Roundtable Discussions Africa) • Jessica Jalbert, Luncheon Rountable Discussions • Rachel E Sobel, FISPE, Industry/Service Provider (Americas) The Andrew McAfee Award (Best abstract submitted by a researcher or student residing in a developing country) Installation of 2016-2017 Officers • Md Jamal Uddin, Shahjalal University of Science & Technology • Tobias Gerhard, FISPE, Vice President Finance • Jesper Hallas, FISPE, President Elect The John Snow Award • Sonia Hernández-Díaz, FISPE, Immediate (Best abstract submitted by a female researcher or student living in a developing Past President country) • Kiyoshi Kubota, FISPE, President • Sze Ling Celine Chui, The University of Hong Kong Adjournment

32nd

44 MAIN CONFERENCE | SATURDAY, AUGUST 27

3:30-4:00pm 7:30-11:30pm Break/Posters/Exhibits (The Forum) Social Event (Guinness Storehouse)

Located in the heart of the 4:00-5:30pm St James’s Gate Brewery SYMPOSIA AND WORKSHOPS is the Guiness Storehouse. Home to the black stuff Perspectives from Causal Inference in the Era of Big since 1759, this massive (Healthcare) Data [475] (The Auditorium) seven-storey building, a former Guinness® w Susan Gruber, Michele Jonsson Funk, Robert Platt, James M Robins, fermentation plant, has Mireille Schnitzer, Til Stürmer, Alexander M Walker. (United States) been remodelled into the Making Optimal Use of Routinely Collected Data from shape of a giant pint of Guinness®. A visit will United Kingdom Electronic Health Records [476] teach you everything you (The Liffey B) ever wanted to know about w Ian J Douglas, Stephen J Evans, Laurie Tomlinson, Rohini Mathur, Krishnan this world famous beer. The highlight for many visitors ® Bhaskaran, Caroline Minassian, Sara Thomas, Rachel Williams, Wilhelmine is the Gravity Bar , symbolically the ‘Head of the Pint”, Meeraus, Jenni Quint, Janet Valentine, Liam Smeeth. (United Kingdom) where visitors can enjoy unparalleled panoramic views of Dublin city – views that are all the better with a pint in hand. Using “Big Data” in Early Safety Evidence Gathering and Targeted Surveillance for Newly Launched Medicines: Is A FACT: It the Right Time Now? [477] (The Liffey A) Guinness is the perfect diet drink. A pint of the good stuff contains only 198 calories. That’s less than w Hu Li, Andrew Bate, Joshua Gagne, Jim Slattery, Ken Hornbuckle, most light beers, wine, orange juice or even low fat milk. Stephen Motsko. (United States) What’s in a Code? Algorithm Validation in Drug Safety TONIGHT, the Guiness Storehouse will host ISPE. Join us for Studies [478] (Wicklow Hall 2) entertainment, food, dancing and a pint of the black stuff. w Beth L Nordstrom, Sheila Weiss, Stephan Lanes, Cunlin Wang. (United States) Full ICPE registration includes: The Epidemiological Approach to Rare Disease Research: • Admission to the Storehouse by badge or Challenges and Opportunities [479] (Liffey Hall 2) ticket (guests) • Food w Mary E Ritchey, Jessica J Jalbert, Alicia Gilsenan, Theodore Lystig, • Entertainment Michael Peng, Tzuyung D Kou, William Blumentals. (United States) • Transportation. Buses will shuttle between the CCD The Role of Evidence Synthesis in Drug Safety and the Storehouse, with the first bus departing from the CCD at 6:30pm; and from the Storehouse to ISPE Evaluation and Regulation [480] (Liffey Hall 1) meeting hotels w Simone Pinheiro, Wei Liu, Michael Nguyen, Marc Poitras, Yoshiaki A cash bar will be available. Uyama, Peter Arlett. (United States) A Discussion of Data Requirements and Methodologic Considerations for Evaluating the Real-World Effectiveness and Safety of Biosimilar Medicines [481] (Liffey Meeting Room 2) (Sponsored by the Biologics & Biosimilars Special Interest Group) w Veronique Kugener, Michael Kelsh, Brian Bradbury, Thijs Giezen, Jaclyn Bosco, Gianluca Trifirò, Amanda Golembesky. (United States)

5:30-6:15pm ISPE Council Meetings (Open to all participants.) • Academic Council (Liffey Meeting Room 1) • Government/Regulatory Council (Wicklow Meeting Room 3) • Industry/Service Providers Council (Wicklow Meeting Room 4) • Student Council & Chapters (Wicklow Meeting Room 5)

32nd

45 MAIN CONFERENCE | SUNDAY, AUGUST 28

7:00-8:00am 8:30-10:00am CONCURRENT SESSIONS: CONTRIBUTED PAPERS Coffee & Tea From Eve to… (The Liffey A) (The Forum) Moderators: Andrew Margulis & Colin Anderson-Smits Poster Session C Set-up 8:30am 9:15am w Effect of Concomitant Use of Tamoxifen and w Intrauterine Devices and the Risk of Uterine (The Forum & Selective Serotonin Reuptake Inhibitors on Perforations: Final Results from the EURAS- 3rd Floor) Mortality [791] IUD 5-Years Study [794] Macarius M Donneyong, Katsiaryna Bykov, Klaas Heinemann, Sabine Moehner, Thai Do 7:00am-4:30pm Pauline Bosco-Levy, Yaa-Hui Dong, Gagne Minh, Suzanne Reed. (Germany) Registration Joshua. (United States) 9:30am (Ground Foyer) 8:45am w Comparative Risk of Serious Infections w The Effect of BMI on Unintended Pregnancy During Pregnancy in Patients Treated with Rates Amongst Users of Combined Oral Immunomodulatory Agents [795] 7:30am-3:30pm Contraceptives [792] Speakers’ Rishi J Desai, Brian T Bateman, Krista F Anja Bauerfeind, Clare Barnett, Do Minh Thai, Huybrechts, Elisabetta Patorno, Sonia Ready Room Klaas Heinemann. (Germany) Hernández-Díaz, , Yoonyoung Park, Helen Mogun, Seoyoung C Kim. (United States) (Liffey Meeting 9:00am Room 4) w Unwanted Pregnancies in Women Using 9:45am Intrauterine Devices: Final Results from the w Venous Thromboembolism Risk Following 8:00am-1:45pm EURAS-IUD 5-Years Study [793] New Use of NSAIDs in U.S. Women [796] Exhibits/Posters Klaas Heinemann, Sabine Moehner, Suzanne Tracy L Kinsey, Robert J Glynn, Michele Reed, Thai Do Minh. (Germany) Jonsson Funk, Charles Poole, Ross J Simpson, (The Forum) Jr., Til Stürmer. (United States)

© 2016 Optum, Inc. Inc. Optum, © 2016

HEALTHIER IS HERE

Big data can transform our perception of health care — as long as we have the ability to interpret it. As a health services and innovation company, BIG DATA BECOMES Optum® powers modern health care by combining data and analytics with technology and expertise. We embed substantive SMART DATA knowledge and context into our applications and data WITH THE RIGHT products, adapting epidemiologic principles to big data to arrive at actionable insights. EXPERTISE Visit us at booth #25 optum.com/epidemiology

32nd

46 MAIN CONFERENCE | SUNDAY, AUGUST 28

8:30-10:00am CONCURRENT SESSIONS: CONTRIBUTED PAPERS From Eve to… (The Liffey A) My Achy Breaky Heart: Diabetes and CVD (The Liffey B) Moderators: Andrew Margulis & Colin Anderson-Smits Moderators: Cynthia Girman, FISPE & Gillian Caughey

8:30am 9:15am w Relationship Between Glycaemic w Magnitude of HbA1c Reduction and Attainment of Early Glycemic Burden and Micro- and Macrovascular Control Predict Cardiovascular Outcomes and Mortality: A Population- Complications in Patients with Type 2 Based Cohort Study of 24,752 People with Type 2 Diabetes Initiating Diabetes Mellitus [797] First Metformin Therapy [800] Jetty A Overbeek, Rients PT van Wijngaarden, Reimar W Thomsen, Lisbeth M Baggesen, Søren P Johnsen, Lars Joris Diels, Agata Schubert, Huub Straatman, Pedersen, Helene Nørrelund, Esben S Buhl, Christiane L Haase, Elisabeth Hervé Besson, Ewout W Steyerberg, Michiel Svensson. (Denmark) Hemels, Giel Nijpels, Ron MC Herings. (United 9:30am States) w Risk of Acute Myocardial Infarction Associated with Non-Insulin Blood 8:45am Glucose Lowering Drugs. Results from the SAFEGUARD Project [801] w Comparative Effects of Second Line Ingrid Leal, Gwen Muscle, Lorenza Scotti, Giorgia De Berardis, Irene Antidiabetic Agents Added to Metformin Bezemer, Miguel Gil, Elisa Martin, Anita McGregor, Niklas Schmedt, John D on Patient Centered Outcomes: A Seeger, Gianluca Trifirò, Serena Pecchioli, Cristina Varas-Lorenzo, Mark M Retrospective Cohort Study [798] Smits, Peter Rijnbeek, Miriam Sturkenboom, Silvana Romio. (Netherlands) James H Flory, Alvin I Mushlin, Ankit Shah, John 9:45am Cuddeback, Christopher Rowan. (United States) w Risk of Congestive Heart Failure (CHF) Associated with Vildagliptin: 9:00am Pan-European Non-Interventional Safety Study [802] w Changes in Diabetes Therapy One Year Rachael Williams, Raymond Schlienger. (United Kingdom) Before and After Discharge from a Heart Failure Hospitalization Among Patients with Type II Diabetes [1096] Ghadeer K Dawwas, Haesuk Park. (United States)

Keeping Up - A Potpourri (Wicklow Hall 2) Moderators: TBA

8:30am 9:15am w Risk of Erectile Dysfunction Associated with w Seasonality of Guillain-Barré Syndrome in the United Kingdom from Use of 5-Alpha Reductase Inhibitors for April 2005 to March 2015 [806] Benign Prostatic Hyperplasia or Alopecia Tom Cattaert, Germano LC Ferreira, Kaatje Bollaerts, Thomas Verstraeten. [803] (Belgium) Katrina Wilcox Hagberg, Hozefa A Divan, 9:30am Rebecca Persson, J Curtis Nickel, Susan S w Trends in Specialty Drug Spending and Use in Commercial Health Jick. (United States) Plans in the United States: 2003-2014 [807] 8:45am Stacie B Dusetzina. (United States) w Risk of Breast Cancer in Risperidone Users: 9:45am A Nationwide Cohort Study [804] w Identifying Incident Uterine Fibroids Using Electronic Medical Record Johan Reutfors, Louise Wingård, Lena Brandt, Data [808] Yiting Wang, Hong Qiu, Helle Kieler, Shahram Onchee Yu, Susan Reed, Renate Schulze-Rath, Jane Grafton, Kelly Bahmanyar. (Sweden) Hansen, Delia Scholes. (United States) 9:00am w Prescription Opioid Use and Infection- Related Hospitalization in Hemodialysis Patients [805] Abhijit V Kshirsagar, Xiaojuan Li, Magdalene Assimon, M Alan Brookhart. (United States) Student Award Recipient – Third Best Abstract Submitted by a Student/Post-Doc

32nd

47 MAIN CONFERENCE | SUNDAY, AUGUST 28

8:30-10:00am CONCURRENT SESSIONS: CONTRIBUTED PAPERS Adverse Outcomes and Infectious Diseases (Liffey Hall 2) Moderators: Emily Brouwer & Yared Santa-Ana Tellez

8:30am 9:30am w The Association Between Lansoprazole and Tuberculosis Disease; a w Risk of Hepatic Decompensation with Primary Care Based Cohort Study [809] Cumulative Mitochondrial Toxic Nucleoside Ian J Douglas, Laurie Tomlinson, Tom Yates, Krishnan Bhaskaran, Sinead Analogue Use in HIV/Hepatitis C Coinfection Langan, Sara Thomas, Liam Smeeth. (United Kingdom) [813] 8:45am Vincent Lo Re III, Bret Zeldow, Michael J w Do Proton Pump Inhibitors Impact Clinical Outcomes in Kallan, Janet P Tate, Dena M Carbonari, Jay R Staphylococcus Aureus Bacteremia? [810] Kostman, Robert Gross, Amy C Justice, Jason A Roy. (United States) Aisling R Caffrey, Tristan T Timbrook, George Sakoulas, Kerry L LaPlante. (United States) 9:45am w Slow Efavirenz Metabolism Alleles Are 9:00am Associated with Antiretroviral Failure in w Opioid Analgesic Use as a Risk Factor for Laboratory-Confirmed Botswana [814] Invasive Pneumococcal Diseases: A Nested Case-Control Study [811] Robert Gross, Scarlett L Bellamy, Bakgaki Andrew D Wiese, Marie R Griffin, William Schaffner, C Michael Stein, Ratshaa, Xiaoyan Han, Marijana Vujkovic, Edward F Mitchel, Jr., Carlos G Grijalva. (United States) Richard Aplenc, Andrew P Steenhoff, Mosepele 9:15am Mosepele, Athena Zuppa, Brian L Strom, w Hepatitis C Virus Infection Increases Risk of Developing Chronic Gregory P Bisson. (United States) Kidney Disease [812] Chao Chen, Wei Wang, Robert L Cook, Haesuk Park. (United States)

Meet us at ICPE

The power of knowledge. The value of understanding. LEARN MORE Let us help you reduce the uncertainty of risks to patients by investigating disease and connect: epidemiology, drug-outcome associations, and product usage in routine clinical practice rtihs.org/ICPE16 and by evaluating the effectiveness of your risk minimization strategies.

Research Triangle Park - Ann Arbor - Barcelona - Ljungskile - Manchester - Waltham

32nd

48 MAIN CONFERENCE | SUNDAY, AUGUST 28

8:30-10:00am CONCURRENT SESSIONS: CONTRIBUTED PAPERS Vaccines: Hit Me with Your Best Shot (Liffey Hall 1) Moderator: Catherine Cohet

8:30am 9:15am w Narcolepsy Incidence Rates in the SOMNIA (Systematic Observational w Effectiveness of the Quadrivalent Human Method for Narcolepsy and Influenza Immunization) Study [815] Papillomavirus Vaccine (QHPV) Against Caitlin N Dodd, Maria de Ridder, Daniel Weibel, Frank DeStefano, Tom Anogenital Warts (AGWs) in Manitoba, Shimabukuro, Bruce Carleton, Silvia Perez-Vilar, Angela Gentile, Norberto Canada: A Population-Based Study [818] Giglio, Maria Giner-Soriano, Lisen Arnheim Dalstrom, Wan-Ting Huang, Karla Willows, Songul Bozat-Emre, Erich Larry Svenson, Lars Pedersen, Jan Bonhoeffer, Miriam Sturkenboom, Steve Kliewer, Salah Mahmud. (Canada) Black. (Netherlands) 9:30am 8:45am w Long Term Effectiveness of Herpes Zoster w Assessing Quadrivalent HPV Vaccine Safety Using the Self-Controlled Vaccine Among Patients with Autoimmune Tree-Temporal Scan Statistic [816] and Inflammatory Diseases [819] W Katherine Yih, Judith C Maro, Michael D Nguyen, Adamma Mba-Jonas, Huifeng Yun, Fenglong Xie, John W Baddley, Meghan A Baker, Carolyn Balsbaugh, David V Cole, Inna Dashevsky, Martin Kevin L Winthrop, Kenneth G Saag, Jeffrey R Kulldorff. (United States) Curtis. (United States) 9:00am 9:45am w Human Papillomavirus Vaccination and Risk of Autoimmune Diseases: w New Methods to Estimate Vaccination A Large Cohort Study of Over 2 Million Young Girls in France [817] Coverage from Health Care Databases [820] Christophe Chaignot, Sara Miranda, Cedric Collin, Rosemary Dray-Spira, Kaatje Bollaerts, Tom Cattaert, Toon Braeye, Alain Weill, Mahmoud Zureik. (France) Klára Berensci, Marius Gheorge, Vincent Bauchau, Miriam Sturkenboom, Hanne-Dorthe Emborg. (Belgium)

Analytic Approaches for Controlling and Exposure Misclassification(The Auditorium) Moderators: Suzanne Cadarette & Mollie Wood

8:30am 9:15am w Multi-State Models – A Complimentary Approach to Group Based w Adjustment for Unobserved Confounders in Trajectory Models [821] Health Administrative Databases [824] Aaron N Winn, Stacie B Dusetzina. (United States) Bernard Silenou Chawo, Marta Avalos 8:45am Fernandez, Antoine Pariente, Hélène Jacqmin w Covariate Adjustment of Cumulative Incidence Functions for Gadda. (France) Competing Risks Data Using Inverse Probability of Treatment 9:30am Weighting [822] w The Impact of Censoring on Discontinuation Anke Neumann, Cécile Billionnet. (France) When Modeling the Disease Risk Score [825] Justin Bohn, Richard Wyss, Joshua Gagne. 9:00am w Propensity Score Methods for Subgroup Analyses: Investigating (United States) Covariate Balance [823] 9:45am Phyo T Htoo, Caroline J Mariano, Sharon Peacock-Hinton, Katie Reeder- w Survival Bias in Exposure Crossover Studies Hayes, Michele Jonsson Funk, Til Stürmer, Jennifer L Lund. (United States) [826] Thy Do, Emil Scosyrev. (United States)

10:00-10:30am Break/Posters/Exhibits (The Forum)

32nd

49 MAIN CONFERENCE | SUNDAY, AUGUST 28

10:30am-Noon PLENARY SESSION

Multiple Database Study Design and Inference (The Auditorium)

Speakers: expectation of greater precision and/or validity for drug-effect studies. Debate w Miriam Sturkenboom, FISPE, is still ongoing on whether to use all available databases or to select certain Erasmus University Medical Center databases. When multiple databases are analyzed together the question w Olaf Klungel remains whether and under what circumstances a common data model (CDM) University Medical Centre Utrecht is preferred. When using CDMs, which models are available and what are their w Tobias Gerhard, FISPE pros and cons (e.g. Jerboa, OMOP CDM, IMEDS, EMIF, etc)? Rutgers University w Andrew Bate (Chair) Olaf Klungel: Analytic Strategy - How to Decide What Methods to Employ Pfizer Ltd and How Many? When conducting drug-effect hypothesis testing studies multiple choices have Across the globe important experience has been to be made on design and analysis. During the past decades these choices gained with multi-database initiatives such as have become less based on one specific design and analysis based on the OMOP, Mini-Sentinel, CNODES, PROTECT, EU- hypothesized mechanism of action of a drug, including exposure-time-event ADR, and ASPEN. These initiatives used different relationship. More and more, sensitivity analyses on various methodological approaches. In this symposium we will discuss parameters are becoming common practice. Should sensitivity analysis always the lessons learnt from these initiatives —from the be conducted on all parameters and should it include the whole range of perspectives of data, analysis, and interpretation— possible values, or should these be informed by certain plausible ranges, and aiming to elicit common themes, and examining to how to decide on these ranges? what extent discrepancies in findings and lessons learnt can be attributed to differences in approach. Tobias Gerhard: Output - Interpretation of Studies - The Impact of a Priori Versus Post-Hoc Decisions Miriam Sturkenboom: The Data - What Data Sets When drug-effect studies are conducted in multiple databases it is not to Include in a Multiple Country/Site Study? straightforward to decide on consistency of results. When should results across Several multi-country/site initiatives have multiple databases be considered similar and when not? Is a frequentist approach been launched over the past decade with the sufficient to test heterogeneity or should Bayesian approaches be applied?

EVIDENCE GENERATION UNLEASHED

Powerful analytic software for healthcare data Fast, transparent, reproducible analysis Supports multiple, diverse sources of real-world data

evalytica.com

32nd

50 MAIN CONFERENCE | SUNDAY, AUGUST 28

Noon-1: 30pm 1:30-3:00pm 3:15-4:45pm Lunch/Poster SYMPOSIA AND WORKSHOPS CONCURRENT SESSIONS: Session C/ CONTRIBUTED PAPERS Exhibits Pattern Discovery in Observational (The Forum) Health Data - What We Did Not Know Practice of Epidemiology in to Look For [827] (The Auditorium) Pregnancy Studies (The Liffey A) ISPE Board w Meredith Y Smith, Tarek Hammad, Rebecca Moderator: Christina Chambers of Directors Noel, Paul Huckle, Francesco Pignatti, Declan Luncheon Noone. (United States) 3:15pm Clinical And Analytic Considerations w Validity of a Web-Based Questionnaire to (Liffey Meeting Assess Perinatal Outcome [833] In The Selection And Evaluation Room 1) Marleen MHJ van Gelder, Saskia Open to ISPE Of Comparators In Observational Vorstenbosch, Lineke Derks, Bernke te members; members Database Studies [828] (The Liffey B) Winkel, Eugène P Puijenbroek, Nel Roeleveld. may contact info@ w (Netherlands) pharmacoepi.org if they Patrick B Ryan, Saad Shakir, David Madigan. would like to attend. (United States) 3:30pm w Consistency of Measures of Asthma Pharmacoepidemiology and Risk Symptom Control Collected During 12:15-1:15pm Management Planning: Essential Pregnancy vs. Retrospectively at 6 Months Spotlight Enablers for Development of Post-Partum [834] Poster Session Innovative Medicines [829] Christina D Chambers, Ronghui Xu, Mofei Li, (3rd Floor; Lunch Diana L Johnson, Yunjun Luo. (United States) (The Liffey A) 3:45pm available) w Peter R Arlett, June Munro Raine, Almath w Comparison of Electronic Healthcare Data Vaccines • Spooner, Sebastian Schneeweiss, Eva and Prospective Face-to-Face Studies for Flahavan. (United Kingdom) • CER Evaluating Neurodevelopmental Disorders Following In-Utero Medication Exposures • Biologics Transitioning to ICD-10: International [835] Lessons Learned and Strategies for Rachel Charlton, Anita McGrogan, Julia Moving Forward [830] (Wicklow Hall 2) Snowball, Laura Yates, Amanda Wood, Jill w Joshua J Gagne, Lisa M Lix, Sengwee Toh, Clayton-Smith, Henry Smithson, Jonathan David D Dore, Manel Pladevall-Vila. (United Richardson, Neil McHugh, Simon Thomas, Gus States) Baker, Rebecca Bromley. (United Kingdom) Who to Ask and How? Preference- 4:00pm w Bias from Restricting to Live Births in Based Methods for Benefit-Risk a Study of Prescription Drug Use and Assessment [831] (Liffey Hall 2) Pregnancy Complications: A Simulation [836] w Kevin Marsh, Hans L Hillege, Quazi Ataher, Elizabeth A Suarez, Suzanne N Landi, Mitchell Tommi Tervonen. (United Kingdom) M Conover, Michele Jonsson Funk. (United States) The Agony and the Ecstasy: The 4:15pm Creation of the Revised ICH M4E w Utilization Patterns of Drugs or Biologics Benefit-Risk Assessment Guideline with Pregnancy Exposure Registries in and Practical Implications for Patients, Pregnant and Matched Non-Pregnant Women in the Sentinel Database [837] Industry and Regulators [832] Steven T Bird, Lockwood Taylor, Christian (Liffey Hall 1) Hampp, Leyla Sachin, Darren Toh, Susan w Meredith Y Smith, Tarek Hammad, Rebecca Andrade, Katie Haffenreffer, Marsha Reichman, Noel, Paul Huckle, Francesco Pignatti, Declan Kate Gelperin. (United States) Noone. (United States) 4:30pm w Oral Contraceptive Induced Hypertension 3:00-3:15pm and Subsequent Pre-Eclampsia: A Break/Posters/Exhibits (The Forum) Retrospective Cohort Study [838] Brian J Cleary, Maeve Eogan, Sharon Sheehan. (Ireland)

32nd

51 MAIN CONFERENCE | SUNDAY, AUGUST 28

3:15-4:45pm CONCURRENT SESSIONS: CONTRIBUTED PAPERS Disease Burden from Clinical Databases (The Liffey B) Moderators: Shahram Bahmanyar & Daniel Mines

3:15pm 4:00pm w Time Trends Of Idiopathic Pulmonary w Epidemiological Assessment of Real-World Treatment Patterns in Fibrosis (IPF) in the United Kingdom Advanced Pancreatic Neuroendocrine Tumors in the Era of Targeted (UK) from 1999 to 2013 Using the Clinical Therapy: Perspectives from an Academic Tertiary Center and Practice Research Datalink (CPRD) [839] Community Oncology Practices [842] Mellissa Yong, Jenny Chia, David Oliveri, Lynn Huynh, Maurice Herring, Mei S Duh, Francis Vekeman, Audrey Tiew, Hubert Chen, Dorothy Cheung, Matt Cohen, Maureen P Neary, Emily Bergsland. (United States) Pavel Napalkov. (United States) 4:15pm 3:30pm w 10-Year Landmark Survival and Characteristics of Advanced Non- w The Impact and Longevity of Measles- Small Cell Lung Cancer (aNSCLC) Long-Term Survivors [843] Associated Immune Suppression [840] Ben Lyons, Joe Simpson, Margaret E McCusker, Alan B Sandler. Caitlin N Dodd, Kartini Gadroen, Gwen (United States) Masclee, Maria de Ridder, Daniel Weibel, David 4:30pm van de Vijver, Rik de Swart. (Netherlands) w Reoperation Due to Surgical Bleeding in Breast Cancer Patients and 3:45pm Breast Cancer Recurrence: A Danish Population-Based Cohort Study w Blood Pressure and Risk of Dementia in [844] a Cohort of 2.6 Million People Over Two Rikke N Pedersen, Krishnan Bhaskaran, Uffe Heide-Jørgensen, Mette Decades [172] Nørgaard, Peer M Christiansen, Niels Kroman, Henrik T Sørensen, Deirdre Nawab Qizilbash, John Gregson, Michelle P Cronin-Fenton. (Denmark) E Johnson, Neil Pearce, Ian Douglas, Kevin Wing, Stephen JW Evans, Stuart J Pocock. (United Kingdom)

Driving Innovation in Healthcare Analytics BHE combines research expertise, powerful analytic solutions, and a variety of real-world datasets to provide actionable insights to the life science, provider, and payer communities

Visit us at our booth to learn about: Instant Health Data (IHD) • Generating Actionable Insights in Epidemiologic Studies • Analyses in Minutes Rather than Days or Weeks Custom Research • Observational Studies • Statistical, Epidemiologic, and Economic Models

For more information contact Joseph Menzin or Jack Fuller 20 Fox Road / Waltham, MA, 02451 / (781) 290-0808

www.bhei.com 32nd

52 MAIN CONFERENCE | SUNDAY, AUGUST 28

3:15-4:45pm CONCURRENT SESSIONS: CONTRIBUTED PAPERS CV Adverse Events: Affairs of the Heart (Wicklow Hall 2) Moderator: Nancy Santanello, FISPE & J Bradley Layton

3:15pm 4:00pm w Opioid Use Prior to Incident Myocardial w Incidence of Cardiovascular Events in New Users of Overactive Infarction and Subsequent Risk of Ischemic Bladder Medications in Denmark [848] Stroke, Venous Thromboembolism, and Jesper Hallas, Andrea V Margulis, Anton Pottegård, Nina Kristiansen, Death [845] Christine L Bui, Whitney Krueger, Willem Jan Atsma, Kwame Appenteng, Troels Munch, Erzsébet Horváth-Puho, Kasper Billy Franks, Stefan de Vogel, Milbhor D’Silva, Susana Perez-Gutthann, Adelborg, Lars Pedersen, Morten Schmidt, Alejandro Arana. (Denmark) Henrik T Sørensen. (Denmark) 4:15pm 3:30pm w Cardiovascular Risk in Users of Antimuscarinic Drugs for Overactive w Long Acting Bronchodilators and Risk Bladder: A Cohort Study in the Swedish National Registers [849] of Myocardial Infarction in Patients with Marie Linder, Andrea V Margulis, Ingegärd Anveden-Berglind, Shahram Chronic Obstructive Pulmonary Disease and Bahmanyar, Christine L Bui, Willem Jan Atsma, Kwame Appenteng, Billy Who Are at High Risk for Cardiovascular Franks, Stefan de Vogel, Milbhor D’Silva, Susana Perez-Gutthann, Alejandro Disease: A Quasi-Cohort Approach [846] Arana. (Sweden) Sunning Tao, Samy Suissa, Sophie Dell’Aniello, 4:30pm Pierre Ernst. (Canada) w Development of a Predictive Model for Drug-Induced QT Prolongation 3:45pm in the Inpatient Setting Using Electronic Health Record Data [850] w Association of Proton Pump Inhibitor Use Juan M Hincapie-Castillo, Benjamin Staley, Carl Henriksen, Arwa Saidi, Gigi and Acute Myocardial Infarction Among Lipori, Almut G Winterstein. (United States) Privately Insured Adults, 2001-2014 [847] Suzanne N Landi, Jennifer L Lund, Virginia Pate, Robert S Sandler. (United States)

32nd

53 MAIN CONFERENCE | SUNDAY, AUGUST 28

3:15-4:45pm CONCURRENT SESSIONS: CONTRIBUTED PAPERS Adverse Outcomes of Glucocorticoid and Immunomodulator Use (Liffey Hall 2) Moderator: Cunlin Wang

3:15pm 4:00pm w Trends in Oral Glucocorticoid Utilization w Risk of Lymphoma in Users of Topical Tacrolimus, Pimecrolimus and Among Older Adults with Respiratory Corticosteroids (JOELLE Study) [854] Disease [851] Jordi Castellsague, Josephina JG Kuiper, Anton Pottegård, Ingegärd A M Amine Amiche, Linda E Lévesque, Tara Berglind, Daniel Dedman, Lia Gutierrez, Brian Calingaert, Myrthe PP van Gomes, Jonathan D Adachi, Suzanne M Herk-Sukel, Jesper Hallas, Anders Sundström, Arlene Gallagher, James Cadarette. (Canada) A Kaye, Carolina Pardo, Kenneth J Rothman, Susana Perez-Gutthann. (Spain) 3:30pm w Use of Glucocorticoids and Risk of 4:15pm Community-Acquired Staphylococcus w Pharmacological Treatments Preceding Diagnosis Of Progressive aureus Bacteraemia: A Population-Based Multifocal Leukencephalopathy [855] Case-Control Study [852] Sarah Burkill, Ellen Iacobaeus, Shahram Bahmanyar, Lou Brundin, Michael Jesper Smit, Achim Kaasch, Mette Søgaard, Fored, Tomas Olsson, Scott Montgomery. (Sweden) Reimar W Thomsen, Henrik Nielsen, Trine 4:30pm Frøslev, Henrik C Schønheyder. (Denmark) w Association Between Breast Cancer Recurrence With 3:45pm Immunosuppression In Rheumatoid Arthritis And Inflammatory Bowel w Use of Glucocorticoids and the Risk of Disease: A Cohort Study [856] Osteoporotic Fracture in Patients with Ronac Mamtani, Amy S Clark, Frank I Scott, Colleen M Brensinger, Ben Sarcoidosis [853] Boursi, Lang Chen, Fenglong Xie, Huifeng Yun, Mark T Osterman, Jeffrey R Olorunfemi Oshaghagbemi, Johanna Curtis, James D Lewis. (United States) Driessen, Peter Vestergaard, Joop van den Bergh, Frank deVries. (Netherlands)

A KANTAR HEALTH COMPANY

MEET OUR DECISION SUPPORT AND SAFETY EXPERTS AT BOOTHS 35/40 + + DRUG UTILIZATION STUDIES, PASS AND EPI DATABASE® SAFETY REGISTRIES + + CANCERMPACT® PATIENT METRICS GLOBAL NETWORK OF PATIENT-LEVEL + DATASETS 40+ YEARS’ EXPERTISE IN PHYSICIAN + AND PATIENTCENTERED STUDY WORLD-CLASS EPIDEMIOLOGICAL DATA DESIGNS WITH DATA COLLECTED + THROUGH OUR PROPRIETARY, NATIONAL HEALTH AND WELLNESS VALIDATED EDC SYSTEM SURVEY (NHWS)

info.kantarhealth.com/icpe2016

32nd

54 MAIN CONFERENCE | SUNDAY, AUGUST 28

3:15-4:45pm CONCURRENT SESSIONS: CONTRIBUTED PAPERS Thin Blood: Anticoagulants (Liffey Hall 1) Is it Safe Enough? (The Auditorium) Moderator: John Acquavella, FISPE Moderators: Stella Blackburn, FISPE & Ola Caster

3:15pm 3:15pm w Safety and Effectiveness of Dabigatran Relative to Warfarin in Routine w Are Natural Language Processing Models Clinical Practice–Interim Results of a Long-Term Study Program [857] For Pneumonia Surveillance Valid For Krista F Huybrechts, Dorothee B Bartels, Chandrasekar Gopalakrishnan, Benchmarking Event Rates Across John D Seeger, Kristina Zint, Katsiaryna Bykov, Sebastian Schneeweiss. Healthcare Institutions? [863] (United States) Christian M Rochefort, Aman D Verma, 3:30pm Tewodros Eguale, David L Buckeridge, Alan J w Comparative Effectiveness and Safety of New Oral Anticoagulants Forster. (Canada) (NOACs) and Warfarin in Patients with Atrial Fibrillation: A Multi- 3:30pm Database Study in the US and UK [858] w Analysis of Patient Narratives in Disease M Sanni Ali, Rianne van den Ham, Rolf HH Groenwold, Mikkel Z Ankarfeldt, Blogs: Enhancing Pharmacovigilance Using Erpur Adalsteinsson, Cynthia Girman, Olaf H Klungel. (Netherlands) Real-World Health Data on the Internet [864] 3:45pm Shinichi Matsuda, Kotonari Aoki, Shiho w Clinical Events Preceding Changes During Treatment With Non-VKA Tomizawa, Masayoshi Sone, Sawako Satomi, Oral Anticoagulants In Patients With Atrial Fibrillation [859] Terumi Nakayama, Riwa Tanaka, Hiroshi Kuriki, Maja Hellfritzsch, Erik L Grove, Steen E Husted, Lotte Rasmussen, Birgitte K Yoichiro Takahashi. (Japan) Poulsen, Søren P Johnsen, Jesper Hallas, Anton Pottegård. (Denmark) 3:45pm 4:00pm w Prediction Model Based Algorithm for a w Use of New Oral Anticoagulants in the Secondary Care Setting vs Computer-Assisted Database Screening Primary Care in the UK: Interim Results from Two Post-Authorisation Tool [865] Studies [504] Joep Scholl, Florence van Hunsel. (Netherlands) Deborah Layton, Alison Evans, Miranda Davies, Sandeep Dhanda, Saad 4:00pm AW Shakir. (United Kingdom) w Assessment of the US Food and Drug 4:15pm Administration’s Sentinel Analysis Tools: w The Safety and Effectiveness of New Oral Anticoagulants versus Angiotensin-Converting Enzyme Inhibitors Vitamin K Antagonists - Pilot Implementation of a Real-Time And Angioedema [866] Monitoring Program in Italy [861] Joshua J Gagne, Xu Han, Sean Hennessy, Flavia Mayer, Ursula Kirchmayer, Nera Agabiti, Valeria Belleudi, Giovanna Charles E Leonard, Elizabeth A Chrischilles, Cappai, Mirko Di Martino, Danilo Fusco, Sebastian Schneeweiss, Marina Ryan M Carnahan, Shirley V Wang, Candace Davoli, Elisabetta Patorno. (Italy) Fuller, Aarthi Iyer, Hannah Katcoff, Tiffany S 4:30pm Woodworth, Patrick Archdeacon, Tamra E w Stroke, Bleeding, and Mortality Risks in Older Patients Treated with Meyer, Sebastian Schneeweiss, Sengwee Toh. Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation [862] (United States) David J Graham, Marsha E Reichman, Michael Wernecke, Ya-Hui Hsueh, 4:15pm Rima Izem, Mary Ross Southworth, Yuqin Wei, Jiemin Liao, Margie R w An Automatized Model for Sequential Goulding, Katrina Mott, Yoganand Chillarige, Thomas E MaCurdy, Chris Monitoring of Effectiveness of New Drugs Worrall, Jeffrey A Kelman. (United States) Using Dronedarone as Example [867] Thomas Cars, Martin Neovius, Lars Lindhagen, Rickard E Malmström, Jonas Schwieler, Björn Wettermark, Johan Sundström. (Sweden) 4:30pm w Monitoring All Drugs for Specific Outcome in the Sentinel System [88] Judith C Maro, Gerald J Dal Pan, Inna Dashevsky, Jeffrey S Brown, Martin Kulldorff. (United States)

32nd

55 Powerful Data. High-Quality Research. Think Truven Health Analytics.

When you need ‘big’ data for pharmacoepidemiological We are unveiling Treatment research, you also need leading experts in prospective and Pathways’ advanced drug retrospective analytics and data linkages working with you. treatment pattern analysis We have both — data and experienced epidemiologists … capabilities at the conference, plus specialty data found nowhere else. so visit our booth at the ICPE 32nd International Conference § Drug Treatment Pattern Analysis and Visualization Tool on Pharmacoepidemiology & § Retrospective and Prospective Research Therapeutic Risk Management § MarketScan® Research Databases in Dublin. § Linked Data § DRUG-REAX® Data

©2016 Truven Health Analytics, an IBM Company. All rights reserved. All other product names used herein are trademarks of their respective owners. LS_16938_0616

Consulting in Clinical Drug Safety, Pharmacovigilance, and Medical Product Epidemiology since 1988! The Degge Group, Ltd. 9302 Lee Highway, Suite 700, Fairfax, VA 22031 USA +1 571.490.8020 [email protected] www.deggegroup.com Visit Booth #15 to learn more

Identify databases by subscribing to our online compendium of ~275 population database profiles from 36 countries Search, review, and compare database profiles [Profiles are reviewed by respective database managers and frequently updated.] Access specialized glossary and interactive maps of databases

+1 571.490.8400 [email protected] www.bridgetodata.org Your connection to ® healthcare databases B.R.I.D.G.E. TO DATA is an online service provided by DGI, LLC, a non-profit organization worldwide® MAIN CONFERENCE | SUNDAY, AUGUST 28

4:45-5:30pm THE FINAL WORD 5:45-6:30pm 2017 ICPE Scientific Program Spotlight Poster Awards (The Auditorium) Committee Meeting (EcoCem) w Lisa Gai Pont, FISPE, Co-Chair, Spotlight Sessions w J Bradley Layton, Co-Chair, Spotlight Sessions

2017 ISPE Meetings Mid-Year - London w Alison Bourke, FISPE, Co-Chair, Program Planning Committee

ICPE - Halifax w Adrian Levy, Chair, 2017 Scientific Program Committee w Ingrid Sketris, Chair, 2017 Local Host Committee Adjournment of ICPE 2016 w Mary E Ritchey, Chair, ICPE 2016 Scientific Program Committee

ICPE 2017 Drawing for complimentary registrations

See you next year in Halifax!

rd ICPE International33 Conference on Pharmacoepidemiology & Therapeutic Risk Management August 23-27, 2017thalifax convention centRE Nova Scotia Halifax

32nd

57 HEOR/Safety

Drug Payment Predictive Cohort builderTreatment CORE Global Oncology Global oncology Multi-country Enriched Social Scientific, utilization studies by use analytics insights Diabetes Model Insights insights studies datasets media Medical & Safety Trial Patient Drug Retrospective Hybrid/Mixed Economic Market access Patient journey Brand Marketing optimization recruitment utilization studies studies models Performance effectiveness studies

Your Partner of Choice for Building an RWE Ecosystem

IMS Health brings together the real-world data (RWD), technology, analytics, and scientific and commercial expertise you need to support product value, safety, access and price. • 500+ million anonymous longitudinal patient data records including EMR, claims data, hospital data and lab tests in 25+ markets • Data sourcing and enriched RWD capabilities, supported by an expanding RWD Catalogue of 2,200+ sources globally • Leading edge technology and analytics • Experts in 20+ markets with deep specialism in RWE, pharmacoepidemiology, drug safety, HTA, and payer requirements to translate insights into actions • 3,500+ publications building healthcare knowledge

IMS HEALTH REAL-WORLD EVIDENCE IMS Health Real-World Evidence Solutions SOLUTIONS Uncovering insights from real-world data to improve decision making and patient outcomes

[email protected] • www.imshealth.com/rwe USA +1 646 596 6053 • Europe +44 (0) 20 3075 4800 Asia Pacific +65 6412 7365 • Latin America +52 55 5089 5205

IMS Health • 485 Lexington Ave, 26th Floor, New York, NY 10017, USA ©2016 IMS Health Incorporated and its affiliates. All rights reserved. Trademarks are registered in the United States and in various other countries.

IMSH_AP ecosystem tree_advert ICPE 2016.indd 1 04/07/2016 13:55 POSTER SESSION A: Friday, August 26 | 8:00am - 6:00pm

Overview NUMBERING SYSTEM

Poster sessions are designed to give presenters an opportunity Note: Each poster board will be numbered. to discuss informally their research with colleagues interested in Neither ISPE nor Presenters should attach their posters to their research. The purpose of the posters is to visually stimulate the Convention the board number corresponding to the interest in the research, to present sufficient information for Centre Dublin will be number assigned to their poster on that viewers to understand the methods, results, and significance responsible for any day as listed in the Final Program, which poster that is left up of the research, and to promote conversations and networking will be available at the ISPE Registration among conference participants. overnight or is lost or damaged. Desk, as well as included online in Abstracts2view. The POSTER BOARD POSTER SESSION NUMBER is the first number (or letter) listed. The ABSTRACT NUMBER, for use Spotlight Session posters will be displayed in the Third Floor Foyer while all other in locating abstracts in the Final Program posters will be displayed in The Forum of the Convention Centre Dublin, August or in Abstracts2view, is listed after the 26-28. Each day will have a separate poster session and Spotlight Sessions. All posters abstract title. for a specific day’s session must be removed at the end of that day. Example 97 Characteristics of Patients with w Friday, August 26...... Poster Session A Depression Who Initiate Antidepressant and Benzodiazepine Therapy w Saturday, August 27...... Poster Session B Simultaneously, Compared with w Sunday, August 28...... Poster Session C Antidepressant Monotherapy [176] Greta A Bushnell, Alice White, Til Stürmer, 1. Set Up: Bradley N Gaynes, Virginia Pate, Deborah Azrael, Matthew Miller. (United States) 7:00am-8:00am; all posters must be in place by 8:00am. The poster areas Key (including floor) must remain clear and clean of tubes. 97 POSTER BOARD Number 176 PUBLICATION Number 2. Hours: Posters will be displayed from 8:00am to 6:00pm on Friday and Saturday, and 1. Poster Specifications from 8:00am to 1: 45pm on Sunday. Posters must be designed to 3. Discussion Time: fit a freestanding poster board approximately 4 feet WIDE x 8 feet General Poster Sessions: Presenters should be at their posters between 12:15- HIGH (1.2 meter WIDE x 2.4 meters

1:15pm on Friday (A) and Sunday (C); and between 11:45-12:45pm on Saturday (B) HIGH). Only VERTICAL/PORTRAIT [The Forum] posters will be allowed. Spotlight Poster Sessions: Organized by the ISPE Special Interest Groups (SIGs). 2. Disclosure Statement Presenters should be at their posters between 12:15-1:15pm on Friday (A) and A disclosure statement must Sunday (C); and between 11:45-12:45pm on Saturday (B). [Third Floor Foyer] accompany each abstract. This statement should follow the title page The spotlight sessions offer pre-selected presenters the opportunity to present and should be a positive disclosure their work and to discuss their results with an audience. When the spotlight chair of all funding sources for the current and audience stop at your poster, please give a brief, 3-minute, presentation and to project as well as other potentially answer questions about your research. conflicting relationships that existed at any time during the conduct of the Friday w Adherence Spotlight Session Prizes study, or at a minimum, the one-year w Databases A group of judges will select the period before the annual meeting. w Devices best posters of each Spotlight Non-financial conflicts (e.g., a close w Pediatrics Session. The best presenters relationship with, or a strong antipathy Saturday w AsPEN will receive an invitation to to, a person whose interests may be w BRACE display their poster for the affected) should also be disclosed. duration of the ICPE. The w Drug Utilization Research winners will be announced 3. Call4Posters w Medications in Pregnancy during The Final Word at Posters ordered through Call4Posters Sunday w Vaccines 4:45pm, Sunday, August 28. can be picked up in the exhibit hall w CER (The Forum) at the times below. w Biologics & Biosimilars. Poster Pick Up Schedule: Thursday, August 25: 1:00pm-5:00pm 4. Take Down: Friday, August 26: 7:00am-1:00pm Saturday, August 27: 7:00am-1:00pm All posters must be taken down by 6:30pm on Friday and Saturday, and by Sunday, August 26: 7:00am-Noon 5:00pm on Sunday.

32nd

59 POSTER SESSION A: Friday, August 26 | 8:00am - 6:00pm Spotlight Sessions: 12:15 - 1:15pm Spotlight Session-Adherence H. An Example of Exposure Heterogeneity O. Evaluating the Utility of the CPRD When Pooling Epidemiologic Studies GOLD-HTI Linkage: Anticoagulant A. Polypharmacy and Adherence to TNF- for Meta-Analysis of Antiretroviral Prescribing at the GP Practice alpha Inhibitors: Variation by Specific Medication Adherence [87] Compared to Hospital Dispensed Concurrent Medications [80] Mary-Ellen Mackesy-Amiti, Lauren Strand, Medication at Discharge Date [95] Sruthi Adimadhyam, Wan-Ju Lee, Gregory Robin Nance, Redonna Chandler, William Arlene M Gallagher, Rachel Tham, Hassy S Calip. (United States) Cunningham, Elise Riley, Shruti Mehta, Dattani, Adam Collier, Frank de Vries, Tim Frederick Altice, Wendee Wechsberg, Williams. (United Kingdom) B. Predicting Adherence to Chronic Chinazo Cunningham, Charles Cleland, Disease Medications in Patients with Lisa Metsch, Daniel Feaster, Carlos del Long-Term Initial Medication Fills [81] Spotlight Session-Devices Rio, Curt Beckwith, Ann Kurth, Irene Kuo, Julie C Lauffenburger, Jessica M Franklin, Bridget Kruszka, Sandra Springer. (United P. Estimated Effects of Treatment Alexis A Krumme, William H Shrank, States) Changes on Hemoglobin A1c in a Troyen A Brennan, Olga S Matlin, Claire Cohort with Incident Type 1 Diabetes M Spettell, Gregory Brill, Niteesh K Spotlight Session-Databases [96] Choudhry. (United States) Richard S Swain, Janet T Holbrook, Dana I. Pilot Test of the Sentinel Modular Y Teltsch, MAJ Christina L Cristaldi, Jodi B C. Association Between Trajectories of Program for Propensity-Score Segal, G Caleb Alexander. (United States) Diabetes Medication Adherence and Matched Cohort Analyses: Application Hospitalization Risk in a Large Medicaid to Glyburide, Glipizide, and Severe Q. Cement Leakage and New Vertebral Program [82] Hypoglycemia [89] Fractures after Kyphoplasty and Wei-Hsuan Lo-Ciganic, Julie M Donohue, Meijia Zhou, Shirley V Wang, Charles E Vertebroplasty: A Meta-Analysis [97] Bobby L Jones, Joshua M Thorpe, Leonard, Joshua J Gagne, Candace Fuller, Hong Cheng, Yuzhi Hu, Nishant Mishra, Subashan Perera, Zachary A Marcum, Christian Hampp, Patrick Archdeacon, Colin Anderson-Smits. (United States) Walid F Gella. (United States) Sengwee Toh, Aarthi Iyer, Tiffany Siu Woodworth, Elizabeth Cavagnaro, R. Assessing Real-World Use and D. Association Between Patient-Centered Catherine Panozzo, Sophia Axtman, Ryan Outcomes of Newly Marketed Medical Homes and Adherence to M Carnahan, Elizabeth A Chrischilles, Bioprosthetic Aortic Valves Using Chronic Medications [83] Sean Hennessy. (United States) Japanese Nationwide Cardiovascular Julie C Lauffenburger, William H Shrank, Surgical Registry [98] Asaf Bitton, Alexis A Krumme, Olga J. Quality of Diabetes Recording: How Hiraku Kumamaru, Hiroaki Miyata, Noboru S Matlin, Edmund J Pezalla, Claire Does Coding Impact Incidence Motomura, Nobuhiro Handa, Kan Nawata, M Spettell, Gregory Brill, Niteesh K Estimates? [90] Minoru Ono, Shinichi Takamoto. (Japan) Choudhry. (United States) A Rosemary Tate, Sheena Dungey, Simon Glew, Natalia Beloff, Rachael Williams, Tim S. Comparison of New Vertebral Fractures E. Influence of Antidepressant Treatment Williams. After Kyphoplasty and Vertebroplasty on Use of and Adherence to COPD Usinig Medicare Data [99] Maintenance Medications [84] K. Evaluation of Free-Text Comments to Hong Cheng, Yuzhi Hu, Jie Zhou, Colin Yu-Jung Jenny Wei, Linda Simoni-Wastila, Validate Common Cancer Diagnoses in Anderson-Smits. (United States) Jennifer S Albrecht, Ting-Ying Huang, the UK CPRD [91] Patience Moyo, Bilal Khokha, Ilene Harris, Joan Fortuny, James A Kaye, Christine L T. Treatment Patterns in a Cohort of Patricia Langenberg, Giora Netzer, Susan Bui, Alicia W Gilsenan, Jennifer Bartsch, Patients with Incident Type 1 Diabetes Lehmann. (United States) Estel Plana, Lisa J McQuay, Brian [100] Calingaert, Willem Jan Atsma, Kwame Richard S Swain, Jodi B Segal, Dana Y F. Impact of Treatment Satisfaction Appenteng, Billy Franks, Stefan de Vogel, Teltsch, MAJ Christina L Cristaldi, G Caleb and Adverse Drug Events on Milbhor D’Silva, Susana Perez-Gutthann, Alexander, Janet T Holbrook. (United States) Antihypertensive Medication Adherence Alejandro Arana, Andrea V Margulis. in Ambulatory Patients in Ethiopia [85] (Spain) U. Risk Factors for Persistent and Derbew Fikadu Berhe, Katja Taxis, Flora New Chronic Opioid Use in Patients M Haaijer-Ruskamp, Afewerk Mulugeta, L. Abstract Withdrawn [92] Undergoing Total Hip Arthroplasty [101] Yewondwossen Tadesse Mengistu, Peter Maria CS Inacio, Craig Hansen, Elizabeth GM Mol. (Netherlands) M. An Algorithm to Identify Duplicate E Roughead, Nicole L Pratt, Stephen E Patients When Pooling Aggregate Data Graves. (Australia) G. Impact of High Deductible Health Plans from Two Primary Care Databases in on Adherence to Essential Medications the United Kingdom [93] V. A Comparative Analysis of Secondary for Patients with Chronic Conditions Estel Plana, Leah J McGrath, Joan Surgeries of Six Total Cervical Disc [86] Fortuny, Ana Ruigomez, Oscar Fernandez- Arthroplasty Devices to Cervical Jennifer Lewey, Joshua J Gagne, Jessica Cantero, Luis-Alberto Garcia-Rodriguez, Arthrodesis at 5-Years [102] Franklin, Julie Lauffenburger, Samantha Alicia W Gilsenan, Elizabeth Andrews, Colin Anderson-Smits, Davic Sing, Anton Dougherty, Gregory Brill, Niteesh K Cristina Rebordosa, Ryan Ziemiecki. Dmitriev, Hong Cheng. (United States) Choudhry. (United States) (Spain) W. Hospital Variation And Patient N. Methods to Estimate Days’ Supply Characteristics Associated With within Pharmacy Data of the Health Vena Cava Filter Use For Venous Improvement Network (THIN) [94] Thromboembolism [103] Kirsten J Lum, Craig W Newcomb, Jason Joshua D Brown, Jeffery C Talbert. A Roy, Dena M Carbonari, M Elle Saine, (United States) Serena Cardillo, Harshvinder Bhullar, Arlene M Gallagher, Vincent Lo Re III. (United States) 32nd

60 POSTER SESSION A: Friday, August 26 | 8:00am - 6:00pm Spotlight Sessions: 12:15 - 1:15pm Spotlight Session-Pediatrics Burden of Disease - 10. An Algorithm To Identify And Classify Individuals With Type 1 And Type 2 X. Use of Contraindicated Drugs in Alimentary & Metabolic Diabetes Mellitus In A Primary Care Pediatric Outpatients in the Nordic 1. Urosepsis and Urinary and Genital Database [121] Countries [104] Infections Among Diabetes Patients and Sonia J Coton, Irene Petersen, Irwin Tuire Prami, Disa Långström, Ilona Iso- Matched Controls [112] Nazareth, Manuj Sharma. (United Mustajärvi, Niklas Sandler. (Finland) Gregory A Nichols, Kimberly G Brodovicz, Kingdom) Y. Recent U.S. Drug Utilization For Dorothee B Bartels. (United States) 11. Trends in Incidence and Prevalence of Pediatric Inflammatory Bowel Disease, 2. Gastrointestinal Cancer Incidence in Type 2 Diabetes in the United Kingdom 2009-2015 [105] Type 2 Diabetes Mellitus; Results from a (2004 - 2014) Using the Clinical Practice Susan A Hall, Emma W Viscidi, Jeff K Large Retrospective Population-Based Research Datalink (CPRD) [122] Allen, Maneesh Juneja, Susan Eaton, Cohort Study in the UK [113] Salwa S Zghebi, Douglas T Steinke, Suzanne F Cook, Anne B Dilley. (United Ronaldus GPJ de Jong, Paul JHL Peeters, Matthew J Carr, Darren M Ashcroft. States) Andrea M Burden, Marie L de Bruin, (United Kingdom) Z. Psychiatric Diagnoses and Medication Harm R Haak, Ad AM Masclee, Frank 12. Population Trends in the Ten-Year Patterns in a Medicaid-Insured Birth de Vries, Maryska LG Janssen-Heijnen. Incidence and Prevalence of Diabetic Cohort [106] (Netherlands) Retinopathy in the UK: A Cohort Study Dinci Pennap, Julie M Zito, Mehmet Burcu, 3. Association Between Insulin Treatment in the Clinical Practice Research Daniel J Safer. (United States) and Breast Cancer Characteristics [114] Datalink 2004-2014 [123] Rohini Mathur, Krishnan Bhaskaran, Emma AA. Poor Guideline Adherence In The Jetty A Overbeek, Pauline AJ Vissers, Edwards, Helen Lee, Liam Smeeth, Ian Initiation Of Antidepressant Treatment Amber AWA van der Heijden, Heleen K Douglas. (United Kingdom) In Children And Adolescents In The Bronsveld, Myrthe PP van Herk-Sukel, Netherlands: Choice Of Antidepressant Ron MC Herings, Giel Nijpels, Marjanka K 13. Intensification of Basal Insulin And Dose [107] Schmidt. (Netherlands) Treatment Among Patients with Type Ymkje Anna de Vries, Peter de Jonge, 4. A Population Based Study of Metformin 2 Diabetes Mellitus in the Netherlands Luuk Kalverdijk, Jens HJ Bos, Catharina and the Association with Survival in [124] CM Schuiling-Veninga, Eelko Hak. Pancreatic Cancer Patients [115] Jetty A Overbeek, Eline Houben, Sofia (Netherlands) Martine A Frouws, Babs G Sibinga Mulder, I Kring, Jonathan Briers, Fernie JA Penning-van Beest, Amber AWA van der BB. The Association Between Esther Bastiaannet, Marjolein MJ Zanders, Heijden, Giel Nijpels, Ron MC Herings. Fluoroquinolone and Musculoskeletal Myrthe PP Van Herk-Sukel, Eleonora M De (Netherlands) Adverse Events in Pediatrics [108] Leede, Bert A Bonsing, Sven JSD Mieog, Cornelis JH Van de Velde, Gerrit-Jan Ching-Lan Cheng, Yea-Huei Kao Yang, 14. Validation and Incidence of Pneumonia Liefers. (Netherlands) Yi-Fen Hsu. (Taiwan) in Patients with Diabetes in BIFAP 5. Prevalence of Type 1 and Type 2 Database [125] CC. First Time Signal Detection of Global Diabetes Among U.S. Pediatric Javier Gorricho Mendívil, Luis Carlos Saiz Paediatric Data – Putting Theory into Population in the MarketScan Multi- Fernandez, Javier Garjón Parra, Juan Erviti Practice [109] State Medicaid Database, 2002-2013 López, Miguel Gil García, Elisa Martín Kristina Star, Lovisa Sandberg, Imti [116] Merino. (Spain) Choonara, Pia Caduff, I Ralph Edwards. Yong Chen, Tongtong Wang, Ravi Shankar. (Sweden) (United States) Burden of Disease - Infection

DD. The Impact of Birth Season on Time to 6. Renal Function Measurements in 15. A Validation Study of Algorithms to First Antibiotic Use Among Infants Born Diabetes Patients; A Population Based Identify Clostridium difficile Infection in Denmark 2004-2012 [110] Study in the Netherlands [117] Using a Japanese Hospital-Based Administrative Database [126] Alan C Kinlaw, Henrik T Sørensen, Jennifer Elisabeth Smits, Eline Houben, Jetty A L Lund, Christina D Mack, Pedersen Lars, Overbeek, Peter AGM de Smet, Myrthe PP Tomomi Kimura. (Japan) Julie L Daniels, Michael D Kappelman, Til van Herk-Sukel, Martina Teichert, Ron MC Stürmer. (United States) 16. Disease and Treatment Epidemiology Herings. (Netherlands) of Initial Clostridium Difficile Infection EE. Prevalence and Risk Factors for Opioid 7. Prevalence of Combinations of Diabetes (CDI) in a National Cohort [127] Misuse in Youth: Results from a Complications Across NHANES and Tristan Timbrook, Aisling Caffrey, Yan National Study in the US [111] NHWS [118] Wang, Kerry LaPlante, Haley Morrill. Vicki Osborne, Mirsada Serdarevic, Carey Strader, Amir Goren, Marco (United States) Hannah Crooke, Catherine Striley, Linda B DiBonaventura. (United States) Cottler. (United States) 17. Impact of Macrolides Use on 8. Estimating the Prevalence and Hepatotoxicity in 4 European Countries Incidence of Type 2 Diabetes Mellitus [128] Using Population Level Pharmacy Pili Ferrer, Elena Ballarín, Mònica Sabaté, Claims Data [119] Xavier Vidal, Marietta Rottenkolber, Sven Sarah-Jo Sinnott, Sheena McHugh, Helen Schmiedl,

Whelton, Richard Layte, Steve Barron, Luisa Ibáñez. Patricia M Kearney. (United Kingdom) 18. Prevalence of Risk Factors for 9. Incidence of Diabetes in Two National Vancomycin-Associated Nephrotoxicity Surveys – What’s Driving the Trend? in a National Cohort [129] [120] Megan K Luther, Kerry L LaPlante, Aisling R Caffrey, David Dosa, Thomas P Lodise, Carey Strader, Nikoletta Sternbach, Kathy 32nd Annunziata. Haley J Morrill. (United States) 61 POSTER SESSION A: Friday, August 26 | 8:00am - 6:00pm

19. Predictors of Mortality among 28. Cervical Cancer Screening and 37. Risk of Hypertension (HTN) and Unvaccinated Veterans with Serious Subsequent Excisional Procedures Malignant Hypertension (mHTN) in Streptococcus Pneumoniae Infections in Women Below 25 Years in France Patients Treated for Multiple Myeloma [130] Between 2007 and 2013. A Nationwide (MM) [148] Jacob B Morton, Haley J Morrill, Study on the French Healthcare Ajai Chari, Sanjay Aggarwal, Khalid Mezzi, Kerry L LaPlante, Aisling R Caffrey. (United Databases [139] Shao Zhu, Winifred Werther, Diana Felici, States) Géric Maura, Christophe Chaignot, Alexander R Lyon. François Alla, Alain Weill, Isabelle Heard. (United States) 20. Partner Bereavement and Risk of (France) Herpes Zoster: Results from Two 38. Pharmacological Treatments Preceding Population-Based Case-Control Studies 29. Incidence of Myeloid Neoplasms in Diagnosis of Idiopathic Intracranial in Denmark and United Kingdom [131] Patients with Primary Myelofibrosis Hypertension [149 Sigrun AJ Schmidt, Mogens Vestergaard, [140] Sarah Burkill, Anna Sudholm, Olafur Henrik S Pedersen, Henrik C Schønheyder, Alejandro Allepuz, Aleksandra Sarnecka, Sveinsson, Shahram Bahmanyar, Ingela Sara L Thomas, Liam Smeeth, Kathryn Katarzyna Sablinska. (Switzerland) Nilsson. (Sweden) Mansfield, Henrik T Sørensen, Harriet J Forbes, Sinéad M Langan. (Denmark) 30. Incidence of Cardiovascular Disease 39. Risk of Thrombotic and Hemorrhagic Among Early Stage Breast Cancer Event Associated with Oral 21. The Future of Herpes Zoster: Increasing Patients in Denmark [141] Anticoagulants: A Retrospective Incidence? [132] Deirdre Cronin-Fenton, Anders Analysis in a Local Health Authority in Kevin J Friesen, Jamie Falk, Silvia Alessi- Kjærsgaard, Mette Nørgaard, Justyna Northern Italy [150] Severini, Dan Chateau, Shawn Bugden. Amelio, Alex Liede, Rohini K Hernandez, Salvatore Mannino, Alfredo Cocci, Silvia (Canada) Henrik T Sørensen. (Denmark) Lucchi. (Italy) 22. Quantification Of Risk Factors For Burden of Disease - 40. Treatment Practices for Acute Ischemic Postherpetic Neuralgia In Herpes Stroke (AIS) in Quebec (Canada) [151] Zoster Patients: A Cohort Study [133] Hematological and Mareva Faure, Anne-Marie Castilloux, Yola Harriet Forbes, Krishnan Bhaskaran, Sara Cardiovascular Moride, Agnès Lillo-Le-Louët. (Canada) Thomas, Liam Smeeth, Tim Clayton, Kathryn Mansfield, Caroline Minassian, 31. Characteristics And Outcome Of Newly 41. Stroke Risk in Individuals with versus Sinead Langan. (United Kingdom) Diagnosed Immune Thrombocytopenia without Atrial Fibrillation at Varying In Adults: Results From The PGRx CHA2DS2-VASc Score Levels: Burden of Disease - Cancer Information System [142] Implications for Anti-Coagulant Clementine Nordon, Lamiae Grimaldi, Treatment [152] 23. Exploring The Treatment Pathways Of Marc Michel, Lucien Abenhaim, Bertrand Michelle Z Leisner, Anne Ording, Dora Breast Cancer Survivors In Primary Godeau. Körmendiné Farkas, Erzsébet Horváth- Care In England [134] Puhó, Morten Schmidt, Henrik Toft Lydia Tutt, Li-Chia Chen, Claire Anderson, 32. Infection and Anti-Infective Treatment Sørensen, Paolo Prandoni, Morten Olsen. Tracey Thornley. (United Kingdom) Preceding a Diagnosis of Primary (Denmark) Persisting Immune Thrombocytopenia 24. Validity of Cutaneous Squamous Cell [143] 42. Incidence and Risk Factors for Atrial Carcinoma Diagnosis in the Health Donia Sohrabian, Marie Linder, Charlotta Fibrillation in Patients with Newly Improvement Network [135] Ekstrand, Honar Cherif, Helle Kieler, Diagnosed Heart Failure in UK General Zelma C Chiesa Fuxench, Andrea B Troxel, Shahram Bahmanyar. Practice [153] Joel M Gelfand. (United States) Mar Martín-Pérez, Ana Ruigómez, 33. Comorbidities in the Young and Aging Alexander Michel, Luis A García 25. Prevalence Of Bone Metastases In Populations with Haemophilia A [144] Rodríguez. (Spain) Patients With Prostate Cancer: A Meta- Ceri Hirst, James Black. (Switzerland) Analysis [136] 43. One-Year Survival After Acute Kyle Fahrbach, Justyna Amelio, Yingxin 34. Epidemiologic and Clinical Myocardial Infarction (AMI): The Effect Xu, Seye Abogunrin, Susan Talbot, Emma Characteristics of Thalassemia (THAL) of Care Pathway in Italy [154 Booth, Daniela Niepel, Jean-Jacques Intermedia (TI) in the US [145] Valeria Belleudi, Martina Ventura, Paolo Body. (United Kingdom) Elliott Vichinsky, Janet L Kwiatkowski, Sciattella, Nera Agabiti, Mirko Di Martino, Patricia-Jane Giardina, Carole Paley, Riccardo Di Domenicantonio, Marina 26. Incidence of Second Primary Francis Vekeman, Wendy Y Cheng, Davoli, Danilo Fusco. (Italy) Malignancies In Patients With Primary Joseph Damron, Nora McCormick, Medha Myelofibrosis [137 Sasane, Ying Qiu, Mei Sheng Duh, Alexis 44. Epidemiology of Pulmonary Alejandro Allepuz, Aleksandra Sarnecka, Thompson. (United States) Arterial Hypertension in a Large Katarzyna Sablinska. (Switzerland) US Commercially Insured Pediatric 35. Risk Score for Major Hemorrhage Population, 2010-2013 [155] 27. Validation of an Algorithm to Estimate Among Chronic Lymphocytic Lin Li, Susan Jick, Stefanie Breitenstein, Global Cancer Incidence from Health Leukemia Patients in the US Veterans Gemzel Hernandez, Alexander Michel, Administrative Databases in France Administration Healthcare System [146] David Vizcaya. (United States) [138] Peter Georgantopoulos, Huiying Yang, Aya Ajrouche, Candice Estellat, Yann De- Mona Cai, LeAnn Norris, Charles L 45. Doubling of Serum Creatinine and the Rycke, Florence Tubach. Bennett. (United States) Risk of Cardiovascular Outcomes in Patients with Chronic Kidney Disease 36. Diabetes and New-Onset Atrial Fibrillation and with Diabetes Mellitus Type 2: A in a Hypertensive Population [147] Cohort Study [156] Lia Alves-Cabratosa, Maria García-Gil, Cornelia Schneider, Blai Coll, Susan S Marc Comas-Cufí, Ruth Martí, Anna Jick, Christoph R Meier. 32nd Ponjoan, Dídac Parramon, Jordi Blanch, Rafel Ramos. (Spain) 62 POSTER SESSION A: Friday, August 26 | 8:00am - 6:00pm

Burden of Disease - 56. Comparing the Incident Rates 66. Utilization of Psychotropic Drugs in of Multiple Outcomes in Multiple Spouses of Dementia Individuals: A Neurological Sclerosis Population by Marketscan Population-Based Study [178] 46. Use of Antidepressants Before and and Clinformatics Data Mart [167] I Fan Kuo, Andrew Basham, Heather Prior, After Start of Treatment for Psoriasis. Ling Zhang, Susan Colilla, Chuntao Wu, Silvia Alessi-Severini, James Bolton, Alan A Nation-Wide Cohort Crossover Study Jasmanda Wu, Jane Thammakhoune, Katz, Shahin Shooshtari. (Canada) [157] Meera Kumar, Stephanie Tcherny- Ingegärd Anveden-Berglind, Anders Lessenot, Marie-Laure Kurzinger, Susan Burden of Disease - Respiratory Sundström. (Sweden) Welsh, Juhaeri Juhaeri. (United States) 67. The Incidence of Ventilator-Associated 47. Association Between Atopic Diseases 57. Multiple Sclerosis and VTE [168] Pneumonia in Mainland China: A and Attention-Deficit/Hyperactivity Wendy J Carman, Julia LaGuette, David D Systematic Review and Meta-Analysis Disorder: Systematic Review and Meta- Dore, Andrew T McAfee. (United States) [179] Analyses [158] Chengyi Ding, Yuelun Zhang, Zhirong 58. Epidemiology of Treatment Resistant Jurjen van der Schans, Rukiye Cicek, Yang, Jing Wang, Aoming Jin, Weiwei Depression in Taiwan: Estimates and Tjalling W de Vries, Eelko Hak, Pieter J Wang, Ru Chen, Siyan Zhan. (China) Limitations [169] Hoekstra. (Netherlands) Daniel Fife, Yu Feng, Michael Yao-Hsien 68. Validation of Claims Approach to 48. High Prevalence of Hypovitaminosis D Wang, Bruce Wang, C J Chang. (United Identify Asthma and COPD Overlap in Patients with Chronic Low Back Pain: States) Syndrome Patients in the US [180] Evidence from Systematic Review and Bo Ding, Michael DePietro, Bingcao Wu, Meta-Analysis [159] 59. Characterizing the Epidemiology of Ozgur Tunceli, Ralph Turner. (Sweden) Myasthenia Gravis and Neuromyelitis Dipika Bansal, Rambabu Vatte, Chandra Optica Using the Clinical Practice 69. Chronic Oral Corticosteroid Use in Sekhar Boya, Babita Ghai, Kapil Gudala. Research Datalink [170] Adults with Persistent Asthma [181] (India) J Alexander Cole, Christopher Ll Morgan, Trung N Tran, Michael Schatz, Qiaowu Li, 49. Correlates of Osteoporotic Fractures Sara Jenkins-Jones. (United Kingdom) Wansu Chen, Deepak Khatry, Robert S Among Type 2 Diabetic Patients [160] Zeiger. 60. Irritable Bowel Syndrome, Depression Inbal Goldshtein, Julie Chandler, Ann and Antidepressant Dispensing: A Study 70. Use of β-Blockers and Risk of Asthma DePapp, Sophia Ish-Shalom, Gabriel of Administrative Claims [171] Exacerbations [182] Chodick, Allison Martin Nguyen. (Israel) Robert Perry, Chong Kim, Mausam Katia MC Verhamme, Ulrike Goditiabois, 50. Osteonecrosis Of The Jaw And Cancer Patidar, David Tabano, Heather Anderson. Marjolein Engelkes, Miriam CJM Survival: A Danish Population-Based (United States) Sturkenboom, Bruno BC Stricker, Guy GO Cohort Study [161]Priscila Corraini, Uffe Brusselle. (Netherlands) 61. Body Mass Index and Risk of Heide-Jørgensen, Morten Schiødt, Sven Parkinson’s Disease in a Cohort of Two 71. Stability of the Frequent Exacerbator - Erik Nørholt, Henrik Toft Sørensen, Vera Million People Over Two Decades [173] A Danish Nationwide Register-Based Ehrenstein. (Denmark) Nawab Qizilbash, John Gregson, Michelle Study [183] 51. Comorbid Diseases Preceding E Johnson, Neil Pearce, Ian Douglas, Kevin Mette MK Reilev, Jesper Lykkegaard, Diagnosis of Progressive Multifocal Wing, Stephen JW Evans, Stuart J Pocock. Anders Halling, Jørgen Vestbo, Jens Leukencephalopathy [162] (United Kingdom) Søndergaard, Anton Pottegård. (Denmark) Ellen Iacobaeus, Sarah Burkill, Shahram 62. Demographics and Comorbidities in 72. Multimorbidity Clusters Differ by Bahmanyar, Lou Brundin, Mikael Fored, Parkinsons Disease [174] Exacerbation Frequency in Chronic Tomas Olsson, Scott Montgomery. (Sweden) Cynthia C Jones, Jeff Allen, Anne Dilley. Obstructive Pulmonary Disease [184] 52. Comorbid Diseases Preceding Emin Hoxha Ekström, Maria Andersson, Diagnosis of Idiopathic Intracranial 63. Increasing Mental Health Diagnosing Maria Gerhardsson de Verdier, Jan Hedner, and Treatment Among U.S. Medicaid Hypertension [163] Ann Ekberg Jansson, Max Petzold, Kjell Youth, 2001-2010 [175] Anna S Sundholm, Sarah Burkill, Olafur Torén, Mikael Svensson. (Sweden) Sveinsson, Shahram Bahmanyar, Ingela Stephen Crystal, Scott Bilder, Cassandra 73. Review Of The Epidemiology Of Chronic Nilsson Remahl. (Sweden) Simmel. (United States) Obstructive Pulmonary Disease In The 64. Benzodiazepine Use and Risk of Asia-Pacific Region [185] 53. Psoriasis and Suicide [164] Developing Alzheimer’s Disease - A Wendy J Carman, J Michael Woolley, See-Hwee Yeo, Marie-Jo Horner, Sumitra Case-Control Study Based on Swiss Xiangmei Gu, Bruce R Turnbull, Cheryl Shantakumar. Claims Data [176] Enger. (United States) Fabienne Biétry, Alena Pfeil, Oliver Reich, 74. Incidence and Prevalence Time Trends 54. Cluster Headache Diagnosis and Matthias Schwenkglenks, Christoph R of Idiopathic Pulmonary Fibrosis (IPF) in Treatment in the Clinical Practice Meier. (Switzerland) the United States (US) Over a 14-Year Research Datalink (CPRD) [165] Period - A Claims Database Study [186] 65. Association Between Prescription Evelyn M Flahavan, Meghan E Jones, Mellissa Yong, Jenny Chia, David Oliveri, Opioid Use and Insomnia Among Lucy Mitchell, Jonathan L Swain, James M Hubert Chen, Dorothy Cheung, Karina Community Members in Northeast Martinez, Andrew H Ahn. (United Kingdom) Raimundo, Matt Cohen, Pavel Napalkov. Florida [177] (United States) 55. Difference in the Rate of Multiple Mirsada Serdarevic, Vicki L Osborne, Sclerosis-Related Hospitalizations in Linda B Cottler. (United States) Portugal Between 2008 and 2013 [166] Marta Pereira, Dimitra Lambrelli, Radek Wasiak, Sreeram V Ramagopalan. (United Kingdom) 32nd

63 POSTER SESSION A: Friday, August 26 | 8:00am - 6:00pm

Burden of Disease - Other 84. Atopic Diseases and the Risk of Medical Devices Developing Ulcerative Colitis [196] 75. Influence of Age and BMI on Risk of Samman Azim, Eelko Hak, Jens HJ 94. Use of FDA Approved Stents Intended Venous Thromboembolism: A Meta- Bos, Catharina CM Schuiling-Veninga. for Adults for the Treatment of Analysis of 246,513 Women Using (Netherlands) Pulmonary Artery Stenosis in Children Combined Oral Contraceptives Based [206] on 521,516 Women-Years [187] 85. Can Rheumatoid Arthritis Associated Dale Tavris, Frank Ing, Anna Ghambaryan, Clare Barnett, Anja Bauerfeind, Do Minh With Interstitial Lung Disease (RA-ILD) Donald Hagler, Richard E Ringel, Lauren Thai, Klaas Heinemann. (Germany) Be Classified As An Orphan Disease In Deegan, Thomas Forbes, Jamie Magdi, The U.S.? [197] Benjamin C Eloff. (United States) 76. Body Mass Index and Cause-Specific Edgar P Simard, Fee Ruehmkorf, Jennifer Mortality: Population-Based Study CL Hawes, Patrice Verpillat. (Germany) 95. Magnetic Resonance Imaging Among 2 Million UK Adults Using Examination in People with Cardiac Electronic Health Records Linked to 86. Claims-Based Prediction Models Are Implantable Electronic Devices [207] National Mortality Data [188] Unable to Accurately Predict Disease Marianne H Gillam, Maria CS Inacio, Krishnan Bhaskaran, Ian Douglas, Liam Activity for Rheumatoid Arthritis [198] Nicole L Pratt, Elizabeth E Roughead. Smeeth. (United Kingdom) Brian C Sauer, Chai-Chen Teng, Neil (Australia) Accord, Mona M Trivedi, David H Collier, 77. Natural History Of Primary Sclerosing Grant W Cannon. (United States) 96. Spinal Degenerative Disc Disease Cholangitis – A Study Using the UK Procedure Trends in the United States Clinical Practice Research Datalink 87. A Systematic Review of Population- Using the National Inpatient Sample (CPRD GOLD) [189] Based Incidence and Prevalence (2008-2012) [208] Huifang Liang, Sudhakar Manne, Jesse Estimates of Axial Spondyloarthritis, Colin Anderson-Smits, Ariella Apfel, Yuzhi Shick, Punam Bharania, Paul Dolin. Including Ankylosing Spondylitis Hu, Hong Cheng, and Nilsa Loyo-Berrieros (United States) and Non-Radiographic Axial Spondyloarthritis [199] 97. The Impact of Channelling Bias in 78. Statin Use and Risk of Gallstone Rhonda Bohn, Maureen Cooney, Atul Device Epidemiology: Assessing Disease in Switzerland - A Case-Control Deodhar, Jeffrey R Curtis, Amanda Metal-on-Metal Total Hip Arthroplasty Study Based on Swiss Claims Data Golembesky. (United States) Implants [209] [190] Daniel Prieto Alhambra, Andrew Jonathan Fabienne Biétry, Oliver Reich, Matthias 88. Pigmented Villonodular Synovitis Carr, Anne Lübbeke. (United Kingdom) Schwenkglenks, Christoph R Meier. (PVNS): Incidence, Patient (Switzerland) Characteristics, Treatment and 98. Abstract Withdrawn [210] Recurrence: a Cohort Study in Denmark 79. Use of Angiotensin-Converting Enzyme [200] 99. Nationwide Knee Arthroplasty in France Inhibitors and/or Angiotensin-Receptor Søren L Andersen, Ibrahim Qazi, Robert Between 2008 and 2013: Characteristics Blockers and the Risk of Acute Kidney Sikorski, Neil Sankar, John F Acquavella, of the Patients, Implants and Injury After Colorectal Cancer Surgery: Vera Ehrenstein. (Denmark) Procedures [211] A Population-Based Cohort Study [191] Sandrine Colas, Bob-Valery Occean, Charlotte Slagelse, Henrik Gammelager, 89. The Association Between Prior Annie Rudnichi, Rosemary Dray-Spira, Lene Hjerrild Iversen, Sinna Pilgaard Appendicectomy and/or Tonsillectomy Mahmoud Zureik. (France) Ulrichsen, Henrik Toft Sørensen, Christian in Females and Subsequent Pregnancy Fynbo Christiansen. (Denmark) Rate: A Cohort Study [201] 100. Multiple Circular Stapler Use During Li Wei, Thomas M MacDonald, Sami Left-Sided Colon Resections as a 80. Prevalence of Crigler-Najjar in the Shimi. Surrogate Measure of Procedural Turkish Population [192] Complexity [212] Alexander Cole, Sulena Shrestha, Erdem 90. Longitudinal Changes in Prevalence Katherine Etter, Sanjoy Roy, Iftekhar Baser. (United States) of Rare Diseases and Related Costs in Kalsekar, Andrew Yoo. (United States) Taiwan (2003-2014) [202] 81. The Association Between Chronic Jason C Hsu, Christine Y Lu. (Taiwan) 101. Analyses of Surgical Adverse Events – Urticaria and Autoimmune Thyroid The Importance of Procedure Modifiers Disease: A Nationwide Population- 91. Time Trends And Patterns Of [213] Based Study in Taiwan [193] Prescriptions For Drug Pairs With A Chantal E Holy, Howard L Levine. (United Jin-Bon Hong, Chi-Chuan Wang. (Taiwan) Serious Drug-Drug Interaction In UK States) Primary Care [203] 82. Disease Severity and Characteristics Adrian Root, Liam Smeeth, Ian Douglas. 102. Research Using Claims Databases of Patients with Atopic Dermatitis (AD) (United Kingdom) to Evaluate Adherence to Medical Investigated Using Administrative Guidelines: The Case of Tympanostomy Claims Data [194] 92. A Systematic Review and Tube Insertion in the United States [214] Fredrik Nyberg, Ralph Turner, Ozgur Methodological Framework for Chantal E Holy, Howard L Levine. (United Tunceli, Michael J Aitkenhead, Angela E Estimating Prevalence of Rare Diseases States) Williams. (Sweden) [204] Kerstin Müller, Sheena Kayaniyil, Sarah M 83. Stevens-Johnson Syndrome and Toxic Analytical Methods Goring. (Canada) Epidermal Necrolysis: Long-Term 103. Combining Observational Data from Sequelae Based on a 5-Year Follow-Up 93. Mortality Rates in People with Multiple Databases: Comparison of Analysis [195] Intellectual Disabilities [205] Individual Patient Data and Aggregate Maren Paulmann, Carmen Kremmler, Rachael Williams, Jessie Oyinlola, Pauline Data Meta-Analysis in the CARING Peggy Sekula, Laurence Valeyrie- Heslop, Gyles Glover. Study [215] Allanore, Luigi Naldi, Sylvia Kardaun, Maja Nils Ekström, Marloes T Bazelier, Vidar Mockenhaupt. (Germany) Hjellvik, Frank de Vries, Jari Haukka, Peter 32nd Vestergaard, Marie L de Bruin, Morten Andersen. (Sweden) 64 POSTER SESSION A: Friday, August 26 | 8:00am - 6:00pm

104. Analytical Issues Faced When Analysing 114. The Firth Correction: A Simple Solution 124. Predicted Rates of Thromboembolism Recurring Events Over Multiple When Parameter Estimates Diverge to and Major Bleeding with Dabigatran Treatment Patterns [216] Infinity [226] or Warfarin in Patients with Atrial Preeti Datta-Nemdharry, Katherine Claudia A Salinas, Jonathan Swain, Fibrillation: Randomized Controlled Donegan, Mark Lunt, Mohammad Brenda J Crowe. (United States) Trials versus Routine Care [236] Movahedi, Will Dixon. Shirley V Wang, Jessica M Franklin, 115. Performance of Machine Learning Robert J Glynn, Sebastian Schneeweiss, 105. Heterogeneity in Treatment Effect: Algorithms in Statistical Modeling of 30 Wesley Eddings, Joshua J Gagne. (United Dabigatran vs. Warfarin in Patients with Day Heart Failure Readmissions Risks States) Atrial Fibrillation [217] Using Automated and Investigator- Shirley V Wang, Krista F Huybrechts, Specified Covariates [227] 125. Development and Validity of a Michael A Fischer, Jessica M Franklin, Chintan Dave, Abraham Hartzema, Almut Checklist Assessing the Risk of Bias Sebastian Schneeweiss, Robert J Glynn, Winterstein. (United States) of Randomized Trials, Observational Wesley Eddings, Joshua J Gagne. (United Studies and Systematic Reviews States) 116. Risk Period Selection on Performance Analyzing Drug Adverse Events [237] of Self Controlled Case Series (SCCS) Jean-Luc Faillie, Pili Ferrer, Amandine 106. Comparing Decision Tree and Logistic Method for Signal Detection in Gouverneur, Damien Driot, Shoma Regression Methods to Identify Factors Observational Data [228] Berkemeyer, Xavier Vidal, Marietta Affecting the Choice of ACEI/ARB Dose Xiaofeng Zhou, Ian Douglas, Rongjun Rottenkolber, Sven Schmiedl, Mònica Among Elderly Patients After Acute Shen, Andrew Bate. (United States) Sabaté, Elena Ballarín, Luisa Ibáñez. Myocardial Infarction (AMI) [218] (France) Izabela E Annis, Sandra Hanna, Gang 117. Probabilistic Bias Analysis in Fang. (United States) Pharmacoepidemiologic Studies [229] 126. Probabilistic Bias Analysis for Jacob N Hunnicutt, Christine M Ulbricht, Unmeasured Confounders in a Study 107. Cumulative, Weighted Exposure for Stavroula A Chrysanthopoulou, Kate L of Users of Topical Tacrolimus, Modelling the Association Between Lapane. (United States) Pimecrolimus and Corticosteroids Metformin and Heart Failure (JOELLE) Study [238] 118. Competing Risks Modelling of Time- Exacerbation in Patients with Diabetes Jordi Castellsague, Brian Calingaert, Varying Drug Exposures [230] and Pre-Existing Heart Failure [219] Kenneth J Rothman, Lia Gutierrez, Myrthe Daniala L Weir, Michal Abrahamowicz, Coraline Danieli, Michal Abrahamowicz. PP van Herk-Sukel, Josephina JG Kuiper, Dean T Eurich. (Canada) Anton Pottegård, Jesper Hallas, Ingegärd A Berglind, Anders Sundström, Daniel 108. Application of Marginal Structural 119. Simulation Study of Statistical Models Dedman, Arlene Gallagher, James A Kaye, Models to Data from Interval and for the Analysis of Clustered Length of Carolina Pardo, Susana Perez-Gutthann. Clinical Cohorts: A Simulation Study Stay (LOS) Outcomes [231] (Spain) [220] Carl de Moor, Ifti Kalsekar, Jesse Berlin. Edmore Chamapiwa, David Reeves, (United States) 127. Potential Effects of Medicare Payment Darren Ashcroft, Evangelos Kontopantelis. Policy Changes on Hospitalization- (United Kingdom) Clinical Trial Methodology Based Outcomes Research [239] Anne C Beaubrun, David T Gilbertson, 109. Optimal Treatment Strategies For 120. Detecting Suicidal Outcomes: A Power Glenn M Chertow, Kenneth J Rothman, Patients With Newly Diagnosed Type 2 Analysis [232] Wolfgang C Winkelmayer, Keri L Monda, Diabetes: An Application Of Dynamic Richard S Swain, Lockwood G Taylor, Jiannong Liu, Akhtar Ashfaq, M Alan Marginal Structural Models in the Andrew D Mosholder. (United States) Brookhart, Allan J Collins, Brian D Clinical Practice Research Datalink 121. Methods of Defining the Noninferiority Bradbury. (United States) [221] Margin: A Systematic Review [233] Ruth E Farmer, Deborah Ford, Liam 128. New Policies, New Sources of Error: Smeeth, Nishi Chaturvedi, Krishnan Turki AI Althunian, Anthonius de Boer, Impact of Recent Medicare Policies on Bhaskaran. (United Kingdom) Olaf H Klungel, Widya N Insani, Rolf HH Database Research [240] Groenwold. (Netherlands) David T Gilbertson, Jiannong Liu, Anne C 110. Modeling Adverse Events Associate Beaubrun, Glenn M Chertow, Kenneth J with Two Successive Treatments 122. Real Time Aggregate Clinical Safety Rothman, Wolfgang C Winkelmayer, Keri During Chronic Disease [222] Monitoring Methodology-Evaluation of L Monda, Akhtar Ashfaq, Alan Brookhart, Multiple Quantitative Methods [234] Alexandre Lafourcade, Yann De Rycke, Allan J Collins, Brian D Bradbury. Tubach Florence, David Hajage. (France) Syed S Islam, Ran Gao, Mondira Bhattacharya. (United States) 129. Exposure Misclassification Due to 111. Use and Effectiveness of Instrumental Household Availability of Prescription Variable Analysis: A Review of SEER- Confounding/Bias Medications [241] Medicare Studies [223] 123. Improving Short-Term Mortality Marissa J Seamans, Daniel J Westreich, Jeffrey C Yu, Joseph Menzin, Robert I Prediction Using Timing of Acute Timothy Carey, Stephen R Cole, M Alan Griffiths. (United States) Comorbidities During Lookback [235] Brookhart. 112. Bootstrap-Based Inference for the Henry T Zhang, Leah J McGrath, Alan R 130. Assessment of Channelling Bias Among Effects of Changes in Epidemiologic Ellis, Richard Wyss, Jennifer L Lund, Til Initiators of Glucose Lowering Drugs - A Design and Analysis [224] Stürmer. (United States) Cohort Study [242] M Alan Brookhart, Stephen R Cole, Til Mikkel Zöllner Ankarfeldt, Brian Larsen Stürmer. (United States) Thorsted, Rolf Groenwold, M Sanni Ali, Erpur Adalsteinsson, Olaf Klungel. 113. The Regression Discontinuity Design in (Denmark) Epidemiology [225] Irene Petersen, Federico Ricciardi, Irwin Nazareth, Gianluca Baio, Sara Geneletti, 32nd Aidan O’Keeffe. (United Kingdom) 65 POSTER SESSION A: Friday, August 26 | 8:00am - 6:00pm

131. Matching on the Disease Risk Score vs 141. Combining Different Health Care and 150. Do Hemoglobin Lab Test Results the Propensity Score [243] Health System Registries to Identify Increase Detection of Upper Richard Wyss, John Connolly, Joshua J Diseases for Research and Health Gastrointestinal Bleeding (UGIB)? [262] Gagne. Policy Purposes: The Danish Registry of Elisabetta Patorno, Josh Gagne, Kevin Selected Chronic Diseases [253] Haynes, Christine Lu, Jason Roy, Andrew 132. Improving Variable Selection for High- Ulrik Hesse, Katrine Fascius, Pia Sterrett, Xingmei Wang, Marsha Raebel. Dimensional Propensity Scores [244] Christianasen, Anna S Engelbrecht, Ulla Richard Wyss, Sebastian Schneeweiss, Nielsen, Marie-Louise Marthendal Olsen, 151. Cancer Recording In Patients With Type Wesley Eddings, Mark J van der Laan, Katarina M Gesser. (Denmark) 2 Diabetes In Primary Care And Hospital Jessica M Franklin. Admission Data [263] 142. Complementary Observational Rachael Williams, Arlene M Gallagher, 133. Methods to Detect Misspecification in Studies Assessing the Incidence of Tjeerd van Staa, Tarek Hammad, Bert Propensity Score Models [245] a Rare Cancer Outcome by Linking Leufkens, Frank de Vries. Mark Lunt. (United Kingdom) State Cancer Registry Data to Large Pharmacy Claims Databases in the 152. Authenticity Validation of Lung 134. Reporting of the Trimmed Population in United States [254] Cancer Records from a Standardized Propensity Score Analyses [246] Nicole Kellier-Steele, Alicia Gilsenan, Kirk Inpatient EMR Database in China and Ryan Ziemiecki, Dawn Odom, Xiaolei Midkiff, David Harris, Elizabeth Andrews. Comparison of Different Methods [264] Zhou, Steven M Thomas. (United States) (United States) Meng Shu, Wenhua Liang, Yongjing Zhang, Jianxing He. (China) 135. Effectiveness of Triple Therapy with 143. Identification of Associations Between Direct-Acting Antivirals for Hepatitis Prescribed Medications and Cancer: A 153. Ascertaining Pulmonary Hypertension C Genotype 1 Infection: Application of Nationwide Screening Study [255] and Other Conditions in Claims Propensity Score Matching in a National Anton Pottegård, Søren Friis, René D Databases [265] HCV Treatment Registry [247] Christensen, Laurel A Habel, Joshua J David Vizcaya, Alexander Michel, Lin Li, Emma Gray, Aisling O’Leary, David J Gagne, Jesper Hallas. (Denmark) Stefanie Breitenstein, Gemzel Hernandez, Pasta, Suzanne Norris. Montse Soriano-Gabarro, Susan Jick. 144. Semi-Automatic Coding of Case (Germany) 136. Utilizing the Present on Admission Definitions [256] (POA) Variable for Risk Adjustment Benedikt Becker, Erik van Mulligen, Daniel 154. Validation of a Case-Finding Algorithm with the Elixhauser Comorbidity Index: Weibel, Miriam Sturkenboom, Jan Kors. for Symptomatic Uterine Fibroids [266] A Case Study in Thoracic Lobectomy (Netherlands) Sarah R Hoffman, Daniel Westreich, Anissa [248] I Vines, Jacqueline R Halladay, Emily Pfaff, Katherine Etter, Sanjoy Roy, Andrew Yoo, 145. Identifying the Prescribing Physician in Lauren Schiff, Lisa Rahangdale, Aditi Iftekhar Kalsekar. (United States) US Healthcare Claims Data [257] Sundaresan, La-Shell Johnson, Wanda Jane S Der, Fei Xue, M Alan Brookhart. Nicholson. (United States) 137. Better Alternatives to Existing Methods (United States) to Take into Account Prognostic Scores 155. Development and Validation of an in Observational Studies [249] Measurement & Validation Algorithm to Identify Endometrial David Hajage, Yann De Rycke, Guillaume Adenocarcinoma in US Administrative Chauvet, Florence Tubach. (France) Methods Claims Data [267] Daina B Esposito, Ruihua Yin, Leo J 138. Predicting Chronic Medication Count in 146. Evaluation Of Different Missing Data Russo, Marcela G del Carmen, Steven Veterans with and without HIV Infection Strategies In Propensity Score Analyses R Goldstein, Bruce Patsner, Stephan F [250] [258] Lanes. (United States) Janet P Tate, Kirsha M Gordon, Amy C Johanna HM Driessen, Elizabeth J Justice. (United States) Williamson, James R Carpenter, Frank de 156. Development and Validation of an Vries. (Netherlands) Algorithm to Identify Endometrial 139. Missing Cause Approach to Detect and Hyperplasia in US Administrative Claims Reduce Unmeasured Confounding Bias 147. Agreement Between ICD-9 Codes Data [268] in Pharmacoepidemiology [251] and Laboratory Results Indicative of Myelosuppression (MS) in Patients with Daina B Esposito, Ruihua Yin, Leo J Michal Abrahamowicz, Lise M Bjerre, Longer-Term Exposure to Linezolid in a Russo, Gregory Ridgeway, William J Marie-Eve Beauchamp, Jacques LeLorier, Claims Database [259] Finkle, Steven R Goldstein, Khushbakhat Rebecca Burne. (Canada) Thomas Rhodes, Vinay Mehta, Mike Mittal, Brian W Walsh, Stephan F Lanes. (United States) Data Linkage Senderak, Carisa S de Anda, Thomas C Mast. (United States) 157. Can Population-Based Incidences Help 140. Predictability of Electronic Medical Define Bladder Cancer Outcomes in a Record (EMR)-Based Patient 148. Use of Electronic Healthcare Records Medicare Cohort? [269] Characteristics Using Health Care to Identify Complex Patients with Atrial Elizabeth M Garry, John B Buse, Virginia Utilization Data in Patients with Type Fibrillation for Targeted Intervention Pate, Til Stürmer. (United States) 2 Diabetes Mellitus (T2DM) Initiating [260] Glucose-Lowering Agents [252] Shirley V Wang, James R Rogers, Yinzhu 158. Agreement Between Hospital Diagnosis Elisabetta Patorno, Chandrasekar Jin, David W Bates, Michael A Fischer. Codes and Medical Records to Identify Gopalakrishnan, Jessica Franklin, Kimberly (United States) Metastatic Colorectal Cancer and Brodovicz, John Seeger, Dorothee Bartels, 149. Validity of Claims-Based Definitions for Comorbidities in Elderly Patients [270] Jun Liu, Sebastian Schneeweiss. Hospitalized Volume Overload Among Amandine Gouverneur, Diana Dolatkhani, Hemodialysis Patients [261] Magali Rouyer, Angela Grelaud-Boussinot, Magdalene M Assimon, Jennifer E Flythe. Florence Francis, Véronique Gilleron, (United States) Annie Fourrier-Réglat, Pernelle Noize. (France) 32nd

66 POSTER SESSION A: Friday, August 26 | 8:00am - 6:00pm

159. Adding of CPT Codes Improves 167. Validity of the Prescriber Information 177. A Systematic Literature Review on Classification of Type of Bowel in the Danish National Prescription the Efficacy-Effectiveness Gap: Resection Based Only on ICD-9-CM Registry [279] Comparison of Randomized Controlled Procedure Codes [271] Lotte Rasmussen, Julie Valentin, Katarina Trials and Observational Studies of Tongtong Wang, Zhiwen Liu, Daniel Mines. M Gesser, Jesper Hallas, Anton Pottegård. Glucose-Lowering Drugs [289] (United States) (Denmark) Mikkel Zöllner Ankarfeldt, Erpur Adalsteinsson, Rolf Groenwold, Sanni Ali, 160. Validation of Stevens-Johnson 168. Validation of the Recording of Key Olaf Klungel. (Denmark) Syndrome and Toxic Epidermal Medical Conditions in General Practice Necrolysis Diagnoses in the Clinical Data [280] 178. Interim Analyses in Prospective Practice Research Datalink [272] Jenny JL Wong, Suzie Seabroke, Observational Studies of Medical Noel C Frey, Andreas Bircher, Michael Katherine Donegan. (United Kingdom) Product Safety [290] Bodmer, Susan S Jick, Christoph R Meier, Jie Li, Rima Izem. (United States) Julia Spoendlin. (Switzerland) 169. Claims-Based Algorithms Greatly Impact the Estimated Incidence of 179. Incorporating Clinical Factors That 161. Comparing Instant Health Data and Serious Angioedema Among Heart Are Inconsistently Recorded in SAS for Evaluation of Incidence Rates Failure (HF) Patients in the United Electronic Health Records to Improve in Multiple Sclerosis Using MarketScan States (US) [281] Confounding Adjustment in Claims- [273] Thy P Do, Arpamas Seetasith, Rossella Based Comparative Effectiveness Ling Zhang, Susan Colilla, Chuntao Belleli, Raymond Schlienger, Chakkarin Research [291] Wu, Jasmanda Wu, Stephanie Tcherny- Burudpakdee, Hendrik J Streefkerk, Sigrid Peter M Wahl, Jessica M Franklin, Lessenot, Marie-Laure Kurzinger, Wenli Behr. (Switzerland) Jeremy A Rassen, Marc B Rosenman, Hu, Susan Welsh, Juhaeri Juhaeri. Nandini Selvam, Robert J Glynn, Murray 170. Patterns and Predictors of Having a A Mittleman, Sebastian Schneeweiss. 162. Medications Prescription at Hospital Colonoscopy Following Drug Initiation (United States) Discharge in Patients with Validated in Older US Adults with Diabetes [282] Diagnosis of Dementia [274] Phyo T Htoo, M A Marquis, Mugdha 180. Abstract Withdrawn [292] Francesca Palese, Federico Romanese, Gokhale, Virginia Pate, John Buse, Til Fabio Barbone, Federica E Pisa. (Italy) Stürmer. (United States) 181. Abstract Withdrawn [293] 163. Comparing Methods Generating Drug 171. Feasibility of Using Procedural Pediatrics Exposure Time From Prescription Code Combinations for Identifying Register Data [275] Conversion from Video Assisted 182. Early Life Antibiotic Exposure Is Antti Tanskanen, Heidi Taipale, Marjaana Thoracic Surgery (VATS) to Associated with an Increased Risk of Koponen, Anna-Maija Tolppanen, Sirpa Thoracotomy [283] Atopic Eczema and Hay Fever [294] Hartikainen, Riitta Ahonen, Jari Tiihonen. Katherine Etter, Sanjoy Roy, Andrew Yoo, Fariba Ahmadizar, Susanne Vijverberg, (Sweden) Iftekhar Kalsekar. (United States) Hubertus Arets, Anthonius de Boer, Johan Garssen, Aletta Kraneveld, Anke-Hilse 164. A Summary of Clinical Coding Systems Study Design Maitland-van der Zee. by Different Clinical Settings in Healthcare Databases in the US and 172. Influenza Vaccine Effectiveness 183. Abstract Withdrawn [295] UK [276] Estimates in the Dutch Population from 184. Analysis of Splitting Sustained-Release, Yong Chen, Tongtong Wang, Edward A 2003 to 2014: The Test-Negative Design Enteric-Coated Drugs in Pediatric Bortnichak. (United States) Case-Control Study with Different Patients: HIRA-PPS [296] Control Groups [284] 165. Standardizing Diversity of Event Eva van Doorn, Maryam Darvishian, Kiyon Rhew. (Republic of Korea) Definitions in Federated Networks of Frederika Dijkstra, Ge Donker, Pieter 185. Differences Between Genders in Heterogeneous Health Data Sources: Overduin, Adam Meijer, Eelko Hak. Antipsychotic Medication Among The “Component Algorithm Strategy” (Netherlands) Children and Adolescents – Patterns in [277] Use and Underlying Mental Disorders Giuseppe Roberto, Ingrid Leal, Naveed 173. Study Design and Analytic Approach [297] Sattar, Robert Stewart, Maria Garcia-Gil, for Research on the Effectiveness of Paul Avillach, Peter Egger, Rients van Childhood Vaccine Schedules [285] Ragnar Nesvåg, Ingeborg Hartz, Jørgen Wijngaarden, David Ansell, Sulev Reisberg, Anne M Butler, J Bradley Layton, B Diane Bramness, Vidar Hjellvik, Marte Handal, Alessandro Pasqua, Lars Pedersen, Lara Reams, Catherine A Panozzo, M Alan Svetlana Skurtveit. (Norway) Brookhart. (United States) Tramontan, Miguel A Mayer, Talita Duarte, 186. Psychiatric Medication Use Before Ron Herings, Preciosa Coloma, Francesco 174. Investigating the Assumptions of the Self- and After the Onset of Type 1 Diabetes Lapi, Miriam Sturkenboom, Johan van in Children and Adolescents: A Controlled Case Series Method [286] der Lei, Martijn Schuemie, Peter Rijnbeek, Population-Based Cohort Study [298] Rosa Gini. (Italy) Heather Whitaker, Yonas Ghebremichael- Weldeselassie, Paddy Farrington, Ian Soulmaz Fazeli Farsani, Heshu Abdullah- 166. Designing Medical Record Abstraction Douglas, Liam Smeeth. (United Kingdom) Koolmees, Patrick C Souverein, Anthonius Forms for Retrospective Chart de Boer, Aukje K Mantel-Teeuwisse. Review Studies: Considerations and 175. Abstract Withdrawn [287] (Netherlands) Recommendations [278] 176. Effect-Modifiers of Antipsychotic Drugs 187. Abstract Withdrawn [299] Ellen E Korol, Sheena Kayaniyil, Katherine Effect, in Schizophrenia Treatment [288] M Osenenko. (Canada) Clementine Nordon, Witold Wiecek, Helene Chevrou-Severac, Javier Jimenez, Helene Karcher, Lucien Abenhaim. (France) 32nd

67 POSTER SESSION A: Friday, August 26 | 8:00am - 6:00pm

188. Antidepressant Drug use Among Adherence 205. Reliably Estimating Adherence to Adolescents in Norway from 2004 to Therapy in Chronic Patients from Italian 197. Use of Copay as an Instrumental 2013- A Population-Based Register Administrative Databases [317] Variable for Adherence in Comparative Study [300] Rosa Gini, Martijn J Schuemie, Alessandro Effectiveness and Safety Research Ingeborg Hartz, Svetlana Skurtveit, Vidar Pasqua, Patrizio Dazzi, Emanuele Carlini, [309] Hjellvik, Kari Furu, Ragnar Nesvåg, Marte Iacopo Cricelli, Valentina Barletta, Paolo Handal. (Norway) Sapna Rao, Xiaojuan Li, Alan Brookhart. Francesconi, Francesco Profili, Francesco (United States) Lapi, Andrea Donatini, Dal Co Giulia, 189. Proceedings of a Workshop from the 198. Positive Predictive Value of Antidiabetic Cricelli Claudio, Mariadonata Bellentani, USFDA: Evaluation of Long-Term Miriam Sturkenboom, Niek Klazinga. (Italy) Neurocognitive Development in Agent Exposure from EHR Prescribing Data Relative to Pharmacy Dispensing Pediatrics [301] 206. The Use of New Oral Anticoagulants Data in the OptumLabs™ Data Ann W McMahon, Philip H Sheridan, in Patients with Atrial Fibrillation in Warehouse [310] Lynne Yao. (United States) Scotland – A Population-Based Drug Christopher G Rowan, Nikita Stempiewicz, Utilisation Study [318] 190. Drug Utilization Among Norwegian James Flory, Tobi Gerhard, James D Lewis, Tanja Mueller, Samantha Alvarez-Madrazo, Children Diagnosed with Chronic John Cuddeback, Sean Hennessy. (United Chris Robertson, Marion Bennie. (United Fatigue Syndrome / Myalgic States) Kingdom) Encephalomyelitis [302] 199. Primary Non-Adherence Associated Inger J Bakken, Simon Collin, Kari Tveito, 207. Non-Adherence to Methotrexate in with Antidiabetic Agents (ADAs) from Kari Furu, Siri E Håberg. (Norway) Rheumatoid Arthritis; a Prospective Electronic Health Record Prescribing Cohort Study (RAMS) [319] Data (EHRx) in the OptumLabs™ Data 191. Attention Deficit Hyperactivity Disorder Holly F Hope, James Anderson, Anne Warehouse [311] (ADHD) in Under 19s: Prevalence and Barton, Lis Cordingley, Kimme L Hyrich, Predictors of Medication Use in Primary Christopher G Rowan, Nikita Stempiewicz, Jamie Sergeant, Suzan MM Verstappen. Care [303] James Flory, Tobias Gerhard, James D (United Kingdom) Adrian J Hire, Darren M Ashcroft, Douglas Lewis, John Cuddeback, Sean Hennessy. T Steinke. (United Kingdom) (United States) 208. Persistence to Anti-Osteoporosis Treatments in Primary Care Patients 192. Out of Hospital Cardiovascular 200. Medication Possession Ratio Recorded in the Spanish Electronic Associated with Antidiabetic Agents Medication Use in Children with Database BIFAP [320] from Electronic Health Record Congenital Heart Defects [304] Elisa Martín Merino, Arturo Álvarez- Prescribing Data (EHRx) in the Morten Olsen, Nicolas Madsen. (Denmark) Gutierrez, Consuelo Huerta Álvarez, OptumLabs™ Data Warehouse [312] Daniel Prieto-Alhambra, Dolores Montero 193. Obesity Predicts Shorter Time to First Christopher G Rowan, Nikita Stempiewicz, Corominas. (Spain) Exacerbation in Pediatric Patients with James Flory, Tobi Gerhard, James D Lewis, Uncontrolled Mild to Moderate Asthma John Cuddeback, Sean Hennessy. (United 209. Associations Between Personality [305] States) Traits and Adherence to Cristina Longo, Gillian Bartlett, Brenda Antidepressants Assessed Through MacGibbon, Francine M Ducharme, Tracie 201. Abstract Withdrawn [313] Self-Report, Electronic Monitoring, and Barnett. (Canada) Pharmacy Dispensing Data [321] 202. Patient Adherence to Treatment H Wouters, D F Amin, K Taxis, E R 194. Childhood Obesity in Relation to Poor After Discharge for Acute Coronary Heerdink, A CG Egberts, H Gardarsdottir. Asthma Control and Exacerbations Syndrome in Vietnam: A Prospective (Netherlands) [306] Observational Study [314] Fariba Ahmadizar, Susanne Vijverberg, Thang Nguyen, Thao Huong Nguyen, 210. Impact of Pharmaceutical Care on Hubertus Arets, Anthonius de Boer, Hoang Thi-Kim Cao, Khanh Kim Le, Suol Medication Adherence, Hemoglobin Jason Lang, Meyer Kattan, Colin Palmer, Thanh Pham, Hoa Thi-Kim Pham, Phong Levels and Interdialytic Weight Gain Somnath Mukhopadhyay, Steve Turner, Thanh Pham, Ngoc Le-Bao Ho, Tu Thi- Among Hemodialysis Patients – A Anke-Hilse Maitland van der Zee. Ngoc Tran, Tam Thi Pham, Katja Taxis. Multicentric Trial [322] (Viet Nam) Uday Venkat Mateti, Anantha Naik 195. State Register of Medicinal Products Nagappa, Ravindra Prabhu Atturu, of Russian Federation as a Source of 203. Impact of Hospitalization Periods on Shankar N Prasad. (India) Information About Age Restrictions for the Calculation of Adherence Measures Drug Prescription [307] [315] 211. Male Breast Cancer and Adherence to Alexander V Matveev, Nail S Yagya, Natalia Yaa-Hui Dong, Niteesh K Choudhry, Alexis Adjuvant Endocrine Therapy [323 N Yarkova, Alexander Y Ezernitskiy. Krumme, Moa Lee, Li-Chu Wu, Mei-Shu Inyoung Lee, Wan-Ju Lee, Gregory S Lai, Joshua J Gagne. (United States) Calip. (United States) 196. Quality of Pediatric Pharmacoepidemiological Safety 204. Prior Medication Adherence As A 212. Alternative Data Processing in the Culig Strong Predictor Of Future Adherence Studies Published from 1979 to 2013 Adherence Scale [324] [316] [308] Aleksandar Momirovic, Marcel Leppee, Osemeke U Osokogu, Julijana Dukanovic, Hiraku Kumamaru, Moa P Lee, Yaa-Hui Dario Naletilic, Josip Culig. (Croatia) Carmen Ferrajolo, Wichor M Bramer, Dong, Alexis A Krumme, Nazleen Khan, Daniel Weibel, Geert t’ Jong, Katia Gregory Brill, Shun Kohsaka, Hiroaki 213. Predicting Refill Adherence from Verhamme, Florentia Kaguelidou, Miriam Miyata, Niteesh K Choudrhy, Sebastian Alternative Data Sources: Claims, Sturkenboom. (Netherlands) Schneeweiss, Joshua J Gagne. (United Structured Electronic Health Record States) Data, and Physician Notes [325] Jessica M Franklin, Alexis A Krumme, Chandrasekar Gopalakrishnan, Karandeep Singh, James R Rogers, Joe Kimura, 32nd Caroline McKay, Newell McEllwee, Niteesh K Choudhry. (United States) 68 POSTER SESSION A: Friday, August 26 | 8:00am - 6:00pm

214. Pharmacy Inducement Programs Use of Medicines - 231. Determinants of Blood Pressure Control Associated with Better Medication Among Ambulatory Hypertensive Hematological and Adherence: A Cohort Study [326] Patients: A Cross Sectional Study in Scot H Simpson, Mu Lin, Dean T Eurich. Cardiovascular Ethiopia [343] (Canada) 223. The Application of the HAS-BLED Derbew Fikadu Berhe, Katja Taxis, Flora Criteria within Post Authorisation Safety M Haaijer-Ruskamp, Afework Mulugeta, 215. New Self-Questionnaire Way To Yewondwossen Tadesse Mengistu, Peter Measuring Adherence To Medication Studies to Characterise Anticoagulant New User Patients with Non-Valvular GM Mol. (Netherlands) [327] Atrial Fibrillation (AF): Interim Results Martina Bago, Ivana Prga, Marcel Leppée, 232. Adherence to Lipid-Lowering Therapy in from a Specialist Cohort Event Josip Culig, Ivana Radman. (Croatia) Elderly – A Pharmacy Database Study in Monitoring (SCEM) Study [335] Bulgaria [344] Use of Medicines - Deborah Layton, Alison Evans, Miranda Hristina Lebanova, Evgeni Grigorov. Davies, Vicki Osborne, Saad AW Shakir. (Bulgaria) Alimentary & Metabolic (United Kingdom) 233. The Association Between Statin 216. The Quality of Prescribing in Type 2 224. Characteristics of Patients at Initiation Therapy and Neovascular Age-Related of Treatment for Primary Chronic Diabetes Mellitus After Intervention of Macular Degeneration [345] Immune Thrombocytopenia [336] Evidence-Based Drug Formulary in a Wan-Ju Annabelle Lee, Chien-Hsun Li, Private Hospital in Indonesia [328] Charlotta Ekstrand, Marie Linder, Honar Ching-Lan Cheng, Yea-Huei Kao Yang. Erna Kristin, Alfi Yasmina, Iwan Cherif, Helle Kieler, Shahram Bahmanyar. (Taiwan) Dwiprahasto. (Indonesia) (Sweden) 234. Association Between Exposure 217. New Glucose Lowering Drugs (Gld) 225. Factors Associated with Rivaroxaban to Evidence-Based Heart Failure Usage in Portugal: Results of an Prescribing in Specialist Care Setting: Drug Treatment and All-Cause Intensive Monitoring Study in Real-Life Interim Results from the Rivaroxaban Hospitalization and All-Cause Mortality Observational Safety Evaluation (ROSE) Conditions [329] [346] Study [337] Carla Torre, Jose Guerreiro, Patricia Jocelyne Moisan, Catherine Girouard, Longo, Hubert Leufkens, Ana Paula Deborah Layton, Alison Evans, Miranda Norma Pérez, Éric Demers, Jean-Pierre Martins. Davies, Vicki Osborne, Saad AW Shakir. Grégoire. (Canada) (United Kingdom) 218. Utilisation of Once Weekly Exenatide 235. Classification of Drugs Implicated in (Bydureon®) for Type 2 Diabetes 226. Cohort Characteristics and Cases of Proarrhythmia: Results from Mellitus (T2DM): Interim Results from an Determinants of Prescribing the Drug-Induced Arrhythmia Risk Observational Cohort Study in England Rivaroxaban in Primary Care in Evaluation (DARE) Study in England England: Interim Results from a Post [330] [347] Authorisation Safety Study (PASS) [338] Abigail Coughtrie, Deborah Layton, Qing Abigail Coughtrie, Elijah Behr, Deborah Qiao, Saad Shakir. Sandeep Dhanda, Miranda Davies, Layton, Saad Shakir. Deborah Layton, Vicki Osborne, Saad AW 219. How To Use Pharmacy Dispensing Shakir. (United Kingdom) 236. Characterization of New Users of Data To Measure Adherence And Cilostazol in the United Kingdom, Spain, 227. Characterisation of Baseline Risk Identify Nonadherence With Oral Sweden, and Germany [348] Factors for Bleeding Outcomes in Hypoglycaemic Drugs [331] Jordi Castellsague, Brian Calingaert, Patients with Non-Valvular Atrial Fong Sodihardjo-Yuen, Liset van Dijk, Beatriz Poblador-Plou, Maria Giner- Fibrillation (AF) Prescribed Rivaroxaban Michel Wensing, Peter de Smet, Martina Soriano, Marie Linder, Oliver Scholle, in Primary Care in England: Interim Teichert. (Netherlands) Cristina Varas-Lorenzo, Alejandro Arana, Results from a Post Authorisation Christine Bui, Alexandra Prados-Torres, Safety Study (PASS) [339] 220. Factors Associated with T2DM Treatment Francisca Gonzalez-Rubio, Albert Roso- Choice Across Europe [332] Sandeep Dhanda, Miranda Davies, Llorach, Anna Citarella, Edeltraut Garbe, Jetty A Overbeek, Edith M Heintjes, Gillian Deborah Layton, Vicki Osborne, Saad AW Tilo Blenk, Susana Perez-Gutthann. C Hall, Daniel Prieto-Alhambra, Fransesco Shakir. (United Kingdom) Lapi, Katherine Tsai, Niklas Hammar, Irene 237. Physician Adherence to Acute Coronary D Bezemer. (Netherlands) 228. A Retrospective Analysis in a Local Syndrome Prescribing Guidelines in Health Authority in Northern Italy Vietnam: A Prospective Observational to Evaluate the Utilization of Oral 221. Comparison of Glucose Lowering Study [349] Anticoagulants [340] Drugs Usage Between Portugal and 6 Thang Nguyen, Huong Thao Nguyen, European Countries, in 2014 [333] Alfredo Cocci, Silvia Lucchi, Salvatore Hoang Thi-Kim Cao, Khanh Kim Le, Suol Carla Torre, Jose Guerreiro, Patricia Mannino. (Italy) Thanh Pham, Hoa Thi-Kim Pham, Phong Longo, Suzete Costa. (Portugal) 229. How Complete Are Primary Care and Thanh Pham, Linh My Ho, Trang Ngoc- Diem Thai, Tam Thi Pham, Katja Taxis. 222. Medication Use and Potentially High Cardiologist Data in Germany for (Viet Nam) Risk Prescribing in Older Patients Research of Oral Anticoagulants in Hospitalised for Diabetes: A Missed Non-Valvular Atrial Fibrillation? [341] 238. Lipid Profile and Patient Characteristics Opportunity to Improve Care? [334] Shuk-Li Collings, Michelle Johnson, Prior to Initiation of Niaspan (Extended Gillian E Caughey, John D Barratt, Sepehr Sebastian Kloss, David Evans, Andrew Release Niacin) Therapy: Analysis of Shakib, Anna Kemp-Casey, Elizabeth E Maguire, Cinira Lefèvre. (United Kingdom) a Large Electronic Medical Record Roughead. (Australia) Database [350] 230. Compliance and Persistence to Anticoagulation Therapy: A Syed S Islam, Ran Gao, Michael F Jarvis, Retrospective Analysis in a Local Health Ramon Espaillat, Hans P Bacher. (United States) Authority in Northern Italy [342] Silvia Lucchi, Alfredo Cocci, Salvatore 32nd Mannino. (Italy) 69 POSTER SESSION A: Friday, August 26 | 8:00am - 6:00pm

239. The Temporal Trend of the Prevalence 248. Drug-Drug Interactions at Increased 256. Characteristics of Opioid Maintenance of Heart Failure Hospitalization Prior to Risk of Adverse Effects for Therapy (OMT) Prescribers and Their Dispensing of Dronedarone [351] Antipsychotic Users in France from Distribution Among OMT Patients in Chuntao Wu, Andrew Koren, Jane 2007 to 2012: A Population-Based Study Ontario [368] Thammakhoune, Hayet Kechemir, [360] Qi Guan, Sheryl Spithoff, Mina Tadrous, Stephanie Tcherny-Lessenot, Susan Anne Bénard-Laribière, Bernard Bégaud, Meldon Kahan, Tara Kiran, Wayne Khuu, Welsh, Juhaeri Juhaeri. (United States) Elodie Pambrun, Fabienne Bazin, Pernelle Diana Martins, Pamela Leece, Tara Noize, Marie Tournier, Antoine Pariente, Gomes. (Canada) 240. Patterns Of Statin Initiation And Hélène Verdoux. (France) Continuation In Cancer Patients 257. Detection of Aberrant Opioid Use in Towards End-Of-Life [352] 249. Antipsychotic Medication Treatment Prescription Claims Data: Comparison Amelia Smith, Laura Murphy, Ian Barron, of New Depressive Episodes in the US and Validation of Five Algorithms [369] Kathleen Bennett. (Ireland) Medicaid Population [361] Kathryn Rough, Krista F Huybrechts, Tobias Gerhard, T Scott Stroup, Christoph Sonia Hernández-Díaz, , Rishi J Desai, Use of Medicines - Correll, Cecilia Huang, Zhiqiang Tan, Elisabetta Patorno, Bateman T Bateman. Stephen Crystal, Mark Olfson. (United (United States) Neurological States) 241. Continuity of Prescribing and 258. Prescription Opioid Access Patterns Medication Adherence in Patients with 250. Potentially Inappropriate Medications in Australia: A National Observational Schizophrenia and Cardiometabolic in Elderly Patients: Prevalence and Cohort Study [370] Changes During Hospital Stay [362] Comorbidities [353] Bianca Blanch, Louisa Degenhardt, Natasa Joel F Farley, Richard A Hansen, Daniala L Weir, Aude Motulsky, Todd Gisev, Timothy A Dobbins, Briony Larance, Marisa E Domino, Neepa Ray, Nirosha C Lee, Maria-Teresa Moraga, Robyn Sarah Larney, Sallie-Anne Pearson. Mahendraratnam, Matthew L Maciejewski. Tamblyn. (Canada) (Australia) (United States) 251. Initiation Of Strong Prescription Opioids 259. Abstract Withdrawn [371] 242. Time-to-Treatment In The Management In Australia: Cohort Characteristics And 260. Association Between High Risk Opioid Of Relapsing/Remitting Multiple Factors Associated With The Type Of Opioid Initiated [363] Prescribers and Patients [372] Sclerosis [354] Hsien-Yen Chang, Irene Murimi, John Hsieh, Lisa G Pont, Minass Semerdijan, Therese Natasa Gisev, Sallie-Anne Pearson, Bianca G Caleb Alexander. (United States) Burke, Linda Mekhael, Stephen Vucic, Blanch, Briony Larance, Timothy Dobbins, Sarah Larney, Louisa Degenhardt. Vanessa Hughes. (Australia) 261. The Influence of Concomitant Opioids (Australia) on Opioid Utilisation for Tramadol 243. Potentially Inappropriate Prescriptions Users – A Retrospective Cohort Study for Stimulant Medication for Treatment 252. Alcohol and Illicit Drug Use and Their in the UK Primary Care Setting [373] of Attention Deficit Hyperactivity Association with Prescription Opioid Misuse Among Undergraduate and Joyce Wang, Teng-Chou Chen, Li-Chia Disorder Among Canadian Adults [355] Postgraduate Medical Students in Chen, Roger Knaggs. (United Kingdom) Wayne Khuu, Diana Martins, Mina Greece [364] Tadrous, Zhan Yao, Samantha Singh, 262. The Difference in Baseline Georgios Papazisis, Eirini Apostolidou, Michael Paterson, Muhammad M Characteristics Between Persistent Ioannis Tsakiridis, Chryssa Pourzitaki, Mamdani, David N Juurlink, Tara Gomes. Tramadol Users Defined by Different Dimitrios Kouvelas. (Greece) Criteria [374] 244. Psychotropic Medication Use in Patients with Eight Major Cancers in 253. Drug Utilization Study for Teng-Chou Chen, Li-Chia Chen, Roger Japan: A Retrospective Descriptive Lisdexamfetamine Dimesilate in Knaggs. (United Kingdom) Study Using a Health Insurance Claims Australia [365] Database [356] Dorothea von Bredow, Birgit Ehlken, Use of Medicines - Other William A Blumentals, Kolb Nikolaus, Keja Izumi Sato, Hideki Onishi, Koji Kawakami. 263. Monitoring of Medication Uptake in Jacco, Tricia Maxwell. (Germany) (Japan) Difficult Asthma [375] 245. Utilization of Psychosocial Services 254. Use of Benzodiazepines in Debbie E Anderson, Christine E Bucknall, After Initiation of Antipsychotics in High Circumstances at Increased Risk Douglas Cowan, Sean MacBride-Stewart, of Adverse Effects in the French Anne C Boyter. Risk Youth [357] Population [366] Wendy Camelo Castillo, O’Mareen 264. Oral Corticosteroids in Asthma Anne Bénard-Laribière, Pernelle Noize, Spence, Susan dosReis. (United States) Exacerbations: Differences Between Elodie Pambrun, Fabienne Bazin, Hélène Patient-Reported Data and Proxies 246. Correlates of In-Patient Initiation of Verdoux, Marie Tournier, Bernard Bégaud, from Claims Data [376] Antipsychotics Among Elderly Patients Antoine Pariente. (France) Laurent Laforest, Alexandra Dima, Discharged to Nursing Homes [358] 255. Misuse of Benzodiazepines in the Nathalie Texier, Marijn de Bruin, Gimena Kate L Lapane, Bill M Jesdale, Christine French Population: A Cohort Study Hernandez, Maeva Nolin, Eric H Van M Ulbricht, Anne L Hume, Jon DeShazo, in the Echantillon Genéraliste de Ganse, The ASTROLAB Group. (France) Jacob Hunnicutt, Jennifer Tjia, Carmel M Bénéficiaires Between 2007 and 2012 Hughes. (United States) 265. Excess Dosing and Knowledge About [367] Currently Used Acetaminophen- 247. Prevalence and Associated Factors of Arnaud Panes, Regis Lassalle, Caroline Containing Products [377] Psychotropic Medication Use: A Cross- Dureau-Pournin, Antoine Pariente, Annie Sectional Study of the Mexican Teacher Fourrier-Reglat. (France) Judith P Kelly, David W Kaufman, Deena R Battista, Mary K Malone, Rachel Cohort [359] Weinstein, Saul Shiffman. (United States) Rene Soria-Saucedo, Ruy Lopez-Ridaura, Martin Lajous-Loeza, Veronika Wirtz. 266. Abstract Withdrawn [378] (United States) 32nd

70 POSTER SESSION A: Friday, August 26 | 8:00am - 6:00pm

267. Antibiotics Resistance Pattern and 278. Cyproterone/Ethinylestradiol Use and 287. Defining Prescription Quality Indicators Prevalence of Urinary Tract Pathogens Indications in the Netherlands [390] at Primary Care Level in Portugal [399] in Malaysia [379] Irene D Bezemer, Lisa Smits, Fernie JA Milene Fernandes, Ana Costa, Manuela Muhammad Shahid Iqbal, Muhammad Penning-van Beest, Alex Asiimwe, Ron Cruz, Cristina Ribeiro, Luís Rebelo, Vasco Zahid Iqbal, Mohd Baidi Bahari. (Malaysia) MC Herings. (Netherlands) AJ Maria. (Portugal)

268. Antibiotic Use Practices By Pharmacy 279. Incidence of and Factors Associated 288. An European Repository for Electronic Staff: A Cross-Sectional Study in Saint- with Anticholinergic Drugs Among Selection of Explicit Criteria of Petersburg, Russia [380] Women with Urinary Incontinence: A Potentially Inappropriate Prescriptions Tatiana Belkina, Natalia Duvanova, Arina Population-Based Cohort Study [391] (PIPs) in Old Age [400] Korolkova, Jurjen Duintjer Tebbens, Jiri Siri Mauseth, Svetlana Skurtveit, Arnulf Ivana Ivanova, Monique Elseviers, Vlcek. (Czech Republic) Langhammer, Olav Spigset. (Norway) Maarten Wauters, Majda Azermai, Thierry Christiaens, Robert Vander Stichele. 269. Abstract Withdrawn [381] 280. Retention in Methadone Maintenance (Belgium) Treatment (MMT) in Primary Care: 270. Prevalence and Predictors of Post- National Cohort Study Using 289. Evolution of the Medication Use in a Discharge Antibiotic Use Following Proportional Hazards Frailty Model for Cohort of Newly Admitted Nursing Mastectomy [382] Recurrent MMT Episodes [392] Homeresidents (Ageing@NH): Report of Margaret A Olsen, Katelin B Nickel, Gráinne Cousins, Fiona Boland, Joseph the First Follow-Up Observations [401] Victoria J Fraser, Anna E Wallace, David K Barry, Suzi Lyons, Kathleen Bennett, Tom Ivana Ivanova, Maarten Wauters, Robert Warren. (United States) Fahey. (Ireland) Vander Stichele, Thierry Christiaens, Jonas De Wolf, Tine Dilles, Monique Elseviers. 271. Utilization of Antibiotics with QT 281. Quality Use of Medicines Among (Belgium) Prolongation Potential in the United Makkah Community [393] States [383] Abdul Haseeb, Rozan Mohammad Radwan, 290. Comparing Spontaneous Report Yizhou Ye, Aisling R Caffrey. Hani Saleh Faidah, Rehab Adnan Baghdadi, Disproportionality Measures to Estimates (United States) Mahmoud Mohamed Ahmed Mohamed, of Adverse Events from Cochrane Mahmoud E. Elraggal, Fahad Saleem, Azmi Systematic Reviews [690] 272. The Practice Pattern of Initial DMARDs Hassali. (Saudi Arabia) Raphaelle Beau Lejdstrom, Sarah Crook, Treatment and Hepatitis Screening in Tsung Yu, Milo Puhan. (Switzerland) Rheumatoid Arthritis Patients: A Cross- 282. Off-Label Use of the Expensive Orphan National Comparison Between USA And Drug Eculizumab in France 2009-2013 Taiwan [384] and the Impact of Literature: Focus on End Session A Tzu-Chieh Lin, Daniel H Solomon, the Transplantation Field [394] Seoyoung C Kim, Yea-Huei Kao Yang, Johann Castañeda-Sanabria, David Rishi Desai. (United States) Hajage, Mélisande Le-Jouan, Anne Perozziello, Florence Tubach. (France) 273. Perceptions of Oncology Practitioners Towards Off-Label Use of Anti-Cancer 283. Assessment of Vaccine Cold Chain Medicines [385] Management Status at Service Delivery Mohd Masnoon Saiyed, Pei Shi Ong, Lita Health Facilities in Dawro Zone, South Chew. West Ethiopia [395] Abebe Kebede, Michael Mesfin, Seid M 274. The Relationship Between Patient Ahmed. (Ethiopia) Safety Culture and Medication Errors Among Healthcare Professionals in 284. Are Multiple Interventions Needed Private and Public Hospitals in Nigeria To Influence Physician Prescribing [386] Behaviour: Implications For The Future? Beatrice O Odugbemi, Katja Taxis, [396] Eugene Van Puijenbroek, Onoja M Akpa. Ilse Truter, Brian Godman, Amanj Baker, (Netherlands) Anna Bucsics, Joseph Fadare, Ulrik Hesse, Andrew Martin, Hye Young Kwon, Corinne 275. Drug Utilization Study: Evaluation of the Zara, Marion Bennie. (Sweden) Use of Nepafenac in the Netherlands and Denmark [387] 285. Utility of Prescription Drug Monitoring Andrea V Margulis, Eline Houben, Data for Policy Analysis in a State Morten Olesen, Jesper Hallas, Jetty Medicaid Program [397] Overbeek, Anton Pottegard, Wendy Ye, Daniel M Hartung, Luke Middleton, Sharia Dorian Villegas, Susana Perez-Gutthann, M Ahmed, Joshua VanOtterloo, Hyunjee Alejandro Arana. (Spain) Kim, K J McConnell, Shellie Keast, Richard Deyo. (United States) 276. Dispensing Patterns of Ophthalmological Products in 286. Medicine Utilisation Capabilities in Community Pharmacies in South Africa: Africa: Current Status, Implications and A Pharmacoepidemiological Study [388] Future Prospects [398] Ilse Truter. (South Africa) Ilse Truter, Celda Tiroyakgosi, Matshediso Matome, Abayneh Desta, Arno Muller, 277. Cyproterone/Ethinylestradiol And Fola Amu, Joseph Fadare, Dan Kibuule, Concomitant Use Of Other Hormonal Newman Madzikwa, Romuald Mbwasi, Contraceptives In The Netherlands [389] Ester Naikaku, Olayinka Ogunleye, Irene D Bezemer, Lisa Smits, Fernie JA Margaret Oluka, Brian Godman. (Sweden) Penning-van Beest, Alex Asiimwe, Ron 32nd MC Herings. (Netherlands) 71 POSTER SESSION B: Saturday, August 27 | 8:00am - 6:00pm Spotlight Sessions: 11:45 - 12:45pm Spotlight Session-AsPEN J. A Number Needed to Treat Test [491 T. Patient Characteristics Associated with Colin R Dormuth. (Canada) Persistent Tramadol Use for Patients A. Dabigatran versus Warfarin in Patients with Chronic Non-Cancer Pain in U.K. with Non-Valvular Atrial Fibrillation: A K. Additional Risk Minimisation Measures General Practices [501] Population-Wide Cohort Study in Chinese Targeting Patients in the PRAC Era: Teng-Chou Chen, Li-Chia Chen, Roger Patients [482] A Qualitative Review of the European Knaggs. (United Kingdom) Wallis CY Lau, Esther W Chan, Ian CK Wong. Public Assessment Report Database [492] U. Patterns of Tiotropium Dispensing in B. Evaluation of Clinical and Genetic Risk Madalena Arriegas, Annalisa Rubino. the United States and Impact of FDA Factors in the Development of New- (Portugal) Drug Safety Communications [502] Onset Diabetes Mellitus in Malaysian Elizabeth Kang, Simone Pinheiro, Post-Renal Transplant Patients [483] L. Evaluating Physician Knowledge Esther Zhou, Yulan Ding, Sally Seymour, Rhanye Mac Guad, Wan Ahmad Hafiz of Risks and Safe Use of Xarelto Jacqueline M Major. Wan Md Adnan, Raja Elina Raja Aziddin, (Rivaroxaban) [493] Zahurin Mohamed, Nur Lisa Zaharan. Laurie J Zografos, Kiliana Suzart, Andrea V. In-Hospital Antipsychotic Use Among (Malaysia) Horvat-Broecker, Montse Soriano- Elderly Patients Discharged to Nursing Homes [503] C. Association of Aspirin Use and Age- Gabarró, Dan L Wolin, Brian Calingaert, Related Macular Degeneration in Eric K Davenport, Kelly A Hollis, Elizabeth Kate L Lapane, Bill M Jesdale, Christine M Taiwan [484] Andrews. (United States) Ulbricht, Anne L Hume, Jacob Hunnicutt, Jon DeShazo, Jennifer Tjia, Carmel M Wan-ju Annabelle Lee, Ching-lan Cheng, M. Semi-Quantitative Benefit-Risk Hughes. (United States) Yea-Huei Kao Yang. (Taiwan) Assessment for Dengvaxia [494] D. Risk Factors of Trastuzumab Related Lydie F Marcelon, Carine H Cohen, Alena X. Poor Adherence With Non-Vitamin Cardiotoxicity in Taiwanese Breast Khromava, Leon R Ochiai, Anh T Wartel, K Oral Anticoagulant (Dabigatran, Cancer Women [485] Sophia Gailhardou. (France) Rivaroxaban) Among Patients With Nonvalvular Atrial Fibrillation Initiating Hsu-Chih Chien, Yea-Huei Kao Yang, Jane N. Traditional vs. HIV-Specific Anticoagulant Therapy In 2013 In PF Bai. (Taiwan) Cardiovascular Disease Risk Scores in France. A Cohort Study On The French E. Antipsychotic Polypharmacy of Persons Living with HIV [495] Healthcare Databases [505] Schizophrenia Treatment – a Database Robin M Nance, Matthew J Feinstein, Géric Maura, Antoine Pariente, Alain Weill, Approach in China [486] Heidi Crane, Joseph A Delaney, Hongyan François Alla, Cécile Billionnet. (France) Hong Qiu, Yong He, Yongjing Zhang, Minfu Ning, Chad J Achenbach, Michael Saag, He, Jin Liu, Rui Chi, Tianmei Si, Wentian Joseph Eron, Richard Moore, William Spotlight Session- Dong. (United States) C Mathews, Mari Kitahata, Susan R Heckbert, Matthew J Budoff, Donald M Medications in Pregnancy F. Statin Induced Diabetes Mellitus in Lloyd-Jones. (United States) Y. Neurodevelopmental Problems At 18 Cardiovascular Patients: A Multicentric Months Among Children Exposed To Observational Study of Hospital O. Quantitative and Qualitative Methods to Paracetamol In Utero – A Propensity Databases in South Indian Tertiary Support Therapeutic Risk Minimization Score Matched Cohort Study [506] Healthcare Facilities [487] Efforts [496] Richelle Vlenterie, Mollie E Wood, Ragnhild Jessie Margaret Saldanha, K Shetty Ranjan, Noelia Alfaro, Nawab Qizilbash, Annalisa Eek Brandlistuen, Nel Roeleveld, Marleen M Sekhar Sonal. (India) Rubino. (United Kingdom) MHJ van Gelder, Hedvig Nordeng. G. Incidence and Medical Resource P. Additional Risk Minimisation Measures to (Netherlands) Utilization for Cardiovascular Events in Prevent Medication Error in the EU [497] Asia [488] Z. Mood Stabilizer Use and Risk of Esther Artime, Nawab Qizilbash, Annalisa Ischemic Placental Disease [507] Kenneth KC Man, Edward CC Lai, Chien- Rubino. (United Kingdom) Chou Su, Kiyoshi Kubota, Shinya Kimura, Jacqueline M Cohen, Elisabetta Patorno, Krista F Huybrechts, Yoonyoung Park, Paul Stang, Martijn Schuemie, Patrick Ryan, Spotlight Session-DUR Yea-Huei Kao Yang, Yinghong Zhang, Soko Brian T Bateman, Sonia Hernández-Díaz, . Setoguchi, Ian CK Wong. (China) Q. Utilization Heterogeneity of Aromatase (United States) Inhibitor Agents for Breast Cancer AA. Maternal and Infant Characteristics – H. Epidemiology in Asian Treatment in a US Medicare Population Differences and Similarities Between Pharmacoepidemiology Network [498] (AsPEN): Study in Surveillance of Health the Nordic Countries and the United Matthew K Breitenstein. (United States) Care in Asian Network (SCAN) [489] States [508] Kenneth KC Man, Edward CC Lai, Chien- R. Does Concordance with Fixed-Dose Lukas Löfling, Gabriella Bröms, Shahram Chou Su, Kiyoshi Kubota, Shinya Kimura, Combination (FDC) Treatment Guidelines Bahmanyar, Helle Kieler. (Sweden) Paul Stang, Martijn Schuemie, Patrick Ryan, Improve Persistence? An Australian BB. Preconception Use of Pain Relieving Yea-Huei Kao Yang, Yinghong Zhang, Soko Population Based Cohort Study [499] Medication and Time to Pregnancy: A Setoguchi, Ian CK Wong. (China) Andrea L Schaffer, Sallie-Anne Pearson, Prospective Study [509] Nicholas A Buckley. (Australia) Spotlight Session-BRACE Kathryn A McInerney, Elizabeth E Hatch, S. Characterization Of Pregnant Women Amelia K Wesselink, Kenneth J Rothman, I. European Healthcare Professionals’ With Pre-Gestational Diabetes In the Ellen M Mikkelsen, Lauren A Wise. (United Familiarity with and Perceived UK [500] States) Usefulness of Safety Communications on Medicines [490] Lucia Cea Soriano, Sonia Hernández-Díaz, Kimberly G Brodovicz, Dorothee B Bartels, Maartje van der Sar, Sieta de Vries, Peter Lucia Quesada-Muñoz, Luis A García- Mol, On Behalf of SCOPE Workpackage 6. Rodríguez. (Netherlands) 32nd

72 POSTER SESSION B: Saturday, August 27 | 8:00am - 6:00pm Spotlight Sessions: 11:45 - 12:45pm CC. A Systematic Review of Enrollment 5. A Qualitative Study to Identify 14. Improving a Drug Information Leaflet of and Retention in US Pregnancy Interventions to Reduce Pain or Antihypertensives for Senior Citizens; Exposure Registries and Corresponding Syncope Related to Adolescent Employing Performance-Based User- Pharmacovigilance Systems [510] Vaccination [518] Testing [527] Steven T Bird, Christian Hampp, Jennifer L Kuntz, Michelle L Henninger, Iyn-Hyang Lee, Haeri Shim. (Republic of Lockwood Taylor, Kate Gelperin, Marsha Jennifer Schneider, Alison Firemark, Karin Korea) Reichman, Leyla Sahin. (United States) Bok, Jennifer Gordon, Allison L Naleway. (United States) 15. Evaluation of Physician Awareness DD. Antidepressant Use in Pregnancy of Risks Described in the SIMPONI and the Risk of Attention Deficit with 6. Drug Safety of Macrolide and (Golimumab, GLM) EU-RMP Educational or without Hyperactivity Disorder in Quinolone Antibiotics in a Tertiary Care Program [528] Children [511] Hospital: Administration of Interacting Marijo Otero-Lobato, Wim Noël, Anja Comedication and QT-Prolongation Takoua Boukhris, Odile Sheehy, Anick Geldhof, Malkit Ghotra, Lauren Felo. [519] Berard. (Canada) (Netherlands) David F Niedrig, Sarah Mächler, Liesa EE. Estimation of Gestational Age at Birth Hoppe, Natascia Corti, Helen Kovari, 16. Evaluation of Risk Minimisation Using Claims-Based Algorithms in a Stefan Russmann. (Switzerland) Activities for Cyproterone Acetate 2 Commercially Insured US Population mg/Ethinylestradiol 35 μg [529] [512] 7. Media Monitoring Of The HPV Vaccines Kimberly H Davis, Alex Asiimwe, Laurie Debate – What The Public Wants To Anna E Wallace, Brian K Lee, Nandini J Zografos, David J McSorley, Elizabeth Know And Experts Should Address Selvam, Loni Tabb, Michael Yudell, Renee Andrews. (United States) [520] Turchi, Craig J Newschaffer. (United 17. Assessment Of Pharmacist Mediated States) Priya Bahri, Julianna Fogd, Irina Caplanusi, Andrej Segec, Xavier Kurz. Education On Health Related Quality Of FF. Risk of Infections During the First Year (United Kingdom) Life In Type 2 Diabetes Mellitus Patients of Life After In Utero Exposure to Drugs In Rural India [530] Acting on Immunity: A Population- 8. Methodologies to Assess the Benefit Sai Pawan Ramesh Adepu, KV Ramanath, Based Cohort Study [513] and Risk Balances and Examples in Shashikantha Bhat, Steny Sam, Cuckoo Vaccines [521] Lucie Palosse-Cantaloube, Caroline Omanakuttan. (India) Julie Mouchet, Bernard Begaud. (France) Hurault-Delarue, Anna-belle Beau, 18. Programmatic Efficiency of a Jean-Louis Montastruc, Isabelle Lacroix, 9. Digoxin Use After Diagnosis of Prostate Pharmaceutical Risk Management Christine Damase-Michel. (France) Cancer and Survival: A Population- Program: Outcomes from Diabetes Based Cohort Study [522] Screening of Adults Receiving BRACE Reema Karasneh, Liam Murray, Carmel Antipsychotics [531] 1. Predictors and Clinical Impact of Hughes, Chris Cardwell. (United Kingdom) Elaine H Morrato, Elizabeth J Campagna, Indeterminate QuantiFERON-TB Gold Sarah E Brewer. (United States) Testing in Inflammatory Bowel Disease 10. A Framework for the Evaluation of the [514] Effectiveness of Risk Minimisation 19. Compliance with Renal Testing Measures Applied to Retrospective Recommendations for Fampridine Use Ravy K Vajravelu, Mark T Osteroman, Danish Real-World Dabigatran Etexilate in a German Population with Multiple Faten N Aberra, Jason A Roy, Gary R Data [523] Sclerosis [532] Lichtenstein, Ronac Mamtani, David S Goldberg, James D Lewis, Frank I Scott. Martin Erik Nyeland, Flemming Skjøth, Nicholas J Everage, Andrew Maguire, Lalitha (United States) Peter Brønnum Nielsen, Jette Kjældgaard, Mahadavan, Madé Wenten. (United States) Torben Bjerregaard Larsen, Mona 2. The Development And Evaluation Of Vestergaard Laursen, Torbjörn Callréus. 20. Usage Of Valproate In Women In The A Dynamic Risk Model For Hospital (Denmark) UK [533] Associated Hyperkalemia [515] Dervla Quinn, Katherine Donegan. 11. The Association Between Statin Use Yan Li, Benjamin Staley, Carl Henriksen, (United Kingdom) And Kidney Stones In Adult Men: A Paul Kubilis, Gigi Lipori, Babette Systematic Review To Evaluate The 21. Impact of an Opioid Risk Reduction Brumback, Thomas E Johns, Almut G Available Evidence And Provide Benefit/ Initiative on Motor Vehicle Crash Winterstein. (United States) Risk Assessment [524] Risk Among Chronic Opioid Therapy 3. Benefit-Risk of Artemether- Emre Yucel, Aylin Yucel, Latif Ozbay. Patients [534] Lumefantrine versus Artesunate- (United States) Ryan N Hansen, Rod L Walker, Susan Amodiaquine for Uncomplicated M Shortreed, Sascha Dublin, Kathleen Malaria in Under 5 Year Olds in Ghana 12. Assessment of Effectiveness of Saunders, Evette J Ludman, Michael Von Using the PhRMA BRAT Framework Dronedarone Risk Minimization Korff. (United States) [516] Measures Through a Drug Utilization Study in Two European Countries [525] 22. Inappropriate Fentanyl Prescribing Daniel Ankrah, Joseph Turkson. (Ghana) Stephanie Tcherny-Lessenot, Birgit Among Nursing Home Residents in the 4. Knowledge, Attitude, and Perception Ehlken, Chuntao Wu, Hayet Kechemir, United States [535] of Parents Towards Antibiotics Use for Pierre D’Arbigny, Peggy Sarah, Laurence Kevin M Fain, Carlos Castillo-Salgado, David Upper Respiratory Tract Infections in Pedrazzini, Juhaeri Juhaeri, Susan Welsh. D Dore, G Caleb Alexander. (United States) Children in Holy Makkah, Kingdom of (France) Saudi Arabia [517] 13. Cardiovascular Disease, Medications, Abdul Haseeb, Majd Yousuf Lamfon, and Heat: What Precautionary Advice Is Malak Mohammad Almatrafi, Imtinan Available? [526] Abdullah Almasoudi, Fahad Saleem. (Saudi Arabia) Nanthanan Jeyakumaran, Genevieve Gabb, Debra Rowett, Tadros Rami. 32nd (Australia)

73 POSTER SESSION B: Saturday, August 27 | 8:00am - 6:00pm

23. Incidence of Opioid Overdose Among 32. Drug Promotional Activities in Nigeria: 42. Use of Antihypertensive Drugs During Patients Using ER/LA Opioid Analgesics Impact on Prescribing Pattern and Pregnancy in the Netherlands [555] Before and After Implementation of the Practices of Medical Practitioners [545] Josta de Jong, Jens HJ Bos, Catharina Class-Wide Opioid REMS [536] Joseph Fadare, Kazeem Oshikoya, Olayinka CM Schuiling-Veninga, Lolkje TW de Daina B Esposito, Paul M Coplan, M Ogunleye, Olufemi Desalu, Okezie Enwere, Jong-van den Berg. (Netherlands) Taofiki Sunmonu. (Nigeria) Soledad Cepeda, Crystal N Holick, Vibha 43. Exposure To Thiocolchicoside During Desai, Caitlin Knox, Nianya Liu, Shiva- 33. Regulatory Considerations for Pregnancy: First Clinical Data in Krishna Vojjala, Jean-Yves Maziere, Gregory Knowledge, Attitude, and Belief EFEMERIS [556] P Wedin, Stephan Lanes. (United States) Surveys: A Systematic Review of Caroline Hurault-Delarue, Isabelle Lacroix, 24. Experience from the Zyprexa Relprevv Physician Survey Response [546] Jean-Louis Montastruc, Anna-belle Beau, Patient Care Program: 2010-2015 [537] Sarah E Brewer, Elaine H Morrato. Christine Damase-Michel. (France) s) Kristin J Meyers, Meghan E Jones, (United State 44. Venlafaxine Exposure in Pregnancy, A Balasubramanya S Rao, Deborah Falk, 34. Use of Cognitive Testing to Optimize Multicenter ENTIS Study [557 Debra Gash, Himanshu Upadhyaya. Questionnaire Wording and Mode of (United States) Bernke te Winkel, Delphine Beghin, Administration in the Evaluation of Risk Alessandra Pistelli, Marco de Santis, 25. Presentation of Stigma Associated with Minimization Activities [547] Matteo Cassina, Georgios Eleftheriou, Mental Disorders in the News Media [538] Laurie J Zografos, Elizabeth Andrews, Heli Malm, Alice Panchaud, Bracha Stahl. Gerard N Lim, Cheong Hian Goh, Mui-Ling Diane Whalley, Paul Petraro, Zdravko (Netherlands) Tan, Wai-Ping Yau. (Singapore) Vassilev. (United States) 45. Rates of Psychotropic Prescribing in 26. Patient Preference (PP) Studies in 35. A Cross-Sectional Study on the Pregnancy [558] Benefit-Risk Assessment (B-RA): Adequacy of Product Information in Jennifer Campbell, Tarita Murray-Thomas. Is There a Room for Improvement Medical Advertisements Published in (United Kingdom) Through Good Pharmacoepidemiology Print Media [548] Practices (GPP)? [539] Ronald Kah Heng Toh, Cheong Hian Goh, 46. Psychopharmacological Drug Utilization Christine A Radawski, Kenneth Mui-Ling Tan, Wai-Ping Yau. (Singapore) Patterns in Pregnant Women with Hornbuckle, Rebecca A Noel, Meghan E Bipolar Disorder – A Nationwide Jones, Debashish Dey. 36. Content Analysis and Frequency of Register-Based Study [559] Direct-to-Consumer Advertising (DTCA) Sofie C Broeks, Katja Glejsted Ingstrup, 27. Review of the Pharmacoepidemiological of Health Products on Television (TV) in Henriette Thisted Horsdal, Christiane Studies Using the Medical Information Singapore [549] Gasse. (Netherlands) Databases in Japanese Hospitals [540] Dennis Seng Leong Mak, Cheong Katsuhito Hori, Michio Kimura, Kazuhiko Hian Goh, Mui-Ling Tan, Wai-Ping Yau. 47. Impact of Evolution and Intensity Ohe, Naoki Nakajima, Hideto Yokoi, (Singapore) of Prenatal Exposure to Anxiolytics Masahiro Tohkin, Kimie Sai, Takuya Imatoh, and Hypnotics on Neonatal Health: A Tsugumichi Sato, Syunya Ikeda, Yoshiro 37. A Study of “Drug Entry Lags” Between Study in EFEMERIS Using a Trajectory Saito, Junichi Kawakami. (Japan) Japan and the US: Compering the Timing Method [560] of a New Drug Entry, Generic Entry and Caroline Hurault-Delarue, Cecile 28. Applying The Number Needed To Harm Market Exclusivity Periods [550] (NNH) to Benefit-Risk (BR) Assessments Chouquet, Isabelle Lacroix, Anna-belle Of Drugs Withdrawn From The Market Sachiko Masuda. (Japan) Beau, Jean-Louis Montastruc, Nicolas Due To Safety Reasons [541] Savy, Christine Damase-Michel. (France) Pregnancy Diogo Mendes, Carlos Alves, Francisco 48. First Trimester Antidepressant Use in Batel Marques. (Portugal) 38. Prevalence of Preexisting Diabetes in the National Birth Defects Prevention Pregnancy and Associated Prescribing Study [561] 29. Do Patients Store Their Oral Oncolytics Patterns [551] According To Manufacturers’ Storage Jennifer N Lind, Jennita Reefhuis, Jan M Recommendations: An Observational Sonia J Coton, Irwin Nazerath, Irene Friedman, Allen A Mitchell, Tiffany Riehle- Study Of Home Storage Temperatures Petersen. (United Kingdom) Colarusso, Kara N Polen, Margaret A Honein. (United States) [542] 39. Safety Of Antidiabetic Drugs In A Nicolaas D Vlieland, Bart JF van den Bemt, Cohort Of Pregnant Women With Pre- 49. Abstract Withdrawn [562] Marcel L Bouvy, Toine CG Egberts, Helga Gestational Diabetes [552] Gardarsdottir. (Netherlands) Lucia Cea Soriano, Sonia Hernández-Díaz, 50. Should We Treat Or Not Mildly To 30. Is There Scope for Rapid Implementation Kimberly G Brodovicz, Dorothee B Bartels, Moderately Depressed Pregnant of Pharmacoepidemiology Findings Using Luis A García-Rodríguez. Women During Pregnancy? [563] Quality Improvement Methods? [543] Maëlle Dandjinou, Odile Sheehy, Anick 40. Tocilizumab Use in Pregnancy: Analysis Berard. (Canada) Natalie Weir, Rosemary Newham, Ashwag of a Global Safety Database Including Ali Atallah Al-Gethami, Ali Mohammed Abd Data from Clinical Trials and Post- 51. Maternal Depression and Use of Alridha, Emma D Corcoran, Paul Bowie, Marketing Data [553] Antidepressants During Pregnancy Anne Watson, Marion Bennie. (United Maria Hoeltzenbein, Evelin Beck, Richa Increase the Risk of Adverse Pregnancy Kingdom) Rajwanshi, Carina G Skorpen, Erhan Outcomes: An IPD Meta-Analysis [564] 31. Determinants for Healthcare Berber, Christof Schaefer, Monika Richelle Vlenterie, Marleen van Gelder, Professionals to Take Action in Ostensen. (Germany) Monica Pop-Purceleanu, Nel Roeleveld. Response to Safety Communications (Netherlands) on Medicines [544] 41. Congenital Malformations and Maternal Use of Anti-Hypertensive Medication in Maartje van der Sar, Sieta de Vries, Peter the UK [554] Mol, On Behalf of SCOPE Workpackage 6. (Netherlands) Claudia Cabrera, Alison Lee, Karin 32nd Henriksson, Cecilia Falkenberg. (Sweden)

74 POSTER SESSION B: Saturday, August 27 | 8:00am - 6:00pm

52. The Risk Of Specific Congenital 61. Assisted Reproductive Technologies 71. Using Web-Based Questionnaires Anomalies In Relation To Newer and the Risk of Cryptorchidism and to Assess Medication Use During Antiepileptic Drugs; A Literature Review Hypospadias: Population-Based Study Pregnancy: A Validation Study in Two [565] [574] Prospective Cohort Studies [584] Josta de Jong, Ester Garne, Lolkje TW Gabriel Chodick, Britton Trabert, Varda Marleen MHJ van Gelder, Saskia de Jong - van den Berg, Hao Wang. Shalev, Katherine A McGlynn. (Israel) Vorstenbosch, Bernke te Winkel, Eugène P (Netherlands) Puijenbroek, Nel Roeleveld. (Netherlands) 62. Trends in the Prevalence of Drug 53. Prenatal Exposure to Non-Steroidal Prescribing During Pregnancy in UK 72. Development of a Mother-Baby Linkage Anti-Inflammatory Drugs and Child Primary Care, 1995-2014 [575] Using Integrated Claims and Electronic Behavior at 36 Months: Birth Weight and Cormac J Sammon, Irene Petersen. Health Records (EHR) [585] Gestational Age as Mediators [566] Nancy D Lin, Cheryl Enger, Wendy Carman, Mollie E Wood, Hedvig Nordeng. (Norway) 63. Drug Utilization Among Pregnant Michael Doherty, John D Seeger. Women: Real-World Findings from a US 54. Opioid Use Following Discharge After EMR Database [576] 73. Validation of Multiple Births in Medicaid Cesarean Delivery [567] Caitlin A Knox, Elise Kaufman, William K Analytic eXtract (MAX) Data [586] Brian T Bateman, Krista F Huybrechts, Mountford. (United States) Yanmin Zhu, Carl Henriksen, Almut G Jessica Booth, Holly Briggs, Pamela Winterstein. (United States) Flood, Melissa Bauer, Ruth Landau. 64. Safety Profile of Medication Used in (United States) Pregnancy: Results of a Multinational Changing Drug Utilization European Study [577] 55. Opioid Use During Pregnancy: A Johanne N Trønnes, Angela Lupattelli, 74. Changes in Prescription Drug Use After Population-Based Cohort Study [568] Hedvig Nordeng. (Norway) Gastric Bypass Surgery: A Nationwide Jamie Falk, Matt Dahl, Colette Raymond, Cohort Study [587] Dan Chateau, Alan Katz, Christine 65. Improving Safe Use of Medications Sigrid B Gribsholt, Reimar W Thomsen, Leong, Elaine Burland, Shawn C Bugden. During Pregnancy: The Roles of Dorá K Farkas, Henrik T Sørensen, Bjørn (Canada) Patients, Physicians, and Pharmacists Richelsen, Elisabeth Svensson. (Denmark) [578] 56. Increase in Aberrant Prescription Molly M Lynch, Jacqueline Amoozegar, 75. Impacts of Reimbursement Policy for Opioid Use by Pregnant Women in Emily M McClure, Linda B Squiers, Cheryl Targeted Therapies Utilization for Lung a Nationwide Cohort of Medicaid S Broussard, Jennifer N Lind, Kara N Polen, Cancer Treatment in Taiwan [588] Beneficiaries [569] Meghan T Frey, Suzanne M Gilboa, Janis Jason C Hsu, Chen-Fang Wei, Christine Y Kathryn Rough, Sonia Hernández-Díaz, Biermann. (United States) Lu. (Taiwan) , Krista F Huybrechts, Rishi J Desai, Elisabetta Patorno, Brian T Bateman. 66. Unique Approaches for Conducting 76. Reducing Breast Cancer Risk: Why (United States) Lactation and Placental Transfer Aren’t Providers Screening and Studies [579] Prescribing? [589] 57. Risk Of Preterm Birth Following Late Deborah L Covington, Nicole Hurst, Anne Sharon L Larson, H K Kirchner, Haiyun Pregnancy Exposure To Medications Tronel-Peyroz. (United States) Wang. (United States) Used In The Treatment Of Autoimmune Diseases (AD) [570] 67. Utilization of Laboratory Results 77. Prescription Behaviour for Anick Bérard, Odile Sheehy, Sylvie Girard, Data to Enhance Pregnancy Cohort Gastroprotective Drugs in New Users Jin-Ping Zhao. (Canada) Identification [580] as a Result of Communications Kevin Haynes, Andrew Sterrett, Susan Regarding Clopidogrel – Proton Pump 58. Feasibility of Using the Medicaid Shetterly, Mano Selvan, Josh Gange, Inhibitor Interaction [590] Statistical Information System (MSIS) Christine Lu, Azadeh Shoaibi, Marsha A W J Kruik-Kollöffel, J van der Palen, H J to Assess Safety and Effectiveness Raebel. (United States) Kruik, M P van Herk-Sukel, K L Movig. of 3rd Trimester Vaccination: A Case (Netherlands) Study with Tetanus Toxoid, Reduced 68. Spontaneous Preterm Labor (SPTL) Diphtheria Toxoid And Acellular in the Netherlands: Creation Of 78. Changes in Antihypertensive Drug Use Pertussis (Tdap) [571] Linked Mother-Child Cohorts For After the Implementation of Evidence- Yandong Qiang, Yoganand Chillarige, Epidemiological Studies [581] Based Drug Formulary in a Private Maria Said, Tina Liu, Carmen Dekmezian, Libby K Black, Eline Houben, Jeanne Hospital in South Sumatra, Indonesia Scott Winiecki, Michael D Nguyen, Chris M Pimenta, Irene D Bezemer, Elisabeth [591] M Worrall, Jeffrey A Kelman, Michael Smits, Loes van der Leeuw-Harmsen, Erna Kristin, Alfi Yasmina, Iwan Wernecke, Wei Hua. (United States) Fernie JA Penning-van Beest. (United Dwiprahasto. (Indonesia) Kingdom) 59. Prevalence of Maternal and Child 79. Are Statin Prescriptions Determined by Adverse Pregnancy Outcomes 69. What Factors Contribute to Pregnancy Social Position? [592] Recorded in Primary Care in the United Registry Success? [582] Anna-Therese Lehnich, Bernd Kowall, Kingdom [572] Kristin Veley, Ann Mallard, Deborah L Nico Dragano, Raimund Erbel, Susanne Sonia J Coton, Irwin Nazerath, Irene Covington. (United States) Moebus, Karl-Heinz Jöckel, Andreas Petersen. (United Kingdom) Stang. 70. Validity Of Electronic Health Data For 60. Pregnancy Studies Assessing Drug Pregnancy Outcomes [583] 80. Effect of National Drug Utilization Exposure in Populations with Multiple Sascha Dublin, Darios T Getahun, Rod Review System on Co-Medication of Sclerosis [573] L Walker, Victoria L Holt, Jennifer Bobb, Statin and Contraindicated Drug in Whitney S Krueger, Mary S Anthony, Blair Darney, Dmitry Dukhovny, Jasmine Korea: Time-Series Analysis [593] Brigitta Monz, Catherine W Saltus, Ceri Lai, Gaia Pocobelli, Deborah A Wing, Bo Ram Yang, Joongyub Lee, Ju-Young Hirst, Andrea V Margulis, Elizabeth B Aaron B Caughey. (United States) Shin, Xue-Mei Jin, Byung-Joo Park. Andrews. (United States) 32nd

75 POSTER SESSION B: Saturday, August 27 | 8:00am - 6:00pm

81. Predicting Factors for Reaching Drug Utilization and Policy 98. The Recently Introduced System of Stabilized Maintenance with Once- Generic Substitution and Reference Monthly Paliperidone Palmitate in 90. Integration of Medicines Budget Impact Pricing in Ireland: Generic Dispensing, Medicaid Patients with Schizophrenia with Market Uptake Models in Horizon Savings and Costs to the Health Service, [594] Scanning Through Use of the C-Tobia and the Burden of Co-Payment [611] Model – A Collaboration Across Europe Erik Muser, Dominic Pilon, Bruno Emond, Susan Spillane, Cara Usher, Michael Barry. [603] Yongling Xiao, Tony Amos, Patrick (Ireland) Lefebvre, Carmela Benson. (Canada) Roberta Joppi, Renato Guseo, Claudio Jommi, Cinzia Mortarino, Marion Bennie, 99. Determinants of Generic Drug 82. Up-Scheduling of Alprazolam to a Björn Wettermark, Gisbert Selke, Irene Utilization in the United States [612] “Controlled Drug”: Interrupted Time Langner, Thomas Cars, Neil Hawkins, Jodi B Segal, Matthew Daubresse, Series Analysis of Its Impact on Reinhard Schuster, Brian Godman. (United Oluwadamilola Onasanya, Sarah Dutcher, Benzodiazepine (BZD) Prescribing, Kingdom) Wenlei Jiang, Robert Romanelli. (United Dispensing and Poisonings in Australia States) [595] 91. Varying Patterns of Penetration of New Antidiabetic Medications in Asia Andrea L Schaffer, Nicholas A Buckley, 100. Disposal of Unused or Expired and US: A Cross-National Comparison Rose Cairns, Sallie-Anne Pearson. Medications Among a Mexican Sample Study [604] (Australia) [613] Kiyoshi Kubota, Yukari Kamijima, Yea-Huei Arely Vergara Castañeda, Laura Martino 83. Use of an Automated Database Kao, Shinya Kimura, Edward CC Lai, Roaro. (Mexico) to Characterize Aberrant Opioid Kenneth KC Man, Patrick Ryan, Martijn Prescribing, Dispensing and Utilization Schuemie, Paul Stang, Chien-Chou Su, Geriatric at Local Levels [596] Ian CK Wong, Yinghong Zhang, Soko Irene B Murimi, Kate Jackson, Michael Setoguchi. (Japan) Pharmacoepidemiology Baird, Linda Simoni Wastilla, G Caleb 101. Pharmacoeconomic Evaluation of 92. Does Free Medication Impact Drug and Alexander. (United States) Geriatric Diabetics in a Tertiary Care Health Services Use by Low-Income Hospital: A Prospective Study [614] 84. Heterogeneity Among Youth with Diabetic Patients? [605] Ramanath Kattavenkatesh, MM Prabhu, K Serious Mental Illness in Intensive Régis Blais, Michal Abrahamowicz, Jean Nandakumar, K Sreedhara R Pai. (India) Care Management and Post-Discharge Lachaine, Eric Latimer, Robyn Tamblyn. Polypharmacy Use [597] (Canada) 102. Selection of Sulfonylureas Over Susan dosReis, Benjamin S Wu, Wendy Metformin in Elderly Nursing Home 93. The Use of Nitrofurantoïn in France: Camelo Castillo, Ming-Hui Tai. (United Residents with Diabetes Mellitus [615] Assessment of Compliance with States) Therapeutic Indication and Guidelines Andrew R Zullo, David D Dore, Roee 85. Physician Attitudes and Experiences [606] Gutman, Vincent Mor, Robert J Smith. (United States) with Maryland’s Prescription Drug Pierre Nguyen, Fanny Raguideau, Caroline Monitoring Program (PDMP) [598] Semaille, Mahmoud Zureik, Rosemary 103. Polypharmacy: Prevalence and Dora Lin, Eleanor Lucas, Irene Murimi, Dray-Spira. (France) Associated Factors in Elderly with Shannon Frattaroli, Andrea Gielen, Diabetes Mellitus in Minas Gerais, Brazil 94. Detection of Trastuzumab Related Patience Moyo, Kate Jackson, Michael [616] Cardiotoxicity in Taiwanese Breast Baier, Linda Simoni-Wastilla, G Caleb Cancer Women [607] Michael Ruberson Ribeiro da Silva, Alexander. (United States) Leonardo Maurício Diniz, Jéssica Barreto Hsu-Chih Chien, Ching-Lan Cheng, Ribeiro dos Santos, Edna Afonso Reis, 86. Socioeconomic Impacts of Policy on Cheng-Han Lee, Jane PF Bai, Yea-Huei Adriana Rodrigues da Mata, Vania Eloísa de Rx-to-OTC Switch to Prescription of Kao Yang. (Taiwan) Ethical Drugs in Japan [599] Araújo, Juliana Alvares, Francisco de Assis 95. Compliance to Multiple Sclerosis Acurcio. (Brazil) Keisuke Shimazaki, Yuma Takano, Yukiko Disease-Modifying Therapies: A Matsushima, Mayumi Mochizuki, Kunihiko 104. Real-World Risk of Diabetes with Population-Based Cohort Study In The Takahashi, Hisashi Urushihara. (Japan) Second-Generation Antipsychotics in Lazio Region, Italy [608] Older People [617] 87. Management of Complications During Anna Maria Bargagli, Nera Agabiti, Flavia Prasad S Nishtala, Te-yuan Chyou. (New Pregnancy: A Drug Utilization Study in Mayer, Silvia Cascini, Paola Colais, Marina Zealand) Western Nepal [600] Davoli, Multiple Sclerosis Study Group Kadir Alam, Ramesh Devkota, Gulam Lazio Region. (Italy) 105. Increasing Prevalence Of Mohammad Khan, Amisha Regmi. (Nepal) Anticholinergic Medication Use Over 96. Effect of a “Pill Mill” Law on Opioid 20 Years In The UK Older Population: Prescribing and Utilization: The Case of 88. Longitudinal Trend in Assisted Cognitive Function And Ageing Study I Texas [609] Reproductive Technology and Impacts and II [618] of The Law in Taiwan [601] Tatyana Lyapustina, Lainie Rutkow, Hsien- Carlota M Grossi, Ian Maidment, Kathryn Yen Chang, Matthew Daubresse, Alim F Jason C Hsu, Christine Y Lu. (Taiwan) Richardson, Chris Fox, Carol Brayne, Fiona Ramji, Mark Faul, Elizabeth A Stuart, G Matthews, Louise Robinson, George M 89. Impact of the Black Triangle Label on Caleb Alexader. (United States) Prescribing of New Drugs in the United Savva. (United Kingdom) Kingdom [602] 97. Comparison Of Generic-To-Brand Daniel B Horton, Tobias Gerhard, Brian L Switchback Patterns For Authorized Strom. (United States) Generic Vs. Independent Generic Drugs [610] Richard A Hansen, Jingjing Qian, Richard Berg, James Linneman, Enrique Seoane- Vazquez, Sarah Dutcher, Saeid Raofi, 32nd Peggy Peissig. (United States)

76 POSTER SESSION B: Saturday, August 27 | 8:00am - 6:00pm

106. Medications with Potent Anticholinergic 114. Trends in Prescribing of Antipsychotics 123. Factors Influencing the Quality of Activity and Incident Dementia in Dementia: A Population-Based Study Antidepressant Prescribing for Older, Diagnosis in the UK Older Population [627] Community-Dwelling Adults, and the [619] Vicky Sandy, Zeenat Gul, Mary Teeling, Risk of Emergency Outcomes [636] Kathryn Richardson, Chris Fox, Ian MaryJo MacAvin, Kathleen Bennett. Rian Marie Extavour, Matthew Perri. Maidment, Nicholas Steel, Yoon Loke, (Ireland) (Trinidad and Tobago) Antony Arthur, Carlota Grossi, Kathleen Bennett, Phyo Myint, Noll Campbell, 115. Psychotropic Medication Use and 124. Incidence Of Antidepressant Use In Carol Brayne, Fiona E Matthews, Malaz Alzheimer’s Disease: A Story of Sex Community-Dwelling Persons With And Boustani, Louise Robinson, George Savva. Differences in Two Countries [628] Without Alzheimer’s Disease – 13-Year (United Kingdom) Daniela C Moga, Heidi Taipale, Anna-Maija Follow-Up [637] Tolppanen, Antti Tanskanen, Jari Tiihonen, Arto Puranen, Heidi Taipale, Marjaana 107. Antipsychotic Use And The Risk Of Hip Sirpa Hartikainen, Qishan Wu, Gregory A Koponen, Antti Tanskanen, Anna- Fracture Among Community-Dwelling Jicha, Danijela Gnjidic. (United States) Maija Tolppanen, Jari Tiihonen, Sirpa Persons With Alzheimer’s Disease [620] Hartikainen. (Finland) Marjaana Koponen, Heidi Taipale, Piia 116. Risk of Pneumonia Associated with Lavikainen, Antti Tanskanen, Jari Tiihonen, Incident Benzodiazepine Use Among 125. Comorbidity in Vascular Neurocognitive Anna-Maija Tolppanen, Riitta Ahonen, Community-Dwelling Persons with Disorders: A Matched Case–Control Sirpa Hartikainen. (Finland) Alzheimer’s Disease [629] Study [638] Heidi Taipale, Anna-Maija Tolppanen, Ruby Castilla, Miguel Habeych. (United 108. Atypical Antipsychotics and the Risk Marjaana Koponen, Antti Tanskanen, Piia States) of Falls and Fractures Among Older Lavikainen, Reijo Sund, Jari Tiihonen, Adults: A Replication Study [621] Sirpa Hartikainen. (Finland) 126. Outcomes After Induction Agent Use Darmendra Ramcharran, Hong Qiu, Martijn In Older Kidney Transplant Recipients Schuemie, Patrick Ryan. 117. Risk Of Stroke Associated With [639] Benzodiazepine And Related Drug Mara McAdams-DeMarco, Qiong Huang, 109. Risk of Mortality Associated with Use Among Persons With And Without Dorry Segev. Antipsychotic Monotherapy and Alzheimer’s Disease [630] Polypharmacy Among Community- Heidi Taipale, Marjaana Koponen, Antti 127. Time Trends of Vitamin B12 Deficiency Dwelling Persons with Alzheimer’s Tanskanen, Piia Lavikainen, Anna-Maija in Older Adults: A Population-Based Disease [622] Tolppanen, Reijo Sund, Jari Tiihonen, Cohort Study [640] Marjaana Koponen, Heidi Taipale, Piia Sirpa Hartikainen. (Finland) Nancy Presse, Marie-Jeanne Kergoat, Lavikainen, Antti Tanskanen, Jari Tiihonen, Marc Dorais, Sylvie Perreault. (Canada) Anna-Maija Tolppanen, Riitta Ahonen, 118. Comparative Risk Of All-Cause 128. Patterns and Predictors of Potentially Sirpa Hartikainen. (Finland) Mortality In Older Patients Prescribed Codeine Or Tramadol For Non- Inappropriate Medication Use in Older 110. Abstract Withdrawn [623] Malignant Pain: Retrospective Cohort Colon Cancer Patients [641] Study [631] Jennifer L Lund, Sharon Peacock Hinton, 111. Co-Prescription of Antipsychotic and Craig Allen, Wilhelmine Meeraus, Virginia Pate, Hanna K Sanoff, Marcela Antiparkinson Medication Regimens Katherine Donegan. (United Kingdom) Jiron, Jena Ivey Burkhart, Hyman B Muss, Containing Levodopa: Adherence to Til Stürmer. (United States) Guidelines and the STOPP (Screening 119. Long-Term Use of Opioids Among Tool of Older Persons’ Potentially Community-Dwelling Persons with and 129. Prevalence and Predictors of Inappropriate Prescriptions) Criteria in without Alzheimer’s Disease [632] Inappropriate Medications According Beneficiaries of the Nova Scotia [624] Aleksi Hamina, Heidi Taipale, Antti to START/STOPP Criteria Version-2 in Sara Rehan, Ingrid Sketris, Hill-Taylor Tanskanen, Anna-Maija Tolppanen, Jari Indian Elderly [642] Barbara, Rigby Heather. (Canada) Tiihonen, Sirpa Hartikainen. (Finland) Pradeep Gunda, Shyla Sharmeen, Anusha Lokalaboina, Vishwas Hunsur Nagendra, 112. Frequent Use Of Psychotropic Drugs 120. Hospice Use and Pain Management in Satyanaryan Pattnaik. (India) Among Persons with Alzheimer’s Nursing Home Residents with Cancer Disease Aged 90 Years Or More In [633] 130. Effectiveness of the STOPP/START Finland [625] Jacob N Hunnicutt, Jennifer Tjia, Kate L (Screening Tool of Older Persons’ Heidi Taipale, Marjaana Koponen, Antti Lapane. (United States) Potentially Inappropriate Prescriptions/ Tanskanen, Anna-Maija Tolppanen, Jari Screening Tool To Alert Doctors To The Tiihonen, Sirpa Hartikainen. (Finland) 121. Antidepressant Use And Associated Right Treatment) Criteria: Systematic Risk Of Head And Brain Injuries Among Review And Meta-Analysis Of 113. Benzodiazepine and z-Substance Use Persons With And Without Alzheimer’s Randomized Controlled Studies [643] and Risk of Dementia – A German Disease [634] Kieran A Walsh, Barbara Hill-Taylor, Claims Data Analysis [626] Heidi Taipale, Marjaana Koponen, Antti Samuel A Stewart, Jill Hayden, Stephen Willy Gomm, Klaus von Holt, Friederike Tanskanen, Piia Lavikainen, Reijo Sund, Byrne, Ingrid Sketris. (Ireland) Thomé, Karl Broich, Wolfgang Maier, Jari Tiihonen, Sirpa Hartikainen, Anna- Klaus Weckbecker, Anne Fink, Gabriele Maija Tolppanen. (Finland) 131. Potentially Inappropriate Prescribing Doblhammer, Britta Haenisch. (Germany) Measured by STOPP and START and 122. Antidepressant Use And Associated Functional Decline and Quality of Life in Risk Of Hip Fractures Among Older People: A Cohort Study [644] Community-Dwelling Older Persons Frank Moriarty, Kathleen Bennett, With And Without Alzheimer’s Disease Caitriona Cahir, Rose Anne Kenny, Tom In Finland [635] Fahey. (Ireland) Sanna Torvinen-Kiiskinen, Anna- Maija Tolppanen, Marjaana Koponen, Antti Tanskanen, Jari Tiihonen, Sirpa Hartikainen, Heidi Taipale. (Finland) 32nd

77 POSTER SESSION B: Saturday, August 27 | 8:00am - 6:00pm

132. STOPP 2 versus EU(7)-PIM: Comparing Molecular Epidemiology and 149. An Estimation of RAS Mutation Prevalence and Impact of Inappropriate Prevalence Amongst Patients With Prescribing on Mortality and Pharmacogenetics mCRC Using A Meta-Analytical Hospitalisation [645] 141. Feasibility of Using Real-World Approach [662] Maarten Wauters, Monique Elseviers, Databases to Assist Discovery of George Kafatos, Kimberley Lowe, Daniela Bert Vaes, Jan Degryse, Robert Vander Unknown Associations Between Genetic Niepel, Sophie Jenkins-Anderson, Hal Stichele, Thierry Christiaens, Majda Diseases and Other Health Conditions Westhead, Tamer Garawin, Zuzana Azermai. (Belgium) --A Testing Case of Gaucher’s Disease Traugottová, Antonios Bilalis, Edit Molnar, Jozsef Timar, Erika Toth, Nikolaos Gouvas, 133. Drug Burden in Aging Adults with and Parkinson’s Disease [654] George Papaxoinis, Samuel Murray, Nadia Intellectual Disabilities Living in Zhiwen Liu, A Lawrence Gould, David J Mokhtar, Hana Vosmikova, Pavel Fabian, Residential Facilities: A Cross-Sectional Stone, Heiko Runz, Jennifer K Pai, Edward Alena Skalova, Piotr Wójcik, Andrzej Study [646] A Bortnichak. (United States) Tysarowski, Jeannette Rodger, Mario Maire O’Dwyer, Clare Donegan, Philip 142. Meta-Analysis of the Genome Wide Barugel, J Han van Krieken, Jörg Trojan. McCallion, Mary McCarron, Martin Association Studies (GWAS) on the (United Kingdom) Henman. (Ireland) Intolerance of Angiotensin Converting 134. The Effect of Pharmacist-Led Enzyme Inhibitors (ACEIs) [655] Potpourri Interventions in Optimising Prescribing Seyed Hamidreza Mahmoudpour, 150. A Comparative Effectiveness Review of in Older Adults in Primary Care: A Moneeza K Siddiqui, Abirami Veluchamy, Benefits and Harms of PCSK9 Inhibitors Systematic Review [647] Folkert W Asselbergs, Patrick C Souverein, [663] Catherine E de Keyser, Albert Hofman, David J O Riordan, Kieran A Walsh, Rose Marian McDonagh, Kim Peterson, Sergio Bruno H Stricker, Anthonius de Boer, Galvin, Carol Sinnott, Patricia M Kearney, Fazio. (United States) Stephen Byrne. (Ireland) Anke-Hilse Maitland-van der Zee, Colin NA Palmer. (Netherlands) 151. Systematic Evaluation of Interventions 135. Medication Regimen Complexity and to Reduce Overprescribing of Antibiotics Clinical Outcomes in Older People: A 143. Long-Term Survival After Myocardial for Acute Respiratory Tract Infections Systematic Review [648] Infarction: Impact of Patient Non- [664] Barbara C Wimmer, Amanda J Cross, Compliance to the EOLE Study Protocol Marian S McDonagh, Kim Peterson, Natali Jokanovic, Michael D Wiese, [656] Kevin Winthrop, Amy Cantor, Brittany Johnson George, Kristina Johnell, Basia Cécile Droz-Perroteau, Daniel Thomas, Holzhammer, David Buckley. (United Diug, J Simon Bell. (Australia) Nicolas Danchin, Caroline Dureau-Pournin, States) Marie-Agnès Bernard, Regis Lassalle, 136. An Educational Intervention to Reduce Patrick Blin, Nicholas Moore. (France) Acute Health Care Consumption in 152. The Association Between Diabetic Complications and Androgen Elderly Patients with Inappropriate 144. In Silico Integration of Epidemiologic Deprivation Therapy Used for Clinically Drugs - A Cluster Randomised Trial in and Genetic Evidence on Sex/Race- Localized Prostate Cancer [665] Primary Care [649] Related Modifying Effects on Hip Katharina Schmidt-Mende, Morten Arthroplasty Outcomes [657] Marie C Bradley, Grace Zhou, Andrew N Freedman, Reina Haque, Marianne Andersen, Björn Wettermark, Jan Yelizaveta Torosyan, Nilsa Loyo-Berrios, Ulcickas Yood, Stephen K Van Den Eeden, Hasselström. (Sweden) Tigran Karapetyan, Terrie Kitchner, Murray Arnold L Potosky. (United States) Brilliant, Danica Marinac-Dabic. (United 137. Risk Factors For Unplanned States) Readmissions In French Older People 153. Temperature, Real-Time, On-Site, Potency Monitoring Studies of Three Discharged From Acute Geriatric Units 145. Multi-Variant Genetic Panel for Genetic Brands of Amoxicillin Dispersible [650] Risk of Opioid Addiction [658] Tablets Stored in Hospital and Dominique Bonnet-Zamponi, Florence Keri Donaldson, Joe Lopez, Sherman Community Pharmacies in Different Tubach, Marie Line Gaubert-Dahan, Chang. (United States) Part of Kerala [666] Blandine Pasquet, Sophie Lacaille, Sylvie Legrain. (France) 146. KRAS Testing Status in Patients with SS Kiron, M Saritha. (India) Metastatic Colorectal Cancer – A 154. Cohort Study Examining the 138. Pro Re Nata (as Needed) Medication in Danish Population-Based Study [659] Nursing Homes: The Longer You Stay, Contribution of Antiepileptic Drugs to Anne G Ording, Trine Frøslev, Margaret the More You Get? [651] Poisoning Deaths in Epilepsy [667] McCusker, Elaine Cheng, Lisa Wang, Julie Hayley C Gorton, Roger T Webb, Matthew Michael Dörks, Guido Schmiemann, Falk Ta, Vera Ehrenstein, Henrik T Sørensen. J Carr, Darren M Ashcroft. (United Hoffmann. (Germany) (Denmark) Kingdom) 139. Assessment of Frequency and Effects 147. Comorbidity Among Patients with 155. Level of Evidence for Labeled Dosing of Potentially Inappropriate Medications Metastatic Colorectal Cancer According Recommendations in Renal Impairment in Elderly Persons: An Italian to KRAS-Mutation Testing Status – A [668] Population-Based Study [652] Danish Nationwide Prevalence Study Francesco Giorgianni, Ylenia Ingrasciotta, [660] Joshua J Gagne, Nazleen F Khan, Tara S Raj, Lajja R Patel, Niteesh K Choudhry. Ilaria Marcianò, Michele Tari, Achille P Anne G Ording, Trine Frøslev, Margaret (United States) Caputi, Gianluca Trifirò. (Italy) McCusker, Elaine Cheng, Julie Ta, Vera Ehrenstein, Henrik T Sørensen. (Denmark) 140. Changes in Prescription and Over- 156. The DIFFuse Algorithm: A Practical Method for Data Source Identification, the-Counter Medication and Dietary 148. The Prevalence RAS and BRAF Feasibility, and Follow-Up for Use in Supplement Use Among Older Adults in Mutations Among Patients in the Real-World Research Around the Globe the United States, 2005 vs. 2011 [653] Middle East and Northern Africa with [669] Dima Qato, Jocelyn Wilder, Philip Metastatic Colorectal Cancer [661] Margaret S Richards, Kristin M Veley, Schumm, Victoria Gillet, Caleb Alexander. Tamer Garawin, Kimberly Lowe, George (United States) Samantha K Sites. (United States) 32nd Kafatos, Samuel Murray. (United Kingdom)

78 POSTER SESSION B: Saturday, August 27 | 8:00am - 6:00pm

157. Worldwide Mapping of Generic Sources 165. The Role of Poison Data in Regulatory Pharmacovigilance of Real-World Data: A Systematic Decision-Making [678] 175. Development, Applications, and Review [670] Syed Rizwanuddin Ahmad. (United States) Methodological Challenges to the Use of Xuan Wang, Raquel Lahoz, Lisa Burdukova, 166. Determining the Citation Impact of the Propensity Score Matching Approaches Kristijan Kahler, Maria Nassim, Shiva Kumar in FDA’s Sentinel Program [688] Venkata, Shantanu Jawla, Amit Kandhare, Canadian Network for Observational John G Connolly, Judy C Maro, Shirley V Anilkumar Jalapu, Nahila Justo. (United Drug Effect Studies (CNODES) Wang, Sengwee Toh, Candace C Fuller, States) Publications: Methods and Outcomes [679] Cathy A Panozzo, Joshua J Gagne. 158. Dynamic Real World Data Ingrid Sketris, Melissa Rothfus, Robyn (United States) Platform Integrating Automated Traynor, Melissa Helwig, Samuel Stewart. 176. Effect of Lawyer-Submitted Reports on Claims and Registry Data for (Canada) Safety Signals in the FDA Adverse Event Pharmacoepidemiologic Studies [671] Reporting System (FAERS) [689] Syd Phillips, Andre Araujo, Charissa 167. Impact of the EU Orphan Drug James R Rogers, Ameet Sarpatwari, Rishi Proctor, William Malatestinic, Cynthia Regulation on the Development of J Desai, Justin M Bohn, Nazleen F Khan, Larmore, Leslie R Harrold, George W Orphan Drug: A 15-Year Analysis [680] Aaron S Kesselheim, Michael A Fischer, Reed, Deb Casso, Karin Johnson, Jeremy Irene Pan. (Canada) Joshua J Gagne, John G Connolly. (United Stamer, Susan A Oliveria. (United States) 168. Weighted Multiple Imputation of Ethnicity States) 159. Time Trends Of Studies Accounting For Data That Are Mising Not at Random in 177. An Educational Intervention to Improve Immortal-Time Bias – A Review [672] Primary Care Databases [681] Nurses Reporting of Adverse Drug Pareen Vora, Gunnar Brobert, Alex Tra My Pham, Irene Petersen, James Reactions [691] Asiimwe. (Germany) Carpenter, Tim Morris. Susana T Marquez, Maria T Herdeiro, Inês 160. Quality of Cancer Records in 169. The Joint Action Of Patient, Physician R Vaz. (Portugal) the Information System for the And Pharmacist In Order To Improve 178. One Size Does Not Fit All - Right-Sized Development of Primary Care Research Adherence To Medication [682] Signal Detection Systems That Are (SIDIAP) [673] Ivana Prga, Martina Bago, Marcel Leppée, Appropriate for Your Portfolio Benefit- Talita Duarte-Salles, Leonardo Méndez- Josip Culig, Ivana Radman. (Croatia) Risk Management Strategy [692] Boo, Francesc Macià, Marta Banqué, 170. Counselling In Community Pharmacies Deirdre M McCarthy. (United States) Ricard Riel-Cabrera, Cristian Llàcer-Pinós, In The Nelson Mandela Metropole, Maria del Mar Garcia-Gil. (Spain) South Africa: Codeine-Containing 179. Abstract Withdrawn [693] Analgesics [683] 161. The Danish Centre for Strategic 180. PRR Computations Over Time Continue Research in Type 2 Diabetes (DD2) Study Brent C Knoesen, Ilse Truter. (South Africa) to Reveal Serious Safety Signals Aoon Cohort: Presentation of 5,870 Patients After Drug Approval [694] with New Type 2 Diabetes Enrolled from 171. The EpiChron Cohort Proven Useful for 2010 Through 2014 [674] Pharmacoepidemiological Studies [684] Keith L Altman. (United States) Diana H Christensen, Sia K Nicolaisen, Alexandra Prados-Torres, Beatriz Poblador- 181. Utilising Electronic Healthcare Data To Klára Berencsi, Henning Beck-Nielsen, Plou, Francisca Gonzalez-Rubio, Jordi Support Early Phases Of Safety Signal Jørgen Rungby, Søren Friborg, Ivan Castellsague, Susana Perez-Gutthann, Assessment [695] Alejandro Arana. (Spain) Brandslund, Jens S Christiansen, Allan Katherine Donegan, Helena Bird, Brian Vaag, Henrik T Sørensen, Jens S Nielsen, 172. Training Pharmacy Students and Burch, Alex Smith, Olutoyin Agbaje, Reimar W Thomsen. (Denmark) Disseminating Information on Temitope Ibitoye, Jenny Wong, Rebecca 162. The Surveillance of HealthCare in Appropriate Use of Medicines: The Owen, Phil Tregunno. (United Kingdom) Weblog as a Tool [685] Asian Network (SCAN): Infrastructure 182. Identification of Generic Drugs in the Development for Multinational Joyce CM Faria, Daniela RG Junqueira, FDA Adverse Event Reporting System Pharmacoepidemiologic Studies Raissa CF Cândido, Alba VSM Moraes, [696] (MPES) [675] Alessandra ACM Frade, Daniela F Silva, Geetha S Iyer, Sathiya Priya Marimuthu, Jodi Erika PS Santos, Louisse CO Santos, Edward Chia-Cheng Lai, Martijn Schuemie, B Segal, Sonal Singh. (United States) Patrick Ryan, Paul Stang, Yukari Kamijima, Mariana FL Nascimento, Weverton T Shinya Kimura, Kiyoshi Kubota, Kenneth Silva, Alessandra R Mesquita, Cristiane A 183. The Landscape of Active Surveillance KC Man, Rae Woong Park, Chien-Chou Menezes de Pádua, Edson Perini. (Brazil) Systems for Postmarketing Drug Safety Su, Ian CK Wong, Yea-Huei Kao Yang, Monitoring [697] 173. Description of 2014-2015 ICPE Abstract Yinghong Zhang, Soko Setoguch-Iwata. Submissions [686] Ayad K Ali, Kristin J Meyers, Yu-Jing (United States) Huang, Claudia A Salinas, Hu Li. (United Mary E Ritchey. (United States) States) 163. A Study to Assess the Capture of 174. Lost in Translation: No Effect of a Sublingual Immunotherapy Within an 184. Web-Based Query Log Reaction Score High-Profile Publication on the Co- Electronic Health Record (EHR) System Methods to Detect Safety Signals for Prescribing of Interacting Drugs [687] [676] Pharmaceutical Drugs [698] Emily K Acton, Charles E Leonard, Warren Florence T Wang, Edward Green, Daniel Susan Colilla, Elad Yom Tov, Ying Zhang, B Bilker, Sean Hennessy. (United States) Mines, Vinay Mehta, Nancy D Lin. (United Marie-Laure Kurzinger, Stephanie Tcherny- States) Lessenot, Susan Welsh, Juhaeri Juhaeri. (United States) 164. Pitfalls and Value of Clinical and Laboratory Values in Electronic Health Record Data [677] Anita M Loughlin, Stephen M Ezzy, Anthony P Nunes, Cheryl L Enger, David D 32nd Dore, John D Seeger. (United States)

79 POSTER SESSION B: Saturday, August 27 | 8:00am - 6:00pm

185. Can Facebook and Twitter Monitoring 194. What are Patients Asking Social Media 204. The Documentation of Clinical Yield Earlier Detection of Safety Signals About Drug Products and Treatments? Information of Adverse Drug Reaction for Medical Products? [699] [708] Reports: A Paired Comparison of Nabarun Dasgupta, Carrie E Pierce, Khaled Soraya Shaikh, Heidi G Bell, Laurie S ‘Duplicate’ Reports of Patients and Bouri, Carol Pamer, Scott Proestel, Harold Anderson, Gregory E Powell. (United Healthcare Professionals [718] W Rodriguez, Hoa Van Le, Clark C Freifeld, Kingdom) Leàn Rolfes, Laura van der Linden, John S Brownstein, Mark Walderhaug, I Florence van Hunsel, Katja Taxis, Eugène Ralph Edwards. (United States) 195. Web-Based Signal Detection Using van Puijenbroek. (Netherlands) Medical Forums Data in France from 186. Risk Management and Specialist 2005-2015 [709] Pharmacovigilance by Cohort-Event Monitoring – Responding Marie-Laure Kürzinger, Nathalie Texier, to Change [700] Stéphane Schuck, Carole Faviez, Thierry Geography Deborah Layton, Saad AW Shakir. (United Deliens, Ling Zhang, Stéphanie Tcherny- 205. National Prevalence and Trends in Drug Kingdom) Lessenot, Juhaeri Juhaeri, Susan Welsh. Allergies Among Admissions in the (France) Veterans Affairs Health System from 187. Knowledge and Attitude Towards 2000-2014 [719] Adverse Drug Reactions Among 196. Medication Name Entity Recognition in Healthcare Professionals [701] Tweets Using Global Dictionary Lookup Kevin W McConeghy, Haley Morrill, Aisling and Word Sense Disambiguation [710] R Caffrey, Amal Trivedi, Kerry L LaPlante. Young-Hee Nam, Hyun Jung Jin, Soo-Keol (United States) Lee. (Republic of Korea) Johan Ellenius, Tomas Bergvall, Nabarun Dasgupta, Sara Hedfors, Carrie Pierce, G 206. Prevalence and Predictors of Adverse 188. Implementation of Pharmacovigilance Niklas Norén. (Sweden) Drug Reactions in Hospitalized Elderly Practices by Clinical Pharmacists in an Patients of India [720] Oncology Hospital--A Step to Improve 197. Impact of the 2012 European Patient Safety Monitoring During Pharmacovigilance Legislation on Shyla Sharmeen, Pradeep Gunda, Anusha Cancer Care [702] Required Additional Risk Minimisation Lokalaboina, Vishwas Hunsur Nagendra, Satyanaryan Pattnaik. (India) Himanshu Patel, Parthasarathi Measures [711] Gurumurthy, Ramesh Madhan. (India) RDC Francisca, IM Zomerdijk, MCJM 207. [NEWCOMER TRACK] A Hospital-Based Sturkenboom, SMJM Straus. (Netherlands) Prospective Cohort for Adverse Herbal 189. Assessing Studies of Patients Drug Reactions [721] Spontaneously Reported Adverse Drug 198. An Analysis of Characteristics of Post- Reactions (ADR’s): A Review Study Authorisation Safety Studies Registered Mikyung Kim, Chang-ho Han. (Republic [703] on ENCePP [712] of Korea) Sondus I Ata, Tariq M Alhawassi, Nasser Sreeram Ramagopalan, Radek Wasiak, 208. Rate of Off-Label Prescriptions in M Bin Dhim, Lisa G Pont, Hisham S Dimitra Lambrelli. (United Kingdom) Adverse Drug Reactions in Crimean Aljadhey. (Saudi Arabia) Children [722] 199. Studies Evaluating Effectiveness of Risk 190. Performance of Disproportionality Minimisation Measures [713] Alexander V Matveev, Alexander Y Ezernitskiy, Elena I Konyaeva, Natalya V Analysis for Statistical Signal Detection RDC Francisca, IM Zomerdijk, MCJM Matveeva. in Social Media Data [704] Sturkenboom, SMJM Straus. (Netherlands) Ola Caster, Magnus Lerch, Benoit Vroman, 209. Patient Relevant Outcomes Associated 200. Development of Patient Reporting John van Stekelenborg. (Sweden) with Generic Drugs in FDA’s Adverse Systems - A Worldwide View [714] Event Reporting System [723] 191. Assessment of Reported Medication Cristiano Matos, Florence van Hunsel, Sathiya Priya Marimuthu, Geetha S Iyer, Errors in General Medicine Wards in a Linda Härmark. (Spain) Tertiary Care Hospital [705] Jodi B Segal, Sonal Singh. (United States) 201. Assessment of Impact of Structured Sri Harsha Chalasani, Madhan Ramesh. 210. Current State of Pharmacovigilance in Educational Intervention on Adverse (India) the Arab and Eastern Mediterranean Drug Reaction Reporting Behaviour of Region: Results of a 2015 Survey [724] 192. Barriers and Facilitators to Using Community Pharmacists in South India a Mobile App for Two-Way Risk [715] Danya M Qato. Communication: A Qualitative Study MS Srikanth, Ramesh Adepu. (India) 211. Prescribing Errors Incidence in Four [706] Hospitals in Saudi Arabia [725] 202. Development and Validity Testing of a Sieta T de Vries, Lisa Wong, Carmen Hisham Aljadhey, Mansour Adam Lasheras Ruiz, François Houyez, Sandra Clinical Documentation-Tool to Assess Individual Case Safety Reports in an Mahmoud, Mohamed Azmi Hassali. Fernandes, Raphael van Eemeren, Alastair (Saudi Arabia) Sutcliffe, Peter GM Mol, IMI WEB/RADR International Setting [716] Work Package 3b. Ingrid Oosterhuis, Leàn Rolfes, Corine 212. Knowledge, Attitude and Concept of Ekhart, Annemarie Muller-Hansma, Linda Pharmacovigilance Among Community 193. Improving the Yield of Relevant Data Härmark. (Netherlands) Health-Care Professionals in Saudi for Pharmacovigilance Analysis by Arabia [726] Reducing Search Term Complexity – A 203. Evaluation of a Newly Developed Thamir M Alshammari, Arshad Hussain, Study on Reddit Data [707] Intelligent Drug Alert System for Mukhtar Ansari. (Saudi Arabia) Sara Hedfors, Tomas Bergvall, Michael Enforcing Medication Safety [717] Gilbert, Carrie Pierce, Nabarun Dasgupta, Ibrahim Oreagba, Sunday Eyaru, Olufunsho 213. First Characterization Of Adverse Drug Johan Ellenius. (Sweden) Awodele, Sunday Olayemi. (Nigeria) Reactions in the Dominican Republic [727] Nicolas Thurin, Adrian Puello, Marianne Mouly, Carla Garrido, Françoise Haramburu. (France)

32nd

80 POSTER SESSION B: Saturday, August 27 | 8:00am - 6:00pm

214. Development of a New Trigger Tool for 224. Development of a Detection Algorithm 234. A Prospective Observational Adverse Drug Reaction Detection at a for Prednisolone-Induced Diabetes Pharmacovigilance Study to Evaluate Large Teaching Hospital, Thailand [728] Mellitus Using a Medical Information Incidence, Onset and Severity of Nicharee Inprasit, Pramote Tragulpiankit, Database [738] Adverse Effects During Anti-Tubercular Ticha Rerkpattanapipat. (Thailand) Imatoh Takuya, Sai Kimie, Hori Katsuhito, Therapy [748] Segawa Katsunori, Kimura Michio, Akhil Bharat Agrawal. (India) 215. Testing of ADR Thai Trigger in Surgical Kawakami Junichi, Saito Yoshiro. (Japan) Patients at a Large Teaching Hospital, 235. Use of an Automated Short Message Thailand [729] 225. FDA AERS Data Shows a Strong Signal Service to Monitor Adverse Events Nicharee Inprasit, Pramote Tragulpiankit, for SGLT2 Inhibitors and Diabetic Following Immunization with a Ticha Rerkpattanapipat. (Thailand) Ketoacidosis [739] Quadrivalent Influenza Vaccine in Keith L Altman. (United States) Mexico [749] 216. Adverse Drug Reactions in Medicine Adel Abou-Ali, Sonja Banga, Miguel Wards at a Large Teaching Hospital, 226. Adverse Drug Reactions Related to Betancourt-Cravioto, Roberto Tapia- Thailand [730] DPP-4 Inhibitors - A Review [740] Conyer, Rodrigo R Feregrino, Javier M Nicharee Inprasit, Pramote Tragulpiankit, Cristiano Matos, Andreia Pestana, Rita Castellanos-Martínez, Patricia Cervantes- Ticha Rerkpattanapipat. (Thailand) Pereira. (Portugal) Powell, Alena Khromava.

217. Drug Therapy Related Problems Among 227. A Population-Based Cohort Study 236. Comparing Systolic and Diastolic Blood Critical Care Patients in A Tertiary Care Suggests No Elevated Risk of Severe Pressure by Initial ART Regimen [750] Hospital in Nepal [731] Joint Pain in Association with Dipeptidyl Robin M Nance, Joseph A Delaney, Kadir Alam, Nilanjan Ghosh, Yugal Kishor. Peptidase-4 Inhibitors Use in Patients Michael Mugavero, James Willig, Greer (Nepal) with Type 2 Diabetes [741] Burkholder, Stephen Boswell, William C Wen-Hsuan Hou, Kai-Cheng Chang, Mathews, Joseph J Eron, Richard Moore, 218. Pharmacovigilance in Pakistan - Chung-Yi Li, Huang-Tz Ou. (Taiwan) Elvin Geng, Benigno Rodriguez, Michael Hospital Pharmacists’ Views [732] Saag, Mari Kitahata, Heidi Crane. (United 228. Changes in Health Parameters Over Muhammad Shahid Iqbal, Muhammad States) Zahid Iqbal, Mohd Baidi Bahari. (Malaysia) 12 Months in Users of Once Weekly Exenatide (Bydureon®) [742] Pharmacovigilance - Cancer 219. A Survey to Evaluate Electronic Abigail Coughtrie, Deborah Layton, Qing Healthcare Databases for Potential Qiao, Saad Shakir. 237. Pharmacovigilance of Capecitabine: Post-Marketing Drug Safety Hepatic Function Alterations in Mexican Surveillance in China [733] 229. Identification of Potential Signals of Women with Breast Cancer [751] Yu Yang, Xiaofeng Zhou, Yuji FENG, Renfei Serious Risks for Sitagliptin: Analysis of Alejandra Rodriguez-Castellanos, Mariana Fang, Siyan Zhan. (China) Spontaneous Adverse Event Reports in Fernandez-Paramo, Brenda Carbajal- VigiBase® [743] Saldaña, Laura Martino-Roaro, Arely 220. Adverse Drug Reactions Among Krishna Undela, Pramod Adusumilli, Vergara-Castañeda. (Mexico) Hospitalised Children in South Africa Parthasarathi Gurumurthy. (India) [734] 238. Study Update for a Postmarketing Case Johannes P Mouton, Nicole Jobanputra, 230. Managing the Risk of Medication Errors Series Study of Adult Osteosarcoma Ushma Mehta, Karl Technau, Chris Scott, - Where to Start? [744] and Teriparatide in the US [752] Karen Cohen. (South Africa) Angela van der Salm. (Netherlands) Kirk D Midkiff, David H Harris, Alicia W Gilsenan, David J McSorley, Nicole A 221. Attitudes of Community Pharmacy Pharmacovigilance - Kellier-Steele, Daniel N Masica, Elizabeth Professionals Towards Consumers B Andrews. (United States) Reporting in Portugal [735] Anti-infectives Cristiano Matos, Liliana Rodrigues, João 231. Postmarketing Safety Profile of 239. Completeness of Reporting of Basal Joaquim, Maria Clara Rocha. (Portugal) Ledipasvir/Sofosbuvir Chronic HCV Cell Carcinoma and Squamous Cell Infection Therapy [745] Carcinoma to a Pharmacovigilance 222. Abstract Withdrawn [736] Register and the Health and Social Care Ayad K Ali. (United States) Information Centre [753] Pharmacovigilance - 232. Effect of Antibiotic Exposure on Kayleigh J Mason, Mark Lunt, Nick J Alimentary and Metabolic Stevens-Johnson Syndrome and Toxic Reynolds, Darren M Ashcroft, A David Epidermal Necrolysis [746] Burden, Anthony D Ormerod, Jonathan 223. Risk of Hemorrhagic Stroke Associated Katherine J Sullivan, Robert Valuck, NWN Barker, Catherine H Smith, Adele with Non-Insulin Blood Glucose Meghan N Jeffres, Heather D Anderson. Green, Hassan Ali, Ian Evans, Shamila Lowering Drugs. Results from the (United States) Irshad, Kathleen McElhone, Victoria Wilde, SAFEGUARD Project [737] Christopher EM Griffiths. (United Kingdom) Miguel Gil, Silvana Romio, Lorenza 233. Neuropsychiatric Events Associated Scotti, Ingrid Leal, Gwen MC Masclee, with the Use of Helicobacter Pylori 240. Role of Clinical Pharmacists in Niklas Schmedt, Cristina Varas-Lorenzo, Eradication Therapy Containing- Monitoring Radiation Related Adverse Manel Pladevall-Vila, Mark M Smits, Irene Clarithromycin: Self-Controlled Case Events in Patients on Radiation or Bezemer, John D Seeger, Georgia de Series [747] Chemo-Radiation Therapy [754] Beradis, Serena Pecchioli, Gianluca Trifirò, Angel YS Wong, Ian CK Wong, Celine SL Himanshu Patel, Acsah Annie Paul, Anita McGrogan, Peter Rijnbeek, Miriam Chui, Edwin HM Lee, WC Chang, Eric YH Rajesh Hadia, Baharul Islam, YS Madhavi, Stukenboom. (Spain) Chen, Wai K Leung, Esther W Chan. Parthasarathi Gurumurthy. (India)

32nd

81 POSTER SESSION B: Saturday, August 27 | 8:00am - 6:00pm

241. Adverse Drug Reactions (ADRs) of 249. A Novel Approach to Study the Impact 258. Social Media Mining to Investigate Tumour Necrosis Factor Inhibitors of Ethnicity on Reporting of Cough/ Multiple Sclerosis Treatment Patterns (Adalimumab, Infliximab, Etanercept) Angioedema with RAS Inhibitors in and Adverse Effects [772] in a Paediatric Population: An Analysis VigiBase [763] Selin Cooper, Radek Wasiak, Sreeram V of Individual Case Safety Reports from Fawaz F Alharbi, Anzhelika AV Kholod, Ramagopalan. VigiBase [755] Patrick C Souverein, Ronald H Meyboom, Amandine Roussière, Vanessa Rousseau, Mark CH Groot, Anthonius de Boer, Olaf H 259. Lymphopenia in Multiple Sclerosis Marie-Céline Casaurancq, Jean-Louis Klungel. (Netherlands) Patients Treated with Delayed-Release Montastruc, Geneviève Durrieu. Dimethyl Fumarate: Analysis of 2 Pharmacoviglance - Electronic Health Record Databases in 242. Intravenous Immune Globulin and the US [773] Thromboembolic Adverse Events: A Pain and Neurological Made Wenten, Nicholas Everage, Teesta Systematic Review and Meta-Analysis 250. Cardiovascular and Gastrointestinal Somani, Cathy Lally, Maneesh Juneja, of Randomized Controlled Trials [756] Safety of Paracetamol in French Susan Eaton, Claudia Prada, Anne Dilley. Eric M Ammann, Cole B Haskins, Kelsey M Population: A Self-Controlled Cohort (United States) Fillman, Rebecca L Ritter, Xiaomei Gu, Scott Study [764] K Winiecki, Ryan M Carnahan, James C 260. Rapidly Increasing Atypical Mai Duong, Régis Lassalle, Cécile Droz, Antipsychotic Use in Middle Age Torner, Bruce H Fireman, Michael P Jones, Nicholas Moore. (France) Elizabeth A Chrischilles. (United States) Australians [774] 251. Cardiovascular and Gastrointestinal Debra S Rowett, Alicia Segrave, Maxine Pharmacovigilance - Safety of OTC and Prescription-Only Robinson, Frances Wilson. (Australia) Ibuprofen versus Paracetamol in French 261. Metabolic Syndrome Among Clients On Cardiovascular Population [765] Atypical Antipsychotics In Jos, Plateau 243. Evaluation of New Oral Anticoagulants Mai Duong, Régis Lassalle, Cécile Droz, State [775] (NOACs) Bleeding Adverse Reaction Nicholas Moore. (France) Reports in the FDA Adverse Events Rachel U Odesanya, Moses D Audu, Reporting System (FAERS) [757] 252. Cardiovascular and Gastrointestinal Chioma D Nwozor. (Nigeria) Safety of and Prescription-Only Ahmed Fahmy, Mohamed Mekkawy, Adel 262. Safety of Brotizolam in Hospitalized NSAIDs versus Paracetamol in French Abou-Ali. (Egypt) Patients in Internal Medicine Population [766] Departments [776] 244. Risks of Bleeding Among New Oral Mai Duong, Régis Lassalle, Cécile Droz, Ophir Lavon, Shmuel Bejell. (Israel) Anticoagulants Compared to Warfarin: Nicholas Moore. (France) Analysis of Post Marketing FDA 263. Associations Between Anticholinergic 253. Gastrointestinal Toxicity Among Adverse Event Reporting System Burden and Adverse Health Outcomes Patients Taking Selective Cox-2 (FAERS) Database, 2010-2015 [758] in Parkinson Disease [777] Inhibitors or Conventional NSAIDs Thamir M Alshammari, Tariq M Alhawassi, James AG Crispo, Allison W Willis, Dylan Hisham S Aljadhey. (Saudi Arabia) Alone or Combined with Proton Pump Inhibitors: A Case Control Study [767] P Thibault, Yannick Fortin, Harlen D Hays, Douglas S McNair, Lise M Bjerre, Dafna E 245. The Effect of Race, Age, and Sex Mohammad Bakhriansyah, Patrick C Kohen, Santiago Perez-Lloret, Donald R on the Risk of Angioedema Among Souverein, Anthonius de Boer, Olaf H Mattison, Daniel Krewski. (Canada) Heart Failure (HF) Patients Initiating Klungel. (Netherlands) Angiotensin Converting Enzyme Inhibitors (ACEIs) [759] 254. Safety Of Non-Prescription NSAIDs Pharmacovigilance - Other Thy P Do, Arpamas Seetasith, Raymond [768] Therapeutic Schlienger, Rossella Belleli, Chakkarin Elina Pradhan, Lisa G Pont. (Australia) 264. Eosinophilic Pneumonia and NSAIDs : Burudpakdee, Hendrik J Streefkerk, Sigrid 255. Codeine Use in Children with Common Contribution of Spontaneous Reports Behr. (Switzerland) Cold in Taiwan: Data from National Database [778] 246. Abstract Withdrawn [760] Health Insurance Research Database Aurelien Provoost, Francois Krabansky, (NHIRD) and National Adverse Drug Pauline Zeller, Aurore Morel, Malak Abou 247. Signal Detection Using Temporal Pattern Reaction (ADR) Reporting System [769] Taam, Thierry Trenque. (France) Discovery (TPD) in Electronic Health Ching-Huan Wang, Chih-Wan Lin, Fei- Records (EHRs) - Lessons from Statins Yuan Hsiao, Wei-I Huang, Wei-Ming Ke, 265. Abstract Withdrawn [779] and Rhabdomyolysis [761] Pi-Hui Chao, Wen-Wen Chen. (Taiwan) 266. Varenicline and Risk of Self-Harm: A Manfred Hauben, Qing Liu, Eric Hung, Nested Case-Control Study [780] William Blackwell, David Fram, Andrew 256. Automating Opioid Overdose Bate. (United States) Surveillance Using Natural Language Mina Tadrous, Diana Martins, Zhan Yao, Processing [770] Muhammad M Mamdani, David N Juurlink, 248. The Impact of Age and Gender on Brian L Hazlehurst, Carla A Green, Nancy Tara Gomes, Tony Antoniou. (Canada) Reporting of Cough and Angioedema A Perrin, Angela DeVeaugh-Geiss, Paul M 267. Adverse Drug Reaction Monitoring at with RAS Inhibitors: A Case/Non-Case Coplan. (United States) in VigiBase [762] a Regional Pharmacovigilance Centre (B.P.K.I.H.S.) [781] Fawaz F Alharbi, Anzhelika AV Kholod, 257. Antiepileptic Drugs, Risk Of Suicide Patrick C Souverein, Ronald H Meyboom, Attempts And The Impact Of Underlying Gajendra Prasad Rauniar. (Nepal) Mark CH Groot, Anthonius de Boer, Olaf H Medical Conditions: Results From The 268. Daily Limit of Acetaminophen More Klungel. (Netherlands) PGRX Information System [771] Likely to be Exceeded in Cold/Flu Lamiae Grimaldi-Bensouda, Clementine Season [782] Nordon, Michel Rossignol, Xavier Kurz, Frederic Rouillon, Lucien Abenhaim. Saul Shiffman, Deena R Battista, Judith P (France) Kelly, Mary K Malone, Rachel Weinstein, David W Kaufman. (United States) 32nd

82 POSTER SESSION B: Saturday, August 27 | 8:00am - 6:00pm

269. Evaluation of Impact of a Japanese 278. Safety, Efficacy and Pharmacokinetic Regulatory Action Against Denosumab- Bioequivalence of Biosimilar Tumor Induced Hypocalcemia Using the Necrosis Factor-alpha (TNF-a) Inhibitors Japanese Adverse Reaction Reporting Compared with Their Reference Database [783] Biologics: A Systematic Review [884] Kimie Sai, Mayu Ichihara, Katsunori Francine Chingcuanco, Jodi Segal, Segawa, Noriyasu Hirasawa, Takuya Seoyoung C Kim, G Caleb Alexander. Imatoh, Yoshiro Saito. (Japan)

270. Effectiveness of Trigger Tools to Detect Other Safety & Effectiveness Adverse Drug Events from Discharge 279. Proton-Pump Inhibitor Induced Risk of Summaries [784] Liver Cancer: A Nested Case-Control V Rajesh, Elstin Anburaj, M Surulivelrajan, Study [1029] Weena Stanley. (India) Yu-Hsuan Joni Shao, Kitaw Demissie, Szu-Yuan Wu. (Taiwan) 271. Psychosocial Predictors of Acetaminophen Use Exceeding the Daily Limit [785] End Session B Saul Shiffman, Judith P Kelly, Deena R Battista, Mary K Malone, Rachel Weinstein, David W Kaufman. (United States)

272. Abstract Withdrawn [786]

273. Drug Causality in Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis in Europe: Analysis of 10 Years RegiSCAR-Study [787] Maja Mockenhaupt, Ariane Dunant, Maren Paulmann, Peggy Sekula, Martin Schumacher, Sylvia Kardaun, Luigi Naldi, Teresa Bellon, Daniel Creamer, Cynthia Haddad, Bruno Sassolas, Benedicte Lebrun-Vignes, Laurence Valeyrie- Allanore, Jean-Claude Roujeau. (Germany)

274. Use of Sildenafil or Other Phosphodiesterase Inhibitors and Risk of Melanoma [788] Anton Pottegård, Sigrun AJ Schmidt, Anne B Olesen, Ninah Achacoso, Stephen K Van Den Eeden, Jesper Hallas, Henrik T Sørensen, Søren Friis, Laurel A Habel. (Denmark)

275. Androgen-Deprivation Therapy and Cardiovascular Risk (ADTCR): A Nationwide Population-Based Cohort Study [789] Lucie-Marie Scailteux, Sébastien Vincendeau, Emmanuel Nowak, André Happe, Frédéric Balusson, Christophe Leclerc, Elisabeth Polard, Emmanuel Oger. (France)

276. Liver Enzyme Elevations Associated With Two-Month Rifampicin, Isoniazid, Pyrazinamide, And Ethambutol Anti- Tubercular Therapy In Indonesia [790] Waqqas Hanafi, Ully A Mulyani, Dyah Perwitasari, Jarir Atthobari. (Indonesia)

277. Beta-Thalassemia Treatment and Complications in Two Large US Insured Population Databases [841] Nancy N Maserejian, Li Li, Jin Wang, William E Hobbs, Catherine Madigan. (United States)

32nd

83 POSTER SESSION C: Sunday, August 28 | 8:00am - 1:45pm Spotlight Sessions: 12:15 - 1:15 pm Spotlight Session-Vaccines J. Comparative Incidence of Cardiovascular S. Real-World Effectiveness of Events in Older Adults Initiating DPP- Omalizumab for the Treatment of A. Autoimmune Disorders Following HPV 4 Inhibitors versus Other Antidiabetic Severe Asthma [887] Vaccination in Young Women: Is the Risk Drugs [878] Real? [869] Mina Tadrous, Kimberly Fernandes, Mugdha N Gokhale, John B Buse, Michele Wayne Khuu, Gerald Lebovic, Matthew Lamiae Grimaldi-Bensouda, Michel Jonsson Funk, Jeniffer L Lund, Ross Stanbrook, Diana Martins, J Michael Rossignol, Fatiha Karam, Thomas Papo, Simpson, Til Stürmer. (United States) Paterson, Muhammad M Mamdani, David Patrick Vermersh, Isabelle Bourgault, Roger N Juurlink, Tara Gomes. (Canada) Dachez, Gerart Breart, Lucien Abenhaim. L. Comparing the Safety Profile of (United Kingdom) Two Formulations of Tiotropium Biologics (Handihaler® vs Respimat®): A 1. Risk of Serious Infections During Use B. Rotavirus Vaccine Schedules and Population Based Cohort Study [880] of Biologic Therapies for Psoriasis: A Vaccine Response Among Infants in Systematic Review [889] Low- and Middle-Income Countries: A Francesco Trotta, Stefania Spila Alegiani, Systematic Review [870] Roberto Da Cas, Maja Rajevic, Mauro Zenas ZN Yiu, Lesley S Exton, Zarif Venegoni, Mariangela Rossi, Valentino Jabbar-Lopez, M Firouz Mohd Mustapa, Joann F Gruber, Lucinda M Gruber, Rachel Conti, Giuseppe Traversa. Eleanor Samarasekera, David Burden, Palmieri Weber, Sylvia Becker-Dreps, Ruth Murphy, Caroline M Owen, Richard Michele Jonsson Funk. (United States) Spotlight Session-Biologics Parslew, Vanessa Venning, Darren M Ashcroft, Christopher EM Griffiths, C. Cluster Analysis of HPV Vaccine Reports M. Inclusion of Elderly Patients in Catherine H Smith, Richard B Warren. in a Global Database of Suspected Randomized Controlled Trials on (United Kingdom) Adverse Events [871] Targeted Agents in the Treatment Rebecca E Chandler, Jonas Fransson, of Metastatic Colorectal Cancer: A 2. Quality of Life Outcomes of a 12-Month- Kristina Juhlin, Ola Caster, I Ralph Edwards, Systematic Review [881] Follow-Up Brazilian Cohort of Patients G Niklas Norén. (Sweden) Amandine Gouverneur, Francesco Salvo, with Rheumatic Diseases Using D. Safety of TDaP Vaccination in Pregnancy Driss Berdaï, Annie Fourrier-Réglat, Biological Agents [890] [872] Pernelle Noize. (France) Haliton Alves de Oliveira Junior, Jéssica Barreto dos Santos, Bruna Assis Viana, J Bradley Layton, Anne M Butler, Dongmei N. The Long-Term Use of Biologics in Francisco Assis Acurcio, Alessandra Li, Kim A Boggess, Sylvia Becker-Dreps. Hong Kong [882] (United States) Maciel Almeida, Juliana Alvares, Kenneth KC Man, Shirley X Li, Esther W Mariangela Leal Cherchiglia. (Brazil) E. Methodological Approaches to Enhanced Chan, Ian CK Wong. (China) 3. Identifying Anti-TNF Use for Crohn’s Safety Surveillance for Seasonal Flu O. Assessment of Biosimilar Somatropin Disease and Ulcerative Colitis in Vaccines: Early Experience in the UK Use in Italian Routine Care: A 6-Year, Primary Care [891] [873] Multicenter, Retrospective Study Using Andrew Maguire, Jorge Puelles. Lorna Hazell, Saad AW Shakir, Andrew a Database Network [883] (United Kingdom) Finlay, Hannah Coulter, Robert S Brody, Ilaria Marcianò, Ylenia Ingrasciotta, Robert P Wise. (United Kingdom) Francesco Giorgianni, Alessandro 4. Incidence of Bowel Surgery in a Cohort of Crohn’s Disease Patients Treated F. Passive Enhanced Safety Surveillance Chinellato, Jenny Bolcato, Roberta Pirolo, with Infliximab or Adalimumab in Lazio, In Children Receiving Fluenz® Tetra Michele Tari, Valentina Ientile, Rosa Gini, Italy [892] Vaccination In England During The Early Armando A Genazzani, Ilaria Uomo, 2015/2016 Influenza Season [874] Maurizio Pastorello, Sebastiano W Pollina Riccardo Di Domenicantonio, Nera Agabiti, Addario, Salvatore Scondotto, Pasquale Silvia Cascini, Francesco Trotta, Antonio Lorna Hazell, Saad AW Shakir, Andrew Cananzi, Roberto Da Cas, Giuseppe Addis, Anna Kohn, Marina Davoli. (Italy) Finlay, Hannah Coulter, Robert S Brody, Traversa, Mariangela Rossi, Achille P Robert P Wise. (United Kingdom) Caputi, Gianluca Trifirò. (Italy) 5. Top-Down versus Step-Up Strategy of Tumor Necrosis Factor Alpha Inhibitors Spotlight Session-CER P. Determining the Optimal Position For in Children and Young Adults with Vedolizumab In The Current Treatment Inflammatory Bowel Disease [893] G. Rates of Therapy Switching Is Higher Paradigm For Ulcerative Colitis: A Among Initiators Insulin Glargine versus Wan-Ju Lee, Leslie Briars, Todd A Lee, Markov Model [888] of Insulin NPH in a Population-Based Gregory S Calip, Katie J Suda, Glen T Type 1 Diabetes Mellitus Cohort [875] Frank I Scott,Yash Shah,Karen Schumock. (United States) Lasch,Michelle Luo, James D Lewis. Cristiano S Moura, Michal Abrahamowicz, (United States) 6. Effectiveness and Safety of Cetuximab Sasha Bernatsky, Hassan Behlouli, Louise in First-Line Therapy of Metastatic Pilote. (Canada) Q. Real-World Comparative Risks of Colorectal Cancer According to Frailty Herpes Virus Infections in Tofacitinib in the EREBUS Study [894] H. The Science and Art of Evaluating and Biologic-Treated Rheumatoid Heterogeneity in Treatment Effects [876] Amandine Gouverneur, Juliette Coutureau, Arthritis Patients [885] Magali Rouyer, Denis Smith, Eric François, Shirley V Wang, Florence Yong, Robert J Jeffrey R Curtis, Fenglong Xie, Huifeng Alain Monnereau, Aurélie Balestra, Jérémy Glynn, Sebastian Schneeweiss, Jessica M Yun, Sasha Bernatsky, Kevin L Winthrop. Jové, Régis Lassalle, Nicholas Moore, Annie Franklin. Fourrier-Réglat, Pernelle Noize. (France) R. Use of Systemic Antibacterials Before I. Empirical Identification of Treatment and After Start of Topical, Non-Biologic 7. Tracking Trastuzumab (H) Therapy Regimens for Studies of Long-Term Systemic or Biologic Therapy for in Early Through Late Stage HER2- Exposure [877] Psoriasis. A Nation-Wide Cohort Cross- Positive Breast Cancer (HER2BC) in Xiaojuan Li, Abhijit V Kshirsagar, M Alan Over Study [886] Australia: A National, Retrospective Brookhart. (United States) Anders Sundström, Ingegärd Anveden- Cohort Study [895] Berglind. (Sweden) Benjamin Daniels, Sallie-Anne Pearson. 32nd (Australia)

84 POSTER SESSION C: Sunday, August 28 | 8:00am - 1:45pm

Vaccines Safety & Effectiveness - 25. Risk of Gynecomastia with Use of 5-Alpha Reductase Inhibitors for Benign 8. Risk of Type 1 Diabetes Mellitus Cancer Prostatic Hyperplasia [913] Associated with Vaccination During 17. Systematic Review and Quantitative Katrina Wilcox Hagberg, Hozefa A Divan, Childhood and Adolescence [896] Synthesis of Evidence to Support J Curtis Nickel, Shona Fang, Susan S Jick. Dan Beziz, Michel Rossignol, Marc Regulatory Review of Oncaspar for (United States) Nicolino, Pierre-Yves Benhamou, Elisabeth Treatment of Acute Lymphoblastic Requeda, Nadine Lucidarme, Jacques Leukemia (ALL) [905] 26. Population-Based Comparison of Beltrand, Clementine Dupuis, Laurence Ryan D Kilpatrick, Michael D Hale, Cristina the Risks of Serious Adverse Events Leitenschenck, Nathalie Roudaut, Ivanescu, Montserrat Casamayor, Claudia from Intermittent versus Continuous Albane Simon, Isabelle Bruckert, Sophie Lebedinsky. (United States) Androgen Deprivation Therapy in Jacqueminet, Anne Mayer, Lucien Advanced Prostate Cancer Patients Abenhaim, Lamiae Grimaldi-Bensouda. 18. Treatment Regimens and Duration of [914] (United Kingdom) Lines of Therapy in Medicare-Enrolled Huei-Ting Tsai, Ruth Pfeiffer, George Patients with Multiple Myeloma [906] Philips, Ana Barac, Alex Z Fu, Grace Y 9. Social Determinants of Zoster Vaccine Akeem A Yusuf, Tanya Natwick, Diana Zhou, Arnold Potosky. Uptake in England: Use of Electronic Felici, Winifred Werther. (United States) Health Records for Ascertainment of 27. Oral Contraceptives and VTE Across Inequity Parameters [897] 19. Transitions Across Different Lines of the Sentinel Data Network – An IMEDS Anu Jain, Albert Jan van Hoek, Sara L Therapy in Medicare-Enrolled Patient Evaluation Pilot Assessment [915] Thomas. (United Kingdom) Populations with Multiple Myeloma Andrew Bate, Rachel E Sobel, Jim [907] Marshall, Greg Daniel, Troy McCall, Robert 10. Is Mortality Associated with Akeem A Yusuf, Tanya Natwick, Diana F Reynolds, Jeff Brown. (United Kingdom) Combination DTPa Vaccines? A Linkage Felici, Winifred Werther. (United States) Study Among Australian Children Using 28. Testosterone Replacement Therapy 12 Years of Data [898] 20. Risk of Skin Cancer in Users of (TRT) and Risk of Acute Myocardial Katherine M Duszynski, Nicole M Pratt, Topical Tacrolimus, Pimecrolimus Infarction (AMI): An Administrative John W Lynch, Michael S Gold. (Australia) and Corticosteroids. JOint European Healthcare Claims Study [916] Longitudinal Lymphoma and Skin Hu Li, Xiang Zhang, Lucy Mitchell, Darell 11. Uptake and Predictors of TDaP Cancer Evaluation (JOELLE) Study [908] Heiselman, Stephen Motsko. Immunization During Pregnancy in Jordi Castellsague, Myrthe PP van Herk- Privately-Insured US Women, 2010-2013 Sukel, Jesper Hallas, Anders Sundström, 29. Effects of Supplemental Intravenous [899] Arlene Gallagher, Lia Gutierrez, Brian Agents to Mitigate Peri-Operative Anne M Butler, J Bradley Layton, Dongmei Calingaert, Josephina JG Kuiper, Anton Complications Arising from Inhaled Li, Michael G Hudgens, Kim A Boggess, Pottegård, Ingegärd A Berglind, Daniel Anesthetics [917] Leah J McGrath, Sylvia Becker-Dreps. Dedman, James A Kaye, Carolina Pardo, Kyle P Paredes, Aaron WC Kamauu, Rebekah K Paredes, Andrew Wilson. 12. Measles, Mumps, and Rubella (MMR) Kenneth J Rothman, Susana Perez- (United States) Vaccines Differ Considerably with Gutthann. (Spain) Regards to Immediate Injection Pain: 21. Phosphodiesterase Type 5 Inhibitors 30. Elevated Bladder and Prostate Cancer A Systematic Literature Review [900] And Risk Of Malignant Melanoma: Rates Following Initiation of OAB Corinne Willame, Ouzama Henry, Laurence Matched Cohort Study Using Primary Medication: Findings from a Danish Baril. (Belgium) Care Data From The UK Clinical Registry [918] Practice Research Datalink [909 Jesper Hallas, Andrea Margulis, 13. Increased Incidence of Narcolepsy Anton Pottegård, James A Kaye, Nina After the 2009 H1N1 Pandemic and Anthony Matthews, Sinead M Langan, Kristiansen, Christine L Bui, Willem Vaccination Campaign in Taiwan [901] Ian Douglas, Liam Smeeth, Krishnan Bhaskaran. (United Kingdom) Jan Atsma, Kwame Appenteng, Billy Wan-Ting Huang, Hsin-Chun Lee, Hui- Franks, Stefan de Vogel, Milbhor D’Silva, Chen Lin, Chin-Hui Yang. (Taiwan) 22. ‘Real World’ Ipilimumab Survival Data in Susana Perez-Gutthann, Alejandro Arana. Ireland [910] 14. Comparison Of Different Collection (Denmark) Laura McCullagh, Susanne Schmitz, Methods For Reported Adverse Events 31. Cancer Risk in Users of Antimuscarinic Following Pandemic And Seasonal Roisin Adams, Michael Barry, Cathal Walsh. (Ireland) Drugs for Overactive Bladder: A Cohort Influenza Vaccination [902] Study in the Swedish National Registers Jeanet Kemmeren, Maaike Honsbeek, Safety & Effectiveness - GU & [919] Frederika Dijkstra, Marit de Lange, Marie Linder, Andrea V Margulis, Ingegärd Nicoline van der Maas, Ronald Hormones Anveden-Berglind, Shahram Bahmanyar, Smallenburg, Carl Koppenschaar, Wim van 23. Cardiovascular Risks of Exogenous Christine L Bui, Willem Jan Atsma, Kwame der Hoek. (Netherlands) Testosterone Use Among Men: A Appenteng, Billy Franks, Stefan de Vogel, 15. Comparison Of The Tolerability Of Systematic Review and Meta-Analysis Milbhor D’Silva, Susana Perez-Gutthann, Newly Introduced Childhood Vaccines [911] Alejandro Arana. (Sweden) In The Netherlands [903] Geetha Iyer, G Caleb Alexander, Eleanor Jeanet Kemmeren, Nicoline van der Maas, Lucas, Dora Lin, Sonal Singh. (United Hester de Melker. (Netherlands) States)

16. Disease and Exposure Misclassification 24. Association Between Exogenous in Studies of Vaccine Effectiveness: A Testosterone and Cardiovascular Simulation Tool [904] Events: An Overview of Systematic Elizabeth Merrall, Denis Macina, Silvia Reviews [912] Perez-Vilar, Silvia Perez-Vilar, Kaat Oluwadamilola Onasanya, Geetha Iyer, Bollaerts. (Netherlands) Eleanor Lucas, Sonal Singh, G Caleb 32nd Alexander. (United States) 85 POSTER SESSION C: Sunday, August 28 | 8:00am - 1:45pm

32. Do Individual Antimuscarinic Drugs to 40. Fracture-Preventing Benefit of 48. Metformin and Other Glucose- Treat Overactive Bladder Have Different Bisphosphonates by Compliance Lowering Drug Initiation and Rates Cardiovascular Risks? A UK CPRD and Its Timing Following Therapy of Community-Based Antibiotic Use Cohort Study [920] Start: A Register-Based Study of and Hospital-Treated Infections in Alejandro Arana, Cristina Varas-Lorenzo, Postmenopausal Women in Sweden Patients with Type 2 Diabetes: A Danish Lisa J McQuay, Ryan Ziemiecki, Christine [928] Nationwide Population-Based Cohort L Bui, Alicia W Gilsenan, Kenneth J Anna Westerlund, David Hägg, Tobias Study [936] Rothman, Willem Jan Atsma, Kwame Svensson, Fredrik Granath, Helle Kieler. Reimar Wernich Thomsen, Anil Mor, Irene Appenteng, Billy Franks, Stefan de Vogel, (Sweden) Petersen, Henrik Toft Sørensen. (Denmark) Milbhor D’Silva, Andrea V Margulis, Susana Perez-Gutthann. (Spain) Safety & Effectiveness - 49. Treatment Discontinuation And Rates Of Hypoglycemia In Type 2 Diabetes 33. Abstract Withdrawn [921] Alimentary Tract and Metabolic Patients Treated With Dipeptidyl 41. Clinical Effectiveness and Safety of Peptidase-4 (DDP-4) Inhibitors or NPH 34. Risk of Major Adverse Cardiovascular Analogue Glargine in Type 1 Diabetes: Insulin As Third-Line Therapy [937] Events Associated with Biologic Systematic Review and Meta-Analysis Cristiano S Moura, Sasha Bernatsky, Therapies in Patients with Plaque [929] Michal Abrahamowicz, Hassan Behlouli, Psoriasis: Systematic Review and Meta- Louise Pilote. (Canada) Analysis of Randomised Controlled Lays Marra, Brian Godman, Vania Araujo, Trials [922] Augusto Guerra Junior, Francisco Acurcio, 50. Risk of Hypoglycaemia in Users of Leonardo Diniz, Juliana Alvarez. (Sweden) Watcharee Rungapiromnan, Richard B Sulphonylureas with Renal Impairment: Warren, Zenas ZN Yiu, Christopher EM 42. Incretin-Based Treatments and the Risk A Population-Based Cohort Study [938] Griffiths, Darren M Ashcroft. (United of Pancreatic Cancer in Patients with Judith van Dalem, Martijn Brouwers, Kingdom) Type 2 Diabetes [930] Coen Stehouwer, André Krings, Hubert Guillaume Avenin, Marion Bertrand, Celine Leufkens, Johanna Driessen, Frank de 35. Development of a Prospective, Non- Vries, Andrea Burden. (Netherlands) Interventional, Longitudinal, Multicenter Druet, Isabelle Yoldjan, Mahmoud Zureick, Registry Study of Patients Initiating a Rosemary Dray-Spira. (France) 51. Adjusting for the Effect of Switching N [923] 43. The Association of Metformin Exposure Basal Insulin Treatment on the Risk of Rita Kristy, Kevin V Carlson, Anna S Deal, and Specific Types of Digestive First Severe Hypoglycaemia [939] Kavita V Nair, Eric S Rovner, Eric Gemmen, Cancers Among Diabetic Patients: Houssem Khanfir, Pasi Korhonen, Sari Eva E Oakkar, Julie Park, Priscilla Real-World Findings from a US EMR Mäkimattila, Fabian Hoti. (Finland) Velentgas, Pamela Bradt, Katherine Database [931] Gooch, Carol Schermer. (United States) 52. Cancer Risk Among Insulin Users: William K Mountford, Elise Kaufman, Comparing Analogues with Human 36. Risk of Urinary Adverse Events Alexandria Portelli, Caitlin A Knox. (United Insulin in the CARING Five-Country Associated with Inhaled States) Study [940] Anticholinergics in Adult Men [924] 44. Cardiovascular Risks Associated Anna But, Marie L De Bruin, Marloes T Scott M Vouri, Seth A Strope, Jiajing with Dipeptidyl-Peptidase 4 Inhibitor Bazelier, Vidar Hjellvik, Morten Andersen, Chen, Margaret A Olsen. (United States) Compared to Other Diabetes Drugs: A Anssi Auvinen, Jakob Starup-Linde, Cohort Study [932] Marjanka K Schmidt, Kari Furu, Frank de 37. Survival In Kidney Transplantation In Maki Komamine, Chieko Ishiguro, Vries, Øystein Karlstad, Nils Ekström, Jari Patients Who Used Cyclosporine Or Haukka. (Finland) Tacrolimus [925] Yoshinori Takeuchi, Yoshiaki Uyama. (Japan) Rosangela Maria Gomes, Augusto Afonso 53. Comparative Effectiveness of Glinides Guerra Júnior, Livia Lovato Pires Lemos, 45. Evaluation of Three HbA1c Metrics in vs. DiPeptidyl Peptidase-4 Inhibitors in Wallace Breno Barbosa, Francisco Assis Relation to Heart Failure in 94,332 UK Diabetic Patients [941] Acurcio. (Brazil) Type II Diabetes Mellitus Subjects [933] Julien Bezin, Yohann Mansiaux, Jérémy Claudia Cabrera, Stanko Skrtic, Marita Jove, Mickael Arnaud, Régis Lassalle, Safety & Effectiveness - Olsson, Volker Schnecke, Marcus Lind. Francesco Salvo, Antoine Pariente. Musculo-Skeletal (Sweden) (France) 38. Risk of Venous Thromboembolism 46. Pharmacoepidemiological Profiles 54. Association Between Type 2 Diabetes Amongst Users of Different Anti- of Glucose-Lowering Drug Use in Mellitus and Cancer – a Methodological Osteoporosis Drugs: A Multinational Patients with Diabetes and Its Impact Approach [942] Population-Based Cohort Study [926] on Mortality from All-Cause and Jetty A Overbeek, Amber AWA van der Elisa Martin-Merino, Irene Petersen, Cardiovascular Disease in the U.S. Heijden, Ron MC Herings, Giel Nijpels. Samuel Hawley, Arturo Álvarez-Gutierrez, Adults [934] (Netherlands) Antonnella Delmestri, Ana Llorente-García, Longjian Liu, Jinggaofu Shi, Barbara 55. Association of Type 2 Diabetes And Kassim Javaid, Tjeerd van Staa, Andrew Simon, Howard J Eisen. (United States) Glucose-Lowering Drugs With Risk Of Judge, Cirus Cooper, Daniel Prieto- Recurrence Or Death Following Breast Alhambra. (Spain) 47. Bile Duct and Gallbladder Diseases and the Use of Incretin-Based Drugs in Cancer: A Population-Based Cohort 39. Preadmission Use of Prescription Drugs Patients with Type 2 Diabetes [935] Study [943] and Risk of Red Blood Cell Transfusion in Jean-Luc Faillie, Oriana H Yu, Hui Yin, Deirdre Cronin-Fenton, Uffe Heide- Elderly Patients Undergoing Hip Fracture Dominique Hillaire-Buys, Alan Barkun, Jørgensen, Reimar W Thomsen, Marianne Surgery [927] Laurent Azoulay. (France) Ewertz, Henrik T Sørensen. (Denmark) Alma B Pedersen, Deirdre Cronin-Fenton, Nickolaj R Kristensen, Mette Nørgaard. (Denmark)

32nd

86 POSTER SESSION C: Sunday, August 28 | 8:00am - 1:45pm

56. Safety and Efficacy of Sofosbuvir with 65. Drug Interactions as a Potential 73. Antiplatelet and Anticoagulant Simeprevir with or without Ribavirin Instrumental Variable: The Example of Prescriptions and Breast Cancer for Hepatitis C Genotype 1 with Severe Effectiveness of Antibiotic Therapy in Recurrence: A Danish Nationwide Renal Impairment: A Meta-Analysis of Exacerbated COPD Patients [953] Prospective Cohort Study [961] Cohort Studies [944] Yuanyuan Wang, Anouk JM Jansen, Jens Simon R Sørensen, Thomas P Ahern, Ruchi Singhal, Pramil Tiwari, Ajay Duseja, Bos, Eelko Hak. (Netherlands) Rikke N Pedersen, Peer Christiansen, Bent Rajiv Ahlawat. (India) Ejlertsen, Henrik T Sørensen, Deirdre P 66. Clinical Outcome Difference Of Cronin-Fenton. (Denmark) 57. Metabolic Syndrome Associated The Patient Treated With Generic to Antiretroviral Therapy: A Cross- Piperacillin-Tazobactam And Innovator 74. Safety And Efficacy Of New Oral Sectional Analysis [945] In Severely Infectious Patients In Anticoagulants, And Low Molecular Debora C Hilario, Leticia P Braga, Cassia Medical Intensive Care Units [954] Weight Heparins Compared To Aspirin CP Mendicino, Andreia Q Ribeiro, Chiu-Ju Chen, Tzu-Ayo Chang, Haw- Associated With Total Knee And Hip Cristiane A Menezes de Padua. (Brazil) Chyuan Lee, Yu-Chin Lily Wang, Wen- Replacement [962] Feng Fang, Ching-Ling Tai. (Taiwan) Johannes TH Nielen, Pieter C Dagnelie, Safety & Effectiveness - Frank de Vries, Pieter Emans, Nicole 67. Effectiveness of Adalimumab and Veldhorst-Janssen, Arief Lalmohamed, Anti-infectives Etanercept for the Treatment of Tjeerd-Pieter van Staa, Bart van den Bemt, 58. Analysis of Regimen Changes Due to Rheumatoid Arthritis in the Public Annelies Boonen. (Netherlands) Adverse Drug Reactions Associated Health System (SUS) Belo Horizonte, with Antiretroviral Therapy in HIV Minas Gerais, Brazil [955] 75. Outcomes Associated With Non- Patients [946] Jéssica B dos Santos, Brian B Godman, Adherence To Anti-Hypertensives And Statins [963] Sareeya Wechwithan. (Thailand) Alessandra M Almeida, Francisco de A Acurcio, Adriana M Kakehas, Haliton A de Kathleen Bennett, Mary Connolly, Pedro 59. Real-World Effectiveness of HCV Oliveira Junior, Augusto A Guerra Junior, Okuh, Caitriona Cahir, MaryJo MacAvin, Infection from an Irish National HCV Marion Bennie, Juliana Alvarez. (Sweden) Mary Teeling. (Ireland) Registry [947] Emma Gray, Aisling O’Leary, Suzanne 68. The Associations Between Bullous 76. De-Novo Post-Diagnosis Statin Use Norris. Pemphigoid and Drug Use: A And Mortality In Women With Stage I-III Prescription Sequence Symmetry Breast Cancer [964] 60. The Association Between the Analysis [956] Amelia Smith, Laura Murphy, Linda Sharp, Use of Oral Fluoroquinolones and Chao-Kai Hsu, Edward Chia-Cheng Lai, Darran O’Connor, William Gallagher, Neuropsychiatric Events: A Self- Chien-Huei Huang, Yea-Huei Kao Yang, Kathleen Bennett, Ian Barron. (Ireland) Controlled Case Series Study [948] Ching-Lan Cheng. (Taiwan) 77. The Association Between Statin Use Celine SL Chui, Ian CK Wong, Angel YS 69. Safety and Efficacy/Effectiveness and Risk of Cancer Among Elderly Wong, Edwin HM Lee, WC Chang, Eric YH of 2nd-Line Treatments in Immune Medicare Beneficiaries [965] Chen, Esther W Chan. John Snow Award Recipient Thrombocytopenia (ITP): A Systematic Jing Yuan, Kevin Z Lu. (United States) Review of the Literature [957] 61. Incidence of Myelosuppression in Karynsa Cetin, Fiona Callaghan, Jon P 78. Beta Blockers and Cancer Prognosis Patients with Longer-Term Exposure Fryzek, Lauren C Bylsma, Carla Bezold, – the Role of Immortal Time Bias: A to Linezolid in an Outpatient Claims Bhakti Mehta. (United States) Comprehensive Systematic Review and Database [949] Meta-Analysis [966] 70. Patient Characteristics and Overall Janick Weberpals, Lina Jansen, Prudence Vinay Mehta, Thomas Rhodes, Michael Survival (OS) in the Post-Docetaxel Senderak, Carisa De Anda, Chris Mast. Carr, Michael Hoffmeister, Hermann Metastatic Castration-Resistant Brenner. (Germany) 62. Intravenous Vancomycin and the Risk Prostate Cancer (mCRPC) Community of Clostridium difficile Infection [950] Setting [958] 79. Protection Against Colorectal Cancer with Use of Low-Dose Aspirin: Selection Vanessa W Stevens, Karim Khader, Wendy Y Cheng, Raymond Miao, Mei Sheng Duh, Francis Vekeman, Jennifer Bias Is Unlikely Based on Results Using Kevin A Brown, Richard E Nelson, Molly Three Different Study Designs [967] Leecaster, William Ray, Damon Toth, Sung, Marjolaine Gauthier-Loiselle, Michael A Rubin. (United States) Jonathan Fortier, Ravinder Dhawan, Lucía Cea Soriano, Montse Soriano- William K Oh. (United States) Gabarró, Luis A García Rodríguez. (Spain) 63. Clarithromycin Resistance to Helicobacter Pylori: A Prospective 71. Abstract Withdrawn [959] 80. New Use of Statins and the Risk of Insight from Malaysia [951] Achilles or Biceps Tendon Rupture: Safety & Effectiveness - A Propensity-Score Matched Cohort Muhammad Shahid Iqbal, Muhammad Zahid Study [968] Iqbal, Mohd Baidi Bahari. (Malaysia) Cardiovascular Julia Spoendlin, J Bradley Layton, Mallika 64. Antibiotics and Infection/Colonization 72. The Quality of Warfarin Therapy Among Mundkur, Christian Meier, Susan S Jick, by Carbapenem-Non-Sensitive P. Atrial Fibrillation Patients in Finland - Christoph R Meier. aeruginosa: A Nested Case-Case- Results from the FinWAF Registry [960] Control Study [952] 81. Impact of Treatment with Lipid- Juha Mehtälä, Pekka Raatikainen, Riitta Lowering Drugs on Longitudinal and Maider Coppry, Camille Jeanne-Leroyer, Lassila, Houssem Khanfir, Pasi Korhonen, Secular Decrease in Total Cholesterol Marion Saly, Pernelle Noize, Catherine Fabian Hoti, Mika Lehto. (Finland) Levels. The Tromsø Study 1979-2008 Dumartin, Romuald Riem, Alexandre [969] Boyer, Veronique Dubois, Anne-Marie Rogues. (France) Laila A Hopstock, Kaare H Bønaa, Anne E Eggen, Sameline Grimsgaard, Bjarne K Jacobsen, Maja-Lisa Løchen, Ellisiv B Mathiesen, Inger Njølstad, Tom Wilsgaard. (Norway) 32nd

87 POSTER SESSION C: Sunday, August 28 | 8:00am - 1:45pm

82. Fertility Treatment and the Risk 90. Effectiveness Of Preventing Stroke 99. Outcomes of Intravenous of Cardiovascular Diseases in the Between Different Rhythm Control Corticosteroids in Patients Undergoing Offspring [970] Agents For Atrial Fibrillation: Coronary Artery Bypass Grafting Annefleur MC Bakker, Eelko Hak, Jens Retrospective Cohort Study From Surgery [987] HJ Bos, Catharina CM Schuiling-Veninga. A Nationwide And Single-Center Macarius M Donneyong, Pauline Levy- (Netherlands) Database [978] Bosco, Joshua J Gagne. (United States) Yu-Wen Wang, Po-Yu Chen, Mu-Mei Hu, 83. Effectiveness of Ezetimibe on Blood Jui Wang, Kuo-Liong Chien, Fe-Lin Lin 100. The Impact of Comorbidity and Age Lipids in Real-Life Clinical Practice Wu, Zhen-Fang Lin. (Taiwan) on Treatments for Acute Coronary [971] Syndrome [988] Jean Ferrières, Jean Dallongeville, Lucian 91. The Impact of Comorbidity with Heart Wei Ho, Jui Wang, Kuo-Liong Chien, Fe- Abenhaim, Michel Rossignol, Lamiae Failure on Treatments and Outcomes in Lin Lin Wu, Zhen-Fang Lin. (Taiwan) Grimaldi-Bensouda. (United Kingdom) Patients with Acute Coronary Syndrome [979] 101. Health-Related Quality of Life and 84. Clinical Characteristics, Lipid Treatment Yi-Jung Wu, Jui Wang, Kuo-Liong Chien, Burden of Disease in Patients Suffering and Goal Attainment in a Familial Zhen-Fang Lin. (Taiwan) from an Acute Coronary Syndrome: Hypercholesterolemia Cohort in the Evidences from the Use of Validated Netherlands: A Cross Sectional Study 92. Population-Based Effectiveness Instruments in the PGRx-3 Real World [972] and Safety of Different Antiplatelet Dataset [989] Josephina G Kuiper, Edith H Heintjes, Regimens as Secondary Prevention for Jesus Cuervo, Clementine Nordon, Michel Eline Houben, Fernie JA Penning-van Ischemic Stroke/Transient Ischemic Rossignol, Nicolas Morisot, Jacques Beest, Ron MC Herings. (Netherlands) Attack [980] Benichou, Nicolas Danchin, Lucien Alfi Yasmina, Anthonius de Boer, Vera Abenhaim, Lamiae Grimaldi. (Spain) 85. Modelling Of Average Endpoint HM Deneer, Jurrien M ten Berg, Patrick C Postponement For Cardiovascular Souverein, Olaf H Klungel. (Netherlands) 102. Switching of Angiotensin Receptor Outcomes In Statin Trials [973] Blockers to Angiotensin-Converting Morten Rix Hansen, Anton Pottegård, 93. Age-Stratified Outcome Of Genotype- Enzyme Inhibitors in Patients with Asbjørn Hróbjartsson, Per Damkier, René Guided Dosing Algorithm For Hypertension: Is It a Cost-Saving DePont Christensen, Morten Olesen, Acenocoumarol And Phenprocoumon Strategy? [990] Jesper Hallas. (Denmark) [981] Amanj Baker, Li-Chia Chen, Rachel Elliott. Yumao Zhang, Anthonius de Boer, Talitha I 86. Blood Pressure-Lowering Effect of Verhoef, Felix JM van der Meer, Saskia Le 103. Characteristics of Different Spironolactone in Hypertensive Patients Cessie, Vangelis G Manolopoulos, Anke H Antihypertensive Medication Users Without Heart Failure [974] Maitland-van der Zee. (Netherlands) in Observational Comparative Michael D Murray, Wanzhu Tu, Shanshan Effectiveness Studies: A Literature Li, Qing Tang, Anna R Roberts, Julie N 94. Incidence of Intracranial Bleeds in New Review [991] Kippenbrock, Rachel E Hasty, Sarah A Users and Non-Users of Low-Dose M Sanni Ali, Rolf HH Groenwold, Mikkel Z Lynch, Sarah A Hoover, Howard Pratt. Aspirin in the UK [982] Ankarfeldt1, Erpur Adalsteinsson, Cynthia (United States) Lucía Cea Soriano, David Gaist, Montse J Girman, Olaf H Klungel. (Netherlands) Soriano-Gabarró, Luis A García Rodríguez. 87. Effectiveness of Ticagrelor Compared 104. Severe Adverse Events and Treatment to Clopidogrel in Reducing the Risk 95. An Evaluation of the Effect of Discontinuation Among Older Adults of Major Adverse Cardiovascular Spironolactone on the Risk of New Taking Angiotensin-Converting Enzyme Events in Patients with Coronary Heart Onset of Diabetes in a Population- Inhibitors (ACEI) or Angiotensin Disease After Percutaneous Coronary Based Study of Patients with Heart Receptor Blockers (ARB) Following Intervention [975] Failure [983] Acute Myocardial Infarction (AMI) [992] Hendra Wana Nur’amin, Iwan Simon de Denus, Sandra Korol, Michel Gang Fang, Izabela E Annis, Nirosha Dwiprahasto, Erna Kristin. (Indonesia) White, Eileen O’Meara, Rouleau Jean- Mahendraratnam, Til Stürmer, Joel Farley, Lucien, Dorais Marc, Sylvie Perreault. Jennifer G Robinson. (United States) 88. The Comparative Effectiveness of (Canada) 4th Line Anti-Hypertensive Agents in 105. Cholinesterase inhibitors and Risk Patients with Resistant Hypertension: A 96. Novel Oral Anticoagulants and Risk of of Adverse Cardiac Events: Synergic Meta-Analysis [976] Gastrointestinal Bleeding: A Systematic Effects of Cardiosuppressive Drugs in Sarah-Jo Sinnott, Adrian Root, Rohini Review [984] Dementia Patients [993] Mathur, Kathryn Mansfield, Laurie Manal H Ziadeh, Mehmet Burcu, Elisabeth Soko Setoguchi, Isao Iwata, Monera Tomlinson, Ian J Douglas. (United M Oehrlein, Eleanor M Perfetto. Wong, Cheng-Yang Hsieh, Yea-Huei Kao Kingdom) Yang, Edward Lai. (United States) 97. Rivaroxaban vs. Phenprocoumon Use 89. New Statin Use And Left Ventricular in Germany and Risk of Bleeding: A 106. Medication Therapy Modifies the Structure: Estimating Long-Term Claims Data Analysis Based on 80,000 Association Between Longitudinal Associations In The Multi-Ethnic Study Patients [985] eGFR and Cardiovascular Events of Atherosclerosis (MESA) [977] Alexander Fassmer, Kathrin Jobski, Ulrike Among Adults with CKD [994] Lauren N Strand, Rebekah L Young, Haug, Tania Schink. (Germany) H Lester Kirchner, Sharon Larson, Robert Joseph A Delaney, Alain G Bertoni, David Perkins. (United States) A Bluemke, Gregory L Burke, Joao A Lima, 98. Risk Factors for Major Bleeding Events Nona Sotoodehnia, Bruce M Psaty, Susan in Rivaroxaban Users with Atrial R Heckbert, Robyn L McClelland. (United Fibrillation: A Nested Case-Control States) Study [986] Jason C Simeone, CAPT Sally G Tamayo, Beth L Nordstrom, Manesh R Patel, Zhong Yuan, Nicholas M Sicignano, W Frank 32nd Peacock. (United States)

88 POSTER SESSION C: Sunday, August 28 | 8:00am - 1:45pm

Safety & Effectiveness - 116. Efficacy of Anticonvulsant, 125. Antipsychotic Use and Risk of Antidepressant and Opioid in Treating Hospitalisation or Death Due to Neurological Neuropathic Pain – A Systematic Pneumonia in Persons with and without 107. Risk Of First Hip Fracture Associated Review and Meta-Analysis [1004] Alzheimer’s Disease [1013] With Incident Benzodiazepine And Ghaleb Saud Alharbi, Li-Chia Chen, Roger Anna-Maija Tolppanen, Marjaana Related Drug Use In Persons With And Knaggs. Koponen, Antti Tanskanen, Piia Without Alzheimer’s Disease [995] Lavikainen, Reijo Sund, Jari Tiihonen, 117. Impact of Pre-Admission Opioid Laura Saarelainen, Marjaana Koponen, Sirpa Hartikainen, Heidi Taipale. Treatment on One-Year Mortality After Antti Tanskanen, Anna-Maija Tolppanen, Non-Surgical Intensive Care Admission 126. Antidepressant Use and Outcomes Reijo Sund, Jari Tiihonen, Sirpa [1005] in Combination with Contraindicated Hartikainen, Heidi Taipale. (Finland) Troels Munch, Christian F Christiansen, Comedication in a Tertiary Care 108. Association Between Exposure to Lars Pedersen, Henrik T Sørensen. Hospital [1014] Benzodiazepines and Related Drugs (Denmark) David F Niedrig, Sabrina T Müller, Carmen and Total Hip Replacement Survivorship Gött, Waldemar Greil, Stefan Russmann. in Arthritis: A Population-Based Cohort 118. Is Use of Antiepileptic Drugs Associated (Switzerland) Study of 246 940 Patients [996] with an Increased Cataract Risk? A Case-Control Analysis [1006] 127. Applying a Novel Anticholinergic Dan Beziz, Sandrine Colas, Cédric Collin, Toxicity Scoring System to a Rosemary Dray-Spira, Mahmoud Zureik. Claudia Becker, Susan S Jick, Christoph Retrospective Cohort of Managed Care (France) R Meier. Patients [1015] 109. Benzodiazepine Use During 119. Estimating the Association of Adverse Heather Anderson, Katia Hannah, Dong Hospitalization: Automated Health Outcomes Using Three Xu, Vaughn Culbertson, Robert Valuck. Identification of Potential Medication Anticholinergic Medication Toxicity Errors and Systematic Assessment of Scales [1007] 128. A Novel Molecular-Based Preventable Adverse Events [997] Katia Hannah, Heather Anderson, Dong Anticholinergic Toxicity Scoring System as a Basis for Assessing Drug-Induced David F Niedrig, Liesa Hoppe, Sarah Xu, Robert Valuck. (United States) Anticholinergic Burden [1016] Maechler, Heike Russmann, Stefan 120. Psychiatric Medication and School Russmann. (Switzerland) Dong Xu, Vaughn Culbertson, Heather Performance in Primary School Anderson, Katia Hannah, Robert Valuck. 110. Effectiveness and Safety of Smoking Children: An Explorative Study [1008] Cessation Pharmacotherapy: A Jurjen van der Schans, Sefike Vardar, 129. Tolerability/Safety Profile of Cariprazine Retrospective Cohort Study [998] Rukiye Cicek, Jens HJ Bos, Pieter J in Treating Psychotic Disorders/Bipolar Disorder: A Systematic Review with Greg A Carney, Malcolm Maclure, Suzanne Hoekstra, Tjalling W de Vries, Eelko Hak. Meta-Analysis of RCTs [1017] M Taylor, Ken Bassett, Colin Dormuth. (Netherlands) (Canada) Shijian Lao, Ying He, Ian CK Wong, Frank 121. Risk of Parkinson’s Disease In The MC Besag, Esther W Chan. 111. Association Between Buprenorphine/ Users Of Antihypertensive Agents: Naloxone Sublingual Tablet And All- An Evidence From The Meta-Analysis 130. The Risk of Depression, Euphoric Cause Mortality In Patients Receiving Observational Studies [1009] Mood and Sedation with the Use Medication Assisted Treatment For Amarnath Mullapudi, Dipika Bansal, Kapil of Dextromethorphan in Different Opioid Addiction In UK [999] Gudala, Chandra sehkar Boya. (India) Indications. Results from a Systematic Review and Meta-Analysis of Jinghua He, Sabine M Apelt. (United 122. Risk of Mortality in Patients with Randomised Clinical Trials [1018] States) Parkinson’S Disease Exposed to Luis Velez-Nandayapa. (United Kingdom) 112. Hypnotic Drug Use and Cardiovascular Domperidone [1010] Events in Treated Hypertensive Patients Judith van Dalem, Andrea Burden, Sander 131. The Risk of Dizziness with the Use [1000] Pouwels, Frank de Vries. (Netherlands) of Dextromethorphan in Different Indications; Not a Rare Risk as Kaori Nomura, Yasunari Mano, Mariko 123. Outcomes of Three Treatment Described in Label. Results From a Asahi, Shunya Ikeda. (Japan) Strategies in Bipolar Disorder Using Systematic Review and Meta-Analysis 113. First-Line Disease Modifying Therapies Conventional Mood Stabilizers and of Randomised Clinical Trials [1019] in Preventing Multiple Sclerosis Relapse Antipsychotic Drugs [1011] Luis Velez-Nandayapa. (United Kingdom) – A Nationwide Observational Study in Marie Tournier, Anke Neumann, Elodie Taiwan [1001] Pambrun, Alain Weill, Jean-Philippe Safety & Effectiveness - Chaffiol, François Alla, Bernard Bégaud, Chih-Ho Chou, Tzu-Chieh Lin, Ching-Lan Respiratory Cheng, Yea-Huei Kao Yang. (Taiwan) Géric Maura, Hélène Verdoux. (France) 132. Risk of Myocardial Infarction (MI) 124. Use of Antipsychotics and Risk of 114. Comparison of the Effectiveness Associated with Acute Exacerbations of Recurrent Stroke Events: A Population- of Duloxetine versus Pregabalin/ COPD (AECOPD): Effect Modification by Based Retrospective Cohort Study in Gabapentin for Treatment of Diabetic Cardiovascular Drugs [1020] Peripheral Neuropathy [1002] Taiwan [1012] Kieran J Rothnie, Hana Müllerová, Liam Le Dai, Dan-Wei Choo, Jui Wang, Kuo- CR Shabana, Shamlin M Oommen, Sherin Smeeth, Neil Pearce, Ian Douglas, Jennifer Liong Chien, Fe-Lin Lin Wu, Zhen-Fang John Varghese, PS Sabin, K Geetha. K Quint. (United Kingdom) (India) Lin. (Taiwan)

115. Comparative Safety of Long-Acting Opioids for Non-Cancer Pain [1003] Cecilia P Chung, William D Dupont, Katherine T Murray, Kathi Hall, C Michael Stein, Wayne A Ray. 32nd

89 POSTER SESSION C: Sunday, August 28 | 8:00am - 1:45pm

133. Inhaled Corticosteroids and the Risk of 141. The Risk of Alcohol-Related Mortality in 151. Mapping of Existing Data Sources for Hospitalization for Pneumonia. Results Patients with Psoriasis: A Population- the Conduct of Real-World Studies in from the OUTPUL Study [1021] Based Cohort Study Using Linked Duchenne Muscular Dystrophy (DMD) in Silvia Cascini, Nera Agabiti, Lisa Bauleo, Primary Care, Hospital and Mortality North America and Europe [1040] Ursula Kirchmayer, Valeria Belleudi, Records [1030] Aurore Bergamasco, Chung-Yan Yuen, Mirko Di Martino, Riccardo Pistelli, Giulio Rosa Parisi, Roger T Webb, Christopher Tzuyung D Kou, Yola Moride. (France) Formoso, Danilo Fusco, Marina Davoli, EM Griffiths, Darren M Ashcroft. (United OUTPUL Study Group. (Italy) Kingdom) 152. Mapping of Existing Disease-Specific Data Sources in Latin America for the 134. Risk of Cardiovascular Events After 142. Ophthalmic Adverse Effects In Cancer Conduct of Real-World Studies [1041] Glucocorticoid Treatment: A 24-Year Patients Treated With MEK Inhibitors: A Aurore Bergamasco, Teigna Arredondo- Population-Based Cohort Study [1022] Meta-Analysis [1031] Bisono, Gerardo Machnicki, Camilo Erzsébet Horváth-Puhó, Kristina Carlos Alves, Inês Ribeiro, Ana Obando, Julio Azzael Hernandez-Moran, Laugesen, Uffe Heide-Jørgensen, Jens Penedones, Diogo Mendes, Francisco Alan Andryc, Xiaoying Wu, Louis Pozzo, Otto L Jørgensen, Olaf M Dekkers, Irene Batel Marques. (Portugal) Surendranath Gutta, Yola Moride. (France) Petersen, Henrik T Sørensen. (Denmark) 143. Impact Of Anti-Inflammatory Drugs On 153. Mapping Of Existing Disease-Specific 135. Risk of Idiopathic Pulmonary Fibrosis Risk Of Depression And Anxiety After Data Sources For The Conduct Of (IPF) in Patients Exposed to Statins and Intensive Care Requiring Mechanical Pharmacoepidemiologic Studies In Other Lipid Lowering Agents [1023] Ventilation [1032] China [1042] Daina B Esposito, Crystal N Holick, Clara R Medici, Søren D Østergaard, Chung Yan Yuen, Aurore Bergamasco, Macarius Donneyong, Vibha Desai, Henrik T Sørensen, Lars Pedersen, Teigna Arredondo-Bisono, Yola Moride. Stephan Lanes. (United States) Christian F Christiansen. (Denmark) (Canada) 136. Increased Risk of Stroke with Co- 144. Utilization of Belatacept in Renal Informatics Exposure of Acute Respiratory Infection Transplant Recipients in USA [1033] and NSAIDs Use: A Nationwide Case- Xuerong Wen, Karl L Womer, Michael J 154. Assessment and Comparison of Crossover Study [1024] Casey, Alsonso H Santos, Abraham G Competitiveness Between Clinical Trial Yao-Chun Wen, Fei-Yuan Hsiao, Li-Jiuan Hartzema. (United States) Protocols: A Simulation Approach Using Shen, Cheng-Chung Fang. (Taiwan) Publicly Available Registered Clinical 145. Future Perspectives of Study of Acute Trials [1043] 137. The Key Role of Inhaler Use in COPD: A Liver Transplant (SALT): What Is Going Andrew Wilson, Sergey Krikov, Craig Real-Life Study [1025] on Since 2007? [1034] Parker, Allise Kamauu, Rebekah K Mathieu Molimard, Chantale Raherison, Sinem Ezgi Gulmez, Séverine Lignot- Paredes, Aaron WC Kamauu. Stéphanie Lamarque, Séverine Lignot- Maleyran, Sophie Micon, Régis Lassalle, Maleyran, Aurélie Balestra, Anais Chartier, Jérémy Jové, Nicholas Moore. (France) 155. Progress and Future of Medical Régis Lassalle, Cécile Droz-Perroteau, Information Database Network (MID- Pierre-Olivier Girodet. (France) 146. SALT-III: Prospective Study of Drug- NET®) Project [1044] Exposed Acute Liver Failure (ALF) Yu Matsuzaki, Fumitaka Takahashi, 138. LABA Safety in Actual Medical Practice: [1035] Mitsune Yamaguchi, Yoshiaki Uyama, On Results from the Longitudinal, Time- Sinem Ezgi Gulmez, Séverine Lignot- Behalf of MID-NET Project Group. (Japan) Dependent Analyses of the ASTROLAB Maleyran, Sophie Micon, Régis Lassalle, Data [1026] Jérémy Jové, Nicholas Moore. (France) 156. A Framework for Rapid Medical Product Eric H Van Ganse, Laurent Laforest, Safety Assessment: FDA’s Sentinel Sandrine Herbage, Flore Jacoud, 147. Comparison of Outcomes Following a Toolkit [1045] Alexandra Dima, Nathalie Texier, Switch from a Brand to an Authorized Elizabeth Cavagnaro, Hannah Katcoff, Montserrat Ferrer, Marijn de Bruin, The vs. Independent Generic Drug [1036] Candace Fuller, Tiffany S Woodworth, ASTROLAB Group. (France) Richard A Hansen, Jingjing Qian, Richard Jennifer R Popovic, Nicolas Beaulieu, Berg, James Linneman, Enrique Seoane- April Duddy, Eric Gravel, Erick Moyneur, 139. Development of a Risk Model for Vazquez, Sarah Dutcher, Saeid Raofi, Sengwee Toh, Jeffrey Brown. (United Uncontrolled Pneumonia in Hospitalized Peggy Peissig. (United States) States) Patients [1027] Yoonyoung Choi, Benjamin Staley, Carl 148. Potential Prescribing Omissions Among 157. Lessons Learned from the Assembly of Henriksen, Gigi Lipori, Babette Brumback, older US Adults According to START the SENATOR Drug File [1046] Almut G Winterstein. (United States) Criteria [1037] Michael McCarthy, Shane Cullinan, Denis Marcela Jiron, Virginia Pate, Laura C O’Mahony, Stephen Byrne. (Ireland) Other Safety & Effectiveness Hanson, Michele Jonsson Funk, Til Stürmer. (Chile) 158. An eResearch Query Definition Library: 140. Severe Acute Liver Injury Risk Among Methods and Value [1047] Temozolomide Treated Brain Cancer 149. Stevens-Johnson Syndrome and Toxic Maggie Lohnes, Craig Parker, Aaron WC Patients in the HealthCore Integrated Epidermal Necrolysis: A Population- Kamauu. (United States) Research Environment [1028] Based Case-Control Study [1038] Scott C Quinlan, Anne Deitz, Vibha Desai, Noel C Frey, Michael Bodmer, Andreas 159. Integrating ICD-10-CM Coding into Jinghua He, Crystal N Holick, Stephan Bircher, Susan S Jick, Christoph R Meier, RWE Research Using US Healthcare Lanes. (United States) Julia Spoendlin. (Switzerland) Databases: Challenges for Valid Research Practices [1048] 150. Stevens - Johnson Syndrome Associated Irene S Cosmatos, Rebecca J Levin, with Dimenhydrinate [1039] Michael Bulgrien, Jamie Reifsnyder. Sareeya Wechwithan. (Thailand)

32nd

90 POSTER SESSION C: Sunday, August 28 | 8:00am - 1:45pm

160. Assessing the Gaps in Turning Data 169. Association Between Quality of life 179. Quality of Life of Patients with Diabetes into Insights Using Real World Evidence and Medication Use for Baby Boomers Mellitus Types 1 and 2 from a Reference [1049] and Older People, by Cardiovascular Health Care Center in Minas Gerais, Sharon Hensley Alford, Brandon Fiegoli, Disease Status [1058] Brazil [1068] Sarah M Miller, Karen E Wells. (United Bee Leng Per, Anne Taylor, Tiffany Gill. Adriana R Mata, Brian Godman, Juliana States) (Australia) Álvares, Leonardo M Diniz, Michael Ruberson, Bárbara R Alvernaz, Augusto A 161. Comparative Assessment of US 170. Do GPs Adhere to the Guidelines? A Guerra Júnior, Mariangela Leal Cherchiglia, Healthcare Databases and Linkage Study Based on Statins Prescriptions Eli Iola Gurgel Andrade, Francisco de Capabilities for Pharmacoepidemiology [1059] Assis Acurcio. (Sweden) Studies [1050] Irene Petersen, Federico Ricciardi, Irwin Deborah Casso, Karin E Johnson, Syd Nazareth, Gianluca Baio. (United Kingdom) 180. Impact of Patient Counseling on Phillips, Susan A Oliveria. (United States) Medication Adherence Behavior and 171. Costs Analysis Of Traditional And New Quality of Life in Diabetics of Telangana 162. Impact of the US ICD-9 to ICD-10 Code Oral Anticoagulants: A Retrospective Region [1069] Transition on Clinical Research [1051] Analysis In A Local Health Authority In varun Talla, B Rajashekar, P Anusha, Aaron WC Kamauu, Maggie Lohnes, Kyle Northern Italy [1060] Venkateshwar Rao Jupally, Anvesh P Paredes, Scott DuVall. (United States) Silvia Lucchi, Alfredo Cocci, Salvatore Cheera, Sanjeev Kumar Subudhi, Mannino. (Italy) Satyanaraya Patnaik. (India) 163. Leveraging NLP-Assisted Semi- Automated Chart Review for Detecting 172. The Healthcare Costs of Heart Failure 181. Cost-Effective Approach in Rare Clinical Events from Narrative During the Last Five Years of Life: A Management of Diarrhoea in Nigeria: A Clinical Notes [1052] Retrospective Cohort Study [1061] Decision Analytical Model [1070] Aaron WC Kamauu, Nicole Bailey, Andrew William Hollingworth, Mousumi Biswas, Charles E Okafor, Obinna I Ekwunife. Wilson, Patrick Alba, Olga Patterson, Scott Rachel Maishman, Mark Dayer, Theresa (Nigeria) DuVall. McDonagh, Sarah Purdy, Barnaby Reeves, Chris Rogers, Rachael Williams, Maria 182. Resource Utilization of Adult Patients 164. AugMed; Augmented Reality Pufulete. with Sporadic Angiomyolipoma in the Application for Unobtrusive Medical Netherlands [1071] Adherence Measurement [1053] 173. Racial Differences in Productivity Loss Francis Vekeman, Matthew Magestro, Paul Panagiotis Antoniou, Eirini Apostolidou, Attributable to Rheumatoid Arthritis Karner, Jonathan Fortier, Mei Sheng Duh, Dimitrios Kouvelas, Panagiotis Bamidis. Among Patients Taking Disease- Bernard A Zonnenberg. (Canada) (Greece) Modifying Antirheumatic Drugs (DMARDs) [1062] 183. Costs with Medicines and Services 165. Medication Safety Infrastructure at Laura M Bozzi, Priyanka Gaitonde, Fadia in the Treatment by Patients with Saudi Hospitals: A Descriptive Cross- Shaya, Sarah E Tom. (United States) Schizophrenia [1072] Sectional Pilot Study [1054] Wallace Breno Barbosa, Augusto Afonso Mohammed Alsultan, Mohamed Alkelya. 174. Patient Monitoring – the Hidden Costs Guerra Junior, Rosangela Maria Gomes, (Saudi Arabia) of Treatment with Antipsychotics [1063] Juliana Oliveira Costa, Livia Lovato Pires Mariëtte Nederlof, Geert WJ Frederix, Lemos, Francisco Assis Acurcio. (Brazil) 166. Representativeness of Electronic Lennart J Stoker, Wouter W van Solinge, Medical Records to Support Novelty (A Toine CG Egberts, Eibert R Heerdink. 184. Some Statistical Considerations in Novel Observational Longitudinal Study (Netherlands) Estimating a Disease Progression of Patients with Asthma and/or COPD) Model for Chronic Obstructive [1055] 175. Assessment of Predictive Ability of Pulmonary Disease (COPD) [1073] Xia Wang, Alecka Sveréus, Josh Hiller, SLANSS and ID Pain Questionnaires in Alex Exuzides, Chris Colby, Andrew H Diana Wong, Paola Nasuti, Harvey Jenner, Assessing Pain Related Outcomes in Briggs, Nancy Riseborough, Timothy Alexia McKenney, Aaron Kamauu, Kyle Chronic Non-Cancer Neuropathic Pain Baker, Afisi Ismaila. (United States) Martin Flickinger, Maria Gerhardsson de Conditions [1064] Verdier. (United States) Rambabu Vatte, Dipika Bansal, Babita 185. What Are Patient’s Willing to Pay for Ghai, Kapil Gudala. (India) Pharmacogenomic Testing? [1074] HEOR Suzette J Bielinski, Jennifer St. Sauver, 176. A Qualitative Study to Develop Patient Janet E Olson, Mark L Wieland, Carolyn R 167. The Effect of Intensified Anti Materials on Opioid Use in Orthopaedic Vitek, Elizabeth J Bell, Michaela E McGree, Tuberculosis Therapy on Patient’s Surgery [1065] Debra J Jacobson, Jennifer B McCormick, Health Status (Symptoms, Activity and David Smith, Jennifer Schneider, Jennifer Paul Y Takahashi, John L Black, Pedro Respiratory Impact) [1056] Kuntz, Jill Mesa, Xiuhai Yang, Amanda J Caraballo, Richard Sharp, Timothy J Jarir At Thobari, Bryan CG Wibisono, Dyah Petrik, Lynn DeBar. (United States) Beebe, Richard Weinshilboum, Liewei Perwitasari, Ully A Mulyani. (Indonesia) Wang, Veronique L Roger. (United States) 177. What Is the Evidence on Financial 168. Patient-Reported Outcomes in Adults Toxicity of Cancer Treatment? [1066] 186. Policy Options to Lower Prescription Suffering from Acute Coronary Emre Yucel, Aylin Yucel. (United States) Drug Prices in the United States [1075] Syndrome: A Comprehensive Analysis G Caleb Alexander, Jeromie Ballreich, 178. Measuring Outcomes Among from the Pharmacoepidemiology Mariana P Socal, Taruja Karmarkar, Metastatic Prostate Cancer Patients General Research eXtension System Antonio Trujillo, Jeremy Green, Joshua in Administrative Claims Data Using (PGRx-3) [1057] Sharfstein, Gerard Anderson. (United the Center for Medicare and Medicaid Jesus Cuervo, Clementine Nordon, Michel States) Rossignol, Nicolas Morisot, Jacques Services Oncology Care Model [1067] Benichou, Nicolas Danchin, Lucien Debra E Irwin, Liisa A Palmer. Abenhaim, Lamiae Grimaldi. (Spain) (United States)

32nd

91 POSTER SESSION C: Sunday, August 28 | 8:00am - 1:45pm

187. The Role of Real-World Data in Single 197. Use of Proton Pump Inhibitors Among 204. Characteristics of Patients Prescribed Technology Appraisal Submissions in Adults: A Danish Nationwide Drug Prucalopride versus an Active the United Kingdom [1076] Utilization Study [1086] Comparator in England, Wales, and Nathalie A Waser, Sarah M Goring, Sisi Anton Pottegård, Anne Broe, Jesper Northern Ireland [1093] Wang, Rei Tao, Ellen E Korol. (Canada) Hallas, Ove BS de Muckadell, Annmarie T Leah J McGrath, Ana Ruigomez, Estel Lassen, Anders B Lødrup. (Denmark) Plana, Joan Fortuny, Luis-Alberto Garcia- 188. Abstract Withdrawn [1077] Rodriguez, Cristina Rebordosa, Cristina 198. Utilization Of Tacrolimus And Varas-Lorenzo, Ryan Ziemiecki, Alicia 189. Assessment of Pharmacist Pimecrolimus In Europe: Results W Gilsenan, Elizabeth Andrews. (United Interventions of Drug Related Problems from the JOint European Longitudinal States) Among Patients with Impaired Renal Lymphoma and Skin Cancer Evaluation Function [1078] (JOELLE) Study [1087] 205. Influence of Health Insurance Policy Savitha R Sanathan, Madhan Ramesh, Josephina G Kuiper, Myrthe PP van on Oral Anti-Hyperglyecemic Agents in Manjunath S Shetty. (India) Herk-Sukel, Jordi Castellsague, Anton Korean Diabetic Patients [1094] Pottegard, Ingegard A Berglind, Daniel Nanhee Park, Bo Ram Yang, Joongyub DUR - Trends Dedman, Brian Calingaert, Jesper Hallas, Lee, Nam-Kyong Choi, Ye-Jee Kim, Jong- Anders Sundstrom, Arlene M Gallagher, Mi Seong, Mi-Sook Kim, Kyoung-eun 190. New Chronic Disease Medication James A Kaye, Carolina Pardo, Kenneth Kwon, Xue-Mei Jin, Byung-Joo Park. Prescribing by Nurse Practitioners, J Rothman, Suzana Perez-Gutthann. Physician Assistants, and Primary Care (Netherlands) 206. Pattern of Use of Incertin-Based Physicians: A Cohort Study [1079] Medicines in a Large Sample of the Zachary Marcum, Johanna Bellon, DUR - Trends in Alimentary Italian General Population [1095] Jie Li, Walid Gellad, Julie Donohue. Giuseppe Roberto, Francesco Barone (United States) and Metabolic Adesi, Francesco Giorgianni, Valeria Pizzimenti, Carmen Ferraiolo, Francesco 191. Electronic Medication Histories: 199. Impact of Safety Warning on Lapi, Paolo Francesconi, Gianluca Trifirò, Highlighting Potential Adverse Drug Domperidone Prescribing in Ireland Elisabetta Poluzzi, Fabio Baccetti, Rosa Events [1080] [1088] Gini. (Italy) Gillian Bartlett, Cristina Longo, Irina Mary Teeling, MaryJo MacAvin, Kathleen Kudrina, Brenda MacGibbon. (Canada) Bennett. (Ireland) 207. Impact of Pioglitazone Withdrawal in France: A Study Using Data from the 192. Longitudinal Trend and Forecast in 200. Initiation of Anti-TNF Therapy in Patients with Inflammatory Bowel National Healthcare Insurance System Taiwan Pharmaceutical Industry and [1097] International Trade (2009-2018) [1081] Disease in France Between 2011 and 2013: A Nationwide Study Based on Antoine Pariente, Yohann Mansiaux, Jason C Hsu, Christine Y Lu. (Taiwan) Medico-Administrative Databases Francesco Salvo, Cecile Pageot, Andy 193. Trends in the Use of Prescription [1089] Smith, Bernard Bégaud. (France) Medications with Risk Evaluation and Pierre-Olivier Blotière, Jérémie Rudant, 208. Nationwide Trends in Glucose-Lowering Mitigation Strategies Among U.S. Amélie Barré, Antoine Racine, Alain Weill, Drug Use in Denmark, 1999-2014 [1098] Adults: 2003-2004 to 2011-2012 [1082] Franck Carbonnel, François Alla. (France) Diana H Christensen, Jørgen Rungby, Jenny Guadamuz, Caleb Alexander, Dima 201. Treatment Patterns of Thiopurines in Reimar W Thomsen. (Denmark) M Qato. a Danish Population Diagnosed with 209. Treatment of Polycystic Ovary Inflammatory Bowel Disease: A Drug 194. Trends in Medicines Procurement by Syndrome in UK Primary Care 2004- Utilization Study [1090] the Brazilian Federal Government from 2012 [1099] 2006 to 2013 [1083] Marie S Kristensen, Thora M Kjærulff, Tao Ding, Gianluca Baio, Irene Petersen, Lau C Thygesen, Nikoline N Knudsen, Tatiana Chama Borges Luz, Claudia Paul Hardiman, Cormac Simmons. (United Anders Green, Vibeke Andersen, Annette Garcia Serpa Osorio-de-Castro, Rachel Kingdom) Magarinos-Torres, Bjorn Wettermark. K Ersbøll. (Denmark) (Brazil) 202. Drug Utilization Patterns of Tumor DUR - Trends in Anti-infectives Necrosis Factor Inhibitor Agents in a 195. Good Practice Guidelines for Designing, 210. Increase In Prescribing Of Systemic Population with Inflammatory Bowel Conducting, Analyzing and Reporting Tetracyclines And Isotretinoin For Disease from 2009 to 2014 in Denmark Cross-National Comparison Drug Treatment Of Acne Vulgaris In [1091] Utilization Studies [1084] Norwegian Adolescents From 2005 To Yared Santa-Ana-Tellez, Luisa Ibañez, Thora M Kjærulff, Marie S Christensen, 2014 [1100] Annette K Ersbøll, Nikoline N Knudsen, Carlos Durán, Elena Ballarín, Mònica Ingvild Odsbu, Randi Selmer, Cecilia Anders Green, Vibeke Andersen, Lau C Sabaté, Aukje K Mantel-Teeuwisse, Stålsby Lundborg, Hege Salvesen Blix. Thygesen. (Denmark) Veronika J Wirtz, Monique Elseviers, Björn (Sweden) Wettermark, Robert H Vander Stichele. 203. Dispensing Patterns of Prescription- (Netherlands) 211. Retrospective Study on Antibiotics Only Antiobesity Preparations in South Usage Employing Who ATC DDD Africa [1092] 196. Sale of Phthalate Containing Drugs in Methodology [1101] Denmark from 2004 to 2012 [1085] Ilse Truter. (South Africa) Puppala Krishna Geetika, Surulivelrajan Anne Broe, Zandra N Ennis, Jesper Hallas, Mallayasamy, Chiranjay Mukhopadhyay. Thomas Ahern, Anton Pottegaard, Per (India) Damkier. (Denmark) 212. Travel Time to Pharmacy Influence the Use of Antibiotics in Norway [1102] Kristian Svendsen, Håvard Kongsgård, Pål Haugen, Lars Småbrekke. (Norway) 32nd

92 POSTER SESSION C: Sunday, August 28 | 8:00am - 1:45pm

213. Antibiotic Prescribing Trends for 223. Trends in Erlotinib Use for Non-Small 232. Differences in Recording of Urinary Tract Infections (UTI) in a Cell Lung Cancer, 2007-2012 [1113] Characteristics Among Patients U.S. Network of Primary Care Clinics Yi-Ting Chou, Stacie B Dusetzina. (United Prescribed Oral Anticoagulants Using Serving Low-Income Populations [1103] States) Primary Care and Cardiologist Data in Miriam R Elman, Gregory B Tallman, David Germany [1122] T Bearden, Jessina C McGregor. (United 224. Oral Anticancer Drugs Use in France: A Shuk-Li Collings, Michelle Johnson, States) Population-Based Study [1114] Sebastian Kloss, David Evans, Andrew Pauline Bosco-Levy, Paul de Boissieu, Maguire, Cinira Lefèvre. (United Kingdom) 214. Antibiotic Prescribing in Hospital, a Julien Bezin, Annie Fourrier-Réglat. Comparison Point Prevalence Study (France) 233. Differences in Statin Users and Non- Between Ireland and Norway [1104] Users with Bacteremia [1123] Kathrine Berggrav, Trude E Flatebø, 225. Uptake and Cost of Capecitabine Ajinkya M Pawar, Aisling R Caffrey. (United Kirsten K Viktil, Dag Berild, Eoghan O’Neill, versus 5-FU Among Commercially- States) Hilary Humphreys, Hege S Blix. (Norway) Insured Colorectal Cancer Patients [1115] 234. Concurrent Use of Proton Pump 215. Knowledge, Attitude, and Perception Ashley L Cole, Hanna K Sanoff, Stacie B Inhibitor and Clopidogrel Plus Aspirin of Physicians Towards Prescribing Dusetzina. (United States) in the U.S. Ambulatory Setting Between Antibiotics Use for Upper Respiratory 2003 and 2011 [1124] Tract Infections in Holy Makkah, 226. Consumption and Expenditure of Non- Ju Hyeun Kim, Abraham G Hartzema. Kingdom of Saudi Arabia [1105] Targeted and Targeted Cancer Drugs in (United States) Abdul Haseeb, Mahmoud Mohamed Ecuador [1116] Ahmed Mohamed, Mahmoud E. Elraggal, Carlos E Durán, Robert Vander Stichele, DUR - Trends in GU and Hani Saleh Faidah, Fahad Saleem, Thierry Christiaens, Monique Elseviers. Ejazullah Cheema, Mohamed Azmi (Ecuador) Hormones Hassali. (Saudi Arabia) 235. Sex Differences in Factors Predicting 227. A Comparative Study to Evaluate the Type of Bladder Antimuscarinics Treatment Patterns & Resulting Utility 216. Trends in Utilization of Antibiotics in Initiated in Medicare Nursing Homes in Patients of Head & Neck Cancers Norway - Do We Reach the National Residents [1125] Goals? [1106] Under Private Payment Scheme and Government Reimbursement Scheme Daniela C Moga, Qishan Wu, Pratik Doshi, Kari Husabø, Olaug Fenne, Sissel Torheim, Amie J Goodin. (United States) Hege Salvesen Blix, Kari Furu. (Norway) [1117] Himanshu Patel, Parthasarathi 236. Patterns of Use of Antimuscarinic 217. Trends In The Utilization Of Allergy Gurumurthy, YS Madhavi, MS Drugs to Treat Overactive Bladder Medications [1107] Vishveshwara, Ramesh Madhan. (India) in Denmark, Sweden and the United Hege S Blix, Kai-Håkon Carlsen, Åsmund Kingdom [1126] Reikvam. (Norway) 228. Identification & Resolving of Medication Related Problems Associated With Andrea V Margulis, Marie Linder, Alejandro 218. Dispensing Patterns of Anthelmintic Management of Co-Morbidities in Arana, Anton Pottegård, Ingegärd Drugs by a Community Pharmacy Cancer Patients — A Role of Medication Anveden-Berglind, Christine L Bui, Nina Group in South Africa [1108] Therapy Management Service [1118] Kristiansen, Shahram Bahmanyar, Lisa J McQuay, Willem Jan Atsma, Kwame Ilse Truter, Liana Steenkamp. (South Africa) Himanshu Patel, Parthasarathi Appenteng, Billy Franks, Stefan de Vogel, Gurumurthy, Ramesh Madhan. (India) 219. NOACs: Are We Prescribing Milbhor D’Silva, Susana Perez-Gutthann, Appropriately? [1109] DUR - Trends in Jesper Hallas. (Spain) Sinéad Keohane, Vicki Sandys, Michael Cardiovascular 237. Impact of the Introduction of Newer Barry. (Ireland) Long Acting Reversible Contraceptive 229. Impact of Regulatory Action on 220. General Pharmacological Treatments (LARC) Methods on LARC Use in a Prescribing of Renin-Angiotensin Preceding A Primary Chronic Immune Commercially Insured Population [1127] System Blockers in the UK [1119] Thrombocytopenia Diagnosis [1110] Amy Law, Dominic Pilon, Richard Lynen, Craig Allen. (United Kingdom) Lukas Löfling, Marie Linder, Charlotta François Laliberté, Laurence Gozalo, Patrick Lefebvre, Mei S Duh. (Canada) Ekstrand, Honar Cherif, Helle Kieler, 230. Antiplatelet Treatment and Long- Shahram Bahmanyar. (Sweden) Term Mortality After Acute Myocardial 238. Abstract Withdrawn [1128] Infarction in Real-World Data [1120] DUR - Trends in Cancer Dahlia Weitzman, Lori D Bash, Ofer 239. Use Of Cyproterone Acetate/ Ethinylestradiol In The United Kingdom 221. Evolving Australian, and Northern Sharon, Assi Milwidsky, Gabriel Chodick, Prior To And Following Recent Updated European, Utilisation Patterns Varda Shalev. (Israel) Guidance: Prescribing Patterns Using A for Immunosuppressants After 231. Treatment Changes Among Users National Primary Care Database [1129] Transplantation [1111] of Non-Vitamin K Antagonist Oral Lucía Cea Soriano, Alex Asiimwe, Hissba Kyle M Gardiner, Susan E Tett, Christine E Anticoagulants in Atrial Fibrillation Tus-Saboor Khan, Vita Beckert, Ulrike Staatz. (Australia) [1121] Wissinger-Graefenhahn, Luis A García 222. Trends in Prevalence of Lung Cancer Maja Hellfritzsch, Steen E Husted, Erik Rodriguez. and Targeted Therapies Utilization L Grove, Lotte Rasmussen, Birgitte K 240. Cyproterone Acetate/Ethinylestradiol for Lung Cancer Treatment in Taiwan Poulsen, Søren P Johnsen, Jesper Hallas, Prescribing in the UK [1130] (2004-2013) [1112] Anton Pottegård. (Denmark) Lucía Cea Soriano, Alex Asiimwe, Hissba Jason C Hsu, Chen-Fang Wei, Christine Y Tus-Saboor Khan, Vita Beckert, Ulrike Lu. (Taiwan) Wissinger-Graefenhahn, Luis García Rodriguez.

32nd

93 POSTER SESSION C: Sunday, August 28 | 8:00am - 1:45pm

DUR - Trends in 249. Persistence of Antipsychotic 257. Trend and Prescription Patterns of Medications in Patients with Antipsychotic Medications (APMs) Musculo-Skeletal Schizophrenia: A Cross-National Study in Asia and US: A Cross-National 241. Use of Emergency Contraceptives in from the Asian Pharmacoepidemiology Comparison Study [1147] Two European Countries [1131] Network (AsPEN) [1139] Chien-Chou Su, Edward Chia-Cheng Lai, Ria Benko, Claudia Furtado, Teresa Risso, Chien-Chou Su, Edward Chia-Cheng Lai, Kenneth KC Man, Kiyoshi Kubota, Yukari Maria Matuz. (Hungary) Kenneth KC Man, Kiyoshi Kubota, Yukari Kamijima, Shinya Kimura, Paul Stang, Kamijima, Shinya Kimura, Paul Stang, Martijn Schuemie, Patrick Ryan, Yinghong 242. Characteristics of New Users of Martijn Schuemie, Patrick Ryan, Yinghong Zhang, Ian CK Wong, Soko Setoguch- Osteoporosis Drugs Changed Over Zhang, Ian CK Wong, Soko Setoguch- Iwata, Yea-Huei Kao Yang. (Taiwan) Time, Yet High Compliance with Iwata, Yea-Huei Kao Yang. (Taiwan) Therapy Remained Stable [1132] 258. Antipsychotic Use in Dementia: A Joann K Ban, Giulia P Consiglio, Bochao 250. Long-Acting Injectable Antipsychotics: Comparison Between Three European B Hao, Marina Simeonova, Andrea M Patterns of Use and Determinants of Countries [1148] Burden, Suzanne M Cadarette. (Canada) Treatment Failure in a Northern Italy Janet Sultana, Francesco Giorgianni, Area [1140] Ingrid Leal, Miram Sturkenboom, Gianluca 243. Early Analgesics Among Workers’ Lorenzo Berardi, Ippazio C Antonazzo, Trifirò’. (Italy) Compensation Claimants with Carlo Piccinni, Antonella Piazza, Emanuel Low Back Pain from 1998-2009: A Raschi, Elisabetta Poluzzi. (Italy) 259. Antipsychotic Prescription Trend in Population-Based Study in British Hong Kong from 2004 to 2014 [1149] Columbia, Canada [1133] 251. Incident Use of Benzodiazepines in Shijian Lao, Esther W Chan, Kenneth KC Nancy Carnide, Sheilah Hogg-Johnson, France from 2006 to 2012: A Population- Man, Ian CK Wong. Andrea Furlan, Pierre Côté, Mieke Based Study [1141] 260. Antipsychotic Prescribing in a Tertiary Koehoorn. (Canada) Anne Bénard-Laribière, Pernelle Noize, Elodie Pambrun, Fabienne Bazin, Hélène Hospital Under the Financial Crisis in 244. Intra-Articular Injection Switching Verdoux, Marie Tournier, Bernard Bégaud, Greece [1150] Patterns Among Patients with Antoine Pariente. (France) Paraskevi Papaioannidou, Paschalina Knee Osteoarthritis: Data from the Kasviki, Nikolaos P Moschopoulos, Osteoarthritis Initiative [1134] 252. Utilization Patterns of Antidepressants Ioannis Nimatoudis. (Greece) Shao-Hsien Liu, Catherine E Dubé, Jeffrey in France from 2007 to 2012: A 261. Time-to-First Discontinuation in B Driban, Timothy E McAlindon, Charles B Population-Based Study [1142] New Users of Second Generation Eaton, Kate L Lapane. (United States) Anne Bénard-Laribière, Antoine Pariente, Elodie Pambrun, Fabienne Bazin, Pernelle Antipsychotics in Older People [1151] 245. Factors Associated with Use of Disease Noize, Hélène Verdoux, Bernard Bégaud, Henry C Ndukwe, Prasad S Nishtala. (New Modifying Agents for Rheumatoid Marie Tournier. (France) Zealand) Arthritis in the National Ambulatory Medical Care Survey (NAMCS) [1135] 253. Trends and Prescription Patterns of 262. Prevalence, Time Trends and Utilization Patterns of Psychotropic Priyanka Gaitonde, Laura M Bozzi, Fadia T Anti-Alzheimer Drugs Used in Japan Polypharmacy: Evidence from Children Shaya. (United States) from 2010 to 2015: A Descriptive Study Based on Pharmacy Claims Databases and Adolescent Medicaid Beneficiaries, 246. Trends of Allopurinol Use in Norway [1143] 1999-2010 [1152] and in Hungary [1136] Kimiko Kadohara, Izumi Sato, Yuko Doi, Rene Soria-Saucedo, Xinyue Liu, Juan Maria Matuz, Hege Salvesen Blix, Ria Masaru Arai, Yosuke Fujii, Toshiyuki Hincapie-Castillo, Regina Bussing, Almut Benko, Peter Doro, Gyongyver Soos. Matsunaga, Koji Kawakami. (Japan) G Winterstein. (United States) (Norway) 254. Evaluation Of Antidepressant Drug Use 263. Prevalence, Time Trends and In Populations In the UK and Quebec Utilization Patterns of Psychotropic DUR - Trends in Neurological [1144] Polypharmacy: Evidence from Adult 247. Psychotropic Drug Use in Subjects Therese M Sheppard, William G Dixon, Medicaid Beneficiaries, 1999-2010 Presenting with a Cancer Diagnosis Nadyne Girard, Robyn Tamblyn. (United [1153] [1137] Kingdom) Rene Soria-Saucedo, Xinyue Liu, Juan Penichon Marine, Diaz Fabienne, Pambrun Hincapie-Castillo, Regina Bussing, Almut Elodie, Fourrier-Reglat Annie, Tournier 255. Use of Antidepressants Under the Winterstein. (United States) Marie. (France) Financial Crisis in Greece [1145] Paraskevi Papaioannidou, Maria 264. Comparing the Increase in the Cost of 248. Predicting Rehospitalization in Patients Michailidou, Achilleas Ntaralas, Stamatia Drug Prices Among Multiple Sclerosis Treated with Antipsychotics: A Michailidou. (Greece) Drugs: Anticipated vs. Market Prices Prospective Observational Study [1138] Between 2010-2015 [1154] Heshu Abdullah-Koolmees, Helga 256. Assessment of the Impact of Jonathan Campbell, Brandi Vollmer, John Gardarsdottir, Lotte A Minnema, Kamjar Medical Fee Schedule Revision on Corboy, Timothy Vollmer. (United States) Elmi, Lennart J Stoker, Judith Vuyk, Polypharmacy of Psychotropic Agents 265. The Nudge, the Push and the Laurette E Goedhard, Toine CG Egberts, in Japan [1146] Mole: Management of Long-Acting Eibert R Heerdink. (Netherlands) Rie Nishikino, Chie Ito, Shiori Tsuchiya, Yoshie Onishi. (Japan) Oxycodone [1155] Kevin J Friesen, Shawn C Bugden. (Canada)

32nd

94 POSTER SESSION C: Sunday, August 28 | 8:00am - 1:45pm

266. Exploring Factors linked to In-Patient 276. Characteristics of New Users of Hospitalisation Amongst Non-Cancer Aclidinium Bromide in the United Pain Patients Prescribed Long-Term Kingdom [1166] Strong Opioids in UK Primary Care Cristina Rebordosa, Cristina Varas- [1156] Lorenzo, Jordi Castellsague, Estel Plana, Muna Adan, Li-Chia Chen, Roger Knaggs. Christine Bui, Jaume Aguado, Esther (United Kingdom) Garcia Gil, Susana Perez-Gutthann. (Spain) 267. Non-Buprenorphine Opioid Utilization Among Patients Using Buprenorphine/ 277. Predictors for the Prescription of Naloxone [1157] Aclidinium Bromide as Compared to Matthew Daubresse, Brendan Saloner, G Tiotropium Bromide Using German Caleb Alexander. (United States) Claims Data [1167] Nadine Wentzell, Bianca Kollhorst, Tania 268. Opioid Utilizations in Patients with Schink. Diabetes [1158] GYeon Oh, Pratik A Doshi, Daniela C 278. Patterns of Roflumilast Use for the Moga. (United States) Treatment of COPD Across Three Distinct Populations: Findings from the 269. Impact of State Laws to Reduce Roflumilast Pass Study [1168] Prescription Drug Abuse on High-Risk Caitlin A Knox, William K Mountford, Elise Opioid Prescribers [1159] Kaufman, Vasili Mushnikov, Juha Mehtälä, Hsien-Yen Chang, Tatyana Lyapustina, Nadine Wentzell, Bianca Kollhorst, Tania Lainie Rutkow, Matthew Daubresse, Matt Schink, Pasi Korhonen, Fabian Hoti, Richey, Mark Faul, Elizabeth A Stuart, G Gunnar Johansson, Edeltraut Garbe. Caleb Alexander. (United States) (United States)

270. Drugs Used in Intentional Drug 279. COPD Patients Initiating Roflumilast Overdose: Findings from the National in Sweden, Germany and the United Self-Harm Registry Ireland [1160] States: Findings from the Roflumilast Caroline Emer Daly, Eve Griffin, Roger PASS Study [1169] Webb, Ella Arensman. (Ireland) Fabian Hoti, Vasili Mushnikov, Juha Mehtälä, Nadine Wentzell, Bianca DUR - Trends in Respiratory Kollhorst, Tania Schink, Edeltraut Garbe, William K Mountford, Caitlin Knox, Elise 271. Asthma Hospitalization Differences Kaufman, Gunnar Johansson, Pasi Between Generics and Brand of Korhonen. (Finland) Montelukast [1161] Yasser Albogami, Abraham Hartzema. 280. Treatment of Patients with Pulmonary (United States) Tuberculosis in China [1170] Minfu He, Jian Du, Yongjing Zhang, 272. Trends in Asthma Medications Use in Yuhong Liu, Liang Li. (China) the United States from 2008-2014 [1162] Yasser Albogami, Abraham Hartzema. 281. Prevalence and Factors Associated (United States) with Prescription of Overlapping Monotherapy Inhalers of 273. The Role of Patient Characteristics in Corticosteriods and Long-Acting Beta- Dosage Form of ICSLABA Prescriptions Agonists Among US Veterans [1171] [1163] Kristine E Lynch, Benjamin Viernes, Olga Kristine E Lynch, Jill S Helmke, Olga V V Efimova, Jill Helmke, Scott L DuVall. Efimova, Scott L DuVall. (United States) (United States)

274. Montelukast Use 1998-2015 - A Danish 282. Hospitalization and Length of Stay Nationwide Drug Utilization Study Among Patients with Non-Valvular [1164] Atrial Fibrillation Taking Dabigatran or Daniel P Henriksen, Anders Christiansen, Warfarin: A Population-Based Cohort Jesper R Davidsen, Christian B Laursen, Study [860] Per Damkier, Jesper Hallas, Anton Wallis CY Lau, Xue Li, Ian CK Wong, Pottegård. (Denmark) Esther W Chan. (Hong Kong)

275. Variability in the Consumption 283. Discrete Event Simulation for of Inhaled Beta2-Adrenergic Facilitating Between-Study Bronchodilators in 10 European Comparisons [879] Countries, 2007-2011 [1165] Mehdi Najafzadeh, Sebastian Pili Ferrer, Mònica Sabaté, Elena Ballarín, Schneeweiss, Niteesh Choudhry, Shirley Xavier Vidal, Sven Schmiedl, Olaf H Wang, Joshua Gagne. (United States) Klungel, Luisa Ibáñez. (Spain) End Session C

32nd

95 32nd ICPE ABSTRACT INDEX

Pub. Poster Presentation Pub. Poster Presentation # # Time Room Format # # Time Room Format

FRIDAY, AUGUST 26 46 2:15pm The Liffey B Oral 47 2:30pm The Liffey B Oral Meascan de Meds: Utilization and Trends 48 2:45pm The Liffey B Oral 1 10:30am The Liffey A Oral Playing Catch-up in Pediatric Pharmacoepidemiology 2 10:45am The Liffey A Oral 3 11:00am The Liffey A Oral 49 1:30pm Wicklow Hall 2 Oral 4 11:15am The Liffey A Oral 50 1:45pm Wicklow Hall 2 Oral 5 11:30am The Liffey A Oral 51 2:00pm Wicklow Hall 2 Oral 6 11:45am The Liffey A Oral 52 2:15pm Wicklow Hall 2 Oral 53 2:30pm Wicklow Hall 2 Oral BRACE Yourself 54 2:45pm Wicklow Hall 2 Oral 7 10:30am The Liffey B Oral Patients, Prescriptions, Policy & Pennies 8 10:45am The Liffey B Oral 9 11:00am The Liffey B Oral 55 1:30pm Liffey Hall 2 Oral 10 11:15am The Liffey B Oral 56 1:45pm Liffey Hall 2 Oral 11 11:30am The Liffey B Oral 57 2:00pm Liffey Hall 2 Oral 12 11:45am The Liffey B Oral 58 2:15pm Liffey Hall 2 Oral 59 2:30pm Liffey Hall 2 Oral Adverse Events of Cardiovascular Treatment: Head to Toe 60 2:45pm Liffey Hall 2 Oral 13 10:30am Wicklow Hall 2 Oral Adherence: Staying the Course 14 10:45am Wicklow Hall 2 Oral 15 11:00am Wicklow Hall 2 Oral 61 1:30pm Liffey Hall 1 Oral 16 11:15am Wicklow Hall 2 Oral 62 1:45pm Liffey Hall 1 Oral 17 11:30am Wicklow Hall 2 Oral 63 2:00pm Liffey Hall 1 Oral 18 11:45am Wicklow Hall 2 Oral 64 2:15pm Liffey Hall 1 Oral 65 2:30pm Liffey Hall 1 Oral Pregnancy and Beyond 66 2:45pm Liffey Hall 1 Oral 19 10:30am Liffey Hall 2 Oral Study Design Considerations to Address Confounding 20 10:45am Liffey Hall 2 Oral 21 11:00am Liffey Hall 2 Oral 67 1:30pm The Auditorium Oral 22 11:15am Liffey Hall 2 Oral 68 1:45pm The Auditorium Oral 23 11:30am Liffey Hall 2 Oral 69 2:00pm The Auditorium Oral 24 11:45am Liffey Hall 2 Oral 70 2:15pm The Auditorium Oral 71 2:30pm The Auditorium Oral Keeping an I in Opioid Use 72 2:45pm The Auditorium Oral 25 10:30am Liffey Hall 1 Oral Catch the Wave: Diffusion of Methodological Innovation in 26 10:45am Liffey Hall 1 Oral Pharmacoepidemiology 27 11:00am Liffey Hall 1 Oral 28 11:15am Liffey Hall 1 Oral 73 The Auditorium Symposia 29 11:30am Liffey Hall 1 Oral Patient Engagement in Observational 30 11:45am Liffey Hall 1 Oral Pharmacoepidemiology Research: Where Are We, Where do Data Lost and Found We Need to Be, And What are the Steps for Getting There? 31 10:30am The Auditorium Oral 74 The Liffey B Symposia 32 10:45am The Auditorium Oral 33 11:00am The Auditorium Oral Impact of Pharmacovigilance: From Prac Strategy to 34 11:15am The Auditorium Oral Demonstrable Better Health Protection 35 11:30am The Auditorium Oral 75 The Liffey A Symposia 36 11:45am The Auditorium Oral Big Data, Big Picture - Data Visualization of Health Bittersweet: Trends and Treatments in Diabetes 76 Wicklow Hall 2 Symposia 39 1:30pm The Liffey A Oral 38 1:45pm The Liffey A Oral Drug Utilisation in Older Populations: The Irish View on 37 2:00pm The Liffey A Oral Knowing Right From Wrong 40 2:15pm The Liffey A Oral 41 2:30pm The Liffey A Oral 77 Liffey Hall 2 Symposia 42 2:45pm The Liffey A Oral Does Randomization Work? Selection Bias in Pragmatic Cancer: Around the World in Databases Randomized Clinical Trials and Unblinded Observational Studies 43 1:30pm The Liffey B Oral 44 1:45pm The Liffey B Oral 78 Liffey Hall 1 Symposia 45 2:00pm The Liffey B Oral 32nd

96 32nd ICPE ABSTRACT INDEX

Pub. Poster Presentation Pub. Poster Presentation # # Time Room Format # # Time Room Format FRIDAY, AUGUST 26 Cont. Poster Session A: Burden of Disease - Infection Exploring Innovative Methods to Conduct Validation Using 126 15 8:00am -6:00pm The Forum Poster United States Medicare Administrative Claims Data 127 16 8:00am -6:00pm The Forum Poster 79 Liffey Meeting 128 17 8:00am -6:00pm The Forum Poster Room 2 Symposia 129 18 8:00am -6:00pm The Forum Poster 130 19 8:00am -6:00pm The Forum Poster Poster Session A: Spotlight Session-Adherence 131 20 8:00am -6:00pm The Forum Poster 80 A 12:15pm-1:15pm Third Floor Poster 132 21 8:00am -6:00pm The Forum Poster 81 B 12:15pm-1:15pm Third Floor Poster 133 22 8:00am -6:00pm The Forum Poster 82 C 12:15pm-1:15pm Third Floor Poster Poster Session A: Burden of Disease - Cancer 83 D 12:15pm-1:15pm Third Floor Poster 84 E 12:15pm-1:15pm Third Floor Poster 134 23 8:00am -6:00pm The Forum Poster 85 F 12:15pm-1:15pm Third Floor Poster 135 24 8:00am -6:00pm The Forum Poster 86 G 12:15pm-1:15pm Third Floor Poster 136 25 8:00am -6:00pm The Forum Poster 87 H 12:15pm-1:15pm Third Floor Poster 137 26 8:00am -6:00pm The Forum Poster 138 27 8:00am -6:00pm The Forum Poster Poster Session A: Spotlight Session-Databases 139 28 8:00am -6:00pm The Forum Poster 89 I 12:15pm-1:15pm Third Floor Poster 140 29 8:00am -6:00pm The Forum Poster 90 J 12:15pm-1:15pm Third Floor Poster 141 30 8:00am -6:00pm The Forum Poster 91 K 12:15pm-1:15pm Third Floor Poster Poster Session A: Burden of Disease - 92 L 12:15pm-1:15pm Withdrawn by Author Hematological and Cardiovascular 93 M 12:15pm-1:15pm Third Floor Poster 94 N 12:15pm-1:15pm Third Floor Poster 142 31 8:00am -6:00pm The Forum Poster 95 O 12:15pm-1:15pm Third Floor Poster 143 32 8:00am -6:00pm The Forum Poster 144 33 8:00am -6:00pm The Forum Poster Poster Session A: Spotlight Session-Devices 145 34 8:00am -6:00pm The Forum Poster 96 P 12:15pm-1:15pm Third Floor Poster 146 35 8:00am -6:00pm The Forum Poster 97 Q 12:15pm-1:15pm Third Floor Poster 147 36 8:00am -6:00pm The Forum Poster 98 R 12:15pm-1:15pm Third Floor Poster 148 37 8:00am -6:00pm The Forum Poster 99 S 12:15pm-1:15pm Third Floor Poster 149 38 8:00am -6:00pm The Forum Poster 100 T 12:15pm-1:15pm Third Floor Poster 150 39 8:00am -6:00pm The Forum Poster 101 U 12:15pm-1:15pm Third Floor Poster 151 40 8:00am -6:00pm The Forum Poster 102 V 12:15pm-1:15pm Third Floor Poster 152 41 8:00am -6:00pm The Forum Poster 103 W 12:15pm-1:15pm Third Floor Poster 153 42 8:00am -6:00pm The Forum Poster 154 43 8:00am -6:00pm The Forum Poster Poster Session A: Spotlight Session-Pediatrics 155 44 8:00am -6:00pm The Forum Poster 104 X 12:15pm-1:15pm Third Floor Poster 156 45 8:00am -6:00pm The Forum Poster 105 Y 12:15pm-1:15pm Third Floor Poster Poster Session A: Burden of Disease - Neurological 106 Z 12:15pm-1:15pm Third Floor Poster 107 AA 12:15pm-1:15pm Third Floor Poster 157 46 8:00am -6:00pm The Forum Poster 108 BB 12:15pm-1:15pm Third Floor Poster 158 47 8:00am -6:00pm The Forum Poster 109 CC 12:15pm-1:15pm Third Floor Poster 159 48 8:00am -6:00pm The Forum Poster 110 DD 12:15pm-1:15pm Third Floor Poster 160 49 8:00am -6:00pm The Forum Poster 111 EE 12:15pm-1:15pm Third Floor Poster 161 50 8:00am -6:00pm The Forum Poster 162 51 8:00am -6:00pm The Forum Poster Poster Session A: Burden of Disease - 163 52 8:00am -6:00pm The Forum Poster Alimentary & Metabolic 164 53 8:00am -6:00pm The Forum Poster 112 1 8:00am -6:00pm The Forum Poster 165 54 8:00am -6:00pm The Forum Poster 113 2 8:00am -6:00pm The Forum Poster 166 55 8:00am -6:00pm The Forum Poster 114 3 8:00am -6:00pm The Forum Poster 167 56 8:00am -6:00pm The Forum Poster 115 4 8:00am -6:00pm The Forum Poster 168 57 8:00am -6:00pm The Forum Poster 116 5 8:00am -6:00pm The Forum Poster 169 58 8:00am -6:00pm The Forum Poster 117 6 8:00am -6:00pm The Forum Poster 170 59 8:00am -6:00pm The Forum Poster 118 7 8:00am -6:00pm The Forum Poster 171 60 8:00am -6:00pm The Forum Poster 119 8 8:00am -6:00pm The Forum Poster 173 61 8:00am -6:00pm The Forum Poster 120 9 8:00am -6:00pm The Forum Poster 174 62 8:00am -6:00pm The Forum Poster 121 10 8:00am -6:00pm The Forum Poster 175 63 8:00am -6:00pm The Forum Poster 122 11 8:00am -6:00pm The Forum Poster 176 64 8:00am -6:00pm The Forum Poster 123 12 8:00am -6:00pm The Forum Poster 177 65 8:00am -6:00pm The Forum Poster 124 13 8:00am -6:00pm The Forum Poster 178 66 8:00am -6:00pm The Forum Poster 125 14 8:00am -6:00pm The Forum Poster 32nd

97 32nd ICPE ABSTRACT INDEX

Pub. Poster Presentation Pub. Poster Presentation # # Time Room Format # # Time Room Format

FRIDAY, AUGUST 26 Cont. Poster Session A: Clinical Trial Methodology Poster Session A: Burden of Disease - Respiratory 232 120 8:00am -6:00pm The Forum Poster 233 121 8:00am -6:00pm The Forum Poster 179 67 8:00am -6:00pm The Forum Poster 234 122 8:00am -6:00pm The Forum Poster 180 68 8:00am -6:00pm The Forum Poster 181 69 8:00am -6:00pm The Forum Poster Poster Session A: Confounding/Bias 182 70 8:00am -6:00pm The Forum Poster 235 123 8:00am -6:00pm The Forum Poster 183 71 8:00am -6:00pm The Forum Poster 236 124 8:00am -6:00pm The Forum Poster 184 72 8:00am -6:00pm The Forum Poster 237 125 8:00am -6:00pm The Forum Poster 185 73 8:00am -6:00pm The Forum Poster 238 126 8:00am -6:00pm The Forum Poster 186 74 8:00am -6:00pm The Forum Poster 239 127 8:00am -6:00pm The Forum Poster Poster Session A: Burden of Disease - Other 240 128 8:00am -6:00pm The Forum Poster 241 129 8:00am -6:00pm The Forum Poster 187 75 8:00am -6:00pm The Forum Poster 242 130 8:00am -6:00pm The Forum Poster 188 76 8:00am -6:00pm The Forum Poster 243 131 8:00am -6:00pm The Forum Poster 189 77 8:00am -6:00pm The Forum Poster 244 132 8:00am -6:00pm The Forum Poster 190 78 8:00am -6:00pm The Forum Poster 245 133 8:00am -6:00pm The Forum Poster 191 79 8:00am -6:00pm The Forum Poster 246 134 8:00am -6:00pm The Forum Poster 192 80 8:00am -6:00pm The Forum Poster 247 135 8:00am -6:00pm The Forum Poster 193 81 8:00am -6:00pm The Forum Poster 248 136 8:00am -6:00pm The Forum Poster 194 82 8:00am -6:00pm The Forum Poster 249 137 8:00am -6:00pm The Forum Poster 195 83 8:00am -6:00pm The Forum Poster 250 138 8:00am -6:00pm The Forum Poster 196 84 8:00am -6:00pm The Forum Poster 251 139 8:00am -6:00pm The Forum Poster 197 85 8:00am -6:00pm The Forum Poster 198 86 8:00am -6:00pm The Forum Poster Poster Session A: Data Linkage 199 87 8:00am -6:00pm The Forum Poster 252 140 8:00am -6:00pm The Forum Poster 200 88 8:00am -6:00pm The Forum Poster 253 141 8:00am -6:00pm The Forum Poster 201 89 8:00am -6:00pm The Forum Poster 254 142 8:00am -6:00pm The Forum Poster 202 90 8:00am -6:00pm The Forum Poster 255 143 8:00am -6:00pm The Forum Poster 203 91 8:00am -6:00pm The Forum Poster 256 144 8:00am -6:00pm The Forum Poster 204 92 8:00am -6:00pm The Forum Poster 257 145 8:00am -6:00pm The Forum Poster 205 93 8:00am -6:00pm The Forum Poster Poster Session A: Medical Devices Poster Session A: Measurement & Validation Methods 258 146 8:00am -6:00pm The Forum Poster 206 94 8:00am -6:00pm The Forum Poster 259 147 8:00am -6:00pm The Forum Poster 207 95 8:00am -6:00pm The Forum Poster 260 148 8:00am -6:00pm The Forum Poster 208 96 8:00am -6:00pm The Forum Poster 261 149 8:00am -6:00pm The Forum Poster 209 97 8:00am -6:00pm The Forum Poster 262 150 8:00am -6:00pm The Forum Poster 210 98 8:00am -6:00pm Withdrawn by Author 263 151 8:00am -6:00pm The Forum Poster 211 99 8:00am -6:00pm The Forum Poster 264 152 8:00am -6:00pm The Forum Poster 212 100 8:00am -6:00pm The Forum Poster 265 153 8:00am -6:00pm The Forum Poster 213 101 8:00am -6:00pm The Forum Poster 266 154 8:00am -6:00pm The Forum Poster 214 102 8:00am -6:00pm The Forum Poster 267 155 8:00am -6:00pm The Forum Poster Poster Session A: Analytical Methods 268 156 8:00am -6:00pm The Forum Poster 269 157 8:00am -6:00pm The Forum Poster 215 103 8:00am -6:00pm The Forum Poster 270 158 8:00am -6:00pm The Forum Poster 216 104 8:00am -6:00pm The Forum Poster 271 159 8:00am -6:00pm The Forum Poster 217 105 8:00am -6:00pm The Forum Poster 272 160 8:00am -6:00pm The Forum Poster 218 106 8:00am -6:00pm The Forum Poster 273 161 8:00am -6:00pm The Forum Poster 219 107 8:00am -6:00pm The Forum Poster 274 162 8:00am -6:00pm The Forum Poster 220 108 8:00am -6:00pm The Forum Poster 275 163 8:00am -6:00pm The Forum Poster 221 109 8:00am -6:00pm The Forum Poster 276 164 8:00am -6:00pm The Forum Poster 222 110 8:00am -6:00pm The Forum Poster 277 165 8:00am -6:00pm The Forum Poster 223 111 8:00am -6:00pm The Forum Poster 278 166 8:00am -6:00pm The Forum Poster 224 112 8:00am -6:00pm The Forum Poster 279 167 8:00am -6:00pm The Forum Poster 225 113 8:00am -6:00pm The Forum Poster 280 168 8:00am -6:00pm The Forum Poster 226 114 8:00am -6:00pm The Forum Poster 281 169 8:00am -6:00pm The Forum Poster 227 115 8:00am -6:00pm The Forum Poster 282 170 8:00am -6:00pm The Forum Poster 228 116 8:00am -6:00pm The Forum Poster 283 171 8:00am -6:00pm The Forum Poster 229 117 8:00am -6:00pm The Forum Poster 230 118 8:00am -6:00pm The Forum Poster Poster Session A: Study Design 231 119 8:00am -6:00pm The Forum Poster 284 172 8:00am -6:00pm The Forum Poster 32nd

98 32nd ICPE ABSTRACT INDEX

Pub. Poster Presentation Pub. Poster Presentation # # Time Room Format # # Time Room Format

FRIDAY, AUGUST 26 Cont. 337 225 8:00am -6:00pm The Forum Poster 338 226 8:00am -6:00pm The Forum Poster 285 173 8:00am -6:00pm The Forum Poster 339 227 8:00am -6:00pm The Forum Poster 286 174 8:00am -6:00pm The Forum Poster 340 228 8:00am -6:00pm The Forum Poster 287 175 8:00am -6:00pm Withdrawn by Author 341 229 8:00am -6:00pm The Forum Poster 288 176 8:00am -6:00pm The Forum Poster 342 230 8:00am -6:00pm The Forum Poster 289 177 8:00am -6:00pm The Forum Poster 343 231 8:00am -6:00pm The Forum Poster 290 178 8:00am -6:00pm The Forum Poster 344 232 8:00am -6:00pm The Forum Poster 291 179 8:00am -6:00pm The Forum Poster 345 233 8:00am -6:00pm The Forum Poster 292 180 8:00am -6:00pm Withdrawn by Author 346 234 8:00am -6:00pm The Forum Poster 293 181 8:00am -6:00pm Withdrawn by Author 347 235 8:00am -6:00pm The Forum Poster Poster Session A: Pediatrics 348 236 8:00am -6:00pm The Forum Poster 349 237 8:00am -6:00pm The Forum Poster 294 182 8:00am -6:00pm The Forum Poster 350 238 8:00am -6:00pm The Forum Poster 295 183 8:00am -6:00pm Withdrawn by Author 351 239 8:00am -6:00pm The Forum Poster 296 184 8:00am -6:00pm The Forum Poster 352 240 8:00am -6:00pm The Forum Poster 297 185 8:00am -6:00pm The ForumPoster 298 186 8:00am -6:00pm The Forum Poster Poster Session A: Use of Medicines - Neurological 299 187 8:00am -6:00pm Withdrawn by Author 353 241 8:00am -6:00pm The Forum Poster 300 188 8:00am -6:00pm The Forum Poster 354 242 8:00am -6:00pm The Forum Poster 301 189 8:00am -6:00pm The Forum Poster 355 243 8:00am -6:00pm The Forum Poster 302 190 8:00am -6:00pm The Forum Poster 356 244 8:00am -6:00pm The Forum Poster 303 191 8:00am -6:00pm The Forum Poster 357 245 8:00am -6:00pm The Forum Poster 304 192 8:00am -6:00pm The Forum Poster 358 246 8:00am -6:00pm The Forum Poster 305 193 8:00am -6:00pm The Forum Poster 359 247 8:00am -6:00pm The Forum Poster 306 194 8:00am -6:00pm The Forum Poster 360 248 8:00am -6:00pm The Forum Poster 307 195 8:00am -6:00pm The Forum Poster 361 249 8:00am -6:00pm The Forum Poster 308 196 8:00am -6:00pm The Forum Poster 362 250 8:00am -6:00pm The Forum Poster Poster Session A: Adherence 363 251 8:00am -6:00pm The Forum Poster 364 252 8:00am -6:00pm The Forum Poster 309 197 8:00am -6:00pm The Forum Poster 365 253 8:00am -6:00pm The Forum Poster 310 198 8:00am -6:00pm The Forum Poster 366 254 8:00am -6:00pm The Forum Poster 311 199 8:00am -6:00pm The Forum Poster 367 255 8:00am -6:00pm The Forum Poster 312 200 8:00am -6:00pm The Forum Poster 368 256 8:00am -6:00pm The Forum Poster 313 201 8:00am -6:00pm Withdrawn by Author 369 257 8:00am -6:00pm The Forum Poster 314 202 8:00am -6:00pm The Forum Poster 370 258 8:00am -6:00pm The Forum Poster 315 203 8:00am -6:00pm The Forum Poster 371 259 8:00am -6:00pm Withdrawn by Author 316 204 8:00am -6:00pm The Forum Poster 372 260 8:00am -6:00pm The Forum Poster 317 205 8:00am -6:00pm The Forum Poster 373 261 8:00am -6:00pm The Forum Poster 318 206 8:00am -6:00pm The Forum Poster 374 262 8:00am -6:00pm The Forum Poster 319 207 8:00am -6:00pm The Forum Poster 320 208 8:00am -6:00pm The Forum Poster Poster Session A: Use of Medicines - Other 321 209 8:00am -6:00pm The Forum Poster 375 263 8:00am -6:00pm The Forum Poster 322 210 8:00am -6:00pm The Forum Poster 376 264 8:00am -6:00pm The Forum Poster 323 211 8:00am -6:00pm The Forum Poster 377 265 8:00am -6:00pm The Forum Poster 324 212 8:00am -6:00pm The Forum Poster 378 266 8:00am -6:00pm Withdrawn by Author 325 213 8:00am -6:00pm The Forum Poster 379 267 8:00am -6:00pm The Forum Poster 326 214 8:00am -6:00pm The Forum Poster 380 268 8:00am -6:00pm The Forum Poster 327 215 8:00am -6:00pm The Forum Poster 381 269 8:00am -6:00pm Withdrawn by Author Poster Session A: Use of Medicines - Alimentary & Metabolic 382 270 8:00am -6:00pm The Forum Poster 383 271 8:00am -6:00pm The Forum Poster 328 216 8:00am -6:00pm The Forum Poster 384 272 8:00am -6:00pm The Forum Poster 329 217 8:00am -6:00pm The Forum Poster 385 273 8:00am -6:00pm The Forum Poster 330 218 8:00am -6:00pm The Forum Poster 386 274 8:00am -6:00pm The Forum Poster 331 219 8:00am -6:00pm The Forum Poster 387 275 8:00am -6:00pm The Forum Poster 332 220 8:00am -6:00pm The Forum Poster 388 276 8:00am -6:00pm The Forum Poster 333 221 8:00am -6:00pm The Forum Poster 389 277 8:00am -6:00pm The Forum Poster 334 222 8:00am -6:00pm The Forum Poster 390 278 8:00am -6:00pm The Forum Poster Poster Session A: Use of Medicines - 391 279 8:00am -6:00pm The Forum Poster Hematological and Cardiovascular 392 280 8:00am -6:00pm The Forum Poster 393 281 8:00am -6:00pm The Forum Poster 335 223 8:00am -6:00pm The Forum Poster 394 282 8:00am -6:00pm The Forum Poster 336 224 8:00am -6:00pm The Forum Poster 395 283 8:00am -6:00pm The Forum Poster 32nd

99 32nd ICPE ABSTRACT INDEX

Pub. Poster Presentation Pub. Poster Presentation # # Time Room Format # # Time Room Format FRIDAY, AUGUST 26 Cont. CV Effectiveness: How to Fix a Broken Heart 438 1:00pm The Liffey A Oral 396 284 8:00am -6:00pm The Forum Poster 439 1:15pm The Liffey A Oral 397 285 8:00am -6:00pm The Forum Poster 440 1:30pm The Liffey A Oral 398 286 8:00am -6:00pm The Forum Poster 441 1:45pm The Liffey A Oral 399 287 8:00am -6:00pm The Forum Poster 442 2:00pm The Liffey A Oral 400 288 8:00am -6:00pm The Forum Poster 443 2:15pm The Liffey A Oral 401 289 8:00am -6:00pm The Forum Poster 690 290 8:00am -6:00pm The Forum Poster Antispsychotic Use Across the Life Span SATURDAY, AUGUST 27 444 1:00pm The Liffey B Oral 445 1:15pm The Liffey B Oral Psychotropics in Pregnancy 446 1:30pm The Liffey B Oral 402 8:00am The Liffey A Oral 447 1:45pm The Liffey B Oral 403 8:15am The Liffey A Oral 448 2:00pm The Liffey B Oral 404 8:30am The Liffey A Oral 449 2:15pm The Liffey B Oral 405 8:45am The Liffey A Oral To Take or Not to Take? 406 9:00am The Liffey A Oral 407 9:15am The Liffey A Oral 450 1:00pm Wicklow Hall 2 Oral 451 1:15pm Wicklow Hall 2 Oral Pay Attention to Pain: ADHD and Pain Treatment DUS 452 1:30pm Wicklow Hall 2 Oral 408 8:00am The Liffey B Oral 453 1:45pm Wicklow Hall 2 Oral 409 8:15am The Liffey B Oral 454 2:00pm Wicklow Hall 2 Oral 410 8:30am The Liffey B Oral 455 2:15pm Wicklow Hall 2 Oral 411 8:45am The Liffey B Oral Drug-Induced Kidney and Liver Injury 412 9:00am The Liffey B Oral 413 9:15am The Liffey B Oral 456 1:00pm Liffey Hall 2 Oral 457 1:15pm Liffey Hall 2 Oral Psychotropic Trends on Populations from a Multinational 458 1:30pm Liffey Hall 2 Oral Perspective 459 1:45pm Liffey Hall 2 Oral 460 2:00pm Liffey Hall 2 Oral 414 8:00am Wicklow Hall 2 Oral 461 2:15pm Liffey Hall 2 Oral 415 8:15am Wicklow Hall 2 Oral 416 8:30am Wicklow Hall 2 Oral Biologics - Miracle Drug 417 8:45am Wicklow Hall 2 Oral 462 1:00pm Liffey Hall 1 Oral 418 9:00am Wicklow Hall 2 Oral 463 1:15pm Liffey Hall 1 Oral 419 9:15am Wicklow Hall 2 Oral 464 1:30pm Liffey Hall 1 Oral A Sticky Subject: Diabetes Safety 465 1:45pm Liffey Hall 1 Oral 466 2:00pm Liffey Hall 1 Oral 420 8:00am Liffey Hall 2 Oral 467 2:15pm Liffey Hall 1 Oral 421 8:15am Liffey Hall 2 Oral 422 8:30am Liffey Hall 2 Oral A Methods Coddle 423 8:45am Liffey Hall 2 Oral 468 1:00pm The Auditorium Oral 424 9:00am Liffey Hall 2 Oral 469 1:15pm The Auditorium Oral 425 9:15am Liffey Hall 2 Oral 470 1:30pm The Auditorium Oral Broken & Torn 471 1:45pm The Auditorium Oral 472 2:00pm The Auditorium Oral 426 8:00am Liffey Hall 1 Oral 473 2:15pm The Auditorium Oral 427 8:15am Liffey Hall 1 Oral 428 8:30am Liffey Hall 1 Oral Annual Meeting of ISPE Members & Awards Ceremony 429 8:45am Liffey Hall 1 Oral 474 The Auditorium Oral 430 9:00am Liffey Hall 1 Oral 431 9:15am Liffey Hall 1 Oral Perspectives from Causal Inference in the Era of Big Identification and Validation of Outcomes (Healthcare) Data 432 8:00am The Auditorium Oral 475 The Auditorium Symposia 433 8:15am The Auditorium Oral Making Optimal Use of Routinely Collected Data from United 434 8:30am The Auditorium Oral Kingdom Electronic Health Records 435 8:45am The Auditorium Oral 436 9:00am The Auditorium Oral 476 The Liffey B Symposia 437 9:15am The Auditorium Oral Using “Big Data” in Early Safety Evidence Gathering And Targeted Surveillance For Newly Launched Medicines: Is It The Right Time Now? 32nd 477 The Liffey A Symposia 100 32nd ICPE ABSTRACT INDEX

Pub. Poster Presentation Pub. Poster Presentation # # Time Room Format # # Time Room Format SATURDAY, AUGUST 27 Cont. 518 5 8:00am -6:00pm The Forum Poster 519 6 8:00am -6:00pm The Forum Poster What’s in a Code? Algorithm Validation in Drug 520 7 8:00am -6:00pm The Forum Poster Safety Studies 521 8 8:00am -6:00pm The Forum Poster 522 9 8:00am -6:00pm The Forum Poster 478 Wicklow Hall 2 Symposia 523 10 8:00am -6:00pm The Forum Poster The Epidemiological Approach to Rare Disease Research: 524 11 8:00am -6:00pm The Forum Poster Challenges and Opportunities 525 12 8:00am -6:00pm The Forum Poster 526 13 8:00am -6:00pm The Forum Poster 479 Liffey Hall 2 Symposia 527 14 8:00am -6:00pm The Forum Poster The Role of Evidence Synthesis in Drug Safety Evaluation 528 15 8:00am -6:00pm The Forum Poster and Regulation 529 16 8:00am -6:00pm The Forum Poster 530 17 8:00am -6:00pm The Forum Poster 480 Liffey Hall 1 Symposia 531 18 8:00am -6:00pm The Forum Poster A Discussion of Data Requirements and Methodologic 532 19 8:00am -6:00pm The Forum Poster 533 20 8:00am -6:00pm The Forum Poster Considerations for Evaluating the Real-World Effectiveness 534 21 8:00am -6:00pm The Forum Poster and Safety of Biosimilar Medicines 535 22 8:00am -6:00pm The Forum Poster 481 Liffey Meeting Room 2 Symposia 536 23 8:00am -6:00pm The Forum Poster 537 24 8:00am -6:00pm The Forum Poster Poster Session B: Spotlight Session-AsPEN 538 25 8:00am -6:00pm The Forum Poster 482 A 11:45am -12:45pm Third Floor Poster 539 26 8:00am -6:00pm The Forum Poster 483 B 11:45am -12:45pm Third Floor Poster 540 27 8:00am -6:00pm The Forum Poster 484 C 11:45am -12:45pm Third Floor Poster 541 28 8:00am -6:00pm The Forum Poster 485 D 11:45am -12:45pm Third Floor Poster 542 29 8:00am -6:00pm The Forum Poster 486 E 11:45am -12:45pm Third Floor Poster 543 30 8:00am -6:00pm The Forum Poster 487 F 11:45am -12:45pm Third Floor Poster 544 31 8:00am -6:00pm The Forum Poster 488 G 11:45am -12:45pm Third Floor Poster 545 32 8:00am -6:00pm The Forum Poster 489 H 11:45am -12:45pm Third Floor Poster 546 33 8:00am -6:00pm The Forum Poster 547 34 8:00am -6:00pm The Forum Poster Poster Session B: Spotlight Session-BRACE 548 35 8:00am -6:00pm The Forum Poster 549 36 8:00am -6:00pm The Forum Poster 490 I 11:45am -12:45pm Third Floor Poster 550 37 8:00am -6:00pm The Forum Poster 491 J 11:45am -12:45pm Third Floor Poster 492 K 11:45am -12:45pm Third Floor Poster Poster Session B: Pregnancy 493 L 11:45am -12:45pm Third Floor Poster 494 M 11:45am -12:45pm Third Floor Poster 551 38 8:00am -6:00pm The Forum Poster 495 N 11:45am -12:45pm Third Floor Poster 552 39 8:00am -6:00pm The Forum Poster 496 O 11:45am -12:45pm Third Floor Poster 553 40 8:00am -6:00pm The Forum Poster 497 P 11:45am -12:45pm Third Floor Poster 554 41 8:00am -6:00pm The Forum Poster 555 42 8:00am -6:00pm The Forum Poster Poster Session B: Spotlight Session-DUR 556 43 8:00am -6:00pm The Forum Poster 557 44 8:00am -6:00pm The Forum Poster 498 Q 11:45am -12:45pm Third Floor Poster 558 45 8:00am -6:00pm The Forum Poster 499 R 11:45am -12:45pm Third Floor Poster 559 46 8:00am -6:00pm The Forum Poster 500 S 11:45am -12:45pm Third Floor Poster 560 47 8:00am -6:00pm The Forum Poster 501 T 11:45am -12:45pm Third Floor Poster 561 48 8:00am -6:00pm The Forum Poster 502 U 11:45am -12:45pm Third Floor Poster 562 49 8:00am -6:00pm Withdrawn by Author 503 V 11:45am -12:45pm Third Floor Poster 563 50 8:00am -6:00pm The Forum Poster 505 X 11:45am -12:45pm Third Floor Poster 564 51 8:00am -6:00pm The Forum Poster Poster Session B: Spotlight Session-Meds in Pregnancy 565 52 8:00am -6:00pm The Forum Poster 566 53 8:00am -6:00pm The Forum Poster 506 Y 11:45am -12:45pm Third Floor Poster 567 54 8:00am -6:00pm The Forum Poster 507 Z 11:45am -12:45pm Third Floor Poster 568 55 8:00am -6:00pm The Forum Poster 508 AA 11:45am -12:45pm Third Floor Poster 569 56 8:00am -6:00pm The Forum Poster 509 BB 11:45am -12:45pm Third Floor Poster 570 57 8:00am -6:00pm The Forum Poster 510 CC 11:45am -12:45pm Third Floor Poster 571 58 8:00am -6:00pm The Forum Poster 511 DD 11:45am -12:45pm Third Floor Poster 572 59 8:00am -6:00pm The Forum Poster 512 EE 11:45am -12:45pm Third Floor Poster 573 60 8:00am -6:00pm The Forum Poster 513 FF 11:45am -12:45pm Third Floor Poster 574 61 8:00am -6:00pm The Forum Poster Poster Session B: BRACE 575 62 8:00am -6:00pm The Forum Poster 576 63 8:00am -6:00pm The Forum Poster 514 1 8:00am -6:00pm The Forum Poster 577 64 8:00am -6:00pm The Forum Poster 515 2 8:00am -6:00pm The Forum Poster 578 65 8:00am -6:00pm The Forum Poster 516 3 8:00am -6:00pm The Forum Poster 32nd 517 4 8:00am -6:00pm The Forum Poster 101 32nd ICPE ABSTRACT INDEX

Pub. Poster Presentation Pub. Poster Presentation # # Time Room Format # # Time Room Format SATURDAY, AUGUST 27 Cont. 634 121 8:00am -6:00pm The Forum Poster 635 122 8:00am -6:00pm The Forum Poster 579 66 8:00am -6:00pm The Forum Poster 636 123 8:00am -6:00pm The Forum Poster 580 67 8:00am -6:00pm The Forum Poster 637 124 8:00am -6:00pm The Forum Poster 581 68 8:00am -6:00pm The Forum Poster 638 125 8:00am -6:00pm The Forum Poster 582 69 8:00am -6:00pm The Forum Poster 639 126 8:00am -6:00pm The Forum Poster 583 70 8:00am -6:00pm The Forum Poster 640 127 8:00am -6:00pm The Forum Poster 584 71 8:00am -6:00pm The Forum Poster 641 128 8:00am -6:00pm The Forum Poster 585 72 8:00am -6:00pm The Forum Poster 642 129 8:00am -6:00pm The Forum Poster 586 73 8:00am -6:00pm The Forum Poster 643 130 8:00am -6:00pm The Forum Poster Poster Session B: Changing Drug Utilization 644 131 8:00am -6:00pm The Forum Poster 645 132 8:00am -6:00pm The Forum Poster 587 74 8:00am -6:00pm The Forum Poster 646 133 8:00am -6:00pm The Forum Poster 588 75 8:00am -6:00pm The Forum Poster 647 134 8:00am -6:00pm The Forum Poster 589 76 8:00am -6:00pm The Forum Poster 648 135 8:00am -6:00pm The Forum Poster 590 77 8:00am -6:00pm The Forum Poster 649 136 8:00am -6:00pm The Forum Poster 591 78 8:00am -6:00pm The Forum Poster 650 137 8:00am -6:00pm The Forum Poster 592 79 8:00am -6:00pm The Forum Poster 651 138 8:00am -6:00pm The Forum Poster 593 80 8:00am -6:00pm The Forum Poster 652 139 8:00am -6:00pm The Forum Poster 594 81 8:00am -6:00pm The Forum Poster 653 140 8:00am -6:00pm The Forum Poster 595 82 8:00am -6:00pm The Forum Poster Poster Session B: Molecular Epidemiology and 596 83 8:00am -6:00pm The Forum Poster 597 84 8:00am -6:00pm The Forum Poster Pharmacogenetics 598 85 8:00am -6:00pm The Forum Poster 654 141 8:00am -6:00pm The Forum Poster 599 86 8:00am -6:00pm The Forum Poster 655 142 8:00am -6:00pm The Forum Poster 600 87 8:00am -6:00pm The Forum Poster 656 143 8:00am -6:00pm The Forum Poster 601 88 8:00am -6:00pm The Forum Poster 657 144 8:00am -6:00pm The Forum Poster 602 89 8:00am -6:00pm The Forum Poster 658 145 8:00am -6:00pm The Forum Poster Poster Session B: Drug Utilization and Policy 659 146 8:00am -6:00pm The Forum Poster 660 147 8:00am -6:00pm The Forum Poster 603 90 8:00am -6:00pm The Forum Poster 661 148 8:00am -6:00pm The Forum Poster 604 91 8:00am -6:00pm The Forum Poster 662 149 8:00am -6:00pm The Forum Poster 605 92 8:00am -6:00pm The Forum Poster 606 93 8:00am -6:00pm The Forum Poster Poster Session B: Potpourri 607 94 8:00am -6:00pm The Forum Poster 663 150 8:00am -6:00pm The Forum Poster 608 95 8:00am -6:00pm The Forum Poster 664 151 8:00am -6:00pm The Forum Poster 609 96 8:00am -6:00pm The Forum Poster 665 152 8:00am -6:00pm The Forum Poster 610 97 8:00am -6:00pm The Forum Poster 666 153 8:00am -6:00pm The Forum Poster 611 98 8:00am -6:00pm The Forum Poster 667 154 8:00am -6:00pm The Forum Poster 612 99 8:00am -6:00pm The Forum Poster 668 155 8:00am -6:00pm The Forum Poster 613 100 8:00am -6:00pm The Forum Poster 669 156 8:00am -6:00pm The Forum Poster Poster Session B: Geriatric Pharmacoepidemiology 670 157 8:00am -6:00pm The Forum Poster 671 158 8:00am -6:00pm The Forum Poster 614 101 8:00am -6:00pm The Forum Poster 672 159 8:00am -6:00pm The Forum Poster 615 102 8:00am -6:00pm The Forum Poster 673 160 8:00am -6:00pm The Forum Poster 616 103 8:00am -6:00pm The Forum Poster 674 161 8:00am -6:00pm The Forum Poster 617 104 8:00am -6:00pm The Forum Poster 675 162 8:00am -6:00pm The Forum Poster 618 105 8:00am -6:00pm The Forum Poster 676 163 8:00am -6:00pm The Forum Poster 619 106 8:00am -6:00pm The Forum Poster 677 164 8:00am -6:00pm The Forum Poster 620 107 8:00am -6:00pm The Forum Poster 678 165 8:00am -6:00pm The Forum Poster 621 108 8:00am -6:00pm The Forum Poster 679 166 8:00am -6:00pm The Forum Poster 622 109 8:00am -6:00pm The Forum Poster 680 167 8:00am -6:00pm The Forum Poster 623 110 8:00am -6:00pm Withdrawn by Author 681 168 8:00am -6:00pm The Forum Poster 624 111 8:00am -6:00pm The Forum Poster 682 169 8:00am -6:00pm The Forum Poster 625 112 8:00am -6:00pm The Forum Poster 683 170 8:00am -6:00pm The Forum Poster 626 113 8:00am -6:00pm The Forum Poster 684 171 8:00am -6:00pm The Forum Poster 627 114 8:00am -6:00pm The Forum Poster 685 172 8:00am -6:00pm The Forum Poster 628 115 8:00am -6:00pm The Forum Poster 686 173 8:00am -6:00pm The Forum Poster 629 116 8:00am -6:00pm The Forum Poster 687 174 8:00am -6:00pm The Forum Poster 630 117 8:00am -6:00pm The Forum Poster 631 118 8:00am -6:00pm The Forum Poster Poster Session B: Pharmacovigilance 632 119 8:00am -6:00pm The Forum Poster 688 175 8:00am -6:00pm The Forum Poster 633 120 8:00am -6:00pm The Forum Poster 689 176 8:00am -6:00pm The Forum Poster 32nd

102 32nd ICPE ABSTRACT INDEX

Pub. Poster Presentation Pub. Poster Presentation # # Time Room Format # # Time Room Format SATURDAY, AUGUST 27 Cont. Poster Session B: Pharmacovigilance - Anti-infectives

691 177 8:00am -6:00pm The Forum Poster 745 231 8:00am -6:00pm The Forum Poster 692 178 8:00am -6:00pm The Forum Poster 746 232 8:00am -6:00pm The Forum Poster 693 179 8:00am -6:00pm Withdrawn by Author 747 233 8:00am -6:00pm The Forum Poster 694 180 8:00am -6:00pm The Forum Poster 748 234 8:00am -6:00pm The Forum Poster 695 181 8:00am -6:00pm The Forum Poster 749 235 8:00am -6:00pm The Forum Poster 696 182 8:00am -6:00pm The Forum Poster 750 236 8:00am -6:00pm The Forum Poster 697 183 8:00am -6:00pm The Forum Poster Poster Session B: Pharmacovigilance - Cancer 698 184 8:00am -6:00pm The Forum Poster 699 185 8:00am -6:00pm The Forum Poster 751 237 8:00am -6:00pm The Forum Poster 700 186 8:00am -6:00pm The Forum Poster 752 238 8:00am -6:00pm The Forum Poster 701 187 8:00am -6:00pm The Forum Poster 753 239 8:00am -6:00pm The Forum Poster 702 188 8:00am -6:00pm The Forum Poster 754 240 8:00am -6:00pm The Forum Poster 703 189 8:00am -6:00pm The Forum Poster 755 241 8:00am -6:00pm The Forum Poster 704 190 8:00am -6:00pm The Forum Poster 756 242 8:00am -6:00pm The Forum Poster 705 191 8:00am -6:00pm The Forum Poster Poster Session B: Pharmacovigilance - Cardiovascular 706 192 8:00am -6:00pm The Forum Poster 707 193 8:00am -6:00pm The Forum Poster 757 243 8:00am -6:00pm The Forum Poster 708 194 8:00am -6:00pm The Forum Poster 758 244 8:00am -6:00pm The Forum Poster 709 195 8:00am -6:00pm The Forum Poster 759 245 8:00am -6:00pm The Forum Poster 710 196 8:00am -6:00pm The Forum Poster 760 246 8:00am -6:00pm Withdrawn by Author 711 197 8:00am -6:00pm The Forum Poster 761 247 8:00am -6:00pm The Forum Poster 712 198 8:00am -6:00pm The Forum Poster 762 248 8:00am -6:00pm The Forum Poster 713 199 8:00am -6:00pm The Forum Poster 763 249 8:00am -6:00pm The Forum Poster 714 200 8:00am -6:00pm The Forum Poster Poster Session B: Pharmacoviglance - Pain and Neurological 715 201 8:00am -6:00pm The Forum Poster 716 202 8:00am -6:00pm The Forum Poster 764 250 8:00am -6:00pm The Forum Poster 717 203 8:00am -6:00pm The Forum Poster 765 251 8:00am -6:00pm The Forum Poster 718 204 8:00am -6:00pm The Forum Poster 766 252 8:00am -6:00pm The Forum Poster 767 253 8:00am -6:00pm The Forum Poster Poster Session B: Pharmacovigilance by Geography 768 254 8:00am -6:00pm The Forum Poster 719 205 8:00am -6:00pm The Forum Poster 769 255 8:00am -6:00pm The Forum Poster 720 206 8:00am -6:00pm The Forum Poster 770 256 8:00am -6:00pm The Forum Poster 721 207 8:00am -6:00pm The Forum Poster 771 257 8:00am -6:00pm The Forum Poster 722 208 8:00am -6:00pm The Forum Poster 772 258 8:00am -6:00pm The Forum Poster 723 209 8:00am -6:00pm The Forum Poster 773 259 8:00am -6:00pm The Forum Poster 724 210 8:00am -6:00pm The Forum Poster 774 260 8:00am -6:00pm The Forum Poster 725 211 8:00am -6:00pm The Forum Poster 775 261 8:00am -6:00pm The Forum Poster 726 212 8:00am -6:00pm The Forum Poster 776 262 8:00am -6:00pm The Forum Poster 727 213 8:00am -6:00pm The Forum Poster 777 263 8:00am -6:00pm The Forum Poster 728 214 8:00am -6:00pm The Forum Poster Poster Session B: Pharmacovigilance - Other Therapeutic 729 215 8:00am -6:00pm The Forum Poster 730 216 8:00am -6:00pm The Forum Poster 778 264 8:00am -6:00pm The Forum Poster 731 217 8:00am -6:00pm The Forum Poster 779 265 8:00am -6:00pm Withdrawn by Author 732 218 8:00am -6:00pm The Forum Poster 780 266 8:00am -6:00pm The Forum Poster 733 219 8:00am -6:00pm The Forum Poster 781 267 8:00am -6:00pm The Forum Poster 734 220 8:00am -6:00pm The Forum Poster 782 268 8:00am -6:00pm The Forum Poster 735 221 8:00am -6:00pm The Forum Poster 783 269 8:00am -6:00pm The Forum Poster 736 222 8:00am -6:00pm Withdrawn by Author 784 270 8:00am -6:00pm The Forum Poster 785 271 8:00am -6:00pm The Forum Poster Poster Session B: Pharmacovigilance - 786 272 8:00am -6:00pm Withdrawn by Author Alimentary and Metabolic 787 273 8:00am -6:00pm The Forum Poster 737 223 8:00am -6:00pm The Forum Poster 788 274 8:00am -6:00pm The Forum Poster 738 224 8:00am -6:00pm The Forum Poster 789 275 8:00am -6:00pm The Forum Poster 739 225 8:00am -6:00pm The Forum Poster 790 276 8:00am -6:00pm The Forum Poster 740 226 8:00am -6:00pm The Forum Poster 841 277 8:00am -6:00pm The Forum Poster 741 227 8:00am -6:00pm The Forum Poster 884 278 8:00am -6:00pm The Forum Poster 742 228 8:00am -6:00pm The Forum Poster Poster Session B: Other Safety & Effectiveness 743 229 8:00am -6:00pm The Forum Poster 744 230 8:00am -6:00pm The Forum Poster 1029 279 8:00am -6:00pm The Forum Poster

32nd

103 32nd ICPE ABSTRACT INDEX

Pub. Poster Presentation Pub. Poster Presentation # # Time Room Format # # Time Room Format SUNDAY, AUGUST 28 Pharmacoepidemiology and Risk Management Planning: Essential Enablers for Development of Innovative Medicines From Eve to… 829 The Liffey A Symposia 791 8:30am The Liffey A Oral 792 8:45am The Liffey A Oral Transitioning to ICD-10: International Lessons Learned and 793 9:00am The Liffey A Oral Strategies for Moving Forward 794 9:15am The Liffey A Oral 795 9:30am The Liffey A Oral 830 Wicklow Hall 2 Symposia 796 9:45am The Liffey A Oral Who to Ask And How? Preference-Based Methods for My Achy Breaky Heart: Diabetes and CVD Benefit-Risk Assessment 797 8:30am The Liffey B Oral 831 Liffey Hall 2 Symposia 798 8:45am The Liffey B Oral Implications for Patients, Industry and Regulators 1096 9:00am The Liffey B Oral 800 9:15am The Liffey B Oral 832 Liffey Hall 1 Symposia 801 9:30am The Liffey B Oral Practice of Epidemiology in Pregnancy Studies 802 9:45am The Liffey B Oral 833 3:15pm The Liffey A Oral Keeping Up - A Potpourri 834 3:30pm The Liffey A Oral 803 8:30am Wicklow Hall 2 Oral 835 3:45pm The Liffey A Oral 804 8:45am Wicklow Hall 2 Oral 836 4:00pm The Liffey A Oral 805 9:00am Wicklow Hall 2 Oral 837 4:15pm The Liffey A Oral 806 9:15am Wicklow Hall 2 Oral 838 4:30pm The Liffey A Oral 807 9:30am Wicklow Hall 2 Oral Disease Burden from Clinical Databases 808 9:45am Wicklow Hall 2 Oral 839 3:15pm The Liffey B Oral Adverse Outcomes and Infectious Diseases 840 3:30pm The Liffey B Oral 809 8:30am Liffey Hall 2 Oral 172 3:45pm The Liffey B Oral 810 8:45am Liffey Hall 2 Oral 842 4:00pm The Liffey B Oral 811 9:00am Liffey Hall 2 Oral 843 4:15pm The Liffey B Oral 812 9:15am Liffey Hall 2 Oral 844 4:30pm The Liffey B Oral 813 9:30am Liffey Hall 2 Oral CV Adverse Events: Affairs of the Heart 814 9:45am Liffey Hall 2 Oral 845 3:15pm Wicklow Hall 2 Oral Vaccines: Hit Me with Your Best Shot 846 3:30pm Wicklow Hall 2 Oral 815 8:30am Liffey Hall 1 Oral 847 3:45pm Wicklow Hall 2 Oral 816 8:45am Liffey Hall 1 Oral 848 4:00pm Wicklow Hall 2 Oral 817 9:00am Liffey Hall 1 Oral 849 4:15pm Wicklow Hall 2 Oral 818 9:15am Liffey Hall 1 Oral 850 4:30pm Wicklow Hall 2 Oral 819 9:30am Liffey Hall 1 Oral Adverse Outcomes of Glucocorticoid and 820 9:45am Liffey Hall 1 Oral Immunomodulator Use Analytic Approaches for Controling Confounding and 851 3:15pm Liffey Hall 2 Oral Exposure Misclassification 852 3:30pm Liffey Hall 2 Oral 821 8:30am The Auditorium Oral 853 3:45pm Liffey Hall 2 Oral 822 8:45am The Auditorium Oral 854 4:00pm Liffey Hall 2 Oral 823 9:00am The Auditorium Oral 855 4:15pm Liffey Hall 2 Oral 824 9:15am The Auditorium Oral 856 4:30pm Liffey Hall 2 Oral 825 9:30am The Auditorium Oral Thin Blood: Anticoagulants 826 9:45am The Auditorium Oral 857 3:15pm Liffey Hall 1 Oral Pattern Discovery in Observational Health Data - What We 858 3:30pm Liffey Hall 1 Oral Did Not Know to Look For 859 3:45pm Liffey Hall 1 Oral 827 The Auditorium Symposia 504 4:00pm Liffey Hall 1 ral 861 4:15pm Liffey Hall 1 Oral Clinical and Analytic Considerations in The Selection and 862 4:30pm Liffey Hall 1 Oral Evaluation of Comparators in Observational Database Is it Safe Enough? Studies 863 3:15pm The Auditorium Oral 828 The Liffey B Symposia 864 3:30pm The Auditorium Oral 865 3:45pm The Auditorium Oral 866 4:00pm The Auditorium Oral 32nd 867 4:15pm The Auditorium Oral 88 4:30pm The Auditorium Oral 104 32nd ICPE ABSTRACT INDEX

Pub. Poster Presentation Pub. Poster Presentation # # Time Room Format # # Time Room Format

SUNDAY, AUGUST 28 Cont. 919 31 8:00am -1:45pm The Forum Poster 920 32 8:00am -1:45pm The Forum Poster Poster Session C: Spotlight Session-Vaccines 921 33 8:00am -1:45pm Withdrawn by Author 869 A 12:15pm -1:15pm Third Floor Poster 922 34 8:00am -1:45pm The Forum Poster 870 B 12:15pm -1:15pm Third Floor Poster 923 35 8:00am -1:45pm The Forum Poster 871 C 12:15pm -1:15pm Third Floor Poster 924 36 8:00am -1:45pm The Forum Poster 872 D 12:15pm -1:15pm Third Floor Poster 925 37 8:00am -1:45pm The Forum Poster 873 E 12:15pm -1:15pm Third Floor Poster Poster Session C: Safety & Effectiveness - Musculo-Skeletal 874 F 12:15pm -1:15pm Third Floor Poster 926 38 8:00am -1:45pm The Forum Poster Poster Session C: Spotlight Session-CER 927 39 8:00am -1:45pm The Forum Poster 875 G 12:15pm -1:15pm Third Floor Poster 928 40 8:00am -1:45pm The Forum Poster 876 H 12:15pm -1:15pm Third Floor Poster Poster Session C: Safety & Effectiveness - 877 I 12:15pm -1:15pm Third Floor Poster Alimentary Tract and Metabolic 878 J 12:15pm -1:15pm Third Floor Poster 880 L 12:15pm -1:15pm Third Floor Poster 929 41 8:00am -1:45pm The Forum Poster Poster Session C: Spotlight Session-Biologics 930 42 8:00am -1:45pm The Forum Poster 931 43 8:00am -1:45pm The Forum Poster 881 M 12:15pm -1:15pm Third Floor Poster 932 44 8:00am -1:45pm The Forum Poster 882 N 12:15pm -1:15pm Third Floor Poster 933 45 8:00am -1:45pm The Forum Poster 883 O 12:15pm -1:15pm Third Floor Poster 934 46 8:00am -1:45pm The Forum Poster 888 P 12:15pm -1:15pm Third Floor Poster 935 47 8:00am -1:45pm The Forum Poster 885 Q 12:15pm -1:15pm Third Floor Poster 936 48 8:00am -1:45pm The Forum Poster 886 R 12:15pm -1:15pm Third Floor Poster 937 49 8:00am -1:45pm The Forum Poster 887 S 12:15pm -1:15pm Third Floor Poster 938 50 8:00am -1:45pm The Forum Poster Poster Session C: Biologics 939 51 8:00am -1:45pm The Forum Poster 940 52 8:00am -1:45pm The Forum Poster 889 1 8:00am -1:45pm The Forum Poster 941 53 8:00am -1:45pm The Forum Poster 890 2 8:00am -1:45pm The Forum Poster 942 54 8:00am -1:45pm The Forum Poster 891 3 8:00am -1:45pm The Forum Poster 943 55 8:00am -1:45pm The Forum Poster 892 4 8:00am -1:45pm The Forum Poster 944 56 8:00am -1:45pm The Forum Poster 893 5 8:00am -1:45pm The Forum Poster 945 57 8:00am -1:45pm The Forum Poster 894 6 8:00am -1:45pm The Forum Poster Poster Session C: Safety & Effectiveness - Anti-infectives 895 7 8:00am -1:45pm The Forum Poster Poster Session C: Vaccines 946 58 8:00am -1:45pm The Forum Poster 947 59 8:00am -1:45pm The Forum Poster 896 8 8:00am -1:45pm The Forum Poster 948 60 8:00am -1:45pm The Forum Poster 897 9 8:00am -1:45pm The Forum Poster 949 61 8:00am -1:45pm The Forum Poster 898 10 8:00am -1:45pm The Forum Poster 950 62 8:00am -1:45pm The Forum Poster 899 11 8:00am -1:45pm The Forum Poster 951 63 8:00am -1:45pm The Forum Poster 900 12 8:00am -1:45pm The Forum Poster 952 64 8:00am -1:45pm The Forum Poster 901 13 8:00am -1:45pm The Forum Poster 953 65 8:00am -1:45pm The Forum Poster 902 14 8:00am -1:45pm The Forum Poster 954 66 8:00am -1:45pm The Forum Poster 903 15 8:00am -1:45pm The Forum Poster 955 67 8:00am -1:45pm The Forum Poster 904 16 8:00am -1:45pm The Forum Poster 956 68 8:00am -1:45pm The Forum Poster Poster Session C: Safety & Effectiveness - Cancer 957 69 8:00am -1:45pm The Forum Poster 958 70 8:00am -1:45pm The Forum Poster 905 17 8:00am -1:45pm The Forum Poster 959 71 8:00am -1:45pm Withdrawn by Author 906 18 8:00am -1:45pm The Forum Poster Poster Session C: Safety & Effectiveness - Cardiovascular 907 19 8:00am -1:45pm The Forum Poster 908 20 8:00am -1:45pm The Forum Poster 960 72 8:00am -1:45pm The Forum Poster 909 21 8:00am -1:45pm The Forum Poster 961 73 8:00am -1:45pm The Forum Poster 910 22 8:00am -1:45pm The Forum Poster 962 74 8:00am -1:45pm The Forum Poster Poster Session C: Safety & Effectiveness - GU & Hormones 963 75 8:00am -1:45pm The Forum Poster 964 76 8:00am -1:45pm The Forum Poster 911 23 8:00am -1:45pm The Forum Poster 965 77 8:00am -1:45pm The Forum Poster 912 24 8:00am -1:45pm The Forum Poster 966 78 8:00am -1:45pm The Forum Poster 913 25 8:00am -1:45pm The Forum Poster 967 79 8:00am -1:45pm The Forum Poster 914 26 8:00am -1:45pm The Forum Poster 968 80 8:00am -1:45pm The Forum Poster 915 27 8:00am -1:45pm The Forum Poster 969 81 8:00am -1:45pm The Forum Poster 916 28 8:00am -1:45pm The Forum Poster 970 82 8:00am -1:45pm The Forum Poster 917 29 8:00am -1:45pm The Forum Poster 971 83 8:00am -1:45pm The Forum Poster

918 30 8:00am -1:45pm The Forum Poster 972 84 8:00am -1:45pm The Forum Poster32nd

105 32nd ICPE ABSTRACT INDEX

Pub. Poster Presentation Pub. Poster Presentation # # Time Room Format # # Time Room Format SUNDAY, AUGUST 28 Cont. Poster Session C: Other Safety & Effectiveness 973 85 8:00am -1:45pm The Forum Poster 1028 140 8:00am -1:45pm The Forum Poster 974 86 8:00am -1:45pm The Forum Poster 1030 141 8:00am -1:45pm The Forum Poster 975 87 8:00am -1:45pm The Forum Poster 1031 142 8:00am -1:45pm The Forum Poster 976 88 8:00am -1:45pm The Forum Poster 1032 143 8:00am -1:45pm The Forum Poster 977 89 8:00am -1:45pm The Forum Poster 1033 144 8:00am -1:45pm The Forum Poster 978 90 8:00am -1:45pm The Forum Poster 1034 145 8:00am -1:45pm The Forum Poster 979 91 8:00am -1:45pm The Forum Poster 1035 146 8:00am -1:45pm The Forum Poster 980 92 8:00am -1:45pm The Forum Poster 1036 147 8:00am -1:45pm The Forum Poster 981 93 8:00am -1:45pm The Forum Poster 1037 148 8:00am -1:45pm The Forum Poster 982 94 8:00am -1:45pm The Forum Poster 1038 149 8:00am -1:45pm The Forum Poster 983 95 8:00am -1:45pm The Forum Poster 1039 150 8:00am -1:45pm The Forum Poster 984 96 8:00am -1:45pm The Forum Poster 1040 151 8:00am -1:45pm The Forum Poster 985 97 8:00am -1:45pm The Forum Poster 1041 152 8:00am -1:45pm The Forum Poster 986 98 8:00am -1:45pm The Forum Poster 1042 153 8:00am -1:45pm The Forum Poster 987 99 8:00am -1:45pm The Forum Poster Poster Session C: Informatics 988 100 8:00am -1:45pm The Forum Poster 989 101 8:00am -1:45pm The Forum Poster 1043 154 8:00am -1:45pm The Forum Poster 990 102 8:00am -1:45pm The Forum Poster 1044 155 8:00am -1:45pm The Forum Poster 991 103 8:00am -1:45pm The Forum Poster 1045 156 8:00am -1:45pm The Forum Poster 992 104 8:00am -1:45pm The Forum Poster 1046 157 8:00am -1:45pm The Forum Poster 993 105 8:00am -1:45pm The Forum Poster 1047 158 8:00am -1:45pm The Forum Poster 994 106 8:00am -1:45pm The Forum Poster 1048 159 8:00am -1:45pm The Forum Poster Poster Session C: Safety & Effectiveness - Neurological 1049 160 8:00am -1:45pm The Forum Poster 1050 161 8:00am -1:45pm The Forum Poster 995 107 8:00am -1:45pm The Forum Poster 1051 162 8:00am -1:45pm The Forum Poster 996 108 8:00am -1:45pm The Forum Poster 1052 163 8:00am -1:45pm The Forum Poster 997 109 8:00am -1:45pm The Forum Poster 1053 164 8:00am -1:45pm The Forum Poster 998 110 8:00am -1:45pm The Forum Poster 1054 165 8:00am -1:45pm The Forum Poster 999 111 8:00am -1:45pm The Forum Poster 1055 166 8:00am -1:45pm The Forum Poster 1000 112 8:00am -1:45pm The Forum Poster Poster Session C: HEOR 1001 113 8:00am -1:45pm The Forum Poster 1002 114 8:00am -1:45pm The Forum Poster 1056 167 8:00am -1:45pm The Forum Poster 1003 115 8:00am -1:45pm The Forum Poster 1057 168 8:00am -1:45pm The Forum Poster 1004 116 8:00am -1:45pm The Forum Poster 1058 169 8:00am -1:45pm The Forum Poster 1005 117 8:00am -1:45pm The Forum Poster 1059 170 8:00am -1:45pm The Forum Poster 1006 118 8:00am -1:45pm The Forum Poster 1060 171 8:00am -1:45pm The Forum Poster 1007 119 8:00am -1:45pm The Forum Poster 1061 172 8:00am -1:45pm The Forum Poster 1008 120 8:00am -1:45pm The Forum Poster 1062 173 8:00am -1:45pm The Forum Poster 1009 121 8:00am -1:45pm The Forum Poster 1063 174 8:00am -1:45pm The Forum Poster 1010 122 8:00am -1:45pm The Forum Poster 1064 175 8:00am -1:45pm The Forum Poster 1011 123 8:00am -1:45pm The Forum Poster 1065 176 8:00am -1:45pm The Forum Poster 1012 124 8:00am -1:45pm The Forum Poster 1066 177 8:00am -1:45pm The Forum Poster 1013 125 8:00am -1:45pm The Forum Poster 1067 178 8:00am -1:45pm The Forum Poster 1014 126 8:00am -1:45pm The Forum Poster 1068 179 8:00am -1:45pm The Forum Poster 1015 127 8:00am -1:45pm The Forum Poster 1069 180 8:00am -1:45pm The Forum Poster 1016 128 8:00am -1:45pm The Forum Poster 1070 181 8:00am -1:45pm The Forum Poster 1017 129 8:00am -1:45pm The Forum Poster 1071 182 8:00am -1:45pm The Forum Poster 1018 130 8:00am -1:45pm The Forum Poster 1072 183 8:00am -1:45pm The Forum Poster 1019 131 8:00am -1:45pm The Forum Poster 1073 184 8:00am -1:45pm The Forum Poster Poster Session C: Safety & Effectiveness - Respiratory 1074 185 8:00am -1:45pm The Forum Poster 1075 186 8:00am -1:45pm The Forum Poster 1020 132 8:00am -1:45pm The Forum Poster 1076 187 8:00am -1:45pm The Forum Poster 1021 133 8:00am -1:45pm The Forum Poster 1077 188 8:00am -1:45pm Withdrawn by Author 1022 134 8:00am -1:45pm The Forum Poster 1078 189 8:00am -1:45pm The Forum Poster 1023 135 8:00am -1:45pm The Forum Poster Poster Session C: DUR - Trends 1024 136 8:00am -1:45pm The Forum Poster 1025 137 8:00am -1:45pm The Forum Poster 1079 190 8:00am -1:45pm The Forum Poster 1026 138 8:00am -1:45pm The Forum Poster 1080 191 8:00am -1:45pm The Forum Poster 1027 139 8:00am -1:45pm The Forum Poster 1081 192 8:00am -1:45pm The Forum Poster 1082 193 8:00am -1:45pm The Forum Poster 1083 194 8:00am -1:45pm The Forum Poster 32nd 1084 195 8:00am -1:45pm The Forum Poster

106 32nd ICPE ABSTRACT INDEX

Pub. Poster Presentation Pub. Poster Presentation # # Time Room Format # # Time Room Format

SUNDAY, AUGUST 28 Cont. 1136 246 8:00am -1:45pm The Forum Poster 1085 196 8:00am -1:45pm The Forum Poster Poster Session C: DUR - Trends in Neurological 1086 197 8:00am -1:45pm The Forum Poster 1137 247 8:00am -1:45pm The Forum Poster 1087 198 8:00am -1:45pm The Forum Poster 1138 248 8:00am -1:45pm The Forum Poster Poster Session C: DUR - Trends in Alimentary and Metabolic 1139 249 8:00am -1:45pm The Forum Poster 1140 250 8:00am -1:45pm The Forum Poster 1088 199 8:00am -1:45pm The Forum Poster 1141 251 8:00am -1:45pm The Forum Poster 1089 200 8:00am -1:45pm The Forum Poster 1142 252 8:00am -1:45pm The Forum Poster 1090 201 8:00am -1:45pm The Forum Poster 1143 253 8:00am -1:45pm The Forum Poster 1091 202 8:00am -1:45pm The Forum Poster 1144 254 8:00am -1:45pm The Forum Poster 1092 203 8:00am -1:45pm The Forum Poster 1145 255 8:00am -1:45pm The Forum Poster 1093 204 8:00am -1:45pm The Forum Poster 1146 256 8:00am -1:45pm The Forum Poster 1094 205 8:00am -1:45pm The Forum Poster 1147 257 8:00am -1:45pm The Forum Poster 1095 206 8:00am -1:45pm The Forum Poster 1148 258 8:00am -1:45pm The Forum Poster 1097 207 8:00am -1:45pm The Forum Poster 1149 259 8:00am -1:45pm The Forum Poster 1098 208 8:00am -1:45pm The Forum Poster 1150 260 8:00am -1:45pm The Forum Poster 1099 209 8:00am -1:45pm The Forum Poster 1151 261 8:00am -1:45pm The Forum Poster Poster Session C: DUR - Trends in Anti-infectives 1152 262 8:00am -1:45pm The Forum Poster 1153 263 8:00am -1:45pm The Forum Poster 1100 210 8:00am -1:45pm The Forum Poster 1154 264 8:00am -1:45pm The Forum Poster 1101 211 8:00am -1:45pm The Forum Poster 1155 265 8:00am -1:45pm The Forum Poster 1102 212 8:00am -1:45pm The Forum Poster 1156 266 8:00am -1:45pm The Forum Poster 1103 213 8:00am -1:45pm The Forum Poster 1157 267 8:00am -1:45pm The Forum Poster 1104 214 8:00am -1:45pm The Forum Poster 1158 268 8:00am -1:45pm The Forum Poster 1105 215 8:00am -1:45pm The Forum Poster 1159 269 8:00am -1:45pm The Forum Poster 1106 216 8:00am -1:45pm The Forum Poster 1160 270 8:00am -1:45pm The Forum Poster 1107 217 8:00am -1:45pm The Forum Poster 1108 218 8:00am -1:45pm The Forum Poster Poster Session C: DUR - Trends in Respiratory 1109 219 8:00am -1:45pm The Forum Poster 1161 271 8:00am -1:45pm The Forum Poster 1110 220 8:00am -1:45pm The Forum Poster 1162 272 8:00am -1:45pm The Forum Poster Poster Session C: DUR - Trends in Cancer 1163 273 8:00am -1:45pm The Forum Poster 1164 274 8:00am -1:45pm The Forum Poster 1111 221 8:00am -1:45pm The Forum Poster 1165 275 8:00am -1:45pm The Forum Poster 1112 222 8:00am -1:45pm The Forum Poster 1166 276 8:00am -1:45pm The Forum Poster 1113 223 8:00am -1:45pm The Forum Poster 1167 277 8:00am -1:45pm The Forum Poster 1114 224 8:00am -1:45pm The Forum Poster 1168 278 8:00am -1:45pm The Forum Poster 1115 225 8:00am -1:45pm The Forum Poster 1169 279 8:00am -1:45pm The Forum Poster 1116 226 8:00am -1:45pm The Forum Poster 1170 280 8:00am -1:45pm The Forum Poster 1117 227 8:00am -1:45pm The Forum Poster 1171 281 8:00am -1:45pm The Forum Poster 1118 228 8:00am -1:45pm The Forum Poster 860 282 8:00am -1:45pm The Forum Poster Poster Session C: DUR - Trends in Cardiovascular 879 283 8:00am -1:45pm The Forum Poster 1119 229 8:00am -1:45pm The Forum Poster 1120 230 8:00am -1:45pm The Forum Poster 1121 231 8:00am -1:45pm The Forum Poster 1122 232 8:00am -1:45pm The Forum Poster 1123 233 8:00am -1:45pm The Forum Poster 1124 234 8:00am -1:45pm The Forum Poster Poster Session C: DUR - Trends in GU and Hormones 1125 235 8:00am -1:45pm The Forum Poster 1126 236 8:00am -1:45pm The Forum Poster 1127 237 8:00am -1:45pm The Forum Poster 1128 238 8:00am -1:45pm Withdrawn by Author 1129 239 8:00am -1:45pm The Forum Poster 1130 240 8:00am -1:45pm The Forum Poster Poster Session C: DUR - Trends in Musculo-Skeletal 1131 241 8:00am -1:45pm The Forum Poster 1132 242 8:00am -1:45pm The Forum Poster 1133 243 8:00am -1:45pm The Forum Poster 1134 244 8:00am -1:45pm The Forum Poster 1135 245 8:00am -1:45pm The Forum Poster 32nd

107 MEETING NOTES

Advertisers Index ______

______w Amgen...... 41 w Analysis Group...... 18 ______w Bayer Pharma...... 29 ______w BHE Boston Health Economics...... 52 w Boehringer Ingelheim...... 21 ______w Clinical Practice Research Datalink (CPRD)...... 53 w Department of Clinical Epidemiology, ______Aarhus University Hospital...... 37 ______w Eli Lilly & Company...... 15 w EPID Research...... 31 ______w Evalytica...... 50 w Evidera...... 9 ______w HealthCore...... 13 w IMS Health GmbH & Co...... 58 ______w Kantar Health...... 54 ______w Mapi Group...... 19 w Merck and Company...... 17 ______w Numerus...... 23 w Optum...... 46 ______w Pfizer...... 32 ______w Quintiles...... 25 w RTI Health Solutions...... 48 ______w Takeda...... 36 w The Degge Group and DGI, LLC...... 56 ______w Truven Health Analytics...... 56 w Wiley Publications...... 110 ______

______

______

______

______

______

______

______

______

______

______

32nd

108 MEETING NOTES

______

______

______

______

______

______

______

______

______

______

______

______

______

______

______

______

______

______

______

______

______

______

______

______

______

______

32nd

109 Pharmacoepidemiology PDS & Drug Safety Official Journal of the International Society for Pharmacoepidemiology Editor-In-Chief: Professor Brian L. Strom Pharmacoepidemiology & Drug Safety provides an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology.

Free online access for ISPE members via the society website Impact Factor 2.908*

*2015 Journal Citation Reports®(Thomson Reuters) Congratulations to The Ronald D. Mann Best Article of 2015 Awards Winners

First Prize Honorable Mention: Domperidone, cytochrome P450 3A4 isoenzyme Exposure to systemic antibacterial medications inhibitors and ventricular arrhythmia: during pregnancy and risk of childhood cancer a nationwide case–crossover study Natalie C. Momen, Jørn Olsen, Mika Gissler, Helle Kieler, Hung-Lin Chen and Fei-Yuan Hsiao Bengt Haglund and Jiong Li Volume 24, Issue 8, August 2015, Pages: 841-848 Volume 24, Issue 8, August 2015, Pages: 821-829 Honorable Mention: Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting Joshua A. Roth, Katharine Bradley, Kenneth E. Thummel, David L. Veenstra and Denise Boudreau Volume 24, Issue 6, June 2015, Pages: 619-627

For more information on these top papers and other journal features, please visit www.pdsjournal.org Print ISSN: 1053-8569 • Online ISSN: 1099-1557 • 2016 Volume: 25 • Frequency: Monthly 240710 MEETING INFO: PHARMACOEPI.ORG

33rd ICPE

August 23-27, 2017thalifax convention centre Nova Scotia Halifax

ABSTRACT SUBMISSION DEADLINE: FEBRUARY 15, 2017 SCHOLARSHIPS & STUDENT AWARDS ISPE will award a limited number of scholarships to help defray conference expenses. Information will be YOU ARE INVITED TO SUBMIT AN ABSTRACT posted on pharmacoepi.org Scholarship ISPE invites you to submit an abstract for an oral/poster Submission Deadline: presentation, workshop or symposium at the 33rd ICPE ISPE will grant several student awards to MARCH 1, 2017 in Halifax, Nova Scotia. This pre-eminent conference on recognize and encourage student excellence pharmacoepidemiology will be an invaluable scientific in pharmacoepidemiology. The Scientific Program Committee experience and will allow you to experience Halifax’s dynamic oversees the selection of awards, which will be presented at the and lively personality. 2017 ICPE Annual Meeting of ISPE Members & Awards Ceremony. GUIDELINES FOR SUBMISSIONS SPONSORSHIPS, EXHIBITS & The deadline for receipt of all abstracts is February 15, 2017. ACADEMIC SHOWCASE Please visit pharmacoepi.org, for submission guidelines. The online submission site will be operational by mid-December 2016. ISPE offers organizations, institutions and academic programs opportunities to support the conference while sharing their Questions about abstract submissions should be directed to products and services with attendees. A Conference Sponsorship [email protected]. Note, submissions will not be accepted & Exhibitor Prospectus will be posted on pharmacoepi.org/ until the online submission site is open in December 2016. meetings/33ICPE. REVIEWING/REGISTRATION SAVE THE DATES! The ISPE Scientific Program Committee will review all abstracts August 23-27, 2017 in April 2017. All submitters will be notified by email in early June Halifax Convention Centre 2017. All presenters and panelists (workshop/symposia) must Halifax, Nova Scotia register to attend the 2017 ICPE. Please visit pharmacoepi.org/meetings/33ICPE for updated conference information.

all for stracts d.indd SPACE. WE’RE ABOUT

The Convention Center Dublin

Wicklow Hall 2 Wicklow Meeting Room 5 Wicklow Meeting Room 4 Wicklow Meeting Room 3 Wicklow Meeting Room 2 Wicklow Hall 1 Wicklow Meeting Room 1 Foyer

Ecocem Meeting Room

The Liffey

Liffey Hall 2 Liffey Meeting Room 5 Liffey Hall 1 Liffey Meeting Room 4 Liffey Meeting Room 3 Foyer Liffey Meeting Room 2 Liffey Meeting Room 1 Liffey Boardroom 4

Liffey Boardroom 3 Liffey Boardroom 1 Liffey Boardroom 2

The Forum Foyer

WHEN I DIE ISPE Hotels Map to CCD DUBLIN WILL BE WRITTEN IN MY HEART James Joyce 32nd

15 2 0 1 6

International Conference on Pharmacoepidemiology & Therapeutic Risk Management The Convention Center Dublin pharmacoepi.org